
<html lang="en"     class="pb-page"  data-request-id="d330297c-fe3a-4ac3-893b-9bc58b82e89e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.9b01580;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-24;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer" /></meta><meta name="dc.Creator" content="Yunlong  Lu" /></meta><meta name="dc.Creator" content="Lauren M.  Gutgesell" /></meta><meta name="dc.Creator" content="Rui  Xiong" /></meta><meta name="dc.Creator" content="Jiong  Zhao" /></meta><meta name="dc.Creator" content="Yangfeng  Li" /></meta><meta name="dc.Creator" content="Carlo I.  Rosales" /></meta><meta name="dc.Creator" content="Michael  Hollas" /></meta><meta name="dc.Creator" content="Zhengnan  Shen" /></meta><meta name="dc.Creator" content="Jesse  Gordon-Blake" /></meta><meta name="dc.Creator" content="Katherine  Dye" /></meta><meta name="dc.Creator" content="Yueting  Wang" /></meta><meta name="dc.Creator" content="Sue  Lee" /></meta><meta name="dc.Creator" content="Hu  Chen" /></meta><meta name="dc.Creator" content="Donghong  He" /></meta><meta name="dc.Creator" content="Oleksii  Dubrovyskyii" /></meta><meta name="dc.Creator" content="Huiping  Zhao" /></meta><meta name="dc.Creator" content="Fei  Huang" /></meta><meta name="dc.Creator" content="Amy W.  Lasek" /></meta><meta name="dc.Creator" content="Debra A.  Tonetti" /></meta><meta name="dc.Creator" content="Gregory R. J.  Thatcher" /></meta><meta name="dc.Description" content="The clinical steroidal selective estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of or..." /></meta><meta name="Description" content="The clinical steroidal selective estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of or..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 20, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01580" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01580" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01580" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01580" /></link>
        
    
    

<title>Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01580" /></meta><meta property="og:title" content="Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0019.jpeg" /></meta><meta property="og:description" content="The clinical steroidal selective estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clinical trials. These trials address local breast cancer as well as peripheral metastases, but patients with brain metastases are generally excluded because of the lack of blood–brain barrier penetration. A novel family of benzothiophene SERDs with a basic amino side arm (B-SERDs) was synthesized. Proteasomal degradation of ERα was induced by B-SERDs that achieved the objectives of oral and brain bioavailability, while maintaining high affinity binding to ERα and both potency and efficacy comparable to fulvestrant in cell lines resistant to endocrine therapy or bearing ESR1 mutations. A novel 3-oxyazetidine side chain was designed, leading to 37d, a B-SERD that caused endocrine-resistant ER+ tumors to regress in a mouse orthotopic xenograft model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01580"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01580">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01580&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01580&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01580&amp;href=/doi/10.1021/acs.jmedchem.9b01580" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 11301-11323</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01530" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01641" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yunlong Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yunlong Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Illinois College of Pharmacy, University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yunlong++Lu">Yunlong Lu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lauren M. Gutgesell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lauren M. Gutgesell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Illinois College of Pharmacy, University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lauren+M.++Gutgesell">Lauren M. Gutgesell</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7645-9227" title="Orcid link">http://orcid.org/0000-0002-7645-9227</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rui Xiong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rui Xiong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UICentre (Drug Discovery @ UIC),  Department of Pharmaceutical Sciences, University of Illinois College of Pharmacy, University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rui++Xiong">Rui Xiong</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6350-9037" title="Orcid link">http://orcid.org/0000-0002-6350-9037</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jiong Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiong Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UICentre (Drug Discovery @ UIC), University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiong++Zhao">Jiong Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yangfeng Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yangfeng Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UICentre (Drug Discovery @ UIC), University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yangfeng++Li">Yangfeng Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carlo I. Rosales</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carlo I. Rosales</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Illinois College of Pharmacy, University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carlo+I.++Rosales">Carlo I. Rosales</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Hollas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Hollas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UICentre (Drug Discovery @ UIC), University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Hollas">Michael Hollas</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhengnan Shen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhengnan Shen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UICentre (Drug Discovery @ UIC), University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhengnan++Shen">Zhengnan Shen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jesse Gordon-Blake</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jesse Gordon-Blake</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Illinois College of Pharmacy, University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jesse++Gordon-Blake">Jesse Gordon-Blake</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Katherine Dye</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Katherine Dye</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UICentre (Drug Discovery @ UIC), University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Katherine++Dye">Katherine Dye</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yueting Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yueting Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UICentre (Drug Discovery @ UIC), University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yueting++Wang">Yueting Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sue Lee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sue Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Illinois College of Pharmacy, University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sue++Lee">Sue Lee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hu Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hu Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Psychiatry, University of Illinois at Chicago, 1601 W Taylor Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hu++Chen">Hu Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Donghong He</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Donghong He</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Psychiatry, University of Illinois at Chicago, 1601 W Taylor Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Donghong++He">Donghong He</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Oleksii Dubrovyskyii</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Oleksii Dubrovyskyii</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UICentre (Drug Discovery @ UIC), University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Oleksii++Dubrovyskyii">Oleksii Dubrovyskyii</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huiping Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huiping Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Illinois College of Pharmacy, University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huiping++Zhao">Huiping Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fei Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fei Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UICentre (Drug Discovery @ UIC), University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fei++Huang">Fei Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amy W. Lasek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amy W. Lasek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Psychiatry, University of Illinois at Chicago, 1601 W Taylor Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amy+W.++Lasek">Amy W. Lasek</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7099-2442" title="Orcid link">http://orcid.org/0000-0002-7099-2442</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Debra A. Tonetti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Debra A. Tonetti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Illinois College of Pharmacy, University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Debra+A.++Tonetti">Debra A. Tonetti</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Gregory R. J. Thatcher</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gregory R. J. Thatcher</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">UICentre (Drug Discovery @ UIC), University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</div><div class="loa-info-affiliations-info">Department of Psychiatry, University of Illinois at Chicago, 1601 W Taylor Street, Chicago, Illinois 60612, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#dca8b4bda8bfb4b9ae9ca9b5bff2b9b8a9"><span class="__cf_email__" data-cfemail="8efae6effaede6ebfccefbe7eda0ebeafb">[email protected]</span></a>. Phone: 312-355-5282.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gregory+R.+J.++Thatcher">Gregory R. J. Thatcher</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7757-1739" title="Orcid link">http://orcid.org/0000-0002-7757-1739</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01580&amp;href=/doi/10.1021%2Facs.jmedchem.9b01580" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 11301–11323</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 20, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 September 2019</li><li><span class="item_label"><b>Published</b> online</span>20 November 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 December 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01580" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01580</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D11301%26pageCount%3D23%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYunlong%2BLu%252C%2BLauren%2BM.%2BGutgesell%252C%2BRui%2BXiong%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D24%26contentID%3Dacs.jmedchem.9b01580%26title%3DDesign%2Band%2BSynthesis%2Bof%2BBasic%2BSelective%2BEstrogen%2BReceptor%2BDegraders%2Bfor%2BEndocrine%2BTherapy%2BResistant%2BBreast%2BCancer%26numPages%3D23%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D11323%26publicationDate%3DDecember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01580"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1564</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01580" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yunlong&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Lauren&quot;,&quot;last_name&quot;:&quot;M. Gutgesell&quot;},{&quot;first_name&quot;:&quot;Rui&quot;,&quot;last_name&quot;:&quot;Xiong&quot;},{&quot;first_name&quot;:&quot;Jiong&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Yangfeng&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Carlo&quot;,&quot;last_name&quot;:&quot;I. Rosales&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Hollas&quot;},{&quot;first_name&quot;:&quot;Zhengnan&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Jesse&quot;,&quot;last_name&quot;:&quot;Gordon-Blake&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;Dye&quot;},{&quot;first_name&quot;:&quot;Yueting&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Sue&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Hu&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Donghong&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Oleksii&quot;,&quot;last_name&quot;:&quot;Dubrovyskyii&quot;},{&quot;first_name&quot;:&quot;Huiping&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Fei&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Amy&quot;,&quot;last_name&quot;:&quot;W. Lasek&quot;},{&quot;first_name&quot;:&quot;Debra&quot;,&quot;last_name&quot;:&quot;A. Tonetti&quot;},{&quot;first_name&quot;:&quot;Gregory&quot;,&quot;last_name&quot;:&quot;R. J. Thatcher&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;11301-11323&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01580&quot;},&quot;abstract&quot;:&quot;The clinical steroidal selective estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clinical trials. These trials address local breast cancer as well as peripheral metastases, but patients with brain metastases are generally excluded because of the lack of blood–brain barrier penetration. A novel family of benzothiophene SERDs with a basic amino side arm (B-SERDs) was synthesized. Proteasomal degradation of ERα was induced by B-SERDs that achieved the objectives of oral and brain bioavailability, while maintaining high affinity binding to ERα and both potency and efficacy comparable to fulvestrant in cell lines resistant to endocrine therapy or bearing ESR1 mutations. A novel 3-oxyazetidine side chain was designed, leading to 37d, a B-SERD that caused endocrine-resistant ER+ tumors to regress in a mouse orthotopic xenograft model.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01580&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01580" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01580&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01580" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01580&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01580" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01580&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01580&amp;href=/doi/10.1021/acs.jmedchem.9b01580" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01580" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01580" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01580%26sid%3Dliteratum%253Aachs%26pmid%3D31746603%26genre%3Darticle%26aulast%3DLu%26date%3D2019%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2BBasic%2BSelective%2BEstrogen%2BReceptor%2BDegraders%2Bfor%2BEndocrine%2BTherapy%2BResistant%2BBreast%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D24%26spage%3D11301%26epage%3D11323%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291781" title="Degradation">Degradation</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/jmcmar.2019.62.issue-24/20191226/jmcmar.2019.62.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The clinical steroidal selective estrogen receptor (ER) degrader (SERD), fulvestrant, is effective in metastatic breast cancer, but limited by poor pharmacokinetics, prompting the development of orally bioavailable, nonsteroidal SERDs, currently in clinical trials. These trials address local breast cancer as well as peripheral metastases, but patients with brain metastases are generally excluded because of the lack of blood–brain barrier penetration. A novel family of benzothiophene SERDs with a basic amino side arm (B-SERDs) was synthesized. Proteasomal degradation of ERα was induced by B-SERDs that achieved the objectives of oral and brain bioavailability, while maintaining high affinity binding to ERα and both potency and efficacy comparable to fulvestrant in cell lines resistant to endocrine therapy or bearing <i>ESR1</i> mutations. A novel 3-oxyazetidine side chain was designed, leading to <b>37d</b>, a B-SERD that caused endocrine-resistant ER+ tumors to regress in a mouse orthotopic xenograft model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30564" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30564" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">One in eight women will develop invasive breast cancer during their lifetime and, in Europe and the United States, approximately 190 000 women are expected to die from breast cancer in 2019.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The majority of breast cancers express estrogen receptor α (ERα), which drives proliferation and survival of these tumors.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Endocrine therapy of ER positive (ER+) breast cancer has had a remarkable effect on long-term survival. In premenopausal and postmenopausal women, treatment with tamoxifen (TAM, <b>1a</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and aromatase inhibitors (AIs), respectively, provides effective first line and adjuvant therapy.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> AIs prevent the synthesis of estrogens by inhibiting the aromatase enzyme; whereas, the selective ER modulator (SERM), TAM, binds to ER, stabilizing an antagonist conformation in breast cancer cells, resulting in antiproliferative signaling.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> Notwithstanding these successes, more women die annually of ER+ breast cancer than triple-negative breast cancer (TNBC), despite TNBC having no safe, targeted therapy.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> This is explained by the high prevalence of ER+ breast cancer and the high rate of resistance to endocrine therapy.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The battlefield has therefore shifted to endocrine-resistant, metastatic breast cancer (MBC), in which TAM and AIs have lost efficacy.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the SERD fulvestrant (<b>2</b>), oral SERDs (<b>3</b>, <b>4</b>, <b>8</b>, <b>9</b>), together with “SERM/SERDs” (<b>5</b>, <b>7</b>), and SERMs (<b>1</b>, <b>6</b>). Several of these SERDs are currently being studied in clinical trials: NCT01823835, NCT02316509, NCT03332797, NCT03236974, NCT03616587, NCT02734615, NCT03284957, NCT02338349, NCT03455270.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the resistance setting, up to 90% of tumors remain ER+ (i.e., express ERα), wherein ER provides prosurvival signaling even in the absence of estrogens and/or the presence of TAM.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> ER, therefore, remains a target for therapeutics in endocrine-resistant breast cancer, amply demonstrated by the clinical efficacy of the SERD, fulvestrant, <b>2</b>, which has moved to first line therapy for metastatic ER+ breast cancer.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Importantly, resistance to one endocrine therapy does not lead to “cross-resistance” to all ER-targeted therapeutics.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> For example, patients who have progressed on SERM treatment will commonly be treated with AIs or fulvestrant.<a onclick="showRef(event, 'ref5 ref13'); return false;" href="javascript:void(0);" class="ref ref5 ref13">(5,13)</a> Similarly, patients with breast cancer tumors resistant to AIs will generally respond to fulvestrant.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Resistance to endocrine therapy is multifactorial, including upregulation of growth factor signaling, modifications in prosurvival pathways, ER functioning as a ligand-independent transcription factor, and mutations in ER.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18">(15−18)</a> Hence, Cdk4/6 inhibitors that block an alternate growth pathway in ER-expressing breast cancer, used in combination with AIs and fulvestrant, have rapidly changed standard of care.<a onclick="showRef(event, 'ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21 ref22">(19−22)</a></div><div class="NLM_p">While effective in ER+ breast cancer, fulvestrant (ICI182, 780, <b>2</b>) has significant pharmaceutical liabilities including poor solubility and pharmacokinetics (PK), which require intramuscular injection. The combination of these issues leads to significant clinical problems in establishing stable and efficacious drug levels.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> This has been a strong impetus for the recent entry into clinical trials of orally bioavailable SERDs, including GDC-0810(<b>3a</b>)/GDC-0927(<b>3b</b>)/GDC-9545 (Genentech), AZD9496(<b>4</b>)/AZD9833 (AstraZeneca), LSZ-102 (Novartis), SAR439859 (Sanofi), G1T48 (G1, <b>9b</b>), and RAD1901 (Radius, <b>5</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The classification of a drug as a SERD requires the demonstration of enhanced proteosomal degradation of ERα, in addition to antagonist actions on binding to ER.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In the clinical setting, SERMs are the standard-of-care for premenopausal women because SERMs do not act as antiestrogens in all tissues, in contrast to AIs and fulvestrant; and indeed, the SERM, raloxifene (<b>6</b>), is used clinically to treat postmenopausal osteoporosis.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The SERM, bazedoxifene (<b>7</b>), approved for postmenopausal osteoporosis in Europe, has been described as a SERM/SERD hybrid;<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and RAD1901 (<b>5</b>), labeled as a SERD, preserves bone mass,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> thereby reclassifying it as a SERM/SERD hybrid (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a></div><div class="NLM_p last">A majority of SERDs in clinical trials are nonsteroidal acrylates. The acrylate side chain engages in a hydrogen bonding network with helix 12 (H12), as observed in the co-crystal structure of <b>8a</b> with ERα (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K">1R5K</a>; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), causing displacement and destabilization of H12, a conformational trigger to expose a hydrophobic surface, leading to proteasomal degradation of ER. The acrylate side chain can limit brain bioavailability, and in some cases clinical trials of oral SERDs exclude patients with brain metastases. Patients with brain metastases have extremely poor prognosis; therefore, our motivation in developing a SERD with a basic amino side arm (B-SERD) was to ensure good brain bioavailability to allow treatment of this population.<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30−32)</a> The replacement of an acrylate anion with a basic amino group would be expected to improve blood–brain barrier penetration. We recently developed and optimized a unique benzothiophene chemical scaffold as the basis for a family of potent acrylate benzothiophene SERDs (e.g., <b>9</b>) with oral bioavailability and in vivo efficacy.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> We therefore used this scaffold to explore a variety of basic side arms, with the objective of maintaining the excellent potency and efficacy of <b>2</b>, whilst gaining the oral and brain bioavailability lacking in <b>2</b>.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Structure Design</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17835" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17835" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We have made numerous modifications to benzothiophene scaffolds to diversify the biological activity of ER ligands.<a onclick="showRef(event, 'ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36 ref37 ref38 ref39 ref40 ref41">(34−41)</a> To successfully generate the potent, oral SERD, <b>9</b>, we designed a unique scaffold substituted with an acrylate containing side chain.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Co-crystal structures of SERMs, containing the archetypical SERM 2-phenoxyethylamino side chain, bound to ERα reveal the key salt–bridge interaction between the SERM side chain amino group and Asp-351, and we hypothesized that retaining this interaction and extending the aliphatic side chain would displace H12, expose its hydrophobic surface and result in ERα degradation.<a onclick="showRef(event, 'ref42 ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref44 ref45">(42−45)</a> Molecular modeling of putative B-SERDs using the co-crystal structure of <b>4</b> bound to ERα (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ACC">5ACC</a>) supported this hypothesis; and suggested that favorable interactions targeted for <b>9</b> with the two hydrophobic cavities formed by Leu 384 and Leu 428 (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K">1R5K</a>) could be maintained in a B-SERD (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure design. H-bonding of the amine side chain to Asp-351 in the ERα ligand-binding pocket should allow engagement of ring substituents with hydrophobic pockets formed in the region of Leu-384 and Leu-428 (increasing affinity), whilst displacing H12 (causing ERα degradation). The design of the amine side chain using a conformationally restricted heterocycle considered the ability to interact with H12 (A); the amine basicity (B); and susceptibility to oxidation (C,D). DFT molecular orbital calculations of proton affinity (dPA) (B), ionization energy (dIE) (C), and H-atom abstraction (dHA) (D) were normalized relative to the calculated free energy for the piperidine side chain: dHAr corresponds to heterocyclic ring-C oxidation; dHA refers to oxidation of the alternate carbon. The R group in (A) is modeled by H in calculations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The choice of constrained basic side arm for a B-SERD ranges from the pyrrolidine, piperidine, and azepane rings found in SERMs and SERDs, to the azetidine ring found in a SERD reported in 2019, after completion of our lead optimization campaign (<b>3b</b>).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Effective side arms would presumably need to maintain a salt bridge or H-bond with Asp-351, with the strength of this interaction influenced by amine basicity. In addition, SERMs are well known to undergo oxidative metabolism leading to metabolites formed from <i>N-</i>desalkylation. Because both characteristics are expected to be strongly influenced by ring size (hybridization and ring strain) and electron-withdrawing substituents, calculations were performed on candidate side arms using density functional theory (DFT) molecular orbital calculations at RI-MP2/6-311++G**//B3LYP/6-31+G** (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_001.pdf" class="ext-link">Supporting Information</a>). The influence of ring size is to decrease nitrogen basicity as the ring size contracts, and to further decrease basicity with electron-withdrawing group substitution. In general, a similar trend is seen for ionization energy, indicating that azetidine side arms are less susceptible to oxidation, although a cyclopropyl substituent on the azetidine ring stabilizes the radical cation formed on oxidation. The relative energy for H atom abstraction (dHA) α to N is an indicator of susceptibility to phase 1 oxidation, potentially leading to <i>N-</i>desalkylation (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D). Again, the azetidine ring carbons are predicted to be less readily oxidized, especially in the fluoro-substituted derivatives. Although calculated electronic contributions can be overwhelmed by ligand binding site interactions and the microenvironment, the calculated trends encouraged exploration of azetidine side arms.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To construct the 2-keto-benozothiophene core required by our structure design, commercially available 4-methoxycinnamic acid was used, followed by cyclization to afford 3-chloro-6-methoxybenzo[<i>b</i>]thiophene-2-carbonyl chloride (<b>10</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The acyl chloride was converted to a Weinreb amide, which was subsequently reduced to the corresponding aldehyde (<b>12</b>) with DIBAL-H at −40 °C. A variety of Grignard reagents were shown to react with the aldehyde to afford diverse secondary alcohols <b>13a–d</b> that were oxidized to generate phenyl ketones <b>14b–e</b>. Meanwhile, ketones <b>14a</b>, <b>14f</b>, <b>14h</b>, and <b>14i</b> were obtained from the reaction of Weinreb amide with Grignard reagents at 0 °C. Compound <b>14g</b> was obtained from the Grignard reagent reacting with acyl chloride <b>10</b>. The deprotection of the methoxy group of compounds <b>14</b> was performed with Lewis acid BF<sub>3</sub>·Me<sub>2</sub>S in an ice bath.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The resulting phenol was protected with tetrahydropyran (THP) to afford the primary precursor synthons <b>16a–i</b>. To obtain the azetidine synthon required by our structure design, we started with <i>t</i>-butyl 3-(hydroxymethyl)azetidine-1-carboxylate <b>17</b>, installing the fluoro substitution using tetrabutylammonium fluoride under reflux to generate compound <b>19</b>. The azetidine synthon <b>20</b> was obtained by deprotection using 4 M HCl; and the pyrrolidine synthon <b>24</b> was obtained in a similar way from <b>21</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). For the construction of the side chain, 2-(4-(2-bromoethoxy)phenoxy)tetrahydro-2<i>H</i>-pyran <b>26</b> was obtained from 4-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)phenol <b>25</b>. Coupling of <b>26</b> to the appropriate amine under basic conditions (NaH) gave the THP-protected side chain: <b>27a–f</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Deprotection of the THP protecting group afforded compounds <b>28a–f</b> that underwent the S<sub>N</sub>Ar reaction with synthons <b>16a–i</b> to produce <b>29a–o</b>, which gave final products <b>30a–o</b> after deprotection.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Routes for Precursor Synthons<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SOCI<sub>2</sub>, pyridine, chlorobenzene, reflux, 50%. (b) <i>N</i>-Methoxymethylamine, Et<sub>3</sub>N, DCM, rt, 90%. (c) DIBAL-H, THF, −40 °C, 60%. (d) Grignard reagent, THF, 0 °C to rt, 75–85%. (e) PCC, DCM, rt, 55–65%. (f) (4-Fluoro-2,6-dimethylphenyl)magnesium bromide, CuCN·2LiCl, THF, 0 °C to rt, 90%. (g) Grignard reagent, THF, 0 °C to rt, 70–80%. (h) BBr<sub>3</sub>, DCM, −78 °C to rt, 40–60%. (i) 3,4-Dihydro-2<i>H</i>-pyran, PPTS, DCM, rt, 70–80%. (aa) Methanesulfonyl chloride, Et<sub>3</sub>N, DCM, 0 °C to rt, 95%. (bb) TBAF, 80 °C, 70%. (cc) 6 M HCI MeOH, rt, 60%.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Routes for Candidate Piperidine, Azetidine, and Pyrrolidine B-SERDs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1,2-dibromoethane, KOH, THF, reflux, 50%. (b) Azetidine hydrochloride, 3-methylazetidine hydrochloride, <b>20</b>, <b>24</b>, piperidine, NaH, THF, 0–60 °C, 55%, (c) <i>p</i>-TsOH, MeOH, rt, 60%. (d) <b>16a–i</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C, 55–75%. (e) <i>p</i>-TsOH, MeOH, rt, 60–80%.</p></p></figure><div class="NLM_p">The 3-oxy-azetidine, or “reverse azetidine”, side arm was derived from the reaction of <i>t</i>-butyl 3-iodoazetidine-1-carboxylate with 4-(benzyloxy)phenol <b>31</b> to afford <i>t</i>-butyl 3-(4-(benzyloxy)phenoxy)azetidine-1-carboxylate <b>32</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Deprotection in trifluoroacetic acid (TFA) to give <b>33</b> was followed by alkylation with 1-bromo-3-fluoropropane or (1-ethoxycyclopropoxy) trimethylsilane, to give <b>34a</b> and <b>34b</b>, respectively. Deprotection was performed under Pd/C and H<sub>2</sub> to afford compounds <b>35a,b</b>, which were coupled with the appropriate precursor synthon (<b>16a,b,d,f,g</b>) to yield <b>36a–f</b> using the procedure shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Deprotection of THP under mild acidic conditions gave <b>37a–f</b>.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Routes for Candidate Reverse-Azetidine B-SERDs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 11-boc-3-iodoazetidine, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 140 °C, 50%. (b) CF<sub>3</sub>COOH, DCM, rt, 70%. (c) 1-Bromo-3-fluoropropane, NaH, 0–60 °C, 55%; or (1-methoxycyclopropoxy)trimethylsilane, AcOH, NaBH<sub>3</sub>CH, 80% (d) H<sub>2</sub>, Pd/C, rt, 70%. (e) <b>16a</b>, <b>16b</b>, <b>16d</b>, <b>16f</b>, <b>16g</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C, 75–85%. (f) <i>p</i>-TsOH, MeOH, rt, 70–80%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Biological Testing</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71006" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71006" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since the ultimate goal of this study was to discover an oral SERD suitable for treatment of brain metastases in endocrine-resistant ER+ breast cancer, lead optimization was driven by efficacy in endocrine-resistant, ER+ breast cancer cell lines. A development lead would need to demonstrate efficacy in breast cancer cells bearing mutations in <i>ESR1</i>, brain penetration, and cause regression of endocrine-resistant tumors in a mouse xenograft study.</div><div class="NLM_p">Optimization of the B-SERD scaffold was driven by in vitro assays in 2D and 3D breast cancer cell cultures. The primary objective, to develop new oral SERDs for treatment of MBC resistant to endocrine therapy, required the use of breast cancer cell lines modeling TAM and AI resistance. The MCF7:TAM1 cell line models resistance to TAM and AIs, having been developed by long-term exposure of parental, endocrine-dependent MCF7:WS8 cell cultures to the active metabolite of TAM, 4OH-TAM (<b>1b</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) with concurrent long-term estrogen deprivation (LTED); whereas the MCF7:5C cell line was developed from LTED of MCF7:WS8 cell cultures.<a onclick="showRef(event, 'ref34 ref47'); return false;" href="javascript:void(0);" class="ref ref34 ref47">(34,47)</a> Both cell lines undergo estrogen-independent growth and are insensitive to treatment with <b>1b</b>, in contrast to the parent MCF7:WS8 cell line, growth of which is dependent on estrogens and inhibited by <b>1b</b>. In addition to these cell lines, we evaluated the T47D:Y537S and T47D:D538G cell lines obtained from CRISPR-Cas9 manipulation of T47D-WT cells as described previously.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a><i>ESR1</i> mutations are prevalent in ER+ MBC after AI therapy and the Y537S and D538G mutations are associated with AI resistance and a more aggressive disease.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Not only do the T47D <i>ESR1</i> mutant cell lines provide an additional model of resistance, the T47D cell line itself provides a different ER+ tumor background.</div><div class="NLM_p">In our previous development of oral SERDs, exemplified by <b>9</b>, we used oral SERD <b>3a</b> as a benchmark; however, this oral SERD failed in clinical trials; thus, we now use fulvestrant, <b>2</b>, as a benchmark, because it is currently the only clinical SERD. It should be noted that: <b>2</b> demonstrates high efficacy and potency in cell cultures and cell-derived xenografts (CDX); and the severe pharmacokinetic limitations experienced in the clinic, which limit efficacy, are not recapitulated in preclinical models. Therefore, the desired B-SERD will match the high potency and efficacy of <b>2</b> in cell lines and CDX, but in contrast to <b>2</b>, will demonstrate oral bioavailability and brain exposure. All cell lines used for B-SERD optimization are sensitive to growth inhibition by <b>2</b>. In both cell cultures and in vivo measurements of target engagement and side effects, we have also compared against the SERDs: <b>3b</b> and <b>9</b>; and the SERM/SERDs, <b>5</b> and <b>7</b>.</div><div class="NLM_p last">Cell viability assays were performed in 2D monolayer cell and 3D spheroidal cell cultures to measure the ability of B-SERDs to inhibit growth of both endocrine-resistant and parent cell lines. Full concentration–response curves were obtained for B-SERDs and for <b>2</b> to derive potency for inhibition of cell growth in 2D monolayer cultures of MCF7:WS8 and MCF7:5C cell lines, measuring cell DNA content. The maximum efficacy for inhibition is reported relative to vehicle (0%) and cell medium only (100%), such that the maximum efficacy of <b>2</b> was measured as 66 and 48% inhibition of cell growth in parental and endocrine-resistant breast cancer cell lines, respectively. Inhibition of estrogenic activity, required for SERD activity, was measured in the endocrine-dependent parental cell line in competition with E<sub>2</sub>, using a transient ER response element (ERE)-luciferase transcriptional reporter and compared to relative binding affinity (RBA) to ERα using a radioligand binding assay. The effect of treatments on the ER protein level was measured using in-cell westerns (ICW) in MCF7:WS8 cells and confirmed by western blots in the presence and absence of a proteasome inhibitor to show proteasomal degradation. While the monolayer cell culture allows a higher throughput and allows the multiplate measurement of ER content using ICW, 3D spheroids provide a more physiologically relevant cell model, more closely mimicking the increased cell–cell signaling and hypoxic core, observed in solid tumors.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Cell viability for 3D spheroid cultures was measured in parent MCF7:WS8 and endocrine-resistant MCF7:TAM1 cell cultures as well as in three T47D cell lines, including those with Y537S and D538G mutations in <i>ESR1.</i> The novel B-SERD showing a superior PK profile was: (1) compared with <b>2</b> in an MCF7:TAM1 orthotopic CDX mouse model; (2) compared with <b>2</b> and <b>7</b> in the assessment of unwanted uterotrophic effects in juvenile rats; and (3) compared with <b>9a</b> in assessment of target engagement (ERα immunoassay) in the uterus and ovaries of intact female mice.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02830" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02830" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The benchmark SERD, <b>2</b>, inhibits growth of endocrine-resistant and parental cell lines in 2D cultures with high potency (pIC<sub>50</sub> = 8.8–9.2) and with observed reduced maximal efficacy in the endocrine-resistant MCF7:5C cell line (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Of the B-SERDs with a pyrrolidine side arm, <b>30l</b> showed superior potency and efficacy to <b>2</b> in endocrine-dependent and -independent cell cultures (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The enantiomer, <b>30m</b> was marginally inferior to <b>30n</b> in both cell lines. As also observed for <b>2</b>, all the pyrrolidines studied (<b>30l–n</b>) lost significant efficacy in endocrine-resistant MCF7:5C cells. In contrast to <b>2</b> and to the pyrrolidines, the piperidine <b>30o</b> did not inhibit growth of MCF7:5C cells. MCF7:5C cells are TAM resistant and are cross-resistant to the SERM raloxifene <b>6</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The very similar cellular phenotype induced by <b>6</b> and <b>30o</b> strongly suggests that <b>30o</b> is a SERM and that cross-resistance in MCF7:5C cells also extend to this SERM.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Antiproliferative Activity of Pyrrolidine and Piperidine Ligands in Breast Cancer Cells<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0011.gif" alt="" id="GRAPHIC-d7e1078-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0012.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Potency was determined by DNA content after 4 or 6 days of incubation in MCF:WS8 or MCF7:5C respectively, following treatment with B-SERDs. The signal was normalized to vehicle control. Data shown as mean ± SEM from at least three biological and analytical replicates. Maximum efficacy was normalized to vehicle (0%) and no cells (100%). NA = not applicable; NI = no inhibition.</p></div></div><div></div></div><div class="NLM_p">Moving from a pyrrolidine to an azetidine side arm led to no loss of efficacy and potency in growth inhibition of MCF7:WS8 cells (9.0 < pIC<sub>50</sub> < 10.4; <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Comparison of the 2-Me-phenyl-substituted series of azetidine ligands bearing different substitutions on the azetidine ring, <b>30a</b>, <b>30b</b>, and <b>30d</b>, showed identical efficacy, with <b>30b</b> having the higher growth inhibition potency of the parental cell line. As we saw for <b>30o</b> (and <b>6</b>), high potency in the parental cell line can translate to a total loss of efficacy in the MCF7:5C cell line for a SERM (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The unadorned 4-membered azetidine ring of <b>30a</b> confers potent SERD activity in inhibiting growth of both cell lines, but significantly reduced efficacy in MCF7:5C cells. Structurally, <b>30a</b> resembles a SERM; however, the observed activity shows that TAM-resistant MCF7:5C cells that are cross-resistant to the piperidine SERMs, <b>6</b> and <b>30o</b>, are not cross-resistant to <b>30a</b>, leading to speculation that <b>30a</b> may fall in the SERM/SERD classification. Regardless, the lack of cross-resistance supports the selection of the azetidine side arm for further exploration.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antiproliferative Activity of Azetidine Ligands in Breast Cancer Cells<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0013.gif" alt="" id="GRAPHIC-d7e1144-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0014.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Potency was determined by DNA content after 4 or 6 days of incubation in MCF7:WS8 or MCF7:5C respectively, following treatment with B-SERDs. Signal was normalized to vehicle control.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> > 100 nM; 45% inhibition at 1 μM. Data shown as mean ± SEM from at least three biological and analytical replicates. Maximum efficacy was normalized to vehicle (0%) and no cells (100%). NA = not applicable; NI = no inhibition.</p></div></div><div></div></div><div class="NLM_p">Comparison of the nine 3-fluoromethyl azetidine derivatives, <b>30c–k</b>, allows comparison of the effect of different substitution patterns of the benzoyl ring; however, all derivatives potently inhibited growth in MCF7:WS8 cells (8.9 < pIC<sub>50</sub> < 9.8). In endocrine-resistant cells, many derivatives showed a small loss of potency, and a loss of efficacy; with the exception of <b>30g</b> that lost efficacy in MCF7:5C cells. We speculate that the provision of a second phenolic group in <b>30g</b> and <b>30h</b>, in addition to the benzothiophene phenol, facilitates an alternative binding mode that is more akin to a SERM, and MC7:5C cells are, in general, resistant to SERMs. The metasubstitution in <b>30j</b> is also not a preferred substitution as indicated by efficacy in MCF7:5C cells. These observations support the importance of the <i>o</i>-methyl group in exploiting the small hydrophobic pockets created by Leu-384 and Leu-428, explored in the optimization of the SERD <b>9</b>, in maintaining potency in the endocrine-resistant cell line.</div><div class="NLM_p">We next explored derivatives with a “reverse azetidine”, or 3-oxy-azetidine, side arm. This modification moves the conformational lock of the azo-ring closer to the more rigid benzothiophene core. To induce the displacement of H12, which underlies the high potency and efficacy observed with azetidine ligands (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), a longer and flexible fluoropropyl chain was conjugated to the azetidine nitrogen. Given the potential for the <i>N-</i>cyclopropyl substituent to increase stability to phase 1 metabolism (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), compound <b>37f</b> was prepared; although this ligand was potent and effective in MCF7:WS8 cells, disappointingly, it showed a loss of efficacy in TAM-resistant cells (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). All reverse azetidines, <b>37a–f</b>, were potent (9.3 < pIC<sub>50</sub> < 10.2) and efficacious inhibitors of MCF7:WS8 cell growth.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antiproliferative Activity of Reverse Azetidine Ligands in Breast Cancer Cells<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0015.gif" alt="" id="GRAPHIC-d7e1221-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0016.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Potency was determined by DNA content after 4 or 6 days of incubation in MCF7:WS8 or MCF7:5C respectively, following treatment with B-SERDs. Signal was normalized to vehicle control. Data shown as mean ± SEM from at least three biological and analytical replicates. Maximum efficacy was normalized to vehicle (0%) and no cells (100%). NA = not applicable; NI = no inhibition.</p></div></div><div></div></div><div class="NLM_p">As with the 3-fluoromethyl azetidine series, the predicted reduced basicity of the <i>N-</i>fluoropropyl azetidine nitrogen did not influence potency or efficacy. Having established the efficacy of the putative B-SERDs in inhibiting growth of endocrine-resistant and parental cell lines, it was essential to measure ERα levels to confirm the functional identity of these compounds as SERDs. Potency toward degradation of ERα was studied in MCF7:WS8 cells measured by ICW. All B-SERDs that induced growth inhibition also caused the loss of ERα with potency comparable to <b>2</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The SERM, <b>30o</b>, did not induce ER degradation (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_001.pdf" class="ext-link">Figure S1</a>). The cyclopropylidene derivatized reverse-azetidine, <b>37f</b>, showed low efficacy in the ICW assay. Despite predicted stability against metabolic N-desalkylation (see <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) this compound was not considered as a development candidate. Interestingly, the unadorned azetidine (<b>30a</b>) and fluoromethyl pyrrolidine (<b>30n</b>) derivatives also manifested reduced efficacy, as did the bisphenolic derivative, <b>30h</b>. These compounds also showed lower efficacy in growth inhibition of MCF7:5C cells.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. ER degradation, binding, and activation<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a><sup>,</sup><a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0017.gif" alt="" id="GRAPHIC-d7e1274-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0018.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">ER degradation potency and efficacy normalized to vehicle (100%) and 1 μM 2 (0%).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">RBA values, determined by radioligand displacement assays expressed as IC<sub>50</sub> estradiol/IC<sub>50</sub> compound × 100 (RBA, estradiol = 100%).</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Estrogenic activity (ERE IC<sub>50</sub>), as determined by ERE dual luciferase in competition with 1 nM E<sub>2</sub>, normalized to 1 nM E<sub>2</sub> alone (100%) and vehicle (0%).</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Data shown as mean ± SEM from at least three biological and analytical replicates.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">Data shown as mean ± SEM from three analytical replicates. NA = not applicable; NI = no inhibition.</p></div></div><div></div></div><div class="NLM_p">SERDs and SERMs, by definition, antagonize the actions of E<sub>2</sub> in breast cancer cells, by inducing the binding of a repressed ER transcriptional complex to the ERE causing inhibition of selective gene transcription. All B-SERDs tested antagonized ERE-luciferase induction by E<sub>2</sub> with low nanomolar potency, with <b>30h</b>, <b>30m</b>, and <b>37f</b> excluded from further consideration, based on lower potency (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). For selected compounds, RBA was measured to confirm sub-nanomolar affinity for ERα (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The selectivity for ERα/ERβ given by RBA measurements was less than fourfold for all B-SERDs tested (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_001.pdf" class="ext-link">Table S1</a>).</div><div class="NLM_p">Based upon the foregoing data collected in 2D cell cultures, several B-SERDs were excluded from further study; however, many examples remained with high potency and efficacy, and clear evidence of target engagement. The success of the 2,6-dimethyl,4-halo acrylate SERDs (<b>9</b>) in our previous preclinical studies<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> biased us toward these derivatives; therefore, <b>30f</b>, <b>30m</b>, and <b>37d</b>, were prioritized for a preliminary study of oral brain bioavailability. The three B-SERDs tested were delivered orally at 100 mg/kg to C57/BL6 mice with plasma and brain concentrations measured by LC–MS/MS at 30 and 120 min and compared to fulvestrant delivered by the standard s.c. route (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). B-SERDs showed the desired brain bioavailability; for example, the concentration of <b>30f</b> in the brain at 0.5 and 2 h was 600–750 nM and that of <b>37d</b> exceeded 1 μM, whereas the concentration of <b>2</b> in the brain was below the limit of quantification at 30 min. The 3-oxyazetidine side-armed B-SERD, <b>37d</b>, gave substantially higher plasma and brain concentrations compared to the analogues bearing either azetidine (<b>30f</b>) or pyrrolidine side-arms (<b>30m</b>). The pyrrolidine, <b>30m</b>, was not studied further.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Preliminary Pharmacokinetic Screen of 2,6-Dimethyl-4-fluoro B-SERDs Compared to <b>2</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">plasma concentration (nM)</th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">brain concentration (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">0.5 h</th><th class="colsep0 rowsep0" align="center" char="±">2 h</th><th class="colsep0 rowsep0" align="center" char="±">0.5 h</th><th class="colsep0 rowsep0" align="center" char="±">2 h</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char="±">31.2 ± 16.5</td><td class="colsep0 rowsep0" align="char" char="±">301 ± 268</td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 0.8<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">47.4 ± 61.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30f</b></td><td class="colsep0 rowsep0" align="char" char="±">786 ± 179</td><td class="colsep0 rowsep0" align="char" char="±">659 ± 329</td><td class="colsep0 rowsep0" align="char" char="±">750 ± 673</td><td class="colsep0 rowsep0" align="char" char="±">588 ± 274</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30m</b></td><td class="colsep0 rowsep0" align="char" char="±">211 ± 45</td><td class="colsep0 rowsep0" align="char" char="±">163 ± 141</td><td class="colsep0 rowsep0" align="char" char="±">121 ± 61</td><td class="colsep0 rowsep0" align="char" char="±">276 ± 93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37d</b></td><td class="colsep0 rowsep0" align="char" char="±">2490 ± 797</td><td class="colsep0 rowsep0" align="char" char="±">2150 ± 201</td><td class="colsep0 rowsep0" align="char" char="±">1630 ± 1110</td><td class="colsep0 rowsep0" align="char" char="±">1250 ± 406</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Plasma and brain concentration of <b>30f</b>, <b>30m</b> and <b>37d</b> (100 mg/kg p.o.), and <b>2</b> (5 mg s.c.) showing mean and s.d. (<i>N</i> = 3).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Below LOQ<sub>brain</sub> = 5 nM.</p></div></div></div><div class="NLM_p">B-SERDs <b>30f</b> and <b>37d</b> were compared with congeners, <b>30i</b> and <b>37b</b>, respectively, and with SERD <b>2</b> in 3D cultures following treatment for 14 days (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). In the parental, MCF7:WS8 cell line, all SERDs (10 nM) were equally effective in inhibiting growth of spheroids as shown by spheroid size and viability measured by ATP content (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A,B). However, in the TAM-resistant MCF7:TAM1 spheroids, significant differences were observed between treatments, with <b>2</b>, <b>30f</b>, and <b>37d</b> having greater efficacy. Growth of MCF7:TAM1 cells is endocrine-independent and TAM-resistant, and because this is an LTED cell line, it models resistance to AI; however, it does not harbor mutations in <i>ESR1</i>, which are known to be associated with acquired AI resistance. The efficacy of B-SERD <b>37d</b> was compared to SERDs (<b>2</b>, <b>3b</b>) and SERM (<b>1b</b>) in T47D cell lines expressing only mutant ERα (TYS = Y537S; TDG = D538G) or WT ERα.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> B-SERD <b>37d</b> was equally as effective as the SERDs, fulvestrant (<b>2</b>) and GDC-0927 (<b>3b</b>), and as the SERM <b>1b</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C).</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Spheroid viability. (A) MCF7:WS8 and MCF7:TAM1 spheroid viability following treatment with B-SERDs (<b>30f</b>, <b>30i</b>, <b>27b</b>, and <b>37d</b>, 10 nM) compared to <b>2</b> (10 nM). (B) Representative images on day 10 of treatment with DMSO (0.01%), <b>2</b> (10 nM), and <b>37d</b> (10 nM) in MCF7:WS8 and MCF7:TAM1 spheroids. (C) T47D:WT, T47D:TYS, and T47D:TGD cells grown for 3 days were treated for a further 11 days with test compounds (10 nM). (A,C) Luminescence normalized to vehicle/control (1.0) and background (0.0). Data shown as mean ± SEM from three biological and analytical replicates. Significance compared to vehicle/control by one-way ANOVA: <i>p</i> <0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Western blots supported the observations on B-SERD-induced ER degradation in cell cultures made using ICW, and using co-treatment with the proteasomal inhibitor, MG-132, western blots also confirmed the role of the proteasome in degradation (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). Representative western blots demonstrating ERα degradation from treatment of the parent cell line are shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B (and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_001.pdf" class="ext-link">Figure S2</a>), providing a comparison of <b>37d</b> with the structurally related acrylate, <b>9a</b>, clinical SERD, <b>2</b>, and SERM/SERD, <b>5</b>. We extended these in vitro observations to examine the effects of oral administration of the B-SERD, <b>37d</b>, compared to the congenic acrylate SERD, <b>9a</b>, in intact female mice (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). In these experiments, animals were sacrificed and tissues flash frozen, at either 5 or 7 h after oral drug administration. In the acute treatment paradigm, the mice received only one dose before sacrifice; whereas, in chronic treatment, the mice were treated with the drug for 3 days. Treatment with <b>37d</b> or <b>9a</b> (50 mg/kg) under all conditions led to significant (<i>p</i> < 0.01 control vs treated groups) loss of ERα, as quantified by the western blot of tissue homogenates (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). After single dose administration, degradation of ERα in ovaries was significantly greater with <b>37d</b> versus acrylate SERD <b>9a</b>. After multiple doses, degradation of ERα in the uterus was significantly greater with <b>37d</b> versus acrylate SERD <b>9a</b>.</div><div class="NLM_p">The juvenile rat model is widely used for assessment of uterotrophic activity of ER ligands because the young female rat is highly sensitive to ER ligands, but without a background of high levels of circulating endogenous estrogens. Ethinylestradiol (EE2) was administered as a positive control, yielding a significant increase in uterine weight (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D). There was no significant uterotrophic effect of the SERM/SERD, <b>7</b>, nor the SERDs, <b>2</b> and <b>37d</b>, versus the vehicle control.</div><div class="NLM_p">Full PK analysis for <b>37d</b> was conducted in CD-1 mice to determine rigorous oral bioavailability parameters, demonstrating absolute bioavailability of 22%, a half-life of 4.5 h, and a brain/plasma ratio for <i>C</i><sub>max</sub> and AUC<sub>last</sub> of 1.54 and 1.26, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_001.pdf" class="ext-link">Figure S3</a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetics of <b>37d</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>last</sub> (h ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>Inf</sub> (h ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>%Extrap</sub>obs (%)</th><th class="colsep0 rowsep0" align="center" char=".">MRT<sub>Inf</sub>obs (h)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>last</sub>/<i>D</i> (ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Plasma</td><td class="colsep0 rowsep0" align="left">50 p.o.</td><td class="colsep0 rowsep0" align="char" char=".">4.48</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char=".">413</td><td class="colsep0 rowsep0" align="char" char=".">1678</td><td class="colsep0 rowsep0" align="char" char=".">2292</td><td class="colsep0 rowsep0" align="char" char=".">26.8</td><td class="colsep0 rowsep0" align="char" char=".">6.05</td><td class="colsep0 rowsep0" align="char" char=".">33.6</td><td class="colsep0 rowsep0" align="left">21.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Brain</td><td class="colsep0 rowsep0" align="left">50 p.o.</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char=".">635</td><td class="colsep0 rowsep0" align="char" char=".">2106</td><td class="colsep0 rowsep0" align="char" char=".">3450</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Plasma</td><td class="colsep0 rowsep0" align="left">5 i.v.</td><td class="colsep0 rowsep0" align="char" char=".">1.68</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1592<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">766</td><td class="colsep0 rowsep0" align="char" char=".">778</td><td class="colsep0 rowsep0" align="char" char=".">1.52</td><td class="colsep0 rowsep0" align="char" char=".">1.07</td><td class="colsep0 rowsep0" align="char" char=".">153</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">PK parameters from measurements at 0.25, 0.5, 1, 2, 4, 8 and 24 h (<i>N</i> = 5).</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last"><i>C</i><sub>0</sub>.</p></div></div></div><div class="NLM_p last">Efficacy in MCF7:TAM1 spheroids is predictive of efficacy in xenografts and therefore <b>37d</b> was tested in breast cancer tumors that had been established by injecting MCF7:TAM1 cells into the mammary fat pads of nude mice. Tumors in mice treated with the vehicle or <b>1a</b> continued to grow over the treatment period, whereas in mice treated with <b>2</b> (s.c.) or <b>37d</b> (p.o.) tumor regression was observed (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). The observations with <b>1a</b> reinforced that these breast cancer tumors are TAM resistant. Analysis of individual tumors is shown for SERD treatment compared to the no treatment (NT) group, to show statistical significance in tumor regression (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B).</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85101" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85101" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The search for an orally, brain bioavailable B-SERD, started with our unique benzothiophene scaffold developed for the acrylate SERD (<b>9b</b>), currently in clinical trials. Modification of this scaffold on the benzoyl ring, and with a basic side chain yielded a number of interesting ERα ligands. The piperidine derivative, <b>30o</b>, demonstrated SERM-like characteristics; whereas most derivatives that substituted the piperidine side arm with a pyrrolidine, azetidine, or reverse azetidine, demonstrated SERD activity. The azetidine <b>30a</b>, a direct analogue of <b>30o</b>, inhibited growth of a TAM-resistant cell line and lowered ERα levels; however, the observed reduced efficacy indicates a mixed SERM/SERD activity. Several other derivatives, such as <b>30g</b>, and the cyclopropyl azetidine <b>37f</b>, showed activity profiles worthy of further study; however, our objective was to select a SERD with comparable potency and efficacy to the clinical SERD <b>2</b>, but with oral and brain bioavailability. The compound selected, <b>37d</b>, bears a novel reverse azetidine side arm.</div><div class="NLM_p">The success of <b>2</b> in treating advanced, metastatic ER+ breast cancer provides the rationale for oral SERD development; therefore, efficacy in endocrine-resistant breast cancer cells is crucial. In parent cell lines, pyrrolidine, azetidine, and reverse azetidine derivatives with potent and high efficacy SERD activity demonstrated high potency and high efficacy inhibition of cell growth. However, almost all compounds demonstrated reduced efficacy in growth inhibition of the endocrine-resistant cell line, including <b>2</b>. In this cell line, derivatives containing fluoromethyl pyrrolidine, fluoromethyl azetidine, or <i>N-</i>fluoropropyl azetidine, bearing benzoyl rings substituted o- or p- with fluoro or methyl groups, demonstrated a higher potency (pIC<sub>50</sub> = 9.3 ± 0.4) and identical efficacy to <b>2</b> (<i>E</i><sub>max</sub> = 48 ± 9%). With no clear bias for benzoyl substitution, analogues with the 2,5-dimethyl-4-fluoro substitution, contained in clinical candidate <b>9b</b>, were selected for progression. Of these, <b>37d</b> demonstrated markedly superior oral bioavailability and excellent brain bioavailability.</div><div class="NLM_p">Compound <b>37d</b>, fulfilled the requirements for a brain bioavailable B-SERD with efficacy in multiple ER+ breast cancer cell lines, including two endocrine-resistant cell lines, and two <i>ESR1</i> mutant cell lines, in 2D and 3D cultures. This B-SERD showed equivalent potency and efficacy to the clinical SERD <b>2</b> both in vitro and in vivo (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>–<named-content content-type="anchor" rid="fig4" type="simple"></named-content><named-content content-type="anchor" rid="fig5" type="simple"></named-content><a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>), but importantly was both orally bioavailable and brain penetrant, in contrast to <b>2</b><i>.</i> As measured by western blotting for ERα, co-administration of a proteasome inhibitor blocked the actions of both <b>2</b> and <b>37d</b>, demonstrating that <b>37d</b> is indeed a SERD, inducing proteasomal degradation of ERα. An almost complete degradation of ERα in gynecological tissues was observed on oral administration of <b>37d</b> to female mice and <b>37d</b> was devoid of uterotrophic effects.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. B-SERD vs SERD comparisons. (A). ERα degradation after 24 h treatment of MCF7:WS8 cells with 10 nM <b>37d</b> or <b>2</b> measured by western blot and inhibited by proteasomal inhibitor MG-132 (1 μM) normalized to vehicle (1.0). (B) ERα western blots after 24 h treatment of MCF7:WS8 cells with 100 nM <b>2</b>, <b>37d</b>, <b>5</b>, and <b>9a</b> measured by the western blot. (C) ERα degradation after oral dosing of female mice with vehicle, <b>37d</b> or <b>9a</b>, measued by western blot analysis of tissues, with representative immunoblots shown from individual mouse uterus. (D) Uterine weight from juvenile female rats dosed with <b>2</b>, <b>7</b>, and <b>37d</b>, compared to EE2 as a positive control. Cell culture data shown as mean ± SEM from three biological and analytical replicates. Statistical analysis by one-way ANOVA with multiple comparisons (<i>p</i>* < 0.01; *** > 0.001; **** < 0.0001).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect on tumor growth. (A) Tumor growth or regression of MCF7:TAM1 CDX grown to 0.3 cm<sup>2</sup> before initiating daily treatment with TAM (<b>1a</b>), <b>37d</b> (100 mg/kg oral gavage) or <b>2</b> (5 mg s.c.). (B) Individual tumor % area change after 4 weeks treatment: ****<i>p</i> < 0.0001 vs NT group, by one-way ANOVA with Dunnett’s test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Summary of B-SERD in vitro activity. 2D growth inhibition in MCF7:WS8 (A) and MCF7:5C (B) cells as a result of treatment with <b>37d</b> (green) or <b>2</b> (orange). Data normalized to vehicle, dimethyl sulfoxide (DMSO) (1.0) and no cells (0.0) shown as mean ± SEM, from three biological and analytical replicates. (C) ER level following treatment for 24 h with <b>37d</b> or <b>2</b> evaluated by ICW. Data corrected to vehicle (1) and 1 μM <b>2</b> shown as mean ± SEM, from three biological and analytical replicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">During completion of this work, a paper was published reporting the substitution of the piperidine ring of the SERM acolbifene (EM-652) with a pyrrolidine ring (<b>38</b>),<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> which can be seen as a similar substitution to that of the piperidine ring in <b>30o</b> with pyrrolidine in <b>30l–n</b>. Interestingly, <i>R</i>-<b>38</b> demonstrated SERD-like properties, whereas <i>S</i>-<b>38</b> did not lower ERα and showed SERM-like properties, which was explained by stereospecific interactions in <b>38</b>/ERα co-crystal structures causing H12 destabilization only for the <i>R</i>-isomer. In our benzothiophene series, reported herein, <b>30o</b> showed SERM-like properties; however both 3-fluoromethyl-pyrrolidine isomers (<b>30m,n</b>) showed SERM/SERD or SERD-like properties. The <i>R-</i><b>38</b>/ERα structure (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UFX">5UFX</a>) was used to model the potential interactions of <b>30f</b> and <b>37d</b> with ERα: the H-bond between Asp-351 and the azetidine N forces the fluoropropyl arm to interact with and destabilize H12 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. B-SERD docking to ER. B-SERDs <b>30f</b> and <b>37d</b> have a common basic side-arm motif: 3-fluoro-<i>N</i>-(2-oxyethyl)propan-1-amine. The structure design envisaged the occupation of the hydrophobic pockets formed by leucines 384, 428, 525, and isoleucine 424 by the substituted benzoyl ring, allowing a salt bridge interaction between the amine side arm amine and Asp-351 in the ERα ligand binding site. B-SERD <b>37d</b> (green) was docked to the ligand binding domain of ERα obtained from the co-crystal structure with the SERD <i>R</i>-<b>38</b> (magenta) (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UFX">5UFX</a>) confirming the proposed binding site interactions leading to destabilization of H12.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In various assays, we compared the B-SERD, <b>37d</b>, with the analogous acrylate SERD <b>9a</b>; SERD <b>2</b>; the SERM/SERDs <b>5</b> and <b>7</b>; and the fluoromethyl azetidine SERD <b>3b</b>. The search for an oral SERD was driven initially by <b>8b</b>, a derivative of the SERM, TAM, which appends an acrylate side arm in place of the SERM amine side arm. This led to the acrylate SERD <b>3a</b> that includes a modification of the TAM scaffold. Similarly, the amine side arm of the SERM acolbifene, was replaced with a methyl pyrrolidine in <i>R-</i><b>38</b>; whereas SERD <b>3b</b> contains a modification of the acolbifene scaffold and a fluoromethyl azetidine side arm. Recent reports on <i>R</i>-<b>38</b> and <b>3b</b> posit that ER degradation is subservient to the silencing of the ER transcriptional complex in growth inhibition of breast cancer cells and xenografts by SERDs.<a onclick="showRef(event, 'ref45 ref51'); return false;" href="javascript:void(0);" class="ref ref45 ref51">(45,51)</a> In particular, in a detailed ChIP-seq, ATAC-seq, and RNA-seq analysis, the acrylate SERD <b>3a</b> was shown to be inferior to <b>3b</b> in this respect. Similar sequencing assays to compare the B-SERD <b>37d</b> with the directly analogous acrylate SERD <b>9b</b> could provide further mechanistic insight and direction for drug development.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76638" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76638" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">B-SERDs were identified with very high potency and efficacy in models of treatment-resistant breast cancer, building out from the unique benzothiophene scaffold optimized in our previous pursuit of acrylate SERDs.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The novel <i>N-</i>fluoropropyl 3-oxyazetidine side-armed B-SERD, <b>37d</b>, was selected as a development candidate, based on the combination of sub-nanomolar potency and superior PK characteristics. The preclinical data support the development of B-SERDs for treatment of patients with metastatic ER+ breast cancer, including those with brain metastases.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15617" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15617" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec8_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Cell Lines and Culture Conditions</h3><div class="NLM_p last">The parental, endocrine-sensitive cell line, MCF7:WS8, was derived from a single-cell clone by the Jordan group. This cell line was maintained in phenol red-containing RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 1% antibiotic–antimycotic, 1% glutamax, and 10 ng/mL insulin at 37 °C and 5% CO<sub>2</sub>. The MCF7:5C cell line was also derived from a single cell clone by the Jordan group.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> These cells were maintained in phenol red-free RPMI-1640 medium supplemented with 10% charcoal:dextran stripped FBS, 1% antibiotic–antimycotic, and 1% glutamax at 37 °C and 5% CO<sub>2</sub>. The MCF7:TAM1 cell line was generated through long-term exposure to increasing concentrations of <b>1b</b> until resistance was established (>25 passages).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> MCF7:TAM1 cells are maintained in <b>1b</b> (1 μM) and phenol red-free, stripped RPMI-1640. The T47D:TYS, T47D:TDG, and parent WT T-47D cell lines were a kind gift from David Shapiro (UIUC) and were cultured and maintained as previously described.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div></div><div id="sec8_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> DNA Content Assay</h3><div class="NLM_p last">MCF7:WS8 cells were stripped of estrogens for 2 days prior to plating each experiment by changing media to phenol red-free RPMI-1640 and stripped FBS. Cells were seeded in a 96-well, clear, flat bottom microplate at a density of 5000 cells/well and treated with either 0.01% (v/v) DMSO, 1 nM E<sub>2</sub>, or the compound of interest. All compounds stored were dissolved in DMSO and diluted to the specific treatment concentration through serial dilution. On day 5 (MCF7:WS8) or day 7 (MCF7:5C), the media was removed and cells were lysed through hydrolysis at −80 °C overnight. DNA content was determined by Hoechst 33258 dye in TNE buffer (1 mg/mL Hoechst in TE buffer + 2 M NaCl). The fluorescence signal was measured using a Synergy Neo (BioTek).</div></div><div id="sec8_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> ER ICW Assay</h3><div class="NLM_p last">MCF7:WS8 cells were stripped using phenol red-free media and stripped FBS for 2 days prior to plating at 2.5 × 10<sup>4</sup> cells/well in black, clear bottom 96-well microplate. Cells were incubated for 48 h prior to treatment for 24 h. Fixation, detection of ERα (H10, Santa Cruz Biotechnologies), and imaging were performed per LI-COR manufacturer’s protocol using the In-Cell Western Assay Kits and LI-COR Odyssey SA imaging system. The IRDye 800CW (anti-rabbit) signal was normalized to CellTag 700 stain.</div></div><div id="sec8_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> ER Western Assay</h3><div class="NLM_p last">Cells were stripped of estrogens for 3 days prior to plating. Cells were grown to 80% confluency in a 6-well plate and treated with vehicle or MG-132 (1 μM) for 30 min followed by 2 h of SERD treatment (10 nM). For comparison of SERDs and B-SERDs, similar experiments were performed without prior treatment with MG-132. ER protein content was quantified by the western blot where ERα (antibody Cell Signaling 8644) was normalized to actin or GAPDH. Blots were quantified using the LI-COR Odyssey SA imaging system.</div></div><div id="sec8_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Spheroid Growth Assay</h3><div class="NLM_p last">The cells were plated at a density of 1000–1500 cells/well in Corning 96-well black, clear round bottom, ultra-low attachment spheroid microplates and grown in the absence of treatment for 1–3 days. Spheroids were then treated with 2× treatment media following the removal of half of the media (100 μL) from each well. Treatment at a 1× concentration was repeated every 2–3 days for 14 days. The CellTiter-Glo 3D Cell Viability Assay protocol was used to determine growth inhibition of the spheroids, as per manufacturer’s instructions. A luminescence signal was read using a Synergy Neo (BioTek). Data were normalized to blank (media with CellTiter Glo 3D reagent).</div></div><div id="sec8_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Binding Affinity Studies</h3><div class="NLM_p last">Binding affinities were determined by a competitive radiometric binding assay using 2 nM [<sup>3</sup>H]estradiol as a tracer (PerkinElmer, Waltham, MA) and full-length purified human ERα (Pan Vera/Invitrogen, Carlsbad, CA), as reported previously.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> The RBA values were calculated using the following equation: IC<sub>50</sub> estradiol/IC<sub>50</sub> compound × 100.</div></div><div id="sec8_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Estrogenicity Assay</h3><div class="NLM_p last">MCF7:WS8 cells were grown in phenol red-free RPMI-1640 and stripped FBS for 3 days prior to plating. Cells were then plated at a density of 1 × 10<sup>5</sup> cells/well in clear, flat bottom, 48-well plates and incubated for 24 h. The cells were co-transfected with 5 μg of the pERE-luciferase plasmid per plate, which contains three copies of the <i>Xenopus laevis</i> vitellogenin A2 ERE upstream of firefly luciferase and 0.5 μg of the pRL-TK plasmid (Promega, Madison, WI) containing a cDNA encoding Renilla luciferase. Transfection was performed for 6 h using a 2 μL/well Lipofectamine 2000 transfection reagent (Invitrogen) in Opti-MEM media. Cells were then treated with test compounds. Luciferase activity was measured after 18 h of treatment using the Dual Luciferase assay system (Promega) with Synergy Neo (BioTek).</div></div><div id="sec8_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Animal Experiments</h3><div class="NLM_p last">The Animal Care and Use Committee of the University of Illinois at Chicago approved all animal procedures. Animal care adhered to the National Institutes of Health Guide for the Care and Use of Laboratory Animals.</div></div><div id="sec8_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Juvenile Rat Study</h3><div class="NLM_p last">Female Sprague Dawley rats (12 days old) were purchased from Envigo, USA. Sucklings were housed with foster nursing dams (6 per dam). After one week of acclimation period, at age 19 days, treatment was initiated by administering: <b>37d</b> or <b>7</b> (Sigma, USA) (p.o. 10 mg/kg suspended in 2% Tween 80, 0.5% methylcellulose); EE2 (Sigma, USA) (p.o. 0.1 mg/kg in peanut oil); <b>2</b> (s.c. 2 mg/kg in peanut oil). Twenty-four h after the last of 3 daily doses, animals were euthanized with CO<sub>2</sub> followed by exsanguination from the abdominal aorta. Uteri, including uterine horn were carefully excised and weighed after removing fat and mesentery. Uteri were cut in the sagittal plane into two equal halves: one half was fixed in phosphate-buffered saline (pH 7.4) buffered 4% paraformaldehyde for 24 h, rinsed with water, washed twice with 70% ethanol, paraffin embedded, and processed for hematoxylin eosin staining and imaging.</div></div><div id="sec8_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Mouse Gynecological Tissue Immunoassay</h3><div class="NLM_p last">Female C57BL/6J mice (8 W) were purchased from the Jackson Laboratory (Bar Harbor, ME) and treated at 9–12 W. The mice were housed in groups of 3–5 with food and water available ad libitum. Dosing: <b>9a</b> (p.o. 50 mg/kg in polyethylene glycol 400 (PEG 400), 0.5% carboxymethyl cellulose, polyvinylpyrrolidone, and Tween-80; 9:90:0.5:0.5 v/v); <b>37d</b> (p.o. 50 mg/kg in PEG 400, 10% (2-hydroxypropyl)-β-cyclodextrin (HPCD); 1:9 v/v); the vehicle control group received the PEG/HPCD vehicle. In the acute experiment, mice (<i>n</i> = 5) were given a single administration of drug and euthanized 5 h later. In the chronic experiments, the mice were administered the drug once daily for 3 days and euthanized 5 h (<i>n</i> = 5) or 7 h (<i>n</i> = 6) after the last drug administration. The mice were euthanized by CO<sub>2</sub> inhalation followed by decapitation. Ovaries and uterus were immediately removed and frozen on dry ice and stored at −80 °C until being processed for western blots. Tissue samples were homogenized in 200 μL of lysis buffer (Cell Signaling Technology, Danvers, MA; 20 mM Tris-HCl, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1 mM ethylene glycol tetraacetic acid, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 μg/mL leupeptin, and 1 μg/mL aprotinin) containing the complete protease inhibitor cocktail (Roche, Indianapolis, IN) and clarified by centrifugation for 15 min at 10 000 rpm at 4 °C. Protein concentrations were determined using the BCA Protein Assay Kit (Thermo Fisher Scientific). Equal amounts of protein (20 μg) were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis on Novex 10% Tris-glycine gels (Thermo Fisher Scientific) and transferred to polyvinylidene fluoride membranes. Membranes were blocked with 5% bovine serum albumin in TBST (25 mM Tris-HCl, 137 mM NaCl and 0.1% Tween-20) and then incubated with primary antibodies overnight at 4 °C (anti-ERα, 1:1000, Millipore Sigma, #06–935; anti-β-actin, 1:10 000; Millipore Sigma, #A5441). Membranes were incubated with IRDye donkey antirabbit and donkey antimouse secondary antibodies (LI-COR Biosciences, Lincoln, NE, #925-32213 and #925-68072) at room temperature. Blots were imaged using the Odyssey Fc Imaging System (LI-COR Biosciences). Band intensities were determined using with LI-COR Image Studio software and ERα normalized to β-actin.</div></div><div id="sec8_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Mouse Xenograft Experiments</h3><div class="NLM_p last">MCF7:TAM1 tumors were established in the 4–6 week old ovariectomized athymic female nude mice (Harlan Laboratories) and E<sub>2</sub> was administered via silastic capsules (1.0 cm) implanted subcutaneously between the scapulae as previously described.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> SERD <b>37d</b> and SERM <b>1a</b> were administered (p.o. 100 mg/kg/day) in 10% HPCD/PEG-400 (9:1 v/v) solution, whereas <b>2</b> was administered (s.c. 5 mg/week) in sesame oil. The tumor cross-sectional area was determined weekly using Vernier calipers and calculated using the formula (length/2) × (width/2) × π as described previously.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> The mean tumor area was plotted against time (in weeks) to monitor tumor growth.</div></div><div id="sec8_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Pharmacokinetic Experiments</h3><div class="NLM_p last">PK screening was conducted in female 3M C57BL/6 mice at two time points (<i>N</i> = 3), collecting plasma and brain tissues from perfused mice postmortem, after gavage administration of <b>30f</b>, <b>30m</b>, or <b>37d</b> in HPβCD/PEG-400, or s.c. administration of <b>2</b>. Standard curves were established in the corresponding biological matrix using a common internal standard and optimization of analyte measurement by LC–MS/MS in the MRM mode. Further PK measurements were performed by Pharmaron Inc. at 10 time points, administering <b>37d</b> in solution (p.o. 50 mg/kg in water and 10% SBE-β-CD/PEG-400 9:1 v/v). Working solutions were made by serial dilution of analyte in 50% acetonitrile in water. Plasma samples were diluted in 50% acetonitrile to achieve a range of dilutions for analysis and quantitation by LC–MS/MS.</div></div><div id="sec8_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Synthetic Procedures</h3><div class="NLM_p">All chemicals and solvents were purchased from Sigma-Aldrich, Fisher Scientific, Matrix Scientific, or Oakwood Chemical and were used without further purification. Synthetic intermediates were purified using a Biotage flash chromatography system on 230–400 mesh silica gel. <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained using a Bruker DPX-400 or AVANCE-400 spectrometer at 400 and 100 MHz, respectively. NMR chemical shifts are described in δ (ppm) using residual solvent peaks as the standard (CDCl<sub>3</sub>, 7.26 ppm (<sup>1</sup>H), 77.16 ppm (<sup>13</sup>C); CD<sub>3</sub>OD, 3.31 ppm (<sup>1</sup>H), 49.00 ppm (<sup>13</sup>C); DMSO-<i>d</i><sub>6</sub>, 2.50 ppm (<sup>1</sup>H), 39.52 ppm (<sup>13</sup>C); acetone-<i>d</i><sub>6</sub>, 2.05 ppm (<sup>1</sup>H), 29.84 ppm, and 206.26 ppm (<sup>13</sup>C)). Data are reported in the following format: chemical shift, multiplicity (s = singlet, d = doublet, dd = doublet of doublet, t = triplet, q = quartet, br = broad, and m = multiplet), coupling constants, and number of protons. High-resolution mass spectral data were measured using a Shimadzu IT-TOF LC/MS for all final compounds. All compounds submitted for biological testing were confirmed to be ≥96% pure by analytical high-performance liquid chromatography (HPLC), supported by <sup>1</sup>H analysis, unless otherwise stated. The purity of final compounds were determined by HPLC using an Agilent Eclipse XDB-C18 column (4.6 × 250 mm, 5 μm) with UV absorbance detection at 254 nm, eluting with a linear gradient from 10% aqueous MeCN to 90% MeCN over 18 min, holding at 90% MeCN for a further 5 min. For the synthesis of Grignard reagents, the following procedure was used: to a dried round-bottomed flask were added aryl bromide (1 equiv) in anhydrous tetrahydrofuran (THF) and magnesium turnings (1.1 equiv) under an argon atmosphere. One granule of iodine was added to initiate the reaction along with a hot fan. The solution turned pale white and then a brownish color along with strong heat release. The Grignard reagent was ready for use without further purification when magnesium was consumed. For full experimental details of all compounds, see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_001.pdf" class="ext-link">Supporting Information</a>. Representative synthetic methods, spectral data, and HRMS for novel compounds are described in detail below. Full spectra and chromatograms are supplied in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_001.pdf" class="ext-link">Supporting Information</a>.</div><div id="sec8_13_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3-Chloro-6-methoxybenzo[<i>b</i>]thiophene-2-carbonyl Chloride (<b>10</b>)</h4><div class="NLM_p last">To a solution of chlorobenzene was added (10 g, 56.18 mmol) (<i>E</i>)-3-(4-methoxyphenyl)acrylic acid, (40 mL, 561.8 mmol) SOCl<sub>2</sub>, (0.45 mL, 5.618 mmol) pyridine, and molecular sieves. The reaction was heated at reflux for 3 days. Excess thionyl chloride was removed under reduced pressure and the remaining material was suspended in hot hexane and then filtered. The filtrate collected and evaporated under reduced pressure to give compound <b>10</b> as a pale solid (yield: 7 g, 40%).</div></div><div id="sec8_13_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3-Chloro-<i>N</i>,6-dimethoxy-<i>N</i>-methylbenzo[<i>b</i>]thiophene-2-carboxamide (<b>11</b>)</h4><div class="NLM_p last">To an oven-dried round-bottom flask was dissolved compound <b>10</b> (2 g, 7.7 mmol) in (15 mL) of anhydrous dichloromethane under an argon atmosphere. <i>N</i>,<i>O</i>-Dimethylhydroxylamine hydrochloride (0.83 g, 8.5 mmol) was added in one portion followed by Et<sub>3</sub>N (5.4 mL, 38.8 mmol) dropwise to the mixture. The reaction was stirred at room temperature and monitored by thin layer chromatography (TLC). Upon completion, the reaction was quenched by water and extracted with ethyl acetate, washed by water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (10–30% ethyl acetate in hexanes) to give a light yellow solid (yield: 1.7 g, 76%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.80 (d, <i>J</i> = 8.9 Hz, 1H), 7.22 (d, <i>J</i> = 2.2 Hz, 1H), 7.08 (dd, <i>J</i> = 8.9, 2.3 Hz, 1H), 3.88 (s, 3H), 3.72 (s, 3H), 3.38 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 161.45, 159.31, 139.78, 129.61, 124.47, 123.58, 122.66, 115.53, 103.71, 61.47, 55.29, 33.16.</div></div><div id="sec8_13_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3-Chloro-6-methoxybenzo[<i>b</i>]thiophene-2-carbaldehyde (<b>12</b>)</h4><div class="NLM_p last">To a solution of anhydrous THF (10 mL) was dissolved compound <b>11</b> (1 g, 3.9 mmol). The reaction mixture was stirred at −78 °C for 0.5 h. Diisobutylaluminium hydride (3.85 mL, 4.29 mmol) was added dropwise slowly to the reaction mixture and then stirred at room temperature until the starting material was consumed completely. Upon completion, the reaction was quenched by potassium sodium tartrate solution at 0 °C and stirred at room temperature until most of the amorphous precipitation was dissolved. The reaction was extracted by ethyl acetate, washed by water and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (10–30% ethyl acetate in hexanes) to give a white solid (yield: 0.5 g, 64%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.27 (s, 1H), 7.90 (d, <i>J</i> = 9.0 Hz, 1H), 7.47 (d, <i>J</i> = 2.2 Hz, 1H), 7.15 (dd, <i>J</i> = 9.0, 2.2 Hz, 1H), 3.95 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 182.88, 161.39, 141.85, 132.85, 131.05, 130.45, 124.79, 117.07, 104.83, 55.83.</div></div><div id="sec8_13_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (3-Chloro-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(<i>o</i>-tolyl)methanol (<b>13a</b>)</h4><div class="NLM_p last">To a solution of THF (8 mL) was added compound <b>12</b> (0.5 g, 2.2 mmol) and stirred at 0 °C for 0.5 h. <i>o</i>-Tolylmagnesium bromide solution (1.3 mL, 2.6 mmol, 2 M in diethyl ether) was dropwise to the reaction mixture slowly at 0 °C. The reaction was then stirred at room temperature for 2 h and monitored by TLC. Upon completion, the reaction was quenched by water and extracted by ethyl acetate, washed by water and brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (10–40% ethyl acetate in hexanes) to give a white solid (yield: 0.5 g, 71%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.71–7.69 (m, 2H), 7.46 (d, <i>J</i> = 2.3 Hz, 1H), 7.29–7.19 (m, 2H), 7.17 (d, <i>J</i> = 7.1 Hz, 1H), 7.11 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 6.46 (d, <i>J</i> = 4.0 Hz, 1H), 5.31 (d, <i>J</i> = 4.0 Hz, 1H), 3.88 (s, 3H), 2.32 (s, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 158.51, 141.11, 139.77, 138.78, 135.17, 130.24, 130.17, 127.57, 125.90, 125.82, 122.02, 116.23, 115.03, 105.38, 66.31, 55.15, 18.37.</div></div><div id="sec8_13_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (3-Chloro-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(phenyl)methanol (<b>13c</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>13a</b> (yield: 0.52 g, 85%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.63 (d, <i>J</i> = 8.8 Hz, 1H), 7.59–7.52 (m, 2H), 7.47 (d, <i>J</i> = 2.3 Hz, 1H), 7.12 (t, <i>J</i> = 7.8 Hz, 2H), 7.09 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 6.33 (d, <i>J</i> = 3.0 Hz, 1H), 5.63 (d, <i>J</i> = 3.5 Hz, 1H), 3.87 (s, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 162.14 (d, <i>J</i> = 243.9 Hz), 158.49, 140.63, 139.27, 139.24, 138.55, 130.26, 128.23 (d, <i>J</i> = 8.2 Hz), 121.93, 115.04, 114.93 (d, <i>J</i> = 21.8 Hz), 105.46, 69.02, 55.17.</div></div><div id="sec8_13_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (2,4-Dimethylphenyl)(6-methoxybenzo[<i>b</i>]thiophen-2-yl)methanol (<b>13e</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>13a</b> (yield: 0.55 g, 85%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.66 (d, <i>J</i> = 8.8 Hz, 1H), 7.56 (d, <i>J</i> = 7.9 Hz, 1H), 7.45 (d, <i>J</i> = 2.2 Hz, 1H), 7.10 (dd, <i>J</i> = 8.9, 2.3 Hz, 1H), 7.07 (d, <i>J</i> = 7.9 Hz, 1H), 6.99 (s, 1H), 6.42 (d, <i>J</i> = 4.0 Hz, 1H), 5.24 (d, <i>J</i> = 4.0 Hz, 1H), 3.87 (s, 3H), 2.29 (s, 6H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 158.46, 140.15, 138.74, 138.20, 136.99, 135.01, 130.91, 130.31, 126.50, 125.91, 121.98, 115.99, 114.98, 105.39, 66.29, 55.15, 20.17, 18.35.</div></div><div id="sec8_13_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (3-Chloro-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(phenyl)methanone (<b>14a</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>13a</b> (yield: 0.5 g, 55%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.95–7.85 (m, 3H), 7.71–7.69 (m, 1H), 7.64 (d, <i>J</i> = 2.1 Hz, 1H), 7.60 (t, <i>J</i> = 7.7 Hz, 2H), 7.24 (dd, <i>J</i> = 9.0, 2.3 Hz, 1H), 3.97 (s, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.19, 160.71, 140.85, 138.19, 133.01, 131.79, 130.60, 129.26, 128.53, 124.35, 123.75, 116.92, 104.78, 55.42.</div></div><div id="sec8_13_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (3-Chloro-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(<i>o</i>-tolyl)methanone (<b>14b</b>)</h4><div class="NLM_p last">To a solution of dichloromethane (5 mL) was added compound <b>13b</b> (0.3 g, 0.94 mmol), pyridinium chlorochromate (PCC; 0.24 g, 1.1 mmol) and stirred at room temperature for 3 h. The reaction was monitored by TLC. Upon completion, the reaction mixture was extracted by dichloromethane and washed by water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (10–20% ethyl acetate in hexanes) to give a yellow solid (yield: 0.14 g, 70%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.83 (d, <i>J</i> = 9.0 Hz, 1H), 7.47–7.39 (m, 2H), 7.33–7.29 (m, 2H), 7.27 (d, <i>J</i> = 2.2 Hz, 1H), 7.12 (dd, <i>J</i> = 9.0, 2.3 Hz, 1H), 3.94 (s, 3H), 2.42 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 190.94, 160.77, 141.69, 139.28, 136.09, 133.74, 131.47, 130.90, 130.60, 127.80, 126.33, 125.64, 125.20, 116.74, 104.32, 55.79, 19.58.</div></div><div id="sec8_13_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (3-Chloro-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(4-fluorophenyl)methanone (<b>14c</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>14b</b> (yield: 0.35 g, 60%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.02–7.94 (m, 2H), 7.85 (d, <i>J</i> = 9.0 Hz, 1H), 7.61 (d, <i>J</i> = 2.1 Hz, 1H), 7.35 (t, <i>J</i> = 8.8 Hz, 2H), 7.22 (dd, <i>J</i> = 9.0, 2.2 Hz, 1H), 3.96 (s, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 186.79, 165.62 (d, <i>J</i> = 252.5 Hz), 160.72, 140.84, 134.57 (d, <i>J</i> = 2.5 Hz), 132.28 (d, <i>J</i> = 9.4 Hz), 131.61, 130.54, 124.35, 123.75, 116.92, 115.56 (d, <i>J</i> = 22.3 Hz), 104.76, 55.43.</div></div><div id="sec8_13_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (3-Chloro-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(3-fluorophenyl)methanone (<b>14d</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>14b</b> (yield: 0.42 g, 62%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.89 (d, <i>J</i> = 9.0 Hz, 1H), 7.78–7.69 (m, 1H), 7.69–7.60 (m, 3H), 7.55–7.46 (m, 1H), 7.24 (dd, <i>J</i> = 9.0, 2.3 Hz, 1H), 3.97 (s, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 186.93, 162.53 (d, <i>J</i> = 246.2 Hz), 160.92, 141.11, 140.45 (d, <i>J</i> = 6.5 Hz), 131.37, 130.69, 130.68 (d, <i>J</i> = 8.3 Hz), 125.28 (d, <i>J</i> = 2.5 Hz), 124.52, 119.64 (d, <i>J</i> = 21.6 Hz), 117.06, 115.59 (d, <i>J</i> = 23.1 Hz), 104.76, 55.45.</div></div><div id="sec8_13_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (2,4-Dimethylphenyl)(6-methoxybenzo[<i>b</i>]thiophen-2-yl)methanone (<b>14e</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>14b</b> (yield: 0.38 g, 65%). <sup>1</sup>H NMR (400 MHz, acetone<i>-d</i><sub>6</sub>): δ 7.83 (d, <i>J</i> = 9.0 Hz, 1H), 7.58 (d, <i>J</i> = 2.2 Hz, 1H), 7.38 (d, <i>J</i> = 7.7 Hz, 1H), 7.23–7.10 (m, 3H), 3.95 (s, 3H), 2.39 (s, 3H), 2.34 (s, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 189.83, 160.95, 141.32, 141.10, 136.49, 136.17, 133.87, 131.64, 130.96, 128.41, 126.28, 125.03, 124.63, 116.91, 104.78, 55.43, 20.55, 18.80.</div></div><div id="sec8_13_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (3-Chloro-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(4-fluoro-2-methylphenyl)methanone (<b>14f</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>13a</b> (yield: 0.5 g, 60%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.84–7.77 (m, 1H), 7.43 (dd, <i>J</i> = 8.4, 5.8 Hz, 1H), 7.25 (d, <i>J</i> = 2.2 Hz, 1H), 7.10 (dd, <i>J</i> = 9.0, 2.3 Hz, 1H), 7.03–6.92 (m, 2H), 3.91 (s, 3H) 2.21 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 189.77, 163.89 (d, <i>J</i> = 250.8 Hz), 160.83, 141.66, 139.85 (d, <i>J</i> = 8.6 Hz), 135.26, 133.62, 131.37, 130.48 (d, <i>J</i> = 9.2 Hz), 126.23, 125.19, 117.87 (d, <i>J</i> = 21.5 Hz), 116.83, 112.70 (d, <i>J</i> = 21.7 Hz), 104.32, 55.80, 19.81.</div></div><div id="sec8_13_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (3-Chloro-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(4-fluoro-2,6-dimethylphenyl)methanone (<b>14g</b>)</h4><div class="NLM_p last">The preparation of Grignard reagent (4-fluoro-2,6-dimethylphenyl)magnesium bromide is as follows, 2-bromo-5-fluoro-1,3-dimethylbenzene (0.57 g, 2.85 mmol) was dissolved in anhydrous THF, magnesium (0.14 g, 5.7 mmol), and iodine (0.07 g, 0.285 mmol) were then added to the reaction mixture, the reaction was stirred at room temperature for 2 h and then ready to use. To a solution of anhydrous THF was added compound <b>10</b> (0.5 g, 1.9 mmol), followed by dropwise addition of (4-fluoro-2,6-dimethylphenyl)magnesium bromide at 0 °C, then the reaction was stirred at room temperature for 5 h, and monitored by TLC. Upon completion, the reaction mixture was quenched by water in an ice bath, extracted by EtOAc and washed by water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were combined, evaporated under reduced pressure, and purified by flash chromatography (10–30% ethyl acetate in hexanes) to give a white solid (yield: 0.4 g, 60%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.79 (d, <i>J</i> = 9.0 Hz, 1H), 7.25 (d, <i>J</i> = 2.0 Hz, 1H), 7.09 (dd, <i>J</i> = 9.0, 2.1 Hz, 1H), 6.80 (d, <i>J</i> = 9.5 Hz, 2H), 3.91 (s, 3H), 2.21 (s, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 191.75, 162.97 (d, <i>J</i> = 247.5 Hz), 161.25, 142.26, 137.08 (d, <i>J</i> = 8.6 Hz), 136.28 (d, <i>J</i> = 3.0 Hz), 134.27, 131.68, 126.98, 125.60, 117.02, 114.67 (d, <i>J</i> = 21.3 Hz), 104.51, 55.92, 19.43, 19.42.</div></div><div id="sec8_13_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (3-Chloro-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(4-methoxyphenyl)methanone (<b>14h</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>13a</b> (yield: 0.35 g, 60%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.95–7.89 (m, 2H), 7.88 (d, <i>J</i> = 8.9 Hz, 1H), 7.65 (d, <i>J</i> = 2.2 Hz, 1H), 7.24 (dd, <i>J</i> = 9.0, 2.3 Hz, 1H), 7.12 (d, <i>J</i> = 8.9 Hz, 2H). 3.97 (s, 3H), 3.95 (s, 3H).</div></div><div id="sec8_13_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (3-Chloro-6-methoxybenzo[<i>b</i>]thiophen-2-yl)(4-methoxyphenyl)methanone (<b>14i</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>13a</b> (yield: 0.4 g, 45%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.83 (d, <i>J</i> = 9.0 Hz, 1H), 7.49 (d, <i>J</i> = 8.5 Hz, 1H), 7.27 (d, <i>J</i> = 2.2 Hz, 1H), 7.12 (dd, <i>J</i> = 9.0, 2.3 Hz, 1H), 6.84 (d, <i>J</i> = 2.2 Hz, 1H), 6.79 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 3.94 (s, 3H), 3.89 (s, 3H). 2.21 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 189.76, 161.76, 160.43, 141.20, 140.08, 134.08, 131.71, 131.31, 131.22, 125.00, 124.91, 116.70, 116.54, 110.60, 104.34, 55.77, 55.33, 20.44.</div></div><div id="sec8_13_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (3-Chloro-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(phenyl)methanone (<b>15a</b>)</h4><div class="NLM_p last">To a solution of dichloromethane (5 mL) was added compound <b>14a</b> (0.2 g, 0.63 mmol) and stirred at −78 °C for 0.5 h. BBr<sub>3</sub> (0.29 mL, 3.1 mmol) was added dropwise slowly to the reaction mixture. The reaction was stirred at room temperature and monitored by TLC. Upon completion, the reaction mixture was quenched by water at 0 °C and extracted by dichloromethane, washed by water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (10–40% ethyl acetate in hexanes) (yield: 0.4 g, 60%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.95–7.79 (m, 3H), 7.71 (t, <i>J</i> = 7.4 Hz, 1H), 7.59 (t, <i>J</i> = 7.6 Hz, 2H), 7.47 (d, <i>J</i> = 1.7 Hz, 1H), 7.20 (dd, <i>J</i> = 8.8, 1.9 Hz, 1H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.22, 158.58, 140.82, 138.30, 132.91, 131.13, 130.01, 129.21, 128.50, 124.72, 123.95, 116.82, 107.43.</div></div><div id="sec8_13_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (3-Chloro-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(<i>o</i>-tolyl)methanone (<b>15b</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>15a</b> (yield: 0.12 g, 68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.80 (d, <i>J</i> = 8.9 Hz, 1H), 7.44 (t, <i>J</i> = 7.5 Hz, 1H), 7.43 (d, <i>J</i> = 7.5 Hz, 1H), 7.32 (d, <i>J</i> = 7.8 Hz, 1H), 7.23 (s, 1H), 7.07 (dd, <i>J</i> = 8.9, 0.9 Hz, 1H), 5.32 (s, 1H), 2.41 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 191.90, 157.45, 141.74, 139.13, 136.03, 133.28, 131.44, 130.98, 130.81, 127.76, 127.21, 125.74, 125.71, 116.62, 107.66, 19.57.</div></div><div id="sec8_13_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (3-Chloro-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(4-fluorophenyl)methanone (<b>15c</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>15a</b> (yield 0.25 g, 57%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 8.01–7.94 (m, 2H), 7.84 (d, <i>J</i> = 8.8 Hz, 1H), 7.46 (d, <i>J</i> = 2.1 Hz, 1H), 7.39–7.31 (m, 2H), 7.20 (dd, <i>J</i> = 8.8, 2.2 Hz, 1H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 186.83, 165.57 (d, <i>J</i> = 252.3 Hz), 158.64, 140.82, 134.69 (d, <i>J</i> = 2.6 Hz), 132.23 (d, <i>J</i> = 9.4 Hz), 130.95, 129.94, 124.73, 123.93, 116.86, 115.53 (d, <i>J</i> = 22.3 Hz), 107.44.</div></div><div id="sec8_13_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (3-Chloro-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(3-fluorophenyl)methanone (<b>15d</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>15a</b> (yield: 0.38 g, 58%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.83 (d, <i>J</i> = 8.9 Hz, 1H), 7.70–7.65 (m, 1H), 7.67–7.56 (m, 2H), 7.52–7.38 (m, 2H), 7.19 (dd, <i>J</i> = 8.8, 2.2 Hz, 1H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 186.90, 162.50 (d, <i>J</i> = 246.2 Hz), 158.79, 141.07, 140.55 (d, <i>J</i> = 6.5 Hz), 131.37, 130.67, 130.63 (d, <i>J</i> = 7.9 Hz), 125.23 (d, <i>J</i> = 2.2 Hz), 124.90, 124.77, 119.52 (d, <i>J</i> = 21.5 Hz), 116.94, 115.55 (d, <i>J</i> = 23.0 Hz), 107.42.</div></div><div id="sec8_13_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (3-Chloro-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(2,4-dimethylphenyl)methanone (<b>15e</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>15a</b> (yield: 0.2 g, 55%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 9.32 (s, 1H), 7.81 (d, <i>J</i> = 8.9 Hz, 1H), 7.43 (d, <i>J</i> = 2.2 Hz, 1H), 7.37 (d, <i>J</i> = 7.7 Hz, 1H), 7.22–7.06 (m, 3H), 2.39 (s, 3H), 2.34 (s, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 189.86, 158.86, 141.29, 140.97, 136.64, 136.04, 133.21, 131.58, 130.37, 128.28, 126.25, 125.03, 124.85, 116.82, 107.46, 20.52, 18.75.</div></div><div id="sec8_13_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (3-Chloro-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(4-fluoro-2-methylphenyl)methanone (<b>15f</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>15a</b> (yield: 0.38 g, 56%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 9.34 (s, 1H), 7.77 (d, <i>J</i> = 8.9 Hz, 1H), 7.52 (dd, <i>J</i> = 8.4, 5.9 Hz, 1H), 7.41 (d, <i>J</i> = 2.0 Hz, 1H), 7.23–6.91 (m, 3H), 2.36 (s, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.95, 163.72 (d, <i>J</i> = 248.7 Hz), 159.07, 141.51, 139.51 (d, <i>J</i> = 8.6 Hz), 135.83, 132.98, 130.46, 130.37, 125.48, 125.18, 117.50 (d, <i>J</i> = 21.7 Hz), 116.95, 112.58 (d, <i>J</i> = 21.8 Hz), 107.50, 18.78.</div></div><div id="sec8_13_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (3-Chloro-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(4-fluoro-2,6-dimethylphenyl)methanone (<b>15g</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>15a</b> (yield: 0.4 g, 55%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 9.40 (s, 1H), 7.83 (d, <i>J</i> = 8.9 Hz, 1H), 7.45 (d, <i>J</i> = 2.1 Hz, 1H), 7.17 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 6.97 (d, <i>J</i> = 9.7 Hz, 2H), 2.22 (s, 6H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 190.54, 162.78 (d, <i>J</i> = 245.6 Hz), 159.41, 141.93, 137.03 (d, <i>J</i> = 8.7 Hz), 136.72 (d, <i>J</i> = 2.7 Hz), 133.47, 130.57, 126.02, 125.54, 117.05, 114.28 (d, <i>J</i> = 21.7 Hz), 107.62, 18.34.</div></div><div id="sec8_13_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (3-Chloro-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(4-hydroxyphenyl)methanone (<b>15h</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>15a</b> (yield: 0.28 g, 55%). <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.84–7.74 (m, 3H), 7.27 (d, <i>J</i> = 2.1 Hz, 1H), 7.08 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.90 (d, <i>J</i> = 8.7 Hz, 2H). <sup>13</sup>C NMR (101 MHz, MeOD): δ 187.90, 162.94, 158.34, 140.46, 132.32, 130.71, 129.62, 129.00, 124.03, 123.01, 116.29, 114.90, 106.76.</div></div><div id="sec8_13_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (3-Chloro-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(4-hydroxy-2-methylphenyl)methanone (<b>15i</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>15a</b> (yield: 0.32 g, 55%). <sup>1</sup>H NMR (400 MHz, MeOD): δ 7.75 (d, <i>J</i> = 8.9 Hz, 1H), 7.35 (d, <i>J</i> = 8.4 Hz, 1H), 7.25 (d, <i>J</i> = 1.8 Hz, 1H), 7.05 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.75 (d, <i>J</i> = 1.4 Hz, 1H), 6.69 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 2.36 (s, 3H). <sup>13</sup>C NMR (101 MHz, MeOD): δ 190.34, 160.43, 158.81, 141.17, 139.87, 132.86, 131.82, 130.01, 129.84, 124.62, 124.49, 117.57, 116.33, 112.06, 106.78, 19.02.</div></div><div id="sec8_13_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (3-Chloro-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(phenyl)methanone (<b>16a</b>)</h4><div class="NLM_p last">To a solution of dichloromethane (5 mL) was added compound <b>15a</b> (0.2 g, 0.66 mmol), 3,4-dihydropyran (0.3 mL, 3.3 mmol), and pyridinium <i>p</i>-toluenesulfonate (0.01 g, 0.07 mmol). The reaction mixture was stirred at room temperature and monitored by TLC. Upon completion, the reaction was extracted by dichloromethane, washed by water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (10–40% ethyl acetate in hexanes) (yield: 0.3 g, 77%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.91 (d, <i>J</i> = 8.4 Hz, 3H), 7.75–7.69 (m, 2H), 7.60 (t, <i>J</i> = 7.7 Hz, 2H), 7.37–7.32 (m, 1H), 5.66 (t, <i>J</i> = 3.1 Hz, 1H), 3.96–3.80 (m, 1H), 3.70–3.60 (m, 1H), 1.78–1.60 (m, 3H), 1.60–1.36 (m, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.23, 157.86, 140.34, 138.12, 133.08, 132.20, 131.18, 129.30, 128.55, 124.29, 123.62, 117.83, 108.45, 96.54, 61.70, 29.99, 25.42, 18.50.</div></div><div id="sec8_13_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (3-Chloro-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(<i>o</i>-tolyl)methanone (<b>16b</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>16a</b> (yield: 0.21 g, 84%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.88 (d, <i>J</i> = 9.0 Hz, 1H), 7.71 (d, <i>J</i> = 2.1 Hz, 1H), 7.50–7.46 (m, 2H), 7.42–7.38 (m, 2H), 7.31 (dd, <i>J</i> = 9.0, 2.2 Hz, 1H), 5.66 (t, <i>J</i> = 3.1 Hz, 1H), 3.88–3.85 (m, 1H), 3.69–3.59 (m, 1H), 2.36 (s, 3H), 2.02–1.81 (m, 3H), 1.79–1.47 (m, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 190.06, 158.28, 141.01, 139.46, 135.69, 134.11, 131.60, 130.84, 130.65, 127.68, 125.77, 125.11, 124.74, 117.88, 108.44, 96.50, 61.71, 29.95, 24.92, 18.65, 18.47.</div></div><div id="sec8_13_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (3-Chloro-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(4-fluorophenyl)methanone (<b>16c</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>16a</b> (yield 0.2 g, 68%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.99–7.97 (m, 2H), 7.89 (d, <i>J</i> = 8.9 Hz, 1H), 7.72 (d, <i>J</i> = 2.0 Hz, 1H), 7.35 (t, <i>J</i> = 6.6 Hz, 2H), 7.32 (dd, <i>J</i> = 6.7, 2.2 Hz, 1H), 5.64 (t, <i>J</i> = 3.0 Hz, 1H), 3.89–3.75 (m, 1H), 3.45–3.42 (m, 1H), 1.94–1.77 (m, 2H), 1.77–1.40 (m, 4H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 186.83, 165.68 (d, <i>J</i> = 252.7 Hz), 157.88, 140.33, 134.52 (d, <i>J</i> = 2.7 Hz), 132.34 (d, <i>J</i> = 9.4 Hz), 131.12, 129.51, 124.30, 123.57, 117.86, 115.59 (d, <i>J</i> = 22.3 Hz), 108.45, 96.53, 61.70, 30.31, 24.93, 18.49.</div></div><div id="sec8_13_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (3-Chloro-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(3-fluorophenyl)methanone (<b>16d</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>16a</b> (yield: 0.3 g, 69%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.89 (d, <i>J</i> = 8.9 Hz, 1H), 7.75–7.72 (m, 2H), 7.68–7.60 (m, 2H), 7.53–7.44 (m, 1H), 7.32 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 5.64 (t, <i>J</i> = 3.0 Hz, 1H), 3.83–3.81 (m, 1H), 3.64–3.61 (m, 1H), 2.05–1.78 (m, 3H), 1.78–1.41 (m, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 186.93, 162.53 (d, <i>J</i> = 246.3 Hz), 158.04, 140.58, 140.36 (d, <i>J</i> = 6.7 Hz), 131.74, 131.18, 130.69 (d, <i>J</i> = 7.9 Hz), 125.34 (d, <i>J</i> = 2.8 Hz), 124.46, 124.41, 119.71 (d, <i>J</i> = 21.5 Hz), 117.92, 115.63 (d, <i>J</i> = 23.0 Hz), 108.38, 96.52, 61.70, 29.97, 24.94, 18.49.</div></div><div id="sec8_13_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (3-Chloro-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(2,4-dimethylphenyl)methanone (<b>16e</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>16a</b> (yield: 0.18 g, 73%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.87 (d, <i>J</i> = 8.9 Hz, 1H), 7.69 (d, <i>J</i> = 1.9 Hz, 1H), 7.39 (d, <i>J</i> = 7.8 Hz, 1H), 7.30 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 7.20 (s, 1H), 7.16 (d, <i>J</i> = 7.8 Hz, 1H), 5.64 (s, 1H), 3.91–3.73 (m, 1H), 3.73–3.58 (m, 1H), 2.40 (s, 3H), 2.35 (s, 3H), 2.02–1.77 (m, 3H), 1.77–1.44 (m, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 189.85, 158.12, 141.18, 140.80, 136.43, 136.23, 134.28, 131.67, 131.54, 128.49, 126.29, 124.60, 124.52, 117.80, 108.43, 96.50, 61.70, 29.97, 24.93, 20.54, 18.82, 18.48.</div></div><div id="sec8_13_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (3-Chloro-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(4-fluoro-2-methylphenyl)methanone (<b>16f</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>16a</b> (yield: 0.35 g, 70%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.88 (t, <i>J</i> = 10.0 Hz, 1H), 7.73 (d, <i>J</i> = 2.0 Hz, 1H), 7.59 (dd, <i>J</i> = 8.5, 5.9 Hz, 1H), 7.37–7.30 (m, 1H), 7.25–7.17 (m, 1H), 7.17–7.06 (m, 1H), 5.67 (s, 1H), 3.97–3.73 (m, 1H), 3.66–3.64 (m, 1H), 2.21 (s, 3H) 2.17–1.80 (m, 2H), 1.80–1.28 (m, 4H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.98, 163.82 (d, <i>J</i> = 249.0 Hz), 158.31, 141.03, 139.69 (d, <i>J</i> = 8.8 Hz), 135.67, 134.07, 131.54, 130.62 (d, <i>J</i> = 9.2 Hz), 125.12, 124.77, 117.93, 117.58 (d, <i>J</i> = 21.7 Hz), 112.63 (d, <i>J</i> = 21.7 Hz), 108.44, 96.51, 93.23, 61.72, 29.96, 24.92, 18.48.</div></div><div id="sec8_13_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (3-Chloro-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(4-fluoro-2,6-dimethylphenyl)-methanone (<b>16g</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>16a</b> (yield: 0.45 g, 75%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.89 (d, <i>J</i> = 9.0 Hz, 1H), 7.73 (d, <i>J</i> = 2.1 Hz, 1H), 7.31 (dd, <i>J</i> = 9.0, 2.2 Hz, 1H), 6.98 (d, <i>J</i> = 9.8 Hz, 2H), 5.67 (t, <i>J</i> = 3.1 Hz, 1H), 3.88–3.78 (m, 1H), 3.70–3.57 (m, 1H), 2.23 (s, 6H), 1.91–1.89 (m, 2H), 1.68–1.64 (m, 4H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 190.66, 161.47 (d, <i>J</i> = 242.4 Hz), 158.63, 141.48, 137.07 (d, <i>J</i> = 8.8 Hz), 136.12, 133.19, 131.75, 125.12, 118.02, 116.59, 114.32 (d, <i>J</i> = 21.6 Hz), 108.54, 96.46, 61.69, 29.91, 24.90, 18.42, 18.34.</div></div><div id="sec8_13_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (3-Chloro-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(4-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)phenyl)methanone (<b>16h</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>16a</b> (yield: 0.35 g, 70%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.97–7.83 (m, 3H), 7.72 (d, <i>J</i> = 1.8 Hz, 1H), 7.33 (dd, <i>J</i> = 8.9, 2.0 Hz, 1H), 7.21 (d, <i>J</i> = 8.8 Hz, 2H), 5.64 (s, 1H), 4.82 (s, 1H), 4.00–3.90 (m, 1H), 3.83–3.81 (m, 1H), 3.64–3.62 (m, 1H), 3.47–3.45 (m, 1H), 1.94–1.92 (m, 6H), 1.78–1.33 (m, 6H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 186.60, 161.56, 157.55, 139.92, 132.09, 123.99, 117.77, 116.01, 108.49, 108.34, 97.51, 96.54, 96.08, 62.00, 61.75, 61.68, 30.72, 30.02, 29.93, 25.40, 24.96, 19.26, 18.49.</div></div><div id="sec8_13_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (3-Chloro-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(2-methyl-4-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)phenyl)methanone (<b>16i</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>16a</b> (yield: 0.3 g, 72%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.88 (d, <i>J</i> = 8.9 Hz, 1H), 7.71 (d, <i>J</i> = 2.1 Hz, 1H), 7.51 (d, <i>J</i> = 8.5 Hz, 1H), 7.32 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 7.04 (d, <i>J</i> = 2.1 Hz, 1H), 7.00 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 5.62–5.60 (m, 2H), 3.85–3.83 (m, 2H), 3.71–3.56 (m, 2H), 3.56–3.38 (m, 1H), 2.41 (s, 3H), 2.04–1.80 (m, 5H), 1.77–1.41 (m, 6H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.93, 159.47, 157.95, 140.56, 139.29, 134.44, 131.89, 131.26, 124.43, 118.81, 117.74, 113.07, 108.47, 96.52, 95.99, 61.69, 61.67, 30.04, 29.98, 24.97, 24.93, 19.42, 19.24, 19.13, 18.56, 18.50.</div></div><div id="sec8_13_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>t</i>-Butyl 3-(((Methylsulfonyl)oxy)methyl)azetidine-1-carboxylate (<b>18</b>)</h4><div class="NLM_p last">To a solution of <i>t</i>-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (5 g, 26.7 mmol), triethylamine (7.4 mL, 53.4 mmol), and dichloromethane (50 mL), methanesulfonyl chloride (32 mL, 401 mmol) was added dropwise over 15 min at 0 °C. The resulting cloudy orange mixture was stirred at 0 °C for 1 h and then diluted with 10% aqueous citric acid (20 mL). The layers were separated, and the organic phase was washed by 10% aqueous citric acid, saturated NaHCO<sub>3</sub>, and water. The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated to give the title compound as dark orange oil (yield: 6 g, 85%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.33 (d, <i>J</i> = 5.3 Hz, 2H), 3.91 (m, 2H), 3.61 (m, 2H), 3.21 (s, 3H), 2.89 (m, 1H), 1.37 (s, 9H).</div></div><div id="sec8_13_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>t</i>-Butyl 3-(Fluoromethyl)azetidine-<i>l</i>-carboxylate (<b>19</b>)</h4><div class="NLM_p last">A solution of compound <b>18</b> (7 g, 26.7 mmol) and tetrabutylammonium fluoride (50 mL, 50 mmol, 1 M in THF) was refluxed for 1 h and monitored by TLC. Upon completion, the reaction mixture was evaporated under reduced pressure to remove the solvent THF. The resulting thick oil was diluted with ethyl acetate and then washed with water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (10–40% ethyl acetate in hexanes) to give yellow oil (yield: 4.2 g, 85% over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.52 (dd, <i>J</i> = 47.3, 5.3 Hz, 2H), 3.94–3.83 (m, 2H), 3.66–3.52 (m, 2H), 2.94–2.77 (m, 1H), 1.37 (s, 9H).</div></div><div id="sec8_13_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 3-(Fluoromethyl)azetidine Hydrochloride (<b>20</b>)</h4><div class="NLM_p last">To a solution of methanol (45 mL) was added compound <b>19</b> (4.2 g, 22.2 mmol), and aqueous HCI (6 M, 11.1 mL, 66.6 mmol) was dropwise added slowly to the reaction at 0 °C. The reaction was stirred at room temperature and monitored by TLC. Upon completion, the reaction was evaporated to become solidified under high vacuum to give the title compound (yield: 2.7 g, 97%) as a hygroscopic white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.18 (br s, 2H), 4.56 (dd, <i>J</i> = 47.6, 5.3 Hz, 2H), 4.03–3.92 (m, 2H), 3.78–3.68 (m, 2H), 3.19–3.00 (m, 1H).</div></div><div id="sec8_13_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (<i>R</i>)-<i>t</i>-Butyl-3-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (<b>22R</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>18</b> (yield: 0.8 g, 88%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.26–4.11 (m, 2H), 3.44–3.28 (m, 2H), 3.26–3.14 (m, 1H), 3.18 (s, 3H), 3.05–2.93 (m, 1H), 2.62–2.49 (m, 1H), 2.00–1.87 (m, 1H), 1.72–1.56 (m, 1H), 1.40 (s, 9H).</div></div><div id="sec8_13_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (<i>R</i>)-<i>t</i>-Butyl 3-(Fluoromethyl)pyrrolidine-1-carboxylate (<b>23R</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>19</b> (yield: 0.2 g, 60%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.49–4.41 (m, 1H), 4.37–4.29 (m, 1H), 3.40–3.28 (m, 2H), 3.24–3.18 (m, 1H), 3.02–2.98 (m, 1H), 2.58–2.52 (m, 1H), 1.95–1.88 (m, 1H), 1.67–1.54 (m, 1H), 1.38 (s, 9H).</div></div><div id="sec8_13_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (<i>R</i>)-3-(Fluoromethyl)pyrrolidine Hydrochloride (<b>24R</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>20</b> (yield: 0.1 g, 70%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, HCI salt): δ 9.35 (br s, 1H), 4.57–4.47 (m, 1H), 4.44–4.33 (m, 1H), 3.33–3.10 (m, 3H), 2.95–2.87 (m, 1H), 2.69–2.57 (m, 1H), 2.05–1.97 (m, 1H), 1.70–1.61 (m, 1H).</div></div><div id="sec8_13_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 2-(4-(2-Bromoethoxy)phenoxy)tetrahydro-2<i>H</i>-pyran (<b>26</b>)</h4><div class="NLM_p last">To a solution of THF (30 mL) was added deoxyarbutin, (2 g, 10.2 mmol), 1,2-dibromoethane (1.2 mL, 0.11 mol), NaOH (1.23 g, 31 mmol). The reaction mixture was reflux for 24 h and monitored by TLC. The reaction mixture was evaporated under reduced pressure and diluted by ethyl acetate, washed by water, brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (10–25% ethyl acetate in hexanes) to give a white solid (yield: 1.4 g, 46%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.05–6.97 (m, 2H), 6.95–6.86 (m, 2H), 5.33 (t, <i>J</i> = 3.2 Hz, 1H), 4.31 (t, <i>J</i> = 5.7 Hz, 2H), 3.95–3.82 (m, 1H), 3.75 (t, <i>J</i> = 5.5 Hz, 2H), 3.56–3.52 (m, 1H), 1.98–1.96 (m, 1H), 1.90–1.73 (m, 2H), 1.71–1.50 (m, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 153.18, 151.77, 117.74, 115.55, 96.95, 68.58, 61.50, 30.33, 30.29, 25.13, 18.79.</div></div><div id="sec8_13_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 1-(2-(4-((Tetrahydro-2<i>H</i>-pyran-2-yl)oxy)phenoxy)ethyl)azetidine (<b>27a</b>)</h4><div class="NLM_p last">To acetonitrile (5 mL) was added compound <b>26</b> (0.5 g, 1.6 mmol), azetidine hydrochloride (0.3 g, 3.2 mmol), and potassium carbonate (0.66 g, 4.8 mmol). The reaction mixture was stirred at 60 °C and monitored by TLC. Upon completion, the reaction was extracted by ethyl acetate, washed by water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (1–10%) of methanol in dichloromethane (yield: 0.3 g, 70%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 6.98 (d, <i>J</i> = 9.1 Hz, 2H), 6.84 (d, <i>J</i> = 9.1 Hz, 2H), 5.30 (t, <i>J</i> = 3.2 Hz, 1H), 3.90 (t, <i>J</i> = 5.8 Hz, 2H), 3.89–3.87 (m, 1H), 3.55–3.53 (m, 1H), 3.24 (t, <i>J</i> = 6.9 Hz, 4H), 2.72 (t, <i>J</i> = 5.8 Hz, 2H), 2.02 (t, <i>J</i> = 6.9 Hz, 2H), 1.97–1.95 (m, 1H), 1.88–1.75 (m, 2H), 1.62–1.59 (m, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 153.92, 151.27, 117.70, 115.00, 97.03, 67.08, 61.48, 58.13, 55.63, 30.39, 25.18, 18.84, 17.91.</div></div><div id="sec8_13_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 3-Methyl-1-(2-(4-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)phenoxy)ethyl)azetidine (<b>27b</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>27a</b> (yield: 0.3 g, 56%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 6.98 (d, <i>J</i> = 9.0 Hz, 2H), 6.84 (d, <i>J</i> = 9.1 Hz, 2H), 5.30 (t, <i>J</i> = 3.3 Hz, 1H), 3.92 (t, <i>J</i> = 5.8 Hz, 2H), 3.51 (t, <i>J</i> = 7.4 Hz, 2H), 2.85 (t, <i>J</i> = 7.0 Hz, 2H), 2.77 (t, <i>J</i> = 5.8 Hz, 2H), 2.51 (dq, <i>J</i> = 13.8, 6.9 Hz, 1H), 2.03–1.89 (m, 1H), 1.89–1.73 (m, 2H), 1.71–1.52 (m, 3H), 1.52–1.36 (m, 2H), 1.15 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 153.87, 151.28, 117.70, 115.03, 97.03, 66.98, 62.39, 61.49, 57.85, 30.37, 26.23, 25.16, 18.82, 18.48.</div></div><div id="sec8_13_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 3-(Fluoromethyl)-1-(2-(4-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)phenoxy)ethyl)azetidine (<b>27c</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>27a</b> (yield: 0.45 g, 88%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.04–6.96 (m, 2H), 6.87–6.79 (m, 2H), 5.31 (t, <i>J</i> = 3.3 Hz, 1H), 4.56 (dd, <i>J</i> = 47.6, 5.3 Hz, 2H), 3.95 (t, <i>J</i> = 5.5 Hz, 2H), 3.72–3.48 (m, 2H), 3.20 (t, <i>J</i> = 7.0 Hz, 2H), 2.99–2.88 (m, 2H), 2.86 (t, <i>J</i> = 5.5 Hz, 2H), 2.08–1.93 (m, 1H), 1.86–1.83 (m, 2H), 1.75–1.56 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 153.67, 151.25, 117.73, 115.28, 97.31, 84.21 (d, <i>J</i> = 167.0 Hz), 66.89, 62.10, 57.91, 56.56 (d, <i>J</i> = 6.9 Hz), 31.50, 31.40 (d, <i>J</i> = 20.3 Hz), 25.26, 18.94.</div></div><div id="sec8_13_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (3<i>R</i>)-3-(Fluoromethyl)-1-(2-(4-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)phenoxy)ethyl)pyrrolidine (<b>27d</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>27a</b> (yield: 0.5 g, 70%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.00 (d, <i>J</i> = 8.9 Hz, 2H), 6.85 (d, <i>J</i> = 8.9 Hz, 2H), 5.31 (t, <i>J</i> = 3.1 Hz, 1H), 4.36 (dd, <i>J</i> = 47.4, 6.6 Hz, 2H), 4.09 (t, <i>J</i> = 5.7 Hz, 2H), 3.99–3.91 (m, 1H), 3.68–3.55 (m, 1H), 3.03–2.81 (m, 3H), 2.81–2.46 (m, 4H), 2.13–1.93 (m, 2H), 1.91–1.78 (m, 2H), 1.77–1.48 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 153.63, 151.29, 117.76, 115.40, 97.30, 85.80 (d, <i>J</i> = 168.8 Hz), 67.27, 62.10, 56.65 (d, <i>J</i> = 5.2 Hz), 54.86, 54.32, 37.71 (d, <i>J</i> = 18.7 Hz), 30.50, 26.12 (d, <i>J</i> = 6.8 Hz), 25.26, 18.94.</div></div><div id="sec8_13_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> (3<i>S</i>)-3-(Fluoromethyl)-1-(2-(4-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)phenoxy)ethyl)pyrrolidine (<b>27e</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>27a</b> (yield: 0.4 g, 77%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.99 (d, <i>J</i> = 9.0 Hz, 2H), 6.84 (d, <i>J</i> = 9.0 Hz, 2H), 5.29 (t, <i>J</i> = 3.3 Hz, 1H), 4.33 (dd, <i>J</i> = 47.4, 6.7 Hz, 2H), 4.04 (t, <i>J</i> = 5.9 Hz, 2H), 3.99–3.89 (m, 1H), 3.59–3.55 (m, 1H), 2.94–2.73 (m, 3H), 2.73–2.48 (m, 4H), 2.09–1.89 (m, 2H), 1.84–1.78 (m, 2H), 1.76–1.43 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 153.72, 151.22, 117.72, 115.35, 97.26, 85.93 (d, <i>J</i> = 168.7 Hz), 67.46, 62.05, 56.72 (d, <i>J</i> = 5.2 Hz), 54.90, 54.31, 37.72 (d, <i>J</i> = 18.7 Hz), 30.49, 26.14 (d, <i>J</i> = 6.8 Hz), 25.26, 18.93.</div></div><div id="sec8_13_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 1-(2-(4-((Tetrahydro-2<i>H</i>-pyran-2-yl)oxy)phenoxy)ethyl)piperidine (<b>27f</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>27a</b> (yield: 0.3 g, 60%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 6.98 (d, <i>J</i> = 9.1 Hz, 2H), 6.90 (d, <i>J</i> = 9.1 Hz, 2H), 5.31 (t, <i>J</i> = 3.3 Hz, 1H), 4.04 (t, <i>J</i> = 6.1 Hz, 2H), 3.93–3.81 (m, 1H), 3.63–3.47 (m, 1H), 2.67 (t, <i>J</i> = 6.0 Hz, 3H), 2.48 (br s, 4H), 2.12–1.86 (m, 2H), 1.86–1.72 (m, 2H), 1.72–1.47 (m, 5H), 1.43–1.41 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 153.92, 151.26, 117.69, 115.10, 97.02, 66.54, 61.47, 57.91, 54.87, 30.35, 25.98, 25.14, 24.19, 18.81.</div></div><div id="sec8_13_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 4-(2-(Azetidin-1-yl)ethoxy)phenol (<b>28a</b>)</h4><div class="NLM_p last">To a solution of methanol (5 mL) was added compound <b>27a</b> (0.18 g, 0.65 mmol) and <i>p</i>-toluenesulfonic acid (0.33 g, 1.95 mmol). The reaction was stirred at room temperature and monitored by TLC. Upon completion, the reaction was extracted by ethyl acetate, washed by saturated NaHCO<sub>3</sub>, water, and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (1–10%) methanol in dichloromethane (yield: 0.15 g, 60%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 6.96 (s, 4H), 3.86 (t, <i>J</i> = 5.8 Hz, 2H), 3.24 (t, <i>J</i> = 6.9 Hz, 4H), 2.71 (t, <i>J</i> = 5.8 Hz, 2H), 2.04–1.96 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 152.30, 151.34, 115.73, 115.33, 67.12, 58.19, 55.58, 17.85.</div></div><div id="sec8_13_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 4-(2-(3-Methylazetidin-1-yl)ethoxy)phenol (<b>28b</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>28a</b> (yield: 0.15 g, 70%). <sup>1</sup>H NMR (400 MHz, MeOD): δ 6.77 (d, <i>J</i> = 9.1 Hz, 2H), 6.71 (d, <i>J</i> = 9.1 Hz, 2H), 3.93 (t, <i>J</i> = 5.3 Hz, 2H), 3.68 (t, <i>J</i> = 8.1 Hz, 2H), 3.03 (t, <i>J</i> = 7.9 Hz, 2H), 2.91 (t, <i>J</i> = 5.3 Hz, 2H), 2.66 (dq, <i>J</i> = 14.4, 7.2 Hz, 1H), 1.18 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (101 MHz, MeOD): δ 152.00, 151.19, 115.47, 115.19, 66.16, 62.09, 57.32, 26.04, 17.71.</div></div><div id="sec8_13_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenol (<b>28c</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>28a</b> (yield: 0.1 g, 71%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 6.76 (s, 4H), 4.55 (dd, <i>J</i> = 47.7, 6.3 Hz, 2H), 3.89 (t, <i>J</i> = 5.7 Hz, 2H), 3.41 (t, <i>J</i> = 7.6 Hz, 2H), 3.13 (d, <i>J</i> = 7.6 Hz, 2H), 2.78–2.76 (m, <i>J</i> = 5.7 Hz, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 152.28, 151.34, 115.72, 115.34, 84.57 (d, <i>J</i> = 164.9 Hz), 67.23, 57.74, 56.39 (d, <i>J</i> = 7.7 Hz), 31.37 (d, <i>J</i> = 20.2 Hz).</div></div><div id="sec8_13_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> (<i>R</i>)-4-(2-(3-(Fluoromethyl)pyrrolidin-1-yl)ethoxy)phenol (<b>28d</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>28a</b> (yield: 0.2 g, 65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 6.72–6.63 (m, 4H), 4.45–4.32 (m, 2H), 4.02 (t, <i>J</i> = 5.7 Hz, 2H), 2.99–2.86 (m, 3H), 2.86–2.76 (m, 1H), 2.76–2.47 (m, 3H), 2.09–1.95 (m, 1H), 1.59 (dq, <i>J</i> = 8.0, 6.0 Hz, 1H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 152.40, 150.22, 116.46, 115.56, 85.67 (d, <i>J</i> = 168.8 Hz), 67.25, 56.82 (d, <i>J</i> = 5.0 Hz), 55.01, 54.51, 37.61 (d, <i>J</i> = 18.8 Hz), 26.04 (d, <i>J</i> = 6.7 Hz).</div></div><div id="sec8_13_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 4-(2-(Piperidin-1-yl)ethoxy)phenol (<b>28f</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>28a</b> (yield: 0.15 g, 58%). <sup>1</sup>H NMR (400 MHz, MeOD): δ 6.79 (d, <i>J</i> = 9.0 Hz, 2H), 6.71 (d, <i>J</i> = 9.0 Hz, 2H), 4.90 (s, 1H), 4.05 (t, <i>J</i> = 5.7 Hz, 2H), 2.75 (t, <i>J</i> = 5.7 Hz, 2H), 2.57 (br s, 4H), 1.65–1.64 (m, 4H), 1.50–1.48 (m, 2H). <sup>13</sup>C NMR (101 MHz, MeOD): δ 152.09, 151.10, 115.43, 115.24, 65.64, 57.73, 54.52, 25.02, 23.61.</div></div><div id="sec8_13_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> (3-(4-(2-(Azetidin-1-yl)ethoxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(<i>o</i>-tolyl)methanone (<b>29a</b>)</h4><div class="NLM_p last">To a solution of dimethylformamide (DMF) (10 mL) was added <b>16b</b> (0.5 g, 1.3 mmol), <b>28a</b> (0.31 g, 1.6 mmol), and cesium carbonate (1.26 g, 3.9 mmol). The reaction mixture was stirred at 110 °C for 5 h and monitored by TLC. Upon completion, the reaction mixture was extracted by ethyl acetate, washed by water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (1–10%) of methanol in DCM (yield: 0.13 g, 63%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.67 (d, <i>J</i> = 2.1 Hz, 1H), 7.44 (d, <i>J</i> = 8.9 Hz, 1H), 7.41–7.35 (m, 1H), 7.29 (td, <i>J</i> = 7.6, 1.2 Hz, 1H), 7.15 (d, <i>J</i> = 6.1 Hz, 2H), 7.10 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.69 (d, <i>J</i> = 9.1 Hz, 2H), 6.46 (d, <i>J</i> = 9.1 Hz, 2H), 5.63 (t, <i>J</i> = 3.0 Hz, 1H), 3.85–3.82 (m, 3H), 3.73–3.58 (m, 1H), 3.25–3.15 (m, 4H), 2.71–2.62 (m, 2H), 2.16 (s, 3H), 2.00–1.96 (m, 2H), 1.92–1.80 (m, 2H), 1.77–1.51 (m, 4H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 189.92, 158.08, 154.54, 152.23, 149.27, 141.39, 139.63, 135.42, 130.32, 129.91, 127.51, 127.47, 125.06, 124.52, 116.94, 116.01, 115.50, 115.04, 108.95, 96.42, 67.18, 61.71, 57.96, 55.56, 29.98, 24.94, 18.52, 18.50, 17.87.</div></div><div id="sec8_13_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> (3-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo-[<i>b</i>]thiophen-2-yl)(2-methyl-4-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)phenyl)methanone (<b>29b</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.18 g, 65%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.67 (d, <i>J</i> = 2.0 Hz, 1H), 7.44 (d, <i>J</i> = 8.9 Hz, 1H), 7.37 (d, <i>J</i> = 7.5 Hz, 1H), 7.29 (m, 1H), 7.15 (d, <i>J</i> = 5.8 Hz, 2H), 7.10 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.69 (d, <i>J</i> = 9.1 Hz, 2H), 6.46 (d, <i>J</i> = 9.1 Hz, 2H), 5.71–5.58 (m, 1H), 3.85 (t, <i>J</i> = 5.8 Hz, 3H), 3.67–3.58 (m, 1H), 3.43 (d, <i>J</i> = 7.2 Hz, 2H), 2.78 (t, <i>J</i> = 4.6 Hz, 2H), 2.70 (t, <i>J</i> = 5.8 Hz, 2H), 2.57–2.41 (m, 2H), 2.16 (s, 3H), 1.88–1.86 (m, 2H), 1.77–1.56 (m, 3H), 1.13 (d, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 189.92, 158.07, 154.55, 152.22, 149.27, 141.39, 139.63, 135.43, 130.32, 129.90, 127.52, 127.47, 125.06, 124.52, 116.94, 116.01, 115.03, 108.94, 96.42, 67.26, 62.50, 61.70, 58.02, 46.12, 29.98, 26.27, 24.95, 18.54, 18.51.</div></div><div id="sec8_13_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> (3-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(phenyl)methanone (<b>29c</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.3 g, 73%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.75 (d, <i>J</i> = 8.3 Hz, 1H), 7.69 (d, <i>J</i> = 2.0 Hz, 1H), 7.57 (t, <i>J</i> = 7.5 Hz, 2H), 7.50–7.38 (m, 3H), 7.13 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.74 (d, <i>J</i> = 9.1 Hz, 2H), 6.62 (d, <i>J</i> = 9.1 Hz, 2H), 5.65 (s, 1H), 4.54 (dd, <i>J</i> = 47.7, 6.2 Hz, 2H), 3.89–3.76 (m, 3H), 3.65–3.62 (m, 2H), 3.49–3.33 (m, 3H), 3.12–3.10 (m, 2H), 2.78–2.67 (m, 1H), 1.88–1.86 (m, 2H), 1.75–1.41 (m, 4H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.26, 157.81, 154.57, 152.11, 148.30, 140.99, 138.66, 132.15, 128.69, 127.93, 127.26, 125.68, 124.36, 116.89, 116.56, 115.15, 108.87, 96.45, 85.40 (d, <i>J</i> = 164.8 Hz), 67.24, 61.71, 57.55, 56.36 (d, <i>J</i> = 6.3 Hz), 31.39 (d, <i>J</i> = 20.2 Hz), 30.00, 24.95, 18.52.</div></div><div id="sec8_13_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> (3-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(<i>o</i>-tolyl) Methanone (<b>29d</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.44 g, 62%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.51 (d, <i>J</i> = 1.9 Hz, 1H), 7.42 (d, <i>J</i> = 8.9 Hz, 1H), 7.29 (d, <i>J</i> = 7.3 Hz, 1H), 7.22 (t, <i>J</i> = 7.4 Hz, 1H), 7.07 (t, <i>J</i> = 6.9 Hz, 2H), 7.01 (dd, <i>J</i> = 8.9, 2.0 Hz, 1H), 6.58 (d, <i>J</i> = 9.0 Hz, 2H), 6.35 (d, <i>J</i> = 9.0 Hz, 2H), 5.51 (t, <i>J</i> = 2.7 Hz, 1H), 4.50 (dd, <i>J</i> = 47.4, 5.6 Hz, 2H), 3.91–3.81 (m, 3H), 3.64 (m, 2H), 3.50 (br s, 2H), 3.16 (br s, 1H), 2.94–2.76 (m, 3H), 2.15 (s, 3H), 2.06–1.95 (m, 1H), 1.90–1.88 (m, 2H), 1.78–1.49 (m, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 190.88, 157.96, 154.04, 152.50, 149.48, 141.70, 139.38, 135.77, 130.39, 129.94, 127.72, 127.62, 127.56, 125.03, 124.69, 116.85, 115.85, 115.04, 108.79, 96.66, 84.13 (d, <i>J</i> = 167.2 Hz), 66.98, 62.10, 57.87, 56.55 (d, <i>J</i> = 6.5 Hz), 31.39 (d, <i>J</i> = 20.4 Hz), 30.21, 25.09, 19.28, 18.54.</div></div><div id="sec8_13_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> (4-Fluoro-2-methylphenyl)(3-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)methanone (<b>29e</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.32 g, 70%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.67 (d, <i>J</i> = 2.0 Hz, 1H), 7.49–7.41 (m, 2H), 7.11 (dd, <i>J</i> = 7.4, 3.7 Hz, 1H), 6.91 (d, <i>J</i> = 13.7 Hz, 2H), 6.73 (d, <i>J</i> = 6.9 Hz, 2H), 6.53–6.46 (d, <i>J</i> = 6.9 Hz, 2H), 5.63 (t, <i>J</i> = 3.0 Hz, 1H), 4.54 (dd, <i>J</i> = 47.7, 6.3 Hz, 2H), 3.97–3.77 (m, 3H), 3.71–3.57 (m, 1H), 3.47–3.28 (m, 2H), 3.14–3.12 (m, 2H), 2.80–2.70 (m, 3H), 2.17 (s, 3H), 2.07–1.79 (m, 3H), 1.78–1.48 (m, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.79, 163.34 (d, <i>J</i> = 247.9 Hz), 158.15, 154.58, 152.25, 149.21, 141.44, 139.27 (d, <i>J</i> = 8.6 Hz), 135.83, 130.20 (d, <i>J</i> = 9.1 Hz), 127.45, 127.32, 124.51, 117.02, 116.92 (d, <i>J</i> = 19.2 Hz), 115.22, 115.13, 111.84 (d, <i>J</i> = 21.7 Hz), 108.94, 96.42, 84.58 (d, <i>J</i> = 165.0 Hz), 67.33, 61.71, 57.56, 56.39 (d, <i>J</i> = 7.2 Hz), 31.39 (d, <i>J</i> = 20.1 Hz), 29.98, 24.94, 18.61, 18.50.</div></div><div id="sec8_13_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> (4-Fluoro-2,6-dimethylphenyl)(3-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)methanone (<b>29f</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.4 g, 58%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.69 (d, <i>J</i> = 2.1 Hz, 1H), 7.37 (d, <i>J</i> = 8.9 Hz, 1H), 7.09 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 6.74 (d, <i>J</i> = 9.1 Hz, 2H), 6.70 (d, <i>J</i> = 9.8 Hz, 2H), 6.50 (d, <i>J</i> = 9.0 Hz, 2H), 5.65 (t, <i>J</i> = 3.2 Hz, 1H), 4.54 (dd, <i>J</i> = 47.7, 6.1 Hz, 2H), 3.90 (t, <i>J</i> = 4.8 Hz, 2H), 3.88–3.76 (m, 2H), 3.64–3.62 (m, 1H), 3.55–3.40 (m, 1H), 2.98–2.95 (m, 2H), 2.87–2.65 (m, 2H), 2.13 (s, 6H), 1.97–1.94 (m, 1H), 1.92–1.79 (m, 2H), 1.78–1.65 (m, 2H), 1.65–1.43 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 190.57, 162.26 (d, <i>J</i> = 244.6 Hz), 158.28, 154.60, 151.79, 149.44, 141.73, 136.98, 136.64 (d, <i>J</i> = 8.6 Hz), 128.40, 127.26, 124.82, 117.08, 115.57, 114.98, 113.68 (d, <i>J</i> = 21.5 Hz), 109.09, 96.39, 93.23, 84.58 (d, <i>J</i> = 165.0 Hz), 67.37, 61.70, 61.54, 57.49, 56.21, 29.94 (d, <i>J</i> = 19.7 Hz), 24.92, 18.46.</div></div><div id="sec8_13_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> (3-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo-[<i>b</i>]thiophen-2-yl)(4-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)phenyl)methanone (<b>29g</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.2 g, 70%). <sup>1</sup>H NMR (400 MHz, acetone<i>-d</i><sub>6</sub>): δ 7.83–7.73 (m, 2H), 7.67 (d, <i>J</i> = 2.1 Hz, 1H), 7.51 (d, <i>J</i> = 8.9 Hz, 1H), 7.13 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 7.10–7.03 (m, 2H), 6.76–6.70 (m, 2H), 6.69–6.60 (m, 2H), 5.62 (m, 2H), 4.53 (dd, <i>J</i> = 47.7, 6.3 Hz, 2H), 3.86–3.84 (m, 2H), 3.68–3.57 (m, 2H), 3.37 (t, <i>J</i> = 7.0 Hz, 2H), 3.08 (t, <i>J</i> = 6.5 Hz, 2H), 2.75–2.74 (m, 1H), 2.73 (t, <i>J</i> = 5.6 Hz, 2H), 1.99 (m, 2H), 1.88 (m, 6H), 1.77–1.51 (m, 6H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 186.73, 160.81, 157.57, 154.51, 152.23, 147.40, 140.53, 131.56, 131.16, 127.40, 125.69, 124.07, 116.81, 116.60, 115.57, 115.15, 108.85, 96.46, 95.96, 84.59 (d, <i>J</i> = 164.9 Hz), 67.22, 61.66, 61.62, 57.58, 56.39 (d, <i>J</i> = 7.7 Hz), 31.37 (d, <i>J</i> = 20.1 Hz), 30.02, 29.92, 24.95, 18.53, 18.47.</div></div><div id="sec8_13_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> (3-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(2-methyl-4-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)phenyl)methanone (<b>29h</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.2 g, 58%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.67 (d, <i>J</i> = 2.0 Hz, 1H), 7.53 (d, <i>J</i> = 8.9 Hz, 1H), 7.43 (d, <i>J</i> = 8.5 Hz, 1H), 7.14 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.85 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 6.81 (d, <i>J</i> = 2.0 Hz, 1H), 6.72–6.67 (m, 2H), 6.50–6.45 (m, 2H). 5.64 (t, <i>J</i> = 3.0 Hz, 1H), 5.53 (t, <i>J</i> = 2.9 Hz, 1H), 4.54 (dd, <i>J</i> = 47.7, 6.3 Hz, 2H), 3.89–3.86 (m, 4H), 3.69–3.56 (m, 2H), 3.39 (t, <i>J</i> = 7.1 Hz, 2H), 3.10 (t, <i>J</i> = 6.4 Hz, 2H), 2.78–2.76 (m, 1H), 2.75 (t, <i>J</i> = 5.4 Hz, 2H), 2.13 (s, 3H), 2.02–1.93 (m, 2H), 1.93–1.79 (m, 4H), 1.75–1.54 (m, 6H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.91, 158.80, 157.92, 154.43, 152.58, 148.50, 140.92, 138.59, 132.32, 130.61, 127.83, 127.42, 124.18, 118.43, 116.90, 115.97, 115.09, 112.72, 108.90, 96.45, 95.83, 84.57 (d, <i>J</i> = 164.9 Hz), 67.31, 61.70, 61.48, 57.54, 56.38 (d, <i>J</i> = 7.7 Hz), 31.38 (d, <i>J</i> = 20.1 Hz), 30.01 25.03, 24.95, 19.03, 18.52, 18.49.</div></div><div id="sec8_13_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> (3-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]-thiophen-2-yl)(3-fluorophenyl)methanone (<b>29j</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.2 g, 70%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.68 (d, <i>J</i> = 1.9 Hz, 1H), 7.57 (d, <i>J</i> = 7.6 Hz, 1H), 7.49–7.41 (m, 3H), 7.32 (td, <i>J</i> = 8.6, 2.5 Hz, 1H), 7.12 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.75 (d, <i>J</i> = 9.1 Hz, 2H), 6.64 (d, <i>J</i> = 9.1 Hz, 2H), 5.63 (t, <i>J</i> = 2.8 Hz, 1H), 4.53 (dd, <i>J</i> = 47.7, 6.3 Hz, 2H), 3.88–3.83 (m, 3H), 3.65–3.62 (m, 1H), 3.37 (t, <i>J</i> = 7.2 Hz, 2H), 3.08 (t, <i>J</i> = 6.4 Hz, 2H), 2.73–2.69 (m, 3H), 2.01–1.80 (m, 3H), 1.76–1.52 (m, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 186.94, 162.22 (d, <i>J</i> = 245.4 Hz), 157.99, 154.67, 152.00, 148.86, 141.30, 140.88 (d, <i>J</i> = 6.6 Hz), 129.99 (d, <i>J</i> = 7.8 Hz), 127.11, 125.23, 124.58, 124.55, 118.72 (d, <i>J</i> = 21.4 Hz), 116.98, 116.54, 115.25, 115.02 (d, <i>J</i> = 23.0 Hz), 108.87, 96.44, 84.60 (d, <i>J</i> = 165.0 Hz), 67.27, 61.71, 57.59, 56.40 (d, <i>J</i> = 7.7 Hz), 31.38 (d, <i>J</i> = 20.1 Hz), 29.98, 24.94, 18.50.</div></div><div id="sec8_13_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> (2,4-Dimethylphenyl)(3-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)methanone (<b>29k</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.2 g, 72%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.67 (d, <i>J</i> = 2.1 Hz, 1H), 7.48 (d, <i>J</i> = 8.9 Hz, 1H), 7.31 (d, <i>J</i> = 7.5 Hz, 1H), 7.12 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 6.98–6.92 (m, 2H), 6.71–6.69 (m, 2H), 6.52–6.42 (m, 2H), 5.64 (d, <i>J</i> = 3.0 Hz, 1H), 4.54 (dd, <i>J</i> = 47.7, 6.3 Hz, 2H), 3.95–3.82 (m, 3H), 3.70–3.60 (m, 1H), 3.39–3.37 (m, 2H), 3.11–3.09 (m, 2H), 2.79–2.72 (m, 3H), 2.32 (s, 3H), 2.13 (s, 3H), 2.03–1.82 (m, 3H), 1.80–1.54 (m, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 189.76, 157.99, 154.49, 152.40, 148.86, 141.14, 140.21, 136.64, 135.80, 131.10, 128.12, 127.67, 127.51, 125.60, 124.36, 116.91, 116.03, 115.00, 108.91, 96.43, 84.57 (d, <i>J</i> = 164.9 Hz), 67.31, 61.70, 57.55, 56.38 (d, <i>J</i> = 7.6 Hz), 31.38 (d, <i>J</i> = 19.8 Hz), 29.99, 24.94, 20.44, 18.56, 18.50.</div></div><div id="sec8_13_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> (3-(4-(2-((<i>R</i>)-3-(Fluoromethyl)pyrrolidin-1-yl)ethoxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(<i>o</i>-tolyl)methanone (<b>29l</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield 0.15 g, 80%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.68 (d, <i>J</i> = 2.1 Hz, 1H), 7.45 (d, <i>J</i> = 8.9 Hz, 1H), 7.39 (d, <i>J</i> = 5.6, 1H), 7.30 (td, <i>J</i> = 7.6, 1.2 Hz, 1H), 7.16 (dd, <i>J</i> = 7.2, 3.4 Hz, 2H), 7.11 (dd, <i>J</i> = 9.0, 2.2 Hz, 1H), 6.77–6.69 (m, 2H), 6.52–6.43 (m, 2H), 5.64 (t, <i>J</i> = 3.1 Hz, 1H), 4.31 (dd, <i>J</i> = 47.7, 6.8 Hz, 2H), 4.03 (t, <i>J</i> = 5.9 Hz, 2H), 3.91–3.75 (m, 1H), 3.68–3.65 (m, 1H), 2.83–2.81 (m, 2H), 2.69–2.67 (m, 2H), 2.55–2.52 (m, 3H), 2.16 (s, 3H), 2.02–1.77 (m, 4H), 1.72–1.66 (m, 4H). <sup>13</sup>C NMR (101 MHz, acetone): δ 189.93, 158.09, 154.50, 152.29, 149.26, 141.38, 139.63, 135.42, 130.32, 129.91, 127.52, 127.47, 125.07, 124.51, 116.95, 116.03, 115.15, 108.95, 96.42, 85.68 (d, <i>J</i> = 167.2 Hz), 67.56, 61.71, 56.41 (d, <i>J</i> = 5.2 Hz), 54.33, 53.82, 37.76 (d, <i>J</i> = 18.6 Hz), 29.98, 25.84 (d, <i>J</i> = 7.0 Hz), 24.94, 18.50.</div></div><div id="sec8_13_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> (4-Fluoro-2,6-dimethylphenyl)(3-(4-(2-((<i>R</i>)-3-(fluoromethyl)pyrrolidin-1-yl)ethoxy)phenoxy)-6-(tetrahydro-2<i>H</i>-pyran-2-yl)benzo[<i>b</i>]thiophen-2-yl)methanone (<b>29m</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.15 g, 72%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.69 (d, <i>J</i> = 2.0 Hz, 1H), 7.37 (d, <i>J</i> = 8.9 Hz, 1H), 7.09 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.80–6.73 (m, 2H), 6.70 (d, <i>J</i> = 9.7 Hz, 2H), 6.55–6.44 (m, 2H), 5.64 (t, <i>J</i> = 2.9 Hz, 1H), 4.31 (dd, <i>J</i> = 47.7, 6.7 Hz, 2H), 4.04 (t, <i>J</i> = 5.9 Hz, 2H), 3.90–3.76 (m, 1H), 3.70–3.54 (m, 1H), 2.82 (d, <i>J</i> = 5.8 Hz, 2H), 2.72–2.62 (m, 2H), 2.59–2.45 (m, 2H), 2.13 (s, 6H), 1.90–1.83 (m, 4H), 1.78–1.52 (m, 4H), 1.52–1.35 (m, 1H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 190.55, 162.26 (d, <i>J</i> = 244.5 Hz), 158.28, 154.58, 151.82, 149.44, 141.73, 136.95, 136.65 (d, <i>J</i> = 8.6 Hz), 128.41, 127.28, 124.82, 124.10, 117.08, 115.58, 115.08, 113.69 (d, <i>J</i> = 21.5 Hz), 109.10, 96.40, 85.68 (d, <i>J</i> = 167.2 Hz), 67.58, 61.70, 56.42 (d, <i>J</i> = 5.2 Hz), 54.33, 53.83, 37.76 (d, <i>J</i> = 18.6 Hz), 29.94, 25.85 (d, <i>J</i> = 6.9 Hz), 24.92, 18.47.</div></div><div id="sec8_13_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> (4-Fluoro-2,6-dimethylphenyl)(3-(4-(2-((<i>R</i>)-3-(fluoromethyl)pyrrolidin-1-yl)ethoxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)methanone (<b>29n</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.3 g, 64%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.69 (d, <i>J</i> = 2.0 Hz, 1H), 7.37 (d, <i>J</i> = 8.9 Hz, 1H), 7.09 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 6.77 (d, <i>J</i> = 9.2 Hz, 2H), 6.71 (s, 1H), 6.69 (s, 1H), 6.51 (d, <i>J</i> = 9.1 Hz, 2H), 5.64 (s, 1H), 4.31 (dd, <i>J</i> = 47.7, 6.8 Hz, 2H), 4.04 (t, <i>J</i> = 5.9 Hz, 2H), 3.84–3.82 (m, 1H), 3.73–3.58 (m, 1H), 2.81–2.79 (m, 2H), 2.68–2.65 (m, 2H), 2.53–2.51 (m, 2H), 2.12 (s, 6H), 2.03–1.83 (m, 4H), 1.66–1.64 (m, 4H), 1.54–1.40 (m, 1H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 190.57, 162.26 (d, <i>J</i> = 244.6 Hz), 158.28, 154.59, 151.82, 149.45, 141.73, 136.97, 136.65 (d, <i>J</i> = 8.6 Hz), 128.41, 127.28, 124.83, 117.09, 115.58, 115.07, 113.69 (d, <i>J</i> = 21.5 Hz), 109.10, 96.39, 85.70 (d, <i>J</i> = 167.2 Hz), 67.60, 61.71, 56.44 (d, <i>J</i> = 5.2 Hz), 54.35, 53.85, 37.76 (d, <i>J</i> = 18.6 Hz), 29.95, 25.86 (d, <i>J</i> = 7.0 Hz), 24.93, 18.47.</div></div><div id="sec8_13_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> (3-(4-(2-(Piperidin-1-yl)ethoxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(<i>o</i>-tolyl)methanone (<b>29o</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.1 g, 65%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.67 (d, <i>J</i> = 1.9 Hz, 1H), 7.44 (d, <i>J</i> = 8.9 Hz, 1H), 7.38 (d, <i>J</i> = 8.0 Hz, 1H), 7.29 (t, <i>J</i> = 7.5 Hz, 1H), 7.17–7.11 (m, 2H), 7.09 (dd, <i>J</i> = 8.9, 2.0 Hz, 1H), 6.71 (d, <i>J</i> = 9.1 Hz, 2H), 6.46 (d, <i>J</i> = 9.1 Hz, 2H), 5.62 (t, <i>J</i> = 3.0 Hz, 1H), 3.99 (t, <i>J</i> = 6.0 Hz, 2H), 3.88–3.79 (m, 1H), 3.74–3.57 (m, 1H), 2.65 (t, <i>J</i> = 6.0 Hz, 2H), 2.45–2.43 (m, 4H), 2.16 (s, 3H), 1.97–1.80 (m, 2H), 1.70–1.68 (m, 2H), 1.65–1.50 (m, 6H), 1.41–1.39 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 189.91, 158.08, 154.54, 152.25, 149.27, 141.40, 139.63, 135.44, 130.33, 129.92, 127.49, 125.07, 124.67, 124.53, 118.16, 116.95, 116.02, 115.16, 108.95, 96.42, 66.63, 61.71, 57.81, 54.87, 29.99, 25.99, 24.96, 24.20, 18.57, 18.51.</div></div><div id="sec8_13_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> (3-(4-(2-(Azetidin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(<i>o</i>-tolyl)methanone (<b>30a</b>)</h4><div class="NLM_p last">To a solution of methanol (5 mL) was added compound <b>29a</b> (0.2 g, 0.37 mmol) and <i>p</i>-toluenesulfonic acid (0.2 g, 1.2 mmol). The reaction was stirred at room temperature and monitored by TLC. Upon completion, the reaction was extracted by ethyl acetate, washed by saturated NaHCO<sub>3</sub>, water, and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (1–10% methanol in dichloromethane) Further purification was by RP-HPLC (phase A 0.05% TFA in water, phase B 0.05% TFA in MeOH) running gradients from 40 to 100% B (yield: 0.02 g, 11%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.43–7.32 (m, 3H), 7.26–7.23 (m, 1H), 7.15–7.07 (m, 2H), 6.96 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.67 (d, <i>J</i> = 9.1 Hz, 2H), 6.43 (d, <i>J</i> = 9.1 Hz, 2H), 3.89 (t, <i>J</i> = 5.6 Hz, 2H), 3.33 (t, <i>J</i> = 7.0 Hz, 4H), 2.79 (t, <i>J</i> = 5.6 Hz, 2H), 2.14 (s, 3H), 2.05–2.02 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 189.85, 159.23, 154.35, 152.31, 149.60, 141.94, 139.84, 135.29, 130.25, 129.74, 127.34, 126.27, 125.97, 125.03, 124.87, 116.19, 115.95, 115.02, 108.05, 66.80, 57.66, 55.52, 18.49, 17.75. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>26</sub>NO<sub>4</sub>S, 460.1504; observed, 460.1509.</div></div><div id="sec8_13_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> (6-Hydroxy-3-(4-(2-(3-methylazetidin-1-l)ethoxy)phenoxy)benzo[<i>b</i>]thiophen-2-yl)(<i>o</i>-tolyl) Methanone (<b>30b</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.047 g, 15%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.42 (d, <i>J</i> = 2.1 Hz, 1H), 7.37 (t, <i>J</i> = 8.4 Hz, 2H), 7.28 (t, <i>J</i> = 7.5 Hz, 1H), 7.14–7.12 (m, 2H), 6.98 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.72–6.66 (m, 2H), 6.47–6.41 (m, 2H), 3.89 (t, <i>J</i> = 5.7 Hz, 2H), 3.51 (t, <i>J</i> = 7.3 Hz, 2H), 2.85 (t, <i>J</i> = 6.8 Hz, 2H), 2.75–2.73 (m, 5H), 2.52–2.50 (m, 1H) 2.15 (s, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 189.84, 158.99, 154.42, 152.28, 149.56, 141.88, 139.82, 135.29, 130.25, 129.74, 127.34, 126.36, 126.08, 125.02, 124.87, 116.05, 115.95, 115.03, 108.00, 67.02, 62.38, 57.74, 45.96, 26.20, 18.46, 18.43. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>28</sub>NO<sub>4</sub>S, 474.1661; observed, 474.1660.</div></div><div id="sec8_13_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> (3-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(phenyl)methanone (<b>30c</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.004 g, 10%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.72–7.66 (m, 2H), 7.51 (t, <i>J</i> = 7.4 Hz, 1H), 7.37–7.34 (m, 2H), 7.33 (d, <i>J</i> = 2.0 Hz, 2H), 6.93 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.73–6.67 (m, 2H), 6.62–6.52 (m, 2H), 4.52 (dd, <i>J</i> = 47.7, 6.3 Hz, 2H), 3.85 (t, <i>J</i> = 5.6 Hz, 2H), 3.34 (t, <i>J</i> = 7.6 Hz, 2H), 3.09–3.02 (m, 2H), 2.71–2.69 (m, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.10, 154.42, 152.19, 148.90, 141.88, 139.09, 134.04, 131.73, 128.55, 127.79, 124.73, 124.57, 123.72, 116.76, 116.45, 115.07, 107.98, 84.62 (d, <i>J</i> = 165.0 Hz), 67.21, 57.64, 56.39 (d, <i>J</i> = 7.7 Hz), 31.37 (d, <i>J</i> = 20.1 Hz). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>25</sub>FNO<sub>4</sub>S, 478.1483; observed, 478.1408.</div></div><div id="sec8_13_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> (3-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(<i>o</i>-tolyl)methanone (<b>30d</b>)</h4><div class="NLM_p last">(Yield: 0.1 g, 20%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.37–7.15 (m, 4H), 7.08–7.06 (m, 2H), 6.81 (dd, <i>J</i> = 8.8, 1.9 Hz, 1H), 6.50 (d, <i>J</i> = 9.1 Hz, 2H), 6.32 (d, <i>J</i> = 9.0 Hz, 2H), 4.46 (dd, <i>J</i> = 47.3, 4.7 Hz, 2H), 3.93 (d, <i>J</i> = 4.7 Hz, 2H), 3.72 (d, <i>J</i> = 7.7 Hz, 2H), 3.39 (t, <i>J</i> = 7.2 Hz, 2H), 2.99 (br s, 3H), 2.16 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 191.02, 158.46, 153.55, 152.61, 149.90, 142.16, 139.48, 135.63, 130.35, 129.88, 127.44, 126.54, 126.29, 125.06, 125.05, 116.22, 115.87, 114.88, 108.36, 83.85 (d, <i>J</i> = 168.2 Hz), 65.97, 57.25, 56.15 (d, <i>J</i> = 6.2 Hz), 50.87, 31.30 (d, <i>J</i> = 20.6 Hz), 19.25. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>27</sub>FNO<sub>4</sub>S, 492.1645; observed, 492.1626.</div></div><div id="sec8_13_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> (4-Fluoro-2-methylphenyl)(3-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)methanone (<b>30e</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.0147 g, 23%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.48–7.42 (m, 1H), 7.40 (d, <i>J</i> = 9.2 Hz, 2H), 6.98 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.92 (d, <i>J</i> = 9.2 Hz, 2H), 6.72 (d, <i>J</i> = 9.1 Hz, 2H), 6.49 (d, <i>J</i> = 9.1 Hz, 2H), 4.54 (dd, <i>J</i> = 47.7, 6.3 Hz, 2H), 3.90 (t, <i>J</i> = 5.6 Hz, 2H), 3.40 (t, <i>J</i> = 7.2 Hz, 2H), 3.15 (t, <i>J</i> = 6.4 Hz, 2H), 2.76–2.74 (m, 3H), 2.17 (s, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.72, 163.26 (d, <i>J</i> = 247.5 Hz), 159.11, 154.47, 152.30, 149.52, 141.96, 139.11 (d, <i>J</i> = 8.6 Hz), 136.03, 130.05 (d, <i>J</i> = 9.1 Hz), 126.13 (d, <i>J</i> = 18.6 Hz), 124.88, 116.96, 116.85 (d, <i>J</i> = 21.6 Hz), 115.82, 115.10, 111.79 (d, <i>J</i> = 21.6 Hz), 108.02, 84.45 (d, <i>J</i> = 165.0 Hz), 67.16, 57.48, 56.35 (d, <i>J</i> = 7.6 Hz), 31.34 (d, <i>J</i> = 20.2 Hz), 18.55. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>26</sub>F<sub>2</sub>NO<sub>4</sub>S, 510.1472; observed, 510.1478.</div></div><div id="sec8_13_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> (4-Fluoro-2,6-dimethylphenyl)(3-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)methanone (<b>30f</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.4 g, 20%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.42 (d, <i>J</i> = 2.0 Hz, 1H), 7.31 (d, <i>J</i> = 8.8 Hz, 1H), 6.96 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.75–6.66 (m, 4H), 6.52–6.45 (m, 2H), 4.54 (dd, <i>J</i> = 47.7, 6.3 Hz, 2H), 3.90 (d, <i>J</i> = 5.6 Hz, 2H), 3.41 (t, <i>J</i> = 7.5 Hz, 2H), 3.12 (t, <i>J</i> = 6.5 Hz, 2H), 2.77–2.75 (m, 3H), 2.12 (s, 6H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 190.40, 162.21 (d, <i>J</i> = 244.4 Hz), 159.13, 154.52, 151.82, 149.70, 142.20, 137.06, 136.61 (d, <i>J</i> = 8.6 Hz), 127.30, 125.91, 125.20, 116.17, 115.52, 114.94, 113.64 (d, <i>J</i> = 21.5 Hz), 108.18, 84.52 (d, <i>J</i> = 165.1 Hz), 67.25, 57.56, 56.38 (d, <i>J</i> = 7.7 Hz), 31.36 (d, <i>J</i> = 20.2 Hz), 18.45. HRMS <i>m</i>/<i>z</i>: (M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>28</sub>F<sub>2</sub>NO<sub>4</sub>S, 524.1702; observed, 524.1694.</div></div><div id="sec8_13_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> (3-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(4-hydroxyphenyl)methanone (<b>30g</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.017 g, 15%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.78–7.66 (m, 2H), 7.43 (d, <i>J</i> = 8.8 Hz, 1H), 7.39 (d, <i>J</i> = 2.1 Hz, 1H), 6.98 (dd, <i>J</i> = 8.8, 2.2 Hz, 1H), 6.90–6.83 (m, 2H), 6.79–6.69 (m, 2H), 6.69–6.60 (m, 2H), 4.53 (dd, <i>J</i> = 47.7, 6.3 Hz, 2H), 3.88 (t, <i>J</i> = 5.6 Hz, 2H), 3.39 (d, <i>J</i> = 4.4 Hz, 2H), 3.10 (t, <i>J</i> = 6.6 Hz, 2H), 2.88–2.61 (m, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 186.50, 161.77, 158.18, 154.43, 152.24, 147.16, 140.87, 131.75, 129.97, 126.01, 124.86, 124.34, 116.56, 115.77, 115.10, 114.72, 107.81, 84.51 (d, <i>J</i> = 165.0 Hz), 67.10, 57.57, 56.34 (d, <i>J</i> = 7.7 Hz), 31.34 (d, <i>J</i> = 20.2 Hz). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>25</sub>FNO<sub>5</sub>S, 494.1359; observed, 494.1357.</div></div><div id="sec8_13_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> (3-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(4-hydroxy-2-methylphenyl)methanone (<b>30h</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.013 g, 18%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.32 (d, <i>J</i> = 8.5 Hz, 2H), 7.22 (d, <i>J</i> = 1.9 Hz, 1H), 6.90 (dd, <i>J</i> = 8.9, 2.0 Hz, 1H), 6.67 (d, <i>J</i> = 9.1 Hz, 2H), 6.61 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 6.57 (d, <i>J</i> = 2.1 Hz, 1H), 6.49 (d, <i>J</i> = 9.1 Hz, 2H), 4.53 (dd, <i>J</i> = 47.7, 6.4 Hz, 2H), 3.86 (t, <i>J</i> = 5.6 Hz, 2H), 3.37 (dd, <i>J</i> = 7.6, 6.3 Hz, 2H), 3.13–3.04 (t, <i>J</i> = 6.2 Hz, 2H), 2.72–2.69 (m, 3H), 2.09 (s, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.39, 163.61, 160.93, 154.18, 152.73, 148.74, 141.88, 138.99, 131.47, 130.01, 124.31, 123.98, 123.77, 117.79, 117.71, 116.09, 114.92, 112.00, 108.22, 84.64 (d, <i>J</i> = 164.9 Hz), 67.25, 57.63, 56.37 (d, <i>J</i> = 7.7 Hz), 31.37 (d, <i>J</i> = 20.1 Hz), 19.24. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>27</sub>FNO<sub>5</sub>S, 508.1516; observed, 508.1511.</div></div><div id="sec8_13_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> (3-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(4-fluorophenyl)methanone (<b>30i</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.015 g, 18%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.91–7.71 (m, 2H), 7.42–7.39 (m, 2H), 7.18 (t, <i>J</i> = 8.8 Hz, 2H), 7.00 (dd, <i>J</i> = 8.9, 2.0 Hz, 1H), 6.74 (d, <i>J</i> = 9.1 Hz, 2H), 6.64 (d, <i>J</i> = 9.1 Hz, 2H), 4.54 (dd, <i>J</i> = 47.7, 6.3 Hz, 2H), 3.89 (t, <i>J</i> = 5.6 Hz, 2H), 3.39 (t, <i>J</i> = 7.2 Hz, 2H), 3.10 (t, <i>J</i> = 6.5 Hz, 2H), 2.76–2.74 (m, 1H), 2.75 (t, <i>J</i> = 5.5 Hz, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 186.79, 165.02 (d, <i>J</i> = 250.6 Hz), 158.73, 154.54, 152.09, 148.53, 141.55, 135.19 (d, <i>J</i> = 2.0 Hz), 131.47 (d, <i>J</i> = 9.2 Hz), 125.78, 124.71, 124.39, 116.39, 115.98, 115.18, 114.83 (d, <i>J</i> = 22.1 Hz), 107.82, 84.53 (d, <i>J</i> = 165.0 Hz), 67.18, 57.53, 56.37 (d, <i>J</i> = 7.6 Hz), 31.35 (d, <i>J</i> = 20.2 Hz). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>24</sub>F<sub>2</sub>NO<sub>4</sub>S, 496.1316; observed, 496.1322.</div></div><div id="sec8_13_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> (3-(4-(2-(3-(Fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(3-fluorophenyl)methanone (<b>30j</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.034 g, 15%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.55 (dt, <i>J</i> = 7.6, 1.1 Hz, 1H), 7.49–7.38 (m, 4H), 7.36–7.26 (m, 1H), 6.98 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.74 (d, <i>J</i> = 9.2 Hz, 2H), 6.63 (d, <i>J</i> = 9.2 Hz, 2H), 4.54 (dd, <i>J</i> = 47.7, 6.3 Hz, 2H), 3.89 (t, <i>J</i> = 5.6 Hz, 2H), 3.39 (td, <i>J</i> = 7.7, 1.3 Hz, 2H), 3.13–3.05 (m, 2H), 2.84–2.68 (m, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 186.90, 162.20 (d, <i>J</i> = 245.3 Hz), 158.82, 154.60, 152.04, 149.15, 141.81, 141.06 (d, <i>J</i> = 6.7 Hz), 129.94 (d, <i>J</i> = 7.8 Hz), 125.79, 124.93, 124.51 (d, <i>J</i> = 2.8 Hz), 124.24, 118.53 (d, <i>J</i> = 21.5 Hz), 116.46, 116.06, 115.22, 114.95 (d, <i>J</i> = 23.1 Hz), 107.92, 84.54 (d, <i>J</i> = 164.9 Hz), 67.19, 57.57, 56.36 (d, <i>J</i> = 7.7 Hz), 31.35 (d, <i>J</i> = 20.1 Hz). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>24</sub>F<sub>2</sub>NO<sub>4</sub>S, 496.1316; observed, 496.1322. HPLC purity 95.04%.</div></div><div id="sec8_13_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> (2,4-Dimethylphenyl)(3-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)methanone (<b>30k</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.067 g, 18%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.42–7.38 (m, 2H), 7.28 (d, <i>J</i> = 7.5 Hz, 1H), 6.98 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.95 (s, 2H), 6.70 (d, <i>J</i> = 9.1 Hz, 2H), 6.46 (d, <i>J</i> = 9.1 Hz, 2H), 4.54 (dd, <i>J</i> = 47.7, 6.3 Hz, 2H), 3.89 (t, <i>J</i> = 5.6 Hz, 2H), 3.40 (t, <i>J</i> = 7.6 Hz, 2H), 3.11 (t, <i>J</i> = 6.5 Hz, 2H), 2.85–2.68 (m, 3H), 2.31 (s, 3H), (2.10, s, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 189.71, 158.80, 154.41, 152.42, 149.17, 141.66, 140.02, 136.82, 135.67, 131.03, 127.99, 126.44, 126.31, 125.56, 124.74, 115.97, 115.24, 114.95, 107.94, 84.54 (d, <i>J</i> = 165.1 Hz), 67.26, 57.57, 56.37 (d, <i>J</i> = 7.6 Hz), 31.37 (d, <i>J</i> = 20.2 Hz), 20.44, 18.54. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>29</sub>H<sub>29</sub>FNO<sub>4</sub>S, 506.1723; observed, 506.1713.</div></div><div id="sec8_13_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> (<i>R</i>)-(3-(4-(2-(3-(Fluoromethyl)pyrrolidin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(<i>o</i>-tolyl)methanone (<b>30l</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.028 g, 16%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.44–7.32 (m, 3H), 7.31–7.22 (m, 1H), 7.17–7.09 (m, 2H), 6.98 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.73 (d, <i>J</i> = 6.9 Hz, 2H), 6.45 (d <i>J</i> = 6.9 Hz, 2H), 4.34 (dd, <i>J</i> = 47.6, 6.8 Hz, 2H), 4.12–4.07 (m, 2H), 2.92–2.90 (m, 2H), 2.81–2.78 (m, 2H), 2.72–2.43 (m, 3H), 2.15 (s, 3H), 2.00–1.85 (m, 1H), 1.56–1.52 (m, 1H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 189.85, 158.89, 154.30, 152.37, 149.53, 141.87, 139.79, 135.31, 130.26, 129.77, 127.36, 126.41, 126.16, 125.03, 124.88, 116.03, 115.98, 115.16, 108.01, 85.46 (d, <i>J</i> = 167.1 Hz), 67.12, 56.28 (d, <i>J</i> = 5.1 Hz), 54.24, 53.83, 37.68 (d, <i>J</i> = 18.7 Hz), 25.75 (d, <i>J</i> = 6.9 Hz), 18.48. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>29</sub>H<sub>29</sub>FNO<sub>4</sub>S, 506.1796; observed, 506.1727.</div></div><div id="sec8_13_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> (<i>R</i>)-(4-Fluoro-2,6-dimethylphenyl)(3-(4-(2-(3-(fluoromethyl)pyrrolidin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)methanone (<b>30m</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.04 g, 20%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.45 (d, <i>J</i> = 1.8 Hz, 1H), 7.30 (d, <i>J</i> = 8.8 Hz, 1H), 6.98 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 6.78–6.73 (m, 2H), 6.68 (d, <i>J</i> = 9.8 Hz, 2H), 6.48 (d, <i>J</i> = 9.0 Hz, 2H), 4.34 (dd, <i>J</i> = 47.6, 6.8 Hz, 2H), 4.08 (t, <i>J</i> = 5.7 Hz, 2H), 2.92 (t, <i>J</i> = 5.7 Hz, 2H), 2.79–2.76 (m, 2H), 2.75–2.65 (m, 1H), 2.65–2.47 (m, 2H), 2.12 (s, 6H), 2.01–1.89 (m, 1H), 1.52–1.49 (m, 1H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 190.39, 162.21 (d, <i>J</i> = 244.4 Hz), 159.47, 154.37, 151.93, 149.75, 142.19, 137.07, 136.62 (d, <i>J</i> = 8.6 Hz), 127.15, 125.74, 125.10, 116.33, 115.54, 115.07, 113.64 (d, <i>J</i> = 21.5 Hz), 108.23, 85.47 (d, <i>J</i> = 167.2 Hz), 67.14, 56.30 (d, <i>J</i> = 5.3 Hz), 54.27, 53.86, 37.69 (d, <i>J</i> = 18.7 Hz), 25.78 (d, <i>J</i> = 6.9 Hz), 18.48. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>30</sub>H<sub>30</sub>F<sub>2</sub>NO<sub>4</sub>S, 538.1785; observed, 538.1798.</div></div><div id="sec8_13_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> (<i>S</i>)-(4-Fluoro-2,6-dimethylphenyl)(3-(4-(2-(3-(fluoromethyl)pyrrolidin-1-yl)ethoxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)methanone (<b>30n</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.10 g, 25%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.41 (d, <i>J</i> = 1.9 Hz, 1H), 7.31 (d, <i>J</i> = 8.8 Hz, 1H), 6.95 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.75 (d, <i>J</i> = 9.1 Hz, 2H), 6.70 (s, 1H), 6.67 (s, 1H), 6.48 (d, <i>J</i> = 9.1 Hz, 2H), 4.32 (dd, <i>J</i> = 47.7, 6.8 Hz, 2H), 4.05 (t, <i>J</i> = 5.7 Hz, 2H), 2.84 (t, <i>J</i> = 5.7 Hz, 2H), 2.76–2.66 (m, 2H), 2.62–2.46 (m, 3H), 2.12 (s, 6H), 1.92–1.85 (m, 1H), 1.48–1.45 (m, 1H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 190.41, 162.22 (d, <i>J</i> = 244.5 Hz), 159.14, 154.49, 151.86, 149.71, 142.20, 137.07 (d, <i>J</i> = 2.8 Hz) 136.62 (d, <i>J</i> = 8.7 Hz), 127.31, 125.92, 125.20, 116.19, 115.53, 115.03, 113.64 (d, <i>J</i> = 21.4 Hz), 108.20, 85.65 (d, <i>J</i> = 167.2 Hz), 67.48, 56.41 (d, <i>J</i> = 5.4 Hz), 54.36, 53.84, 37.74 (d, <i>J</i> = 18.6 Hz), 25.84 (d, <i>J</i> = 6.9 Hz), 18.47. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>30</sub>H<sub>30</sub>F<sub>2</sub>NO<sub>4</sub>S, 538.1785; observed, 538.1798.</div></div><div id="sec8_13_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> (6-Hydroxy-3-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)benzo[<i>b</i>]thiophen-2-yl)(<i>o</i>-tolyl) Methanone (<b>30o</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.04 g, 17%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.43 (d, <i>J</i> = 2.1 Hz, 1H), 7.37 (t, <i>J</i> = 8.3 Hz, 2H), 7.28 (td, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.14–7.12 (m, 2H), 6.98 (dd, <i>J</i> = 8.8, 2.2 Hz, 1H), 6.71 (d, <i>J</i> = 9.1 Hz, 2H), 6.45 (d, <i>J</i> = 9.1 Hz, 2H), 4.02 (t, <i>J</i> = 6.0 Hz, 2H), 2.69 (t, <i>J</i> = 6.0 Hz, 2H), 2.50–2.49 (m, 4H), 2.15 (s, 3H), 1.55–1.53 (m, 4H), 1.46–1.36 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 189.84, 159.07, 154.44, 152.29, 149.60, 141.89, 139.83, 135.30, 130.25, 129.75, 127.36, 126.31, 126.04, 125.03, 124.86, 116.11, 115.96, 115.13, 108.02, 66.45, 57.73, 54.79, 25.83, 24.08, 18.49. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>29</sub>H<sub>30</sub>NO<sub>4</sub>S, 488.1817; observed, 488.1819.</div></div><div id="sec8_13_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> <i>t</i>-Butyl 3-(4-(Benzyloxy)phenoxy)azetidine-1-carboxylate (<b>32</b>)</h4><div class="NLM_p last">To a solution of DMF (5 mL) was added 4-(benzyloxy)phenol (0.3 g, 1.5 mmol), <i>t</i>-butyl 3-(4-(benzyloxy)phenoxy)azetidine-1-carboxylate (0.5 g, 1.8 mmol), and cesium carbonate (1.4 g, 4.5 mmol). The reaction mixture was stirred at 140 °C for 3 h and monitored by TLC. Upon completion, the reaction mixture was extracted by ethyl acetate, washed by water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (10–50%) ethyl acetate in hexanes to give a white solid (yield: 0.33 g, 63%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.46–7.30 (m, 5H), 6.92 (d, <i>J</i> = 9.0 Hz, 2H), 6.70 (d, <i>J</i> = 9.0 Hz, 2H), 5.04 (s, 2H), 4.89–4.83 (m, 1H), 4.28 (dd, <i>J</i> = 9.6, 6.4 Hz, 2H), 4.01 (dd, <i>J</i> = 9.7, 4.1 Hz, 2H), 1.47 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 156.19, 153.62, 150.87, 137.11, 128.59, 127.96, 127.47, 116.04, 115.51, 79.78, 70.65, 66.05, 56.48, 28.38.</div></div><div id="sec8_13_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> 3-(4-(Benzyloxy)phenoxy)azetidine (<b>33</b>)</h4><div class="NLM_p last">To a solution of dichloromethane (5 mL) was added compound <b>32</b> (0.5 g, 1.9 mmol), followed by dropwise addition of TFA (0.72 mL, 9.5 mmol) at 0 °C. The reaction mixture then was stirred at room temperature and monitored by TLC. Upon completion, the reaction mixture was extracted by dichloromethane, washed by water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (1–10% methanol in dichloromethane) to give a white solid (yield: 0.3 g, 85%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.47 (d, <i>J</i> = 7.6 Hz, 2H), 7.40 (dd, <i>J</i> = 8.0, 7.0 Hz, 2H), 7.33 (t, <i>J</i> = 6.7 Hz, 1H), 6.96 (d, <i>J</i> = 8.9 Hz, 2H), 6.81 (d, <i>J</i> = 8.9 Hz, 2H), 5.08 (s, 2H), 4.75 (br s, 1H), 3.99–3.69 (m, 2H), 3.54–3.44 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 153.47, 151.28, 137.75, 128.37, 127.66, 127.46, 115.86, 115.58, 70.04, 65.29, 53.41.</div></div><div id="sec8_13_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> 3-(4-(Benzyloxy)phenoxy)-1-(3-fluoropropyl)azetidine (<b>34a</b>)</h4><div class="NLM_p last">To a solution of anhydrous DMF was added compound <b>33</b> (0.5 g, 1.9 mmol), followed by addition of NaH (0.15 g, 3.8 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 0.5 h. 1-Bromo-3-fluoropropane (0.53 g, 3.8 mmol) was added slowly to the reaction mixture in an ice bath. The reaction was stirred at 40 °C and monitored by TLC. Upon completion, the reaction was quenched by water and extracted by EtOAc, washed by water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic phase was evaporated under reduced pressure and purified by flash chromatography (1–100% EtOAc in hexanes) to give a white powder (yield: 0.37 g, 50%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.39–7.36 (m, 5H), 7.00–6.88 (m, 3H), 6.82–6.69 (m, 1H), 5.07 (s, 2H), 4.71 (p, <i>J</i> = 5.7 Hz, 1H), 4.49 (dt, <i>J</i> = 47.5, 6.1 Hz, 2H), 3.82–3.72 (m, 1H), 3.02–2.94 (m, 1H), 2.90–2.64 (m, 2H), 2.65–2.54 (m, 2H), 1.94–1.61 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 153.32, 151.56, 137.78, 128.36, 127.65, 127.47, 115.81, 115.43, 81.90 (d, <i>J</i> = 145.1 Hz), 70.05, 66.79, 61.21, 55.16 (d, <i>J</i> = 5.6 Hz), 27.62.</div></div><div id="sec8_13_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> 4-((1-(3-Fluoropropyl)azetidin-3-yl)oxy)phenol (<b>35a</b>)</h4><div class="NLM_p last">To a solution of methanol (10 mL) was added compound <b>34a</b> (0.5 g, 1.5 mmol) and palladium carbon (0.15 g, 0.15 mmol, 10 wt %). The reaction was degassed by hydrogen for at least three times and stirred at room temperature for 5 h monitored by TLC. Upon completion, the reaction mixture was extracted by ethyl acetate, washed by water and brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic extracts were evaporated under reduced pressure and purified by flash chromatography (1–10% methanol in dichloromethane) to give a white solid (yield: 0.3 g, 85%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 6.79–6.71 (m, 2H), 6.71–6.62 (m, 2H), 4.70–4.60 (m, 1H), 4.49 (dt, <i>J</i> = 47.5, 6.1 Hz, 2H), 3.78 (td, <i>J</i> = 6.1, 1.9 Hz, 1H), 2.98 (td, J = 5.7, 1.9 Hz, 2H), 2.88–2.64 (m, 1H), 2.55 (t, <i>J</i> = 6.9 Hz, 2H), 1.91–1.64 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 151.63, 150.53, 115.85, 115.52, 81.80 (d, <i>J</i> = 162.4 Hz), 70.05, 66.80, 61.28, 55.18 (d, <i>J</i> = 5.5 Hz).</div></div><div id="sec8_13_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> 4-((1-Cyclopropylazetidin-3-yl)oxy)phenol (<b>35b</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>35a</b> (yield: 0.14 g, 55%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): 6.80 (d, <i>J</i> = 9.0 Hz, 2H), 6.60 (d, <i>J</i> = 9.0 Hz, 2H), 5.75 (br s, 1H), 4.95 (m, 1H), 4.09 (dd, <i>J</i><sub><i>1</i></sub> = 11.6 Hz, <i>J</i><sub>2</sub> = 6.6 Hz, 2H), 3.54 (dd, <i>J</i><sub>1</sub> = 11.5, <i>J</i><sub>2</sub> = 5.8 Hz, 2H), 2.89 (m, 1H), 0.95 (m, 2H), 0.86 (m, 2H).</div></div><div id="sec8_13_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> (3-(4-((1-(3-Fluoropropyl)azetidin-3-yl)oxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(phenyl)methanone (<b>36a</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.13 g, 77%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.78–7.65 (m, 3H), 7.60–7.52 (m, 1H), 7.52–7.37 (m, 3H), 7.12 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 6.68–6.55 (m, 4H), 5.65–5.61 (m, 1H), 4.75–4.62 (m, 1H), 4.49 (dt, <i>J</i> = 47.5, 5.3 Hz, 2H), 3.78–3.69 (m, 4H), 2.97–2.95 (m 2H), 2.57–2.55 (m, 2H), 1.94–1.79 (m, 3H), 1.77–1.62 (m, 5H). <sup>13</sup>C NMR (101 MHz, acetone): δ 188.22, 157.83, 152.74, 152.46, 148.21, 140.98, 138.62, 132.19, 128.71, 127.96, 127.29, 125.67, 124.31, 116.94, 116.67, 115.38, 108.88, 96.46, 81.81 (d, <i>J</i> = 162.6 Hz), 66.80, 61.72, 61.05, 61.04, 55.13 (d, <i>J</i> = 5.0 Hz), 30.01, 24.97, 18.53.</div></div><div id="sec8_13_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> (4-Fluoro-2-methylphenyl)(3-(4-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)methanone (<b>36c</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.2 g, 72%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.68 (d, <i>J</i> = 2.1 Hz, 1H), 7.48 (d, <i>J</i> = 8.9 Hz, 1H), 7.12 (dd, <i>J</i> = 8.9, 2.2 Hz, 1H), 7.03 (d, <i>J</i> = 9.1 Hz, 1H), 6.92 (d, <i>J</i> = 9.3 Hz, 1H), 6.79 (d, <i>J</i> = 9.1 Hz, 1H), 6.64 (d, <i>J</i> = 9.1 Hz, 2H), 6.49 (d, <i>J</i> = 9.2 Hz, 2H), 5.64 (s, 1H), 4.72–4.64 (m, 1H), 4.48 (dt, <i>J</i> = 47.5, 6.1 Hz, 2H), 3.93–3.71 (m, 4H), 3.02 (br s, 4H), 2.58 (t, <i>J</i> = 6.8 Hz, 2H), 2.15 (s, 3H), 2.01–1.83 (m, 3H), 1.80–1.54 (m, 3H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.76, 163.38 (d, <i>J</i> = 247.9 Hz), 161.92, 158.19, 152.64, 149.09, 141.42, 139.32 (d, <i>J</i> = 8.6 Hz), 135.90, 130.25 (d, <i>J</i> = 9.2 Hz), 127.51, 124.43, 117.08, 117.07 (d, <i>J</i> = 23.0 Hz), 115.95, 115.42, 115.33, 111.86 (d, <i>J</i> = 21.7 Hz), 108.95, 96.44, 81.82 (d, <i>J</i> = 162.5 Hz), 66.83, 61.73, 61.14, 61.02, 55.12 (d, <i>J</i> = 5.4 Hz), 35.29, 29.97, 24.94, 18.50.</div></div><div id="sec8_13_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> (4-Fluoro-2,6-dimethylphenyl)(3-(4-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)methanone (<b>36d</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.16 g, 62%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.69 (d, <i>J</i> = 2.1 Hz, 1H), 7.39 (d, <i>J</i> = 8.9 Hz, 1H), 7.10 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.70 (s, 1H), 6.67 (s, 1H), 6.65 (d, <i>J</i> = 9.1 Hz, 2H), 6.48 (d, <i>J</i> = 9.1 Hz, 2H). 5.63–5.59 (m, 1H), 4.69–4.65 (m, 1H), 4.55 (t, <i>J</i> = 6.0 Hz, 1H), 4.43 (t, <i>J</i> = 6.0 Hz, 1H), 3.89–3.70 (m, 3H), 3.70–3.52 (m, 1H), 2.98–2.96 (m, 2H), 2.61–2.58 (m, 2H), 2.11 (s, 6H), 1.94–1.92 (m, 3H), 1.67–1.65 (m, 5H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 190.51, 162.28 (d, <i>J</i> = 244.6 Hz), 158.32, 152.74, 152.19, 149.26, 141.70, 136.86, 136.67 (d, <i>J</i> = 8.7 Hz), 128.52, 127.35, 124.73, 117.15, 115.60, 115.17, 113.70 (d, <i>J</i> = 21.5 Hz), 109.09, 96.39, 81.78 (d, <i>J</i> = 162.6 Hz), 66.85, 61.70, 60.98, 55.05 (d, <i>J</i> = 5.2 Hz), 29.94, 24.93, 18.47.</div></div><div id="sec8_13_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> (3-Fluorophenyl)(3-(4-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)methanone (<b>36e</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.1 g, 73%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.68 (d, <i>J</i> = 1.9 Hz, 1H), 7.56 (d, <i>J</i> = 7.7 Hz, 1H), 7.52–7.39 (m, 3H), 7.32–7.28 (m, 1H), 7.13 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.72–6.59 (m, 4H), 5.64 (t, <i>J</i> = 2.9 Hz, 1H), 4.71–4.68 (m, 1H), 4.49 (dt, <i>J</i> = 47.5, 6.0 Hz, 2H), 3.89–3.75 (m, 4H), 3.03 (d, <i>J</i> = 7.9 Hz, 2H), 2.61 (t, <i>J</i> = 7.0 Hz, 2H), 1.91–1.89 (m, 3H), 1.83–1.65 (m, 5H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 186.91, 162.23 (d, <i>J</i> = 245.5 Hz), 158.03, 152.78, 152.42, 148.73, 141.27, 140.85 (d, <i>J</i> = 6.6 Hz), 130.02 (d, <i>J</i> = 7.9 Hz), 127.14, 125.21, 124.59 (d, <i>J</i> = 2.7 Hz), 124.46, 118.75 (d, <i>J</i> = 21.4 Hz), 117.03, 116.63, 115.00 (d, <i>J</i> = 23.0 Hz), 114.89, 108.87, 96.44, 81.74 (d, <i>J</i> = 162.7 Hz), 66.73, 61.71, 60.94, 60.93, 54.95 (d, <i>J</i> = 5.5 Hz), 29.98, 24.94, 18.50.</div></div><div id="sec8_13_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> (3-(4-((1-Cyclopropylazetidin-3-yl)oxy)phenoxy)-6-((tetrahydro-2<i>H</i>-pyran-2-yl)oxy)benzo[<i>b</i>]thiophen-2-yl)(4-fluoro-2,6-dimethylphenyl)methanone (<b>36f</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>29a</b> (yield: 0.11 g, 75%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.70 (d, <i>J</i> = 2.0 Hz, 1H), 7.40 (d, <i>J</i> = 8.9 Hz, 1H), 7.11 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.70 (s, 1H), 6.67 (d, <i>J</i> = 6.6 Hz, 1H), 6.64 (d, <i>J</i> = 9.1 Hz, 2H), 6.48 (d, <i>J</i> = 9.1 Hz, 2H). 5.65 (t, <i>J</i> = 2.8 Hz, 1H), 4.65–4.62 (m, 1H), 3.92–3.81 (m, 1H), 3.78 (t, <i>J</i> = 7.2 Hz, 2H), 3.71–3.58 (m, 1H), 3.20–3.18 (m, 2H), 2.12 (s, 6H), 2.01–1.82 (m, 3H), 1.77–1.55 (m, 3H). 0.41–0.35 (m, 3H), 0.30–0.28 (m, 2H).</div></div><div id="sec8_13_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> (3-(4-((1-(3-Fluoropropyl)azetidin-3-yl)oxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(phenyl)methanone (<b>37a</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.03 g, 18%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.73–7.69 (m, 2H), 7.57–7.51 (m, 1H), 7.45–7.37 (m, 4H), 6.99 (dd, <i>J</i> = 8.9, 2.1 Hz, 1H), 6.66–6.53 (m, 4H), 4.67–4.63 (m, 1H), 4.48 (dt, <i>J</i> = 47.5, 6.1 Hz, 2H), 3.80–3.68 (m, 2H), 3.05–2.89 (m, 2H), 2.58 (t, <i>J</i> = 7.0 Hz, 2H), 1.82–1.63 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.19, 158.85, 152.65, 152.51, 148.54, 141.50, 138.82, 131.98, 128.60, 127.88, 125.82, 124.64, 124.54, 116.59, 116.08, 115.35, 107.91, 81.78 (d, <i>J</i> = 162.6 Hz), 66.78, 61.01, 55.10 (d, <i>J</i> = 5.7 Hz). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>25</sub>FNO<sub>4</sub>S, 478.1410; observed, 478.1472.</div></div><div id="sec8_13_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> (3-(4-((1-(3-Fluoropropyl)azetidin-3-yl)oxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)(<i>o</i>-tolyl)methanone (<b>37b</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.006 g, 17%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.43–7.41 (m, 2H), 7.36 (d, <i>J</i> = 7.6 Hz, 1H), 7.32–7.26 (m, 1H), 7.14 (t, <i>J</i> = 7.7 Hz, 2H), 6.98 (dd, <i>J</i> = 8.8, 1.9 Hz, 1H), 6.61 (d, <i>J</i> = 9.0 Hz, 2H), 6.44 (d, <i>J</i> = 9.0 Hz, 2H), 4.68 (dt, <i>J</i> = 11.3, 5.7 Hz, 1H), 4.49 (dt, <i>J</i> = 47.5, 6.1 Hz, 2H), 3.78–3.73 (m, 2H), 2.98–2.95 (m, 2H), 2.57 (t, <i>J</i> = 6.9 Hz, 2H), 2.13 (s, 3H), 1.82–1.65 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 189.79, 158.84, 152.67, 152.63, 149.41, 141.85, 139.71, 135.36, 130.27, 129.83, 127.41, 126.44, 126.26, 125.04, 124.82, 116.03, 115.22, 115.21, 107.97, 81.79 (d, <i>J</i> = 162.5 Hz), 66.81, 61.05, 55.13 (d, <i>J</i> = 5.6 Hz), 18.44. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>27</sub>FNO<sub>4</sub>S, 492.1639; observed, 492.1627.</div></div><div id="sec8_13_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> (4-Fluoro-2-methylphenyl)(3-(4-((1-(3-fluoropropyl)azetidin-3-yl)oxy) phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)methanone (<b>37c</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.015 g, 19%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.47–7.39 (m, 3H), 6.98 (dd, <i>J</i> = 8.8, 2.2 Hz, 1H), 6.94–6.86 (m, 2H), 6.63 (d, <i>J</i> = 9.1 Hz, 2H), 6.47 (d, <i>J</i> = 9.1 Hz, 2H), 4.77–4.64 (m, 1H), 4.49 (dt, <i>J</i> = 47.5, 6.1 Hz, 2H), 3.77 (t, <i>J</i> = 7.0 Hz, 2H), 3.06–2.96 (m, 2H), 2.59 (t, <i>J</i> = 6.9 Hz, 2H), 2.14 (s, 3H), 1.83–1.65 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 188.67, 163.30 (d, <i>J</i> = 247.6 Hz), 159.05, 149.38, 141.93, 139.17 (d, <i>J</i> = 8.6 Hz), 135.90, 130.11 (d, <i>J</i> = 9.1 Hz), 126.25, 126.15, 124.81, 117.80, 116.87 (d, <i>J</i> = 21.7 Hz), 116.17, 115.89, 115.42, 115.31, 111.80 (d, <i>J</i> = 21.8 Hz), 108.01, 81.79 (d, <i>J</i> = 162.7 Hz), 66.83, 61.00, 55.12 (d, <i>J</i> = 5.6 Hz), 18.54. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>26</sub>F<sub>2</sub>NO<sub>4</sub>S, 510.1545; observed, 510.1537.</div></div><div id="sec8_13_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> (4-Fluoro-2,6-dimethylphenyl)(3-(4-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)methanone (<b>37d</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 2.0 g, 25%). <sup>1</sup>H NMR (400 MHz, acetone): δ 7.42 (d, <i>J</i> = 2.0 Hz, 1H), 7.34 (d, <i>J</i> = 8.8 Hz, 1H), 6.97 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.75–6.59 (m, 4H), 6.54–6.39 (m, 2H), 4.77–4.65 (m, 1H), 4.55 (t, <i>J</i> = 6.0 Hz, 1H), 4.43 (t, <i>J</i> = 6.1 Hz, 1H), 3.77–3.75 (m, 2H), 3.10–2.92 (m, 2H), 2.60 (t, <i>J</i> = 6.9 Hz, 2H), 2.11 (s, 6H), 1.75–1.65 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 190.36, 162.25 (d, <i>J</i> = 244.6 Hz), 159.15, 152.69, 152.22, 149.54, 142.18, 136.98, 136.64 (d, <i>J</i> = 8.6 Hz), 127.44, 126.03, 125.12, 116.23, 115.57, 115.15, 113.66 (d, <i>J</i> = 21.5 Hz), 108.19, 81.80 (d, <i>J</i> = 162.6 Hz), 66.86, 61.01, 60.98, 55.12 (d, <i>J</i> = 5.6 Hz), 18.46. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>29</sub>H<sub>28</sub>F<sub>2</sub>NO<sub>4</sub>S, 524.1629; observed, 524.1627.</div></div><div id="sec8_13_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> (3-Fluorophenyl)(3-(4-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen-2-yl)methanone (<b>37e</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.03 g, 22%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.53 (d, <i>J</i> = 7.6 Hz, 1H), 7.50–7.35 (m, 4H), 7.30 (td, <i>J</i> = 8.4, 1.8 Hz, 1H), 7.00 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 6.63 (q, <i>J</i> = 9.3 Hz, 4H), 4.68 (p, <i>J</i> = 5.7 Hz, 1H), 4.48 (dt, <i>J</i> = 47.5, 6.1 Hz, 2H), 3.75 (t, <i>J</i> = 7.2 Hz, 2H), 3.05–2.91 (m, 2H), 2.58 (t, <i>J</i> = 6.9 Hz, 2H), 1.83–1.63 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 186.85, 162.20 (d, <i>J</i> = 245.2 Hz), 159.30, 152.75, 152.42, 149.13, 141.84, 141.08 (d, <i>J</i> = 6.7 Hz), 129.94 (d, <i>J</i> = 7.8 Hz), 125.56, 124.78, 124.51, 124.01, 118.51 (d, <i>J</i> = 21.5 Hz), 116.54, 116.27, 115.44, 114.92 (d, <i>J</i> = 23.0 Hz), 107.94, 81.79 (d, <i>J</i> = 162.5 Hz), 66.80, 60.99, 55.11 (d, <i>J</i> = 5.6 Hz). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>24</sub>F<sub>2</sub>NO<sub>4</sub>S, 496.1389; observed, 496.1402.</div></div><div id="sec8_13_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> (3-(4-((1-Cyclopropylazetidin-3-yl)oxy)phenoxy)-6-hydroxybenzo[<i>b</i>]thiophen -2-yl)(4-fluoro-2,6-dimethylphenyl)methanone (<b>37f</b>)</h4><div class="NLM_p last">This compound was prepared using a procedure similar to that of <b>30a</b> (yield: 0.03 g, 19%). <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>): δ 7.44 (d, <i>J</i> = 2.1 Hz, 1H), 7.32 (d, <i>J</i> = 8.8 Hz, 1H), 6.98 (dd, <i>J</i> = 8.8, 2.1 Hz, 1H), 6.69 (s, 1H), 6.66 (s, 1H), 6.64 (d, <i>J</i> = 9.1 Hz, 2H), 6.46 (d, <i>J</i> = 9.1 Hz, 2H). 4.64–4.61 (m, 1H), 3.79–3.69 (m, 2H), 3.20–3.10 (m, 2H), 2.12 (s, 6H), 1.90–1.88 (m, 1H), 0.36–0.34 (m, 2H), 0.30–0.22 (m, 2H). <sup>13</sup>C NMR (101 MHz, acetone-<i>d</i><sub>6</sub>): δ 190.31, 162.23 (d, <i>J</i> = 244.4 Hz) 159.53, 152.72, 152.20, 149.59, 142.19, 137.03, 136.63 (d, <i>J</i> = 8.7 Hz), 126.82, 125.80, 125.02, 116.35, 115.54, 115.09, 113.63 (d, <i>J</i> = 21.5 Hz), 108.18, 66.91, 60.34, 37.94, 18.44, 4.52. HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>29</sub>H<sub>27</sub>FNO<sub>4</sub>S, 504.1567; observed, 504.1572.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i128"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01580" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17137" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17137" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01580?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01580</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings, effect of <b>30o</b> treatment on the ER level. , representative western blot, PK profiles for <b>37d</b>., ER isoform binding specificity, molecular orbital calculations, final compound spectra, final compound purity, and PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K">1R5K</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ACC">5ACC</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UFX">5UFX</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_001.pdf">jm9b01580_si_001.pdf (7.8 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_002.csv">jm9b01580_si_002.csv (2.8 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01580" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87012" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87012" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregory R. J. Thatcher</span> - <span class="hlFld-Affiliation affiliation">UICentre
(Drug Discovery @ UIC), 
     and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Psychiatry, University of Illinois at
Chicago, 1601 W Taylor Street, Chicago, Illinois 60612, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7757-1739" title="Orcid link">http://orcid.org/0000-0002-7757-1739</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a1d5c9c0d5c2c9c4d3e1d4c8c28fc4c5d4"><span class="__cf_email__" data-cfemail="6f1b070e1b0c070a1d2f1a060c410a0b1a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yunlong Lu</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences,
University of Illinois College of Pharmacy and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lauren M. Gutgesell</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences,
University of Illinois College of Pharmacy and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7645-9227" title="Orcid link">http://orcid.org/0000-0002-7645-9227</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rui Xiong</span> - <span class="hlFld-Affiliation affiliation">UICentre
(Drug Discovery @ UIC), 
    Department of Pharmaceutical Sciences,
University of Illinois College of Pharmacy, 
     and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6350-9037" title="Orcid link">http://orcid.org/0000-0002-6350-9037</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiong Zhao</span> - <span class="hlFld-Affiliation affiliation">UICentre
(Drug Discovery @ UIC) and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yangfeng Li</span> - <span class="hlFld-Affiliation affiliation">UICentre
(Drug Discovery @ UIC) and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carlo I. Rosales</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences,
University of Illinois College of Pharmacy and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Hollas</span> - <span class="hlFld-Affiliation affiliation">UICentre
(Drug Discovery @ UIC) and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhengnan Shen</span> - <span class="hlFld-Affiliation affiliation">UICentre
(Drug Discovery @ UIC) and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jesse Gordon-Blake</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences,
University of Illinois College of Pharmacy and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine Dye</span> - <span class="hlFld-Affiliation affiliation">UICentre
(Drug Discovery @ UIC) and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yueting Wang</span> - <span class="hlFld-Affiliation affiliation">UICentre
(Drug Discovery @ UIC) and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sue Lee</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences,
University of Illinois College of Pharmacy and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hu Chen</span> - <span class="hlFld-Affiliation affiliation">Department
of Psychiatry, University of Illinois at
Chicago, 1601 W Taylor Street, Chicago, Illinois 60612, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donghong He</span> - <span class="hlFld-Affiliation affiliation">Department
of Psychiatry, University of Illinois at
Chicago, 1601 W Taylor Street, Chicago, Illinois 60612, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Oleksii Dubrovyskyii</span> - <span class="hlFld-Affiliation affiliation">UICentre
(Drug Discovery @ UIC) and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huiping Zhao</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences,
University of Illinois College of Pharmacy and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fei Huang</span> - <span class="hlFld-Affiliation affiliation">UICentre
(Drug Discovery @ UIC) and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amy W. Lasek</span> - <span class="hlFld-Affiliation affiliation">Department
of Psychiatry, University of Illinois at
Chicago, 1601 W Taylor Street, Chicago, Illinois 60612, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7099-2442" title="Orcid link">http://orcid.org/0000-0002-7099-2442</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Debra A. Tonetti</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Sciences,
University of Illinois College of Pharmacy and , University of Illinois at Chicago, 833 S Wood Street, Chicago, Illinois 60612, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.L. and L.G. contributed equally. The manuscript was written and the research directed by G.T. Drug design and synthesis was directed by R.X. and synthesis performed by Y.L. Cell culture bioassays were designed and data collected by L.G. who assisted in writing. Intermediate synthesis, scale-up, synthetic optimization, and purification was supported by Y.L., C.R., M.H., Z.S., J.G.-B. Cell line and bioassay development was led by J.Z. and D.T. PK was run by Y.W. and K.D. Biological support was provided by O.D., H.Z., S.L. and F.H. Intact mouse immunoassays were performed by A.L., H.C., and D.H. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i130">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44055" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44055" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">For financial support: Chancellor’s Proof-of-Concept Fund, UICentre (Drug Discovery @ UIC), UIC Center for Clinical and Translational Science grant UL1RR029879 and UL1TR002003. We would also like to thank John A. Katzenellenbogen, Kathryn Carlson and Teresa Martin (Department of Chemistry, University of Illinois at Urbana–Champaign), for carrying out RBA assays and scientific insight. We thank David Shapiro (Department of Biochemistry, University of Illinois at Urbana-Champaign) for providing <i>ESR1</i> mutant cell lines.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AIs</td><td class="NLM_def"><p class="first last">aromatase inhibitors</p></td></tr><tr><td class="NLM_term">B-SERD</td><td class="NLM_def"><p class="first last">basic selective estrogen receptor degrader</p></td></tr><tr><td class="NLM_term">Cdk</td><td class="NLM_def"><p class="first last">cyclin-dependent kinases</p></td></tr><tr><td class="NLM_term">ER+</td><td class="NLM_def"><p class="first last">estrogen receptor positive</p></td></tr><tr><td class="NLM_term">ERα</td><td class="NLM_def"><p class="first last">estrogen receptor α</p></td></tr><tr><td class="NLM_term">ERβ</td><td class="NLM_def"><p class="first last">estrogen receptor β</p></td></tr><tr><td class="NLM_term">E<sub>2</sub></td><td class="NLM_def"><p class="first last">estradiol</p></td></tr><tr><td class="NLM_term">ERE</td><td class="NLM_def"><p class="first last">estrogen response element</p></td></tr><tr><td class="NLM_term">HPCD</td><td class="NLM_def"><p class="first last">2-hydroxypropyl-β-cyclodextrin</p></td></tr><tr><td class="NLM_term">ICW</td><td class="NLM_def"><p class="first last">in-cell western</p></td></tr><tr><td class="NLM_term">MBC</td><td class="NLM_def"><p class="first last">metastatic breast cancer</p></td></tr><tr><td class="NLM_term">PEG-400</td><td class="NLM_def"><p class="first last">polyethylene glycol 400</p></td></tr><tr><td class="NLM_term">PCC</td><td class="NLM_def"><p class="first last">pyridinium chlorochromate</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">RBA</td><td class="NLM_def"><p class="first last">relative binding affinity</p></td></tr><tr><td class="NLM_term">RT</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SBE-β-CD</td><td class="NLM_def"><p class="first last">sulfobutylether-β-cyclodextrin</p></td></tr><tr><td class="NLM_term">SERM</td><td class="NLM_def"><p class="first last">selective estrogen receptor modulator</p></td></tr><tr><td class="NLM_term">SERD</td><td class="NLM_def"><p class="first last">selective estrogen receptor degrader</p></td></tr><tr><td class="NLM_term">TAM</td><td class="NLM_def"><p class="first last">tamoxifen</p></td></tr><tr><td class="NLM_term">4OH-TAM</td><td class="NLM_def"><p class="first last">4-hydroxy tamoxifen</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyran</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i132">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64402" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64402" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 55 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soerjomataram, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Global Cancer Statistics 2018: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.3322/caac.21492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.3322%2Fcaac.21492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=30207593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BB3c3otVGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2018&pages=394-424&author=F.+Brayauthor=J.+Ferlayauthor=I.+Soerjomataramauthor=R.+L.+Siegelauthor=L.+A.+Torreauthor=A.+Jemal&title=Global+Cancer+Statistics+2018%3A+Globocan+Estimates+of+Incidence+and+Mortality+Worldwide+for+36+Cancers+in+185+Countries&doi=10.3322%2Fcaac.21492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</span></div><div class="casAuthors">Bray Freddie; Ferlay Jacques; Soerjomataram Isabelle; Siegel Rebecca L; Torre Lindsey A; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">394-424</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.  There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018.  In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality.  Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality).  Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality.  The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors.  It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries.  The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts.  CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQaW5wv8ocuhLxanA7vODO6fW6udTcc2eYFVRkQjFtfb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3otVGlsg%253D%253D&md5=48529f8f794092779d70a27eec5c9017</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21492%26sid%3Dliteratum%253Aachs%26aulast%3DBray%26aufirst%3DF.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DSoerjomataram%26aufirst%3DI.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520Cancer%2520Statistics%25202018%253A%2520Globocan%2520Estimates%2520of%2520Incidence%2520and%2520Mortality%2520Worldwide%2520for%252036%2520Cancers%2520in%2520185%2520Countries%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2018%26volume%3D68%26spage%3D394%26epage%3D424%26doi%3D10.3322%2Fcaac.21492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuqua, S.</span></span> <span> </span><span class="NLM_article-title">The Role of the Estrogen Receptor in Tumor Progression</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/0960-0760(95)00269-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2F0960-0760%2895%2900269-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=8603051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK28XitVeqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1996&pages=87-91&author=P.+Lemieuxauthor=S.+Fuqua&title=The+Role+of+the+Estrogen+Receptor+in+Tumor+Progression&doi=10.1016%2F0960-0760%2895%2900269-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the estrogen receptor in tumor progression</span></div><div class="casAuthors">Lemieux, Pierre; Fuqua, Suzanne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1-6</span>),
    <span class="NLM_cas:pages">87-91</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review, with 21 refs., on two estrogen receptor (ER) variants that may play a role in breast cancer initiation or progression.  One is a truncated receptor, which has been named the exon 5 ER deletion variant, and the other is called a hypersensitive variant of the ER that is sensitive to low levels of hormone.  Both ER variants differ from the wild-type ER in their hormone binding domains (HBD).  The exon 5 ER deletion variant lacks a large portion of the HBD, while the hypersensitive ER variant has a point mutation is a conserved region of the HBD.  The exon 5 ER deletion variant is transcriptionally active in the absence of hormone, and is thus considered constitutively-active.  In contrast, the hypersensitive ER variant is functionally active in response to subphysiol. concns. of estrogen.  Both ER variants may form productive heterodimers with wild-type receptor to modify the normal function of ER in the breast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMqMnUTYnH0LVg90H21EOLACvtfcHk0ljtiElFT8QnVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitVeqt70%253D&md5=4dc70b88baf6be60b13b3aff06762f35</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0960-0760%2895%2900269-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-0760%252895%252900269-3%26sid%3Dliteratum%253Aachs%26aulast%3DLemieux%26aufirst%3DP.%26aulast%3DFuqua%26aufirst%3DS.%26atitle%3DThe%2520Role%2520of%2520the%2520Estrogen%2520Receptor%2520in%2520Tumor%2520Progression%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D1996%26volume%3D56%26spage%3D87%26epage%3D91%26doi%3D10.1016%2F0960-0760%2895%2900269-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuqua, S. A. W.</span></span> <span> </span><span class="NLM_article-title">Estrogen Receptor and Breast Cancer</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1006/scbi.2001.0389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1006%2Fscbi.2001.0389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=11562176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmvVGgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=339-352&author=S.+Sommerauthor=S.+A.+W.+Fuqua&title=Estrogen+Receptor+and+Breast+Cancer&doi=10.1006%2Fscbi.2001.0389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor and breast cancer</span></div><div class="casAuthors">Sommer, Stephanie; Fuqua, Suzanne A. W.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">339-352</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review.  Breast cancer, the most common malignancy in women, was already known to be assocd. with the steroid hormone estrogen more than a century ago.  The discovery of the estrogen receptor (ER) provided not only a powerful predictive and prognostic marker, but also an efficient target for the treatment of hormone-dependent breast cancer with antiestrogens.  In this paper the authors will sketch the important role of ER in the development, progression, and treatment of the disease, which is complicated by the receptor's interaction with co-regulatory proteins, its cross-talk with other signal transduction pathways, and its involvement in the development of antiestrogen resistance.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosLN8VQ1UX_bVg90H21EOLACvtfcHk0lhvB3EVybK0Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmvVGgtro%253D&md5=6681648d7604b4c3c3404e6782888818</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1006%2Fscbi.2001.0389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fscbi.2001.0389%26sid%3Dliteratum%253Aachs%26aulast%3DSommer%26aufirst%3DS.%26aulast%3DFuqua%26aufirst%3DS.%2BA.%2BW.%26atitle%3DEstrogen%2520Receptor%2520and%2520Breast%2520Cancer%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2001%26volume%3D11%26spage%3D339%26epage%3D352%26doi%3D10.1006%2Fscbi.2001.0389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S. R.</span></span> <span> </span><span class="NLM_article-title">Endocrine Therapy—Current Benefits and Limitations</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">S3</span>– <span class="NLM_lpage">S10</span>, <span class="refDoi"> DOI: 10.1007/s10549-005-9036-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1007%2Fs10549-005-9036-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=16247594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCrtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2005&pages=S3-S10&author=R.+I.+Nicholsonauthor=S.+R.+Johnston&title=Endocrine+Therapy%E2%80%94Current+Benefits+and+Limitations&doi=10.1007%2Fs10549-005-9036-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine therapy - current benefits and limitations</span></div><div class="casAuthors">Nicholson, Robert I.; Johnston, Stephen R.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S3-S10</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Endocrine therapy is a valuable option for the treatment of postmenopausal women with estrogen receptor (ER)-pos. breast cancer due to its demonstrated efficacy and favorable safety profile.  Although tamoxifen has been the established treatment for more than 20 years its long-term use is assocd. with several tolerability concerns and may lead to increased risk of endometrial cancer and thromboembolic complications.  In addn., many patients who initially respond to treatment with endocrine agents such as tamoxifen eventually relapse with resistant disease.  Sequential use of endocrine therapies is often used in patients as resistance to individual agents develops.  Several endocrine approaches have been developed that deprive the tumor of estrogen stimulation, either by directly modulating the ER-signaling pathway or by lowering serum or tumor concns. of estrogen.  In the classic pathway of estrogen signal transduction, the steroid hormone binds to its intracellular ER, triggering a cascade of events that ultimately leads to altered gene transcription.  More recently, it has become apparent that ER activation can also occur via estrogen-independent receptor activation or by non-nuclear action through cell surface receptors.  Consequently, mol. cross-talk exists between the ER and growth factor signaling cascades, which is a key factor in de novo and acquired resistance to endocrine therapy.  Inappropriate activation of growth factor signaling can readily promote endocrine therapy failure in breast cancer cells, either by overriding the growth-inhibitory properties of antiestrogenic drugs or by establishment of a new self-propagating autocrine loop that efficiently drives resistant cell growth.  Fulvestrant is a new type of ER antagonist with no agonist effects that binds, blocks and causes degrdn. of the ER.  As multiple signaling pathways are involved in the activation of ER, the use of agents such as fulvestrant that directly target the ER and lead to both degrdn. of the receptor and abrogation of ER signaling may prevent or delay the development of abs. endocrine resistance.  In addn., combining antiestrogenic drugs with inhibitors of cell signaling mols. to target both the ER and growth factor signaling pathways is likely to provide a means of delaying endocrine therapy resistance, leading the way to more effective breast cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnw_J604wgnrVg90H21EOLACvtfcHk0lhvB3EVybK0Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCrtb3O&md5=458ae0143f990ddd739e9ae4dd1cfaea</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs10549-005-9036-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-005-9036-4%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26aulast%3DJohnston%26aufirst%3DS.%2BR.%26atitle%3DEndocrine%2520Therapy%25E2%2580%2594Current%2520Benefits%2520and%2520Limitations%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2005%26volume%3D93%26spage%3DS3%26epage%3DS10%26doi%3D10.1007%2Fs10549-005-9036-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span> <span> </span><span class="NLM_article-title">Aromatase Inhibitors in Breast Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">2431</span>– <span class="NLM_lpage">2442</span>, <span class="refDoi"> DOI: 10.1056/nejmra023246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1056%2Fnejmra023246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=12802030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksFKguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=2431-2442&author=I.+E.+Smithauthor=M.+Dowsett&title=Aromatase+Inhibitors+in+Breast+Cancer&doi=10.1056%2Fnejmra023246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase inhibitors in breast cancer</span></div><div class="casAuthors">Smith, Ian E.; Dowsett, Mitch</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2431-2442</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  This review discusses the role of aromatase inhibitors and assess their potential for clin. use in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYF49NFDFgm7Vg90H21EOLACvtfcHk0lhvB3EVybK0Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksFKguro%253D&md5=da7b56d4a1f0e7b2e27c8819a0ae0951</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2Fnejmra023246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmra023246%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DDowsett%26aufirst%3DM.%26atitle%3DAromatase%2520Inhibitors%2520in%2520Breast%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D2431%26epage%3D2442%26doi%3D10.1056%2Fnejmra023246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for an Unexpected Mode of Serm-Mediated Er Antagonism</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2005.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fj.molcel.2005.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=15893725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=413-424&author=Y.-L.+Wuauthor=X.+Yangauthor=Z.+Renauthor=D.+P.+McDonnellauthor=J.+D.+Norrisauthor=T.+M.+Willsonauthor=G.+L.+Greene&title=Structural+Basis+for+an+Unexpected+Mode+of+Serm-Mediated+Er+Antagonism&doi=10.1016%2Fj.molcel.2005.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span></div><div class="casAuthors">Wu, Ya-Ling; Yang, Xiaojing; Ren, Zhong; McDonnell, Donald P.; Norris, John D.; Willson, Timothy M.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-424</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tamoxifen is effective for the prevention and treatment of estrogen-dependent breast cancers, but is assocd. with an increased incidence of endometrial tumors.  The authors report the crystal structure of the estrogen receptor α (ERα) ligand binding domain (LBD) bound to the structurally similar compd. GW5638, which has therapeutic potential and does not stimulate the uterus.  Like tamoxifen, GW5638 relocates the carboxy-terminal helix (H12) to the known coactivator-docking site in the ERα LBD.  However, GW5638 repositions residues in H12 through specific contacts with the N terminus of this helix.  In contrast to tamoxifen, the resulting increase in exposed hydrophobic surface of ERα LBD correlates with a significant destabilization of ERα in MCF-7 cells.  Thus, the GW5638-ERα LBD structure reveals an unexpected mode of SERM-mediated ER antagonism, in which the stability of ERα is decreased through an altered position of H12.  This dual mechanism of antagonism may explain why GW5638 can inhibit tamoxifen-resistant breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBuyhLNSdbQbVg90H21EOLACvtfcHk0lgHZPksU6N1zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D&md5=c60e01b31b57c07b934da01a34efb255</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DStructural%2520Basis%2520for%2520an%2520Unexpected%2520Mode%2520of%2520Serm-Mediated%2520Er%2520Antagonism%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D18%26spage%3D413%26epage%3D424%26doi%3D10.1016%2Fj.molcel.2005.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span> <span> </span><span class="NLM_article-title">Tamoxifen: Catalyst for the Change to Targeted Therapy</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2007.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fj.ejca.2007.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=18068350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOrurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=30-38&author=V.+C.+Jordan&title=Tamoxifen%3A+Catalyst+for+the+Change+to+Targeted+Therapy&doi=10.1016%2Fj.ejca.2007.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen: Catalyst for the change to targeted therapy</span></div><div class="casAuthors">Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-38</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In the early 1970s, a failed post-coital contraceptive, ICI 46,474, was reinvented as tamoxifen, the first targeted therapy for breast cancer.  A cluster of papers published in the European Journal of Cancer described the idea of targeting tamoxifen to patients with estrogen receptor pos. tumors, and proposed the strategic value of using long-term tamoxifen therapy in an adjuvant setting with a consideration of the antitumor properties of the hydroxylated metabolites of tamoxifen.  At the time, these lab. results were slow to be embraced by the clin. community.  Today, it is estd. that hundreds of thousands of breast cancer patients are alive today because of targeted long-term adjuvant tamoxifen therapy.  Addnl., the first lab. studies for the use of tamoxifen as a chemopreventive were published.  Eventually, the worth of tamoxifen was tested as a chemopreventive and the drug is now known to have an excellent risk benefit ratio in high risk pre-menopausal women.  Overall, the rigorous investigation of the pharmacol. of tamoxifen facilitated tamoxifen's ubiquitous use for the targeted treatment of breast cancer, chemoprevention and pioneered the exploration of selective estrogen receptor modulators (SERMs).  This new concept subsequently heralded the development of raloxifene, a failed breast cancer drug, for the prevention of osteoporosis and breast cancer without the troublesome side-effect of endometrial cancer noted in post-menopausal women who take tamoxifen.  Currently, the pharmaceutical industry is exploiting the SERM concept for all members of the nuclear receptor superfamily so that medicines can now be developed for diseases once thought impossible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVfO9kqT3cB7Vg90H21EOLACvtfcHk0lgHZPksU6N1zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOrurvL&md5=2be14fc39925c60ce7ffe1c0b9991784</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2007.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2007.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DTamoxifen%253A%2520Catalyst%2520for%2520the%2520Change%2520to%2520Targeted%2520Therapy%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2008%26volume%3D44%26spage%3D30%26epage%3D38%26doi%3D10.1016%2Fj.ejca.2007.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haque, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inzhakova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polikoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enger, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, M. F.</span></span> <span> </span><span class="NLM_article-title">Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades</span>. <i>Cancer Epidemiol., Biomarkers Prev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1848</span>– <span class="NLM_lpage">1855</span>, <span class="refDoi"> DOI: 10.1158/1055-9965.epi-12-0474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F1055-9965.epi-12-0474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=22989461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BC38botV2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=1848-1855&author=R.+Haqueauthor=S.+A.+Ahmedauthor=G.+Inzhakovaauthor=J.+Shiauthor=C.+Avilaauthor=J.+Polikoffauthor=L.+Bernsteinauthor=S.+M.+Engerauthor=M.+F.+Press&title=Impact+of+Breast+Cancer+Subtypes+and+Treatment+on+Survival%3A+An+Analysis+Spanning+Two+Decades&doi=10.1158%2F1055-9965.epi-12-0474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades</span></div><div class="casAuthors">Haque Reina; Ahmed Syed A; Inzhakova Galina; Shi Jiaxiao; Avila Chantal; Polikoff Jonathan; Bernstein Leslie; Enger Shelley M; Press Michael F</div><div class="citationInfo"><span class="NLM_cas:title">Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1848-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  We investigated the impact of breast cancer molecular subtypes and treatment on survival in a cohort of medically insured women followed for more than 20 years.  METHODS:  We examined 934 female members of an integrated health care delivery system newly diagnosed with invasive breast cancer between 1988 and 1995 and followed them through 2008.  Tumors were classified into four molecular subtypes on the basis of their expression profile: luminal A; luminal B; basal-like; and HER2-enriched.  We followed women from the surgery date to death, health plan disenrollment, or study's end.  HR and 95% confidence intervals (CI) were fit using Cox proportional hazards models adjusting for cancer treatments and tumor characteristics.  RESULTS:  A total of 223 (23.9%) women died because of breast cancer during the 21-year study period.  Compared with women with luminal A tumors, women with HER2-enriched (HR 2.56, 95% CI 1.53-4.29) and luminal B tumors (HR 1.96, 95% CI: 1.08-3.54) had roughly a two-fold increased adjusted risk of breast cancer mortality.  In addition, the survival curves suggest that risk of late mortality persists in women with luminal A tumors.  CONCLUSION:  Among women with health care coverage, molecular subtypes were important predictors of breast cancer mortality.  Women with HER2-enriched tumors and luminal B subtypes had the poorest survival despite adjusting for important covariates.  IMPACT:  In a cohort followed for more than 20 years, women with HER2-enriched tumors had worse survival, but interestingly, the survival curve for women with luminal A tumors continued to steadily decline after 10 years of follow-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeN7vhwbxeaiCEBeYuoi7AfW6udTcc2eb3Hz57VJTJxLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38botV2juw%253D%253D&md5=5b4b12706786b4ce33dbef167afce819</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1055-9965.epi-12-0474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1055-9965.epi-12-0474%26sid%3Dliteratum%253Aachs%26aulast%3DHaque%26aufirst%3DR.%26aulast%3DAhmed%26aufirst%3DS.%2BA.%26aulast%3DInzhakova%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DAvila%26aufirst%3DC.%26aulast%3DPolikoff%26aufirst%3DJ.%26aulast%3DBernstein%26aufirst%3DL.%26aulast%3DEnger%26aufirst%3DS.%2BM.%26aulast%3DPress%26aufirst%3DM.%2BF.%26atitle%3DImpact%2520of%2520Breast%2520Cancer%2520Subtypes%2520and%2520Treatment%2520on%2520Survival%253A%2520An%2520Analysis%2520Spanning%2520Two%2520Decades%26jtitle%3DCancer%2520Epidemiol.%252C%2520Biomarkers%2520Prev.%26date%3D2012%26volume%3D21%26spage%3D1848%26epage%3D1855%26doi%3D10.1158%2F1055-9965.epi-12-0474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maximov, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span> <span> </span><span class="NLM_article-title">Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations</span>. <i>Horm. Mol. Biol. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1515/hmbci-2011-0004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1515%2Fhmbci-2011-0004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=23308083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtFaitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=143-163&author=E.+E.+Sweeneyauthor=R.+E.+McDanielauthor=P.+Y.+Maximovauthor=P.+Fanauthor=V.+C.+Jordan&title=Models+and+Mechanisms+of+Acquired+Antihormone+Resistance+in+Breast+Cancer%3A+Significant+Clinical+Progress+Despite+Limitations&doi=10.1515%2Fhmbci-2011-0004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations</span></div><div class="casAuthors">Sweeney, Elizabeth E.; McDaniel, Russell E.; Maximov, Philipp Y.; Fan, Ping; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Hormone Molecular Biology and Clinical Investigation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-163</span>CODEN:
                <span class="NLM_cas:coden">HMBCA4</span>;
        ISSN:<span class="NLM_cas:issn">1868-1883</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH</span>)
        </div><div class="casAbstract">A review.  Translational research for the treatment and prevention of breast cancer depends upon the four Ms: models, mols., and mechanisms in order to create medicines.  The process, to target the estrogen receptor (ER) in estrogen-dependent breast cancer, has yielded significant advances in patient survivorship and the first approved medicines (tamoxifen and raloxifene) to reduce the incidence of any cancer in high- or low-risk women.  This review focuses on the crit. role of the few ER-pos. cell lines (MCF-7, T47D, BT474, ZR-75-1) that continue to advance our understanding of the estrogen-regulated biol. of breast cancer.  More importantly, the model cell lines have provided an opportunity to document the development and evolution of acquired antihormone resistance.  The description of this evolutionary process that occurs in micrometastatic disease during up to a decade of adjuvant therapy would not be possible in the patient.  The use of the MCF-7 breast cancer cell line, in particular, has been instrumental in discovering a vulnerability of ER-pos. breast cancer exhaustively treated with antihormone therapy.  Physiol. estradiol acts as an apoptotic trigger to cause tumor regression.  These unanticipated findings in the lab. have translated to clin. advances in our knowledge of the paradoxical role of estrogen in the life and death of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtyanTJfE_vrVg90H21EOLACvtfcHk0ljQhKVctvqvgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtFaitLk%253D&md5=8a5f9d296eced660a25d8292287f7dda</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1515%2Fhmbci-2011-0004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fhmbci-2011-0004%26sid%3Dliteratum%253Aachs%26aulast%3DSweeney%26aufirst%3DE.%2BE.%26aulast%3DMcDaniel%26aufirst%3DR.%2BE.%26aulast%3DMaximov%26aufirst%3DP.%2BY.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DModels%2520and%2520Mechanisms%2520of%2520Acquired%2520Antihormone%2520Resistance%2520in%2520Breast%2520Cancer%253A%2520Significant%2520Clinical%2520Progress%2520Despite%2520Limitations%26jtitle%3DHorm.%2520Mol.%2520Biol.%2520Clin.%2520Invest.%26date%3D2012%26volume%3D9%26spage%3D143%26epage%3D163%26doi%3D10.1515%2Fhmbci-2011-0004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuukasjärvi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kononen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isola, J.</span></span> <span> </span><span class="NLM_article-title">Loss of Estrogen Receptor in Recurrent Breast Cancer Is Associated with Poor Response to Endocrine Therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2584</span>– <span class="NLM_lpage">2589</span>, <span class="refDoi"> DOI: 10.1200/jco.1996.14.9.2584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1200%2Fjco.1996.14.9.2584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=8823339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK28XlvVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1996&pages=2584-2589&author=T.+Kuukasj%C3%A4rviauthor=J.+Kononenauthor=H.+Helinauthor=K.+Holliauthor=J.+Isola&title=Loss+of+Estrogen+Receptor+in+Recurrent+Breast+Cancer+Is+Associated+with+Poor+Response+to+Endocrine+Therapy&doi=10.1200%2Fjco.1996.14.9.2584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy</span></div><div class="casAuthors">Kuukasjarvi, Tuula; Kononen, Juha; Helin, Heikki; Holli, Kaija; Isola, Jorma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2584-2589</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Saunders</span>)
        </div><div class="casAbstract">Up to 30% to 40% of metastases from hormone receptor-pos. primary breast cancer do not respond to endocrine therapy.  The authors studied how often hormone receptor status changes between primary and recurrent tumors and whether such a change might explain unresponsiveness to endocrine therapy.  Primary breast cancer samples and matched asynchronous recurrences were studied from 50 patients who had not received any adjuvant therapy.  Estrogen receptor (ER) and progesterone receptor (PR) status was detd. immunohistochem. from histol. representative formalin-fixed paraffin-embedded tumor samples.  ER status was ascertained by mRNA in situ hybridization.  Thirty-five (70%) of 50 primary tumors were pos. for ER and 30 (60%) for PR.  Hormone receptor status of the recurrent tumor differed from that of the primary tumor in 18 cases (36%).  Discordant cases were due to the loss of ER, loss of PR, or loss of both receptors.  Receptor-neg. primary tumors were always accompanied by receptor-neg. recurrences.  Among 27 patients with ER-pos. primary tumors, loss of ER was a significant predictor of poor response to subsequent endocrine therapy.  Only one of eight patients (12.5%) with lost ER expression responded to tamoxifen therapy, whereas the response rate was 74% (14 of 19) for patients whose recurrent tumors retained ER expression.  Loss of ER expression in recurrent breast cancer should be considered as a cause for poor response to endocrine therapy in primarily ER-pos. patients.  The authors conclude that anal. of recurrent tumor samples may improve the predictive value of ER and PR assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHkl2YS9_wdrVg90H21EOLACvtfcHk0lhDpspHM9rhgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlvVGisL0%253D&md5=5164f876315a64eb023a10552ce21ed6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1200%2Fjco.1996.14.9.2584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.1996.14.9.2584%26sid%3Dliteratum%253Aachs%26aulast%3DKuukasj%25C3%25A4rvi%26aufirst%3DT.%26aulast%3DKononen%26aufirst%3DJ.%26aulast%3DHelin%26aufirst%3DH.%26aulast%3DHolli%26aufirst%3DK.%26aulast%3DIsola%26aufirst%3DJ.%26atitle%3DLoss%2520of%2520Estrogen%2520Receptor%2520in%2520Recurrent%2520Breast%2520Cancer%2520Is%2520Associated%2520with%2520Poor%2520Response%2520to%2520Endocrine%2520Therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1996%26volume%3D14%26spage%3D2584%26epage%3D2589%26doi%3D10.1200%2Fjco.1996.14.9.2584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boér, K.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant in Advanced Breast Cancer: Evidence to Date and Place in Therapy</span>. <i>Ther. Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1177/1758834017711097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1177%2F1758834017711097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=28717399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVSntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=465-479&author=K.+Bo%C3%A9r&title=Fulvestrant+in+Advanced+Breast+Cancer%3A+Evidence+to+Date+and+Place+in+Therapy&doi=10.1177%2F1758834017711097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant in advanced breast cancer: evidence to date and place in therapy</span></div><div class="casAuthors">Boer, Katalin</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Medical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">465-479</span>CODEN:
                <span class="NLM_cas:coden">TAMOB8</span>;
        ISSN:<span class="NLM_cas:issn">1758-8340</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Breast cancer is a classical hormone-dependent tumor; therefore, endocrine therapy is the mainstay of treatment for hormone receptor-pos., human epidermal growth factor 2-neg. advanced breast cancer.  Until recently, classical endocrine agents such as tamoxifen, steroidal and nonsteroidal aromatase inhibitors and fulvestrant have been widely used in postmenopausal patients to treat locally advanced or metastatic disease.  However, for patients with this subtype of breast cancer, the landscape of endocrine therapy is rapidly changing.  Therapies targeting estrogen modulation have evolved in recent years following the introduction of targeted agents, mTOR and CDK 4/6 inhibitors that are administered in combination with hormone therapy.  As a result, options for endocrine therapy have expanded in recent years, and a variety of single-agent or combinations of targeted drugs and endocrine therapies are accepted.  Fulvestrant is a selective estrogen receptor downregulator (SERD) which was introduced to clin. practice in 2002, initially with the indication to treat postmenopausal women with hormone-receptor-pos. advanced breast cancer as second-line therapy postdisease progression after aromatase inhibitors or tamoxifen.  Addnl., fulvestrant has also been shown to be active in patients previously untreated with endocrine therapy, either both in the neoadjuvant and the metastatic setting, alone or in combination with other targeted therapies.  Currently, the std. dose is 500 mg, which is administered with a loading dose.  Fulvestrant received a new FDA indication in Dec. 2016, in combination with palbociclib, both in pre/peri/postmenopausal women with breast cancer progressing after endocrine therapy.  This manuscript aims to give an overview of new efficacy data and the current role of fulvestrant in the systemic therapy of hormone-receptor-pos. advanced breast cancer, in the context of other available therapeutic modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRi8P0FTgbVrVg90H21EOLACvtfcHk0lhDpspHM9rhgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVSntrs%253D&md5=c8ce774327a3523edabfe23c557c5a19</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1177%2F1758834017711097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758834017711097%26sid%3Dliteratum%253Aachs%26aulast%3DBo%25C3%25A9r%26aufirst%3DK.%26atitle%3DFulvestrant%2520in%2520Advanced%2520Breast%2520Cancer%253A%2520Evidence%2520to%2520Date%2520and%2520Place%2520in%2520Therapy%26jtitle%3DTher.%2520Adv.%2520Med.%2520Oncol.%26date%3D2017%26volume%3D9%26spage%3D465%26epage%3D479%26doi%3D10.1177%2F1758834017711097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaar, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouker, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonessa, F.</span></span> <span> </span><span class="NLM_article-title">Molecular and Pharmacological Aspects of Antiestrogen Resistance</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1016/s0960-0760(00)00193-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fs0960-0760%2800%2900193-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=11384865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks1altr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2001&pages=71-84&author=R.+Clarkeauthor=T.+C.+Skaarauthor=K.+B.+Boukerauthor=N.+Davisauthor=Y.+R.+Leeauthor=J.+N.+Welchauthor=F.+Leonessa&title=Molecular+and+Pharmacological+Aspects+of+Antiestrogen+Resistance&doi=10.1016%2Fs0960-0760%2800%2900193-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and pharmacological aspects of antiestrogen resistance</span></div><div class="casAuthors">Clarke, Robert; Skaar, Todd C.; Bouker, Kerrie B.; Davis, Natalie; Lee, Y. Richard; Welch, James N.; Leonessa, Fabio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1-5</span>),
    <span class="NLM_cas:pages">71-84</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 131 refs.  Endocrine therapy is effective in approx. one-third of all breast cancers and up to 80% of tumors that express both estrogen and progesterone receptors.  Despite the low toxicity, good overall response rates, and addnl. benefits assocd. with its partial agonist activity, most Tamoxifen-responsive breast cancers acquire resistance.  The development of new antiestrogens, both steroidal and non-steroidal, provides the opportunity for the development of non-cross-resistant therapies and the identification of addnl. mechanisms of action and resistance.  Drug-specific pharmacol. mechanisms may confer a resistance phenotype, reflecting the complexities of both tumor biol./pharmacol. and the mol. endocrinol. of steroid hormone action.  However, since all antiestrogens will be effective only in cells that express estrogen receptors (ER), many mechanisms will likely be directly related to ER expression and signaling.  For example, loss of ER expression/function is likely to confer a cross-resistance phenotype across all structural classes of antiestrogens.  Altered expression of ERα and ERβ, and/or signaling from transcription complexes driven by these receptors, may produce drug-specific resistance phenotypes.  We have begun to study the possible changes in gene expression that may occur as cells acquire resistance to steroidal and non-steroidal antiestrogens.  Our preliminary studies implicate the altered expression of several estrogen-regulated genes.  However, resistance to antiestrogens is likely to be a multigene phenomenon, involving a network of interrelated signaling pathways.  The way in which this network is adapted by cells may vary among tumors, consistent with the existence of a highly plastic and adaptable genotype within breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7v8b2zxroubVg90H21EOLACvtfcHk0lhDpspHM9rhgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks1altr4%253D&md5=b6425acb62b6eb712b972e3da6dd4553</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fs0960-0760%2800%2900193-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0960-0760%252800%252900193-x%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DR.%26aulast%3DSkaar%26aufirst%3DT.%2BC.%26aulast%3DBouker%26aufirst%3DK.%2BB.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DY.%2BR.%26aulast%3DWelch%26aufirst%3DJ.%2BN.%26aulast%3DLeonessa%26aufirst%3DF.%26atitle%3DMolecular%2520and%2520Pharmacological%2520Aspects%2520of%2520Antiestrogen%2520Resistance%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D76%26spage%3D71%26epage%3D84%26doi%3D10.1016%2Fs0960-0760%2800%2900193-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciruelos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arroyo Vozmediano, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderón, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Funes, H.</span></span> <span> </span><span class="NLM_article-title">The Therapeutic Role of Fulvestrant in the Management of Patients with Hormone Receptor-Positive Breast Cancer</span>. <i>Breast</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/j.breast.2014.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fj.breast.2014.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=24589524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BC2cvpvFSqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=201-208&author=E.+Ciruelosauthor=T.+Pascualauthor=M.+L.+Arroyo+Vozmedianoauthor=M.+Blancoauthor=L.+Mansoauthor=L.+Parrillaauthor=C.+Mu%C3%B1ozauthor=E.+Vegaauthor=M.+J.+Calder%C3%B3nauthor=B.+Sanchoauthor=H.+Cortes-Funes&title=The+Therapeutic+Role+of+Fulvestrant+in+the+Management+of+Patients+with+Hormone+Receptor-Positive+Breast+Cancer&doi=10.1016%2Fj.breast.2014.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer</span></div><div class="casAuthors">Ciruelos Eva; Pascual Tomas; Manso Luis; Parrilla Lucia; Munoz Cesar; Vega Estela; Calderon Monica Jackelin; Cortes-Funes Hernan; Arroyo Vozmediano Maria Luisa; Blanco Marta; Sancho Blanca</div><div class="citationInfo"><span class="NLM_cas:title">Breast (Edinburgh, Scotland)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">201-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although selective estrogen receptor modulators (SERMs), such as tamoxifen, or aromatase inhibitors (AIs), such as anastrozole, are the preferred endocrine treatment approach for most patients with hormone receptor-positive breast cancer, many patients progress despite this therapy or become resistant.  Fulvestrant is a selective estrogen receptor down-regulator (SERD) that has demonstrated activity and efficacy in patients with hormone receptor-positive breast cancer previously untreated or treated with hormonal therapy.  The efficacy of fulvestrant has been demonstrated in the neoadjuvant and metastatic settings, either alone or in combination with other therapies such as anastrozole or targeted drugs.  Additionally, 500 mg of fulvestrant have been shown to be more effective than 250 mg, without significant differences in the toxicity profile.  In this review, the unique mode of action of fulvestrant and the clinical data for different dosing regimens both alone or in combination with other drugs is critically assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS2l_K7JP7ftZPlX7E30qdzfW6udTcc2easU6KJGCTu77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvpvFSqtw%253D%253D&md5=6fe2964c573e1370c2fc65efac3dbab0</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.breast.2014.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.breast.2014.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DCiruelos%26aufirst%3DE.%26aulast%3DPascual%26aufirst%3DT.%26aulast%3DArroyo%2BVozmediano%26aufirst%3DM.%2BL.%26aulast%3DBlanco%26aufirst%3DM.%26aulast%3DManso%26aufirst%3DL.%26aulast%3DParrilla%26aufirst%3DL.%26aulast%3DMu%25C3%25B1oz%26aufirst%3DC.%26aulast%3DVega%26aufirst%3DE.%26aulast%3DCalder%25C3%25B3n%26aufirst%3DM.%2BJ.%26aulast%3DSancho%26aufirst%3DB.%26aulast%3DCortes-Funes%26aufirst%3DH.%26atitle%3DThe%2520Therapeutic%2520Role%2520of%2520Fulvestrant%2520in%2520the%2520Management%2520of%2520Patients%2520with%2520Hormone%2520Receptor-Positive%2520Breast%2520Cancer%26jtitle%3DBreast%26date%3D2014%26volume%3D23%26spage%3D201%26epage%3D208%26doi%3D10.1016%2Fj.breast.2014.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paridaens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolé, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildiers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clément, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köberle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldhirsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thürlimann, B.</span></span> <span> </span><span class="NLM_article-title">Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdl341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1093%2Fannonc%2Fmdl341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=17030543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FisVWntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=64-69&author=L.+Pereyauthor=R.+Paridaensauthor=H.+Hawleauthor=K.+Zamanauthor=F.+Nol%C3%A9author=H.+Wildiersauthor=M.+Ficheauthor=D.+Dietrichauthor=P.+Cl%C3%A9mentauthor=D.+K%C3%B6berleauthor=A.+Goldhirschauthor=B.+Th%C3%BCrlimann&title=Clinical+benefit+of+fulvestrant+in+postmenopausal+women+with+advanced+breast+cancer+and+primary+or+acquired+resistance+to+aromatase+inhibitors%3A+final+results+of+phase+II+Swiss+Group+for+Clinical+Cancer+Research+Trial+%28SAKK+21%2F00%29&doi=10.1093%2Fannonc%2Fmdl341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)</span></div><div class="casAuthors">Perey L; Paridaens R; Hawle H; Zaman K; Nole F; Wildiers H; Fiche M; Dietrich D; Clement P; Koberle D; Goldhirsch A; Thurlimann B</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-9</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI) treatment.  PATIENTS AND METHODS:  This is a phase II, open, multicenter, noncomparative study.  Two patient groups were prospectively considered: group A (n=70) with AI-responsive disease and group B (n=20) with AI-resistant disease.  Fulvestrant 250 mg was administered as intramuscular injection every 28 (+/-3) days.  RESULTS:  All patients were pretreated with AI and 84% also with tamoxifen or toremifene; 67% had bone metastases and 45% liver metastases.  Fulvestrant administration was well tolerated and yielded a clinical benefit (CB; defined as objective response or stable disease [SD] for >or=24 weeks) in 28% (90% confidence interval [CI] 19% to 39%) of patients in group A and 37% (90% CI 19% to 58%) of patients in group B.  Median time to progression (TTP) was 3.6 (95% CI 3.0 to 4.8) months in group A and 3.4 (95% CI 2.5 to 6.7) months in group B.  CONCLUSIONS:  Overall, 30% of patients who had progressed following prior AI treatment gained CB with fulvestrant, thereby delaying indication to start chemotherapy.  Prior response to an AI did not appear to be predictive for benefit with fulvestrant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgdgcuVoVvhr7NkxioyDXTfW6udTcc2easU6KJGCTu77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FisVWntQ%253D%253D&md5=33f52d40ebeba134195a6311c0e8d854</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdl341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdl341%26sid%3Dliteratum%253Aachs%26aulast%3DPerey%26aufirst%3DL.%26aulast%3DParidaens%26aufirst%3DR.%26aulast%3DHawle%26aufirst%3DH.%26aulast%3DZaman%26aufirst%3DK.%26aulast%3DNol%25C3%25A9%26aufirst%3DF.%26aulast%3DWildiers%26aufirst%3DH.%26aulast%3DFiche%26aufirst%3DM.%26aulast%3DDietrich%26aufirst%3DD.%26aulast%3DCl%25C3%25A9ment%26aufirst%3DP.%26aulast%3DK%25C3%25B6berle%26aufirst%3DD.%26aulast%3DGoldhirsch%26aufirst%3DA.%26aulast%3DTh%25C3%25BCrlimann%26aufirst%3DB.%26atitle%3DClinical%2520benefit%2520of%2520fulvestrant%2520in%2520postmenopausal%2520women%2520with%2520advanced%2520breast%2520cancer%2520and%2520primary%2520or%2520acquired%2520resistance%2520to%2520aromatase%2520inhibitors%253A%2520final%2520results%2520of%2520phase%2520II%2520Swiss%2520Group%2520for%2520Clinical%2520Cancer%2520Research%2520Trial%2520%2528SAKK%252021%252F00%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2007%26volume%3D18%26spage%3D64%26epage%3D69%26doi%3D10.1093%2Fannonc%2Fmdl341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montano, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekena, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInerney, E. M.</span></span> <span> </span><span class="NLM_article-title">Antiestrogens: Mechanisms of action and resistance in breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1023/a:1005835428423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1023%2Fa%3A1005835428423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=9164675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK2sXjsFOqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1997&pages=23-38&author=B.+S.+Katzenellenbogenauthor=M.+M.+Montanoauthor=K.+Ekenaauthor=M.+E.+Hermanauthor=E.+M.+McInerney&title=Antiestrogens%3A+Mechanisms+of+action+and+resistance+in+breast+cancer&doi=10.1023%2Fa%3A1005835428423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Antiestrogens: mechanisms of action and resistance in breast cancer</span></div><div class="casAuthors">Katzenellenbogen, Benita S.; Montano, Monica M.; Ekena, Kirk; Herman, Mary E.; McInerney, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-38</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Kluwer</span>)
        </div><div class="casAbstract">A review, with 96 refs.  Antiestrogens have proven to be highly effective in the treatment of hormone-responsive breast cancer.  However, resistance to antiestrogen therapy often develops.  In addn., although tamoxifen-like antiestrogens are largely inhibitory and function as estrogen antagonists in breast cancer cells, they also have some estrogen-like activity in other cells of the body.  Thus, recent efforts are being directed toward the development of even more tissue-selective antiestrogens, i.e. compds. that are antiestrogenic on breast and uterus while maintaining the beneficial estrogen-like actions on bone and the cardiovascular system.  Efforts are also being directed toward understanding ligand structure-estrogen receptor (ER) activity relationships and characterizing the mol. changes that underlie alterations in parallel signal transduction pathways that impact on the ER.  Recent findings show that antiestrogens, which are known to exert most of their effects through the ER of breast cancer cells, contact a different set of amino acids in the hormone-binding domain of the ER than those contacted by estrogen, and evoke a different receptor conformation that results in reduced or no transcriptional activity on most genes.  Resistance to antiestrogen therapy may develop due to changes at the level of the ER itself, and at pre- ad post-receptor points in the estrogen receptor-response pathway.  Resistance could arise in ≥4 ways: (1) ER loss or mutation; (2) post-receptor alterations including changes in cAMP and phosphorylation pathways, or changes in coregulator and transcription factor interactions that affect the transcriptional activity of the ER; (3) changes in growth factor prodn./sensitivity or paracrine cell-cell interactions; or (4) pharmacol. changes in the antiestrogen itself, including altered uptake and retention or metab. of the antiestrogen.  Model cell systems have been developed to study changes that accompany and define the antiestrogen resistant vs. sensitive breast cancer phenotype.  This information should lead to the development of antiestrogens with optimized tissue selectivity and agents to which resistance may develop more slowly.  In addn., antiestrogens which work through somewhat different mechanisms of interaction with ER should prove useful in treatment of some breast cancers that become resistant to a different category of antiestrogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPS2AZBTCG27Vg90H21EOLACvtfcHk0ljBs-8VFGuetA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsFOqs70%253D&md5=7bd30e25f2402cdf83576add26cd6ade</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1023%2Fa%3A1005835428423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252Fa%253A1005835428423%26sid%3Dliteratum%253Aachs%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DMontano%26aufirst%3DM.%2BM.%26aulast%3DEkena%26aufirst%3DK.%26aulast%3DHerman%26aufirst%3DM.%2BE.%26aulast%3DMcInerney%26aufirst%3DE.%2BM.%26atitle%3DAntiestrogens%253A%2520Mechanisms%2520of%2520action%2520and%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D1997%26volume%3D44%26spage%3D23%26epage%3D38%26doi%3D10.1023%2Fa%3A1005835428423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massarweh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span> <span> </span><span class="NLM_article-title">Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1950</span>– <span class="NLM_lpage">1954</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-06-2540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F1078-0432.ccr-06-2540" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=17404074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs12rsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1950-1954&author=S.+Massarwehauthor=R.+Schiff&title=Unraveling+the+Mechanisms+of+Endocrine+Resistance+in+Breast+Cancer%3A+New+Therapeutic+Opportunities&doi=10.1158%2F1078-0432.ccr-06-2540"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities</span></div><div class="casAuthors">Massarweh, Suleiman; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1950-1954</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Two thirds of breast cancers express the estrogen receptor (ER), which contributes to tumor development and progression.  ER-targeted therapy is therefore widely used in breast cancer to inhibit signaling through ER and disrupt breast cancer growth.  This therapeutic strategy, particularly using the antiestrogen tamoxifen, is proven to increase the cure rates in early breast cancer, improve patient outcomes in advanced disease, and reduce breast cancer incidence in the prevention setting.  Despite the recent integration of more powerful endocrine agents into breast cancer care, resistance to all forms of endocrine therapy remains a major problem.  New insight into ER biol. and progress in understanding resistance mechanisms, mediated by mol. crosstalk between ER and various growth factor signaling pathways, are generating tremendous promise for new therapeutic opportunities to target resistance and improve breast cancer disease outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPnrEsFNPYurVg90H21EOLACvtfcHk0ljBs-8VFGuetA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs12rsbo%253D&md5=b13ced2100827f7eb1e1d87b54c6794d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-06-2540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-06-2540%26sid%3Dliteratum%253Aachs%26aulast%3DMassarweh%26aufirst%3DS.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DUnraveling%2520the%2520Mechanisms%2520of%2520Endocrine%2520Resistance%2520in%2520Breast%2520Cancer%253A%2520New%2520Therapeutic%2520Opportunities%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1950%26epage%3D1954%26doi%3D10.1158%2F1078-0432.ccr-06-2540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Endocrine Resistance in Breast Cancer</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-070909-182917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1146%2Fannurev-med-070909-182917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=20887199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVWhtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2011&pages=233-247&author=C.+K.+Osborneauthor=R.+Schiff&title=Mechanisms+of+Endocrine+Resistance+in+Breast+Cancer&doi=10.1146%2Fannurev-med-070909-182917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of endocrine resistance in breast cancer</span></div><div class="casAuthors">Osborne, C. Kent; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">233-247</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The estrogen receptor (ER) pathway plays a pivotal role in breast cancer development and progression.  Endocrine therapy to block the ER pathway is highly effective, but its usefulness is limited by common intrinsic and acquired resistance.  Multiple mechanisms responsible for endocrine resistance have been proposed and include deregulation of various components of the ER pathway itself, alterations in cell cycle and cell survival signaling mols., and the activation of escape pathways that can provide tumors with alternative proliferative and survival stimuli.  Among these, increased expression or signaling of growth factor receptor pathways, esp. the EGFR/HER2 pathway, has been assocd. with both exptl. and clin. endocrine therapy resistance.  New treatment combinations targeting both ER and growth factor receptor signaling to block the crosstalk between these pathways and eliminate escape routes have been proven highly effective in preclin. models.  Results of recent clin. studies, while partly supporting this approach, also highlight the need to better identify a priori the patients whose tumors are most likely to benefit from these specific cotargeting strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23PYELtZJrbVg90H21EOLACvtfcHk0linCR0O07Qc1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVWhtLo%253D&md5=48573e39ea81057b53b5b43b1d72d2d9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-070909-182917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-070909-182917%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DMechanisms%2520of%2520Endocrine%2520Resistance%2520in%2520Breast%2520Cancer%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2011%26volume%3D62%26spage%3D233%26epage%3D247%26doi%3D10.1146%2Fannurev-med-070909-182917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mills, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkovsky, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Resistance in Estrogen Receptor Positive Breast Cancer: Overcoming Resistance to Tamoxifen/Aromatase Inhibitors</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2018.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fj.coph.2018.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=29719270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlOksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=59-65&author=J.+N.+Millsauthor=A.+C.+Rutkovskyauthor=A.+Giordano&title=Mechanisms+of+Resistance+in+Estrogen+Receptor+Positive+Breast+Cancer%3A+Overcoming+Resistance+to+Tamoxifen%2FAromatase+Inhibitors&doi=10.1016%2Fj.coph.2018.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors</span></div><div class="casAuthors">Mills, Jamie N.; Rutkovsky, Alex C.; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-65</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Several mechanisms of resistance have been identified, underscoring the complex nature of estrogen receptor (ER) signaling and the many connections between this pathway and other essential signaling pathways in breast cancer cells.  Many therapeutic targets of cell signaling and cell cycle pathways have met success with endocrine therapy and remain an ongoing area of investigation.  This review focuses on two major pathways that have recently emerged as important opportunities for therapeutic intervention in endocrine resistant breast tumors: PI3K/AKT/mTOR cell signaling and cyclinD1/cyclin-dependent kinase 4/6 cell cycle pathways.  Addnl., we highlight individual and combination strategies in current clin. trials that target these pathways and others under investigation for the treatment of ER pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVYQkU5BQS2LVg90H21EOLACvtfcHk0linCR0O07Qc1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlOksbg%253D&md5=7eb380dd5c8e441b8dd2602b40aa94b5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2018.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2018.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DMills%26aufirst%3DJ.%2BN.%26aulast%3DRutkovsky%26aufirst%3DA.%2BC.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DMechanisms%2520of%2520Resistance%2520in%2520Estrogen%2520Receptor%2520Positive%2520Breast%2520Cancer%253A%2520Overcoming%2520Resistance%2520to%2520Tamoxifen%252FAromatase%2520Inhibitors%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2018%26volume%3D41%26spage%3D59%26epage%3D65%26doi%3D10.1016%2Fj.coph.2018.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleshin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slamon, D. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the Cyclin-Dependent Kinases (Cdk) 4/6 in Estrogen Receptor-Positive Breast Cancers</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">17</span>, <span class="refDoi"> DOI: 10.1186/s13058-015-0661-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1186%2Fs13058-015-0661-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=26857361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCksr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=17&author=R.+S.+Finnauthor=A.+Aleshinauthor=D.+J.+Slamon&title=Targeting+the+Cyclin-Dependent+Kinases+%28Cdk%29+4%2F6+in+Estrogen+Receptor-Positive+Breast+Cancers&doi=10.1186%2Fs13058-015-0661-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers</span></div><div class="casAuthors">Finn, Richard S.; Aleshin, Alexey; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17/1-17/11</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Despite significant advances in early detection and treatment, breast cancer still remains a major cause of morbidity and mortality for women.  Our understanding of the mol. heterogeneity of the disease has significantly expanded over the past decade and the role of cell cycle signaling in both breast cancer oncogenesis and anti-estrogen resistance has gained increasing attention.  The mammalian cell cycle is driven by a complex interplay between cyclins and their assocd. cyclin-dependent kinase (CDK) partners, and dysregulation of this process is one of the hallmarks of cancer.  Despite this, initial results with broadly acting CDK inhibitors were largely disappointing.  However, recent preclin. and phase I/II clin. studies using a novel, oral, reversible CDK4/6 inhibitor, palbociclib (PD-0332991), have validated the role of CDK4/6 as a potential target in estrogen receptor-pos. (ER+) breast cancers.  This review highlights our current understanding of CDK signaling in both normal and malignant breast tissues, with special attention placed on recent clin. advances in inhibition of CDK4/6 in ER+ disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoawxkcYxKDGLVg90H21EOLACvtfcHk0linCR0O07Qc1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCksr3F&md5=6e343e8b171ad2528d6cd989476ac961</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2Fs13058-015-0661-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-015-0661-5%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DAleshin%26aufirst%3DA.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DTargeting%2520the%2520Cyclin-Dependent%2520Kinases%2520%2528Cdk%2529%25204%252F6%2520in%2520Estrogen%2520Receptor-Positive%2520Breast%2520Cancers%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2016%26volume%3D18%26spage%3D17%26doi%3D10.1186%2Fs13058-015-0661-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pernas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, S.</span></span> <span> </span><span class="NLM_article-title">Cdk4/6 Inhibition in Breast Cancer: Current Practice and Future Directions</span>. <i>Ther. Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1758835918786451</span>, <span class="refDoi"> DOI: 10.1177/1758835918786451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1177%2F1758835918786451" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1758835918786451&author=S.+Pernasauthor=S.+M.+Tolaneyauthor=E.+P.+Winerauthor=S.+Goel&title=Cdk4%2F6+Inhibition+in+Breast+Cancer%3A+Current+Practice+and+Future+Directions&doi=10.1177%2F1758835918786451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1177%2F1758835918786451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758835918786451%26sid%3Dliteratum%253Aachs%26aulast%3DPernas%26aufirst%3DS.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DGoel%26aufirst%3DS.%26atitle%3DCdk4%252F6%2520Inhibition%2520in%2520Breast%2520Cancer%253A%2520Current%2520Practice%2520and%2520Future%2520Directions%26jtitle%3DTher.%2520Adv.%2520Med.%2520Oncol.%26date%3D2018%26volume%3D10%26spage%3D1758835918786451%26doi%3D10.1177%2F1758835918786451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Leary, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span> <span> </span><span class="NLM_article-title">Treating Cancer with Selective Cdk4/6 Inhibitors</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2016.26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1038%2Fnrclinonc.2016.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=27030077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsF2iurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=417-430&author=B.+O%E2%80%99Learyauthor=R.+S.+Finnauthor=N.+C.+Turner&title=Treating+Cancer+with+Selective+Cdk4%2F6+Inhibitors&doi=10.1038%2Fnrclinonc.2016.26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Treating cancer with selective CDK4/6 inhibitors</span></div><div class="casAuthors">O'Leary, Ben; Finn, Richard S.; Turner, Nicholas C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">417-430</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathol. process.  Clin. implementation of first-generation, nonselective CDK inhibitors, designed to inhibit this proliferation, was originally hampered by the high risk of toxicity and lack of efficacy noted with these agents.  The emergence of a new generation of selective CDK4/6 inhibitors, including ribociclib, abemaciclib and palbociclib, has enabled tumor types in which CDK4/6 has a pivotal role in the G1-to-S-phase cell-cycle transition to be targeted with improved effectiveness, and fewer adverse effects.  Results of pivotal phase III trials investigating palbociclib in patients with advanced-stage estrogen receptor (ER)-pos. breast cancer have demonstrated a substantial improvement in progression-free survival, with a well-tolerated toxicity profile.  Mechanisms of acquired resistance to CDK4/6 inhibitors are beginning to emerge that, although unwelcome, might enable rational post-CDK4/6 inhibitor therapeutic strategies to be identified.  Extending the use of CDK4/6 inhibitors beyond ER-pos. breast cancer is challenging, and will likely require biomarkers that are predictive of a response, and the use of combination therapies in order to optimize CDK4/6 targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGNYw6CRUf17Vg90H21EOLACvtfcHk0liE5oagofzLYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsF2iurc%253D&md5=6641dc6ab3cbd70edac46319ce4e6f45</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2016.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2016.26%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DB.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26atitle%3DTreating%2520Cancer%2520with%2520Selective%2520Cdk4%252F6%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D13%26spage%3D417%26epage%3D430%26doi%3D10.1038%2Fnrclinonc.2016.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, C. C.</span></span> <span> </span><span class="NLM_article-title">Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-the Emerging Role of Cdk4/6 Inhibitors</span>. <i>Int. J. Cancer Clin. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">4</span>, <span class="refDoi"> DOI: 10.23937/2378-3419/2/4/1029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.23937%2F2378-3419%2F2%2F4%2F1029" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=4&author=C.+C.+O%E2%80%99Sullivan&title=Overcoming+Endocrine+Resistance+in+Hormone-Receptor+Positive+Advanced+Breast+Cancer-the+Emerging+Role+of+Cdk4%2F6+Inhibitors&doi=10.23937%2F2378-3419%2F2%2F4%2F1029"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.23937%2F2378-3419%2F2%2F4%2F1029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.23937%252F2378-3419%252F2%252F4%252F1029%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DC.%2BC.%26atitle%3DOvercoming%2520Endocrine%2520Resistance%2520in%2520Hormone-Receptor%2520Positive%2520Advanced%2520Breast%2520Cancer-the%2520Emerging%2520Role%2520of%2520Cdk4%252F6%2520Inhibitors%26jtitle%3DInt.%2520J.%2520Cancer%2520Clin.%2520Res.%26date%3D2015%26volume%3D2%26spage%3D4%26doi%3D10.23937%2F2378-3419%2F2%2F4%2F1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Kruchten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaudemans, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lanschot, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Faassen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kema, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schröder, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hospers, G. A.</span></span> <span> </span><span class="NLM_article-title">Measuring Residual Estrogen Receptor Availability During Fulvestrant Therapy in Patients with Metastatic Breast Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-14-0697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F2159-8290.cd-14-0697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=25380844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=72-81&author=M.+van%0AKruchtenauthor=E.+G.+de+Vriesauthor=A.+W.+Glaudemansauthor=M.+C.+van+Lanschotauthor=M.+van+Faassenauthor=I.+P.+Kemaauthor=M.+Brownauthor=C.+P.+Schr%C3%B6derauthor=E.+F.+de+Vriesauthor=G.+A.+Hospers&title=Measuring+Residual+Estrogen+Receptor+Availability+During+Fulvestrant+Therapy+in+Patients+with+Metastatic+Breast+Cancer&doi=10.1158%2F2159-8290.cd-14-0697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer</span></div><div class="casAuthors">van Kruchten, Michel; de Vries, Elisabeth G.; Glaudemans, Andor W.; van Lanschot, Meta C.; van Faassen, Martijn; Kema, Ido P.; Brown, Myles; Schroeder, Carolien P.; de Vries, Erik F.; Hospers, Geke A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-81</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Decreased [18F]fluoroestradiol uptake visualized by PET/CT provides a measure of tumor ER availability and correlates with fulvestrant treatment outcome in patients with metastatic breast cancer.  It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer.  We performed a feasibility study to assess ER availability before and during fulvestrant.  Sixteen patients with ER-pos. metastatic breast cancer underwent positron emission tomog./computed tomog. (PET/CT) at baseline (scan 1), day 28 (scan 2), and day 84 (scan 3) to monitor tumor [18F]fluoroestradiol (FES) uptake.  Incomplete redn. in ER availability was predefined as <75% decrease in median tumor FES uptake and a residual standardized uptake value (SUVmax) of ≥1.5.  In total, 131 FES-pos. lesions were identified (median SUVmax of 2.9; range, 1.7-6.5).  The median change in patients during fulvestrant treatment was -85% at scan 2, but varied widely (-99% to +60%).  Fulvestrant reduced tumor FES uptake incompletely at scan 2 in 6 (38%) of the 16 patients, which was assocd. with early progression.  Significance: Serial imaging of tumor estrogen uptake by FES-PET can give insight into the dose needed for ER antagonists to completely abolish ER.  FES-PET showed significant residual ER availability in tumors during fulvestrant therapy in 38% of patients, which was assocd. with early progression.  Cancer Discov; 5(1); 72-81. ©2014 AACR.  This article is highlighted in the In This Issue feature, p. 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyAIvv5LaIyrVg90H21EOLACvtfcHk0liE5oagofzLYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D&md5=c5e8291be59caa5bf772cb6da80d52fb</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.cd-14-0697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.cd-14-0697%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BKruchten%26aufirst%3DM.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26aulast%3DGlaudemans%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BLanschot%26aufirst%3DM.%2BC.%26aulast%3Dvan%2BFaassen%26aufirst%3DM.%26aulast%3DKema%26aufirst%3DI.%2BP.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DC.%2BP.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BF.%26aulast%3DHospers%26aufirst%3DG.%2BA.%26atitle%3DMeasuring%2520Residual%2520Estrogen%2520Receptor%2520Availability%2520During%2520Fulvestrant%2520Therapy%2520in%2520Patients%2520with%2520Metastatic%2520Breast%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D72%26epage%3D81%26doi%3D10.1158%2F2159-8290.cd-14-0697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, O. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renshaw, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaskill, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faratian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, J. M.</span></span> <span> </span><span class="NLM_article-title">Effects of Fulvestrant 750mg in Premenopausal Women with Oestrogen-Receptor-Positive Primary Breast Cancer</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2007.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fj.ejca.2007.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=18083023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2isLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=391-399&author=O.+E.+Youngauthor=L.+Renshawauthor=E.+J.+Macaskillauthor=S.+Whiteauthor=D.+Faratianauthor=J.+S.+J.+Thomasauthor=J.+M.+Dixon&title=Effects+of+Fulvestrant+750mg+in+Premenopausal+Women+with+Oestrogen-Receptor-Positive+Primary+Breast+Cancer&doi=10.1016%2Fj.ejca.2007.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer</span></div><div class="casAuthors">Young, O. E.; Renshaw, L.; Macaskill, E. J.; White, S.; Faratian, D.; Thomas, J. St. J.; Dixon, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">391-399</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Fulvestrant (Faslodextm) is a pure anti-estrogen that reduces markers of hormone sensitivity and proliferation in postmenopausal women with estrogen-receptor (ER)-pos. breast cancer.  This randomized trial compared the effects on the tumors of a single dose of 750 mg fulvestrant to those of daily tamoxifen (20 mg) taken 14-16 days prior to surgery in 60 premenopausal women with ER-pos. primary breast cancer.  There were statistically significant falls in the expression of ER and Ki67 levels compared to the baseline with both drugs.  Both drugs caused a decrease in PgR expression from baseline but this was only statistically significant with fulvestrant.  No statistically significant differences were seen between the two treatment groups.  Fulvestrant caused an increase in circulating levels of estradiol, irresp. of the stage of the menstrual cycle at which patients commenced treatment.  No major changes were seen in LH, FSH and progesterone levels with either drug.  The most common adverse events with fulvestrant were headaches, hot flushes, nausea and disturbance of menses.  Contrary to previous studies with fulvestrant 250 mg, these findings suggest that at a dose of 750 mg fulvestrant is effective at reducing the effects of estrogen on ER-pos. breast cancer in premenopausal women.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp7qL-r2mUbrVg90H21EOLACvtfcHk0ljkdf3XJhotJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2isLg%253D&md5=e7e2fa3d26f37aa2bfe0b131d2ec3981</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2007.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2007.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DO.%2BE.%26aulast%3DRenshaw%26aufirst%3DL.%26aulast%3DMacaskill%26aufirst%3DE.%2BJ.%26aulast%3DWhite%26aufirst%3DS.%26aulast%3DFaratian%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DJ.%2BS.%2BJ.%26aulast%3DDixon%26aufirst%3DJ.%2BM.%26atitle%3DEffects%2520of%2520Fulvestrant%2520750mg%2520in%2520Premenopausal%2520Women%2520with%2520Oestrogen-Receptor-Positive%2520Primary%2520Breast%2520Cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2008%26volume%3D44%26spage%3D391%26epage%3D399%26doi%3D10.1016%2Fj.ejca.2007.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, R. I.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant: An Oestrogen Receptor Antagonist with a Novel Mechanism of Action</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">S2</span>– <span class="NLM_lpage">S6</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6601629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1038%2Fsj.bjc.6601629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=15094757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFaktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2004&pages=S2-S6&author=C.+K.+Osborneauthor=A.+Wakelingauthor=R.+I.+Nicholson&title=Fulvestrant%3A+An+Oestrogen+Receptor+Antagonist+with+a+Novel+Mechanism+of+Action&doi=10.1038%2Fsj.bjc.6601629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant: an estrogen receptor antagonist with a novel mechanism of action</span></div><div class="casAuthors">Osborne, C. K.; Wakeling, A.; Nicholson, R. I.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S2-S6</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Due to their favorable tolerability profiles, endocrine therapies have long been considered the treatment of choice for hormone-sensitive metastatic breast cancer.  However, the estrogen agonist effects of the available selective estrogen receptor modulators, such as tamoxifen, and the development of cross-resistance between endocrine therapies with similar modes of action have led to the need for new treatments that act through different mechanisms.  Fulvestrant (Faslodex') is the first of a new type of endocrine treatment-an estrogen receptor (ER) antagonist that downregulates the ER and has no agonist effects.  This article provides an overview of the current understanding of ER signaling and illustrates the unique mode of action of fulvestrant.  Preclin. and clin. study data are presented in support of the novel mechanism of action of this new type of ER antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8myn0Hcy0CrVg90H21EOLACvtfcHk0ljkdf3XJhotJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFaktbY%253D&md5=291a738f1d67db894e83d88ddfa000e4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601629%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DWakeling%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26atitle%3DFulvestrant%253A%2520An%2520Oestrogen%2520Receptor%2520Antagonist%2520with%2520a%2520Novel%2520Mechanism%2520of%2520Action%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2004%26volume%3D90%26spage%3DS2%26epage%3DS6%26doi%3D10.1038%2Fsj.bjc.6601629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ettinger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitlak, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knickerbocker, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickelsen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genant, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmas, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanchetta, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stakkestad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glüer, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensrud, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avioli, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lips, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, S. R.</span></span> <span> </span><span class="NLM_article-title">Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1001/jama.282.7.637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1001%2Fjama.282.7.637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10517716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK1MXlvVKqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=1999&pages=637-645&author=B.+Ettingerauthor=D.+M.+Blackauthor=B.+H.+Mitlakauthor=R.+K.+Knickerbockerauthor=T.+Nickelsenauthor=H.+K.+Genantauthor=C.+Christiansenauthor=P.+D.+Delmasauthor=J.+R.+Zanchettaauthor=J.+Stakkestadauthor=C.+C.+Gl%C3%BCerauthor=K.+Kruegerauthor=F.+J.+Cohenauthor=S.+Eckertauthor=K.+E.+Ensrudauthor=L.+V.+Avioliauthor=P.+Lipsauthor=S.+R.+Cummings&title=Reduction+of+vertebral+fracture+risk+in+postmenopausal+women+with+osteoporosis+treated+with+raloxifene%3A+results+from+a+3-year+randomized+clinical+trial.+Multiple+Outcomes+of+Raloxifene+Evaluation+%28MORE%29+Investigators&doi=10.1001%2Fjama.282.7.637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene Results from a 3-year randomized clinical trial</span></div><div class="casAuthors">Ettinger, Bruce; Black, Dennis M.; Mitlak, Bruce H.; Knickerbocker, Ronald K.; Nickelsen, Thomas; Genant, Harry K.; Christiansen, Claus; Delmas, Pierre D.; Zanchetta, Jose R.; Stakkestad, Jacob; Gluer, Claus C.; Krueger, Kathryn; Cohen, Fredric J.; Eckert, Stephen; Ensrud, Kristine E.; Avioli, Louis V.; Lips, Paul; Cummings, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">637-645</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known.  The objective of the study was to det. the effect of raloxifene therapy on risk of vertebral and non-vertebral fractures.  The Multiple Outcomes of Raloxifene Evaluation (MORE) study, a multicenter, randomized, blinded, placebo-controlled trial.  A total of 7705 women aged 31 to 80 yr in 25 countries who had been postmenopausal for at least 2 yr and who met World Health Organization criteria for having osteoporosis.  The study began in 1994 and had up to 36 mo of follow-up for primary efficacy measurements and nonserious adverse events and up to 40 mo of follow-up for serious adverse events.  Participants were randomized to 60 mg/day or 120 mg/day of raloxifene or to identically appearing placebo pills; in addn., all women received supplemental calcium and cholecalciferol.  Incident vertebral fracture was detd. radiog. at baseline and at scheduled 24- and 36-mo visits.  Nonvertebral fracture was ascertained by interview at 6-mo-interim visits.  Bone mineral d. was detd. annually by dual-energy x-ray absorptiometry.  At 36 mo of the evaluable radiographs in 6828 women, 503 (7.4%) had at least 1 new vertebral fracture, including 10.1% of women receiving placebo, 6.6% of those receiving 60 mg/d of raloxifene, and 5.4% of those receiving 120 mg/d of raloxifene.  Risk of vertebral fracture was reduced in both study groups receiving raloxifene (for 60-mg/d group: relative risk [RR], 0.7; 95% confidence interval [Cl], 0.5-0.8; for 120-mg/d group: RR, 0.5; 95% Cl, 0.4-0.7).  Frequency of vertebral fracture was reduced both in women who did and did not have prevalent fracture.  Risk of nonvertebral fracture for raloxifene vs. placebo did not differs significantly (RR, 0.9; 95% Cl, 0.8-1.1 for both raloxifene groups combined).  Compared with placebo, raloxifene increased bone mineral d. in the femoral neck by 2.1% (60 mg) and 2.4% (120 mg) and in the spine by 2.6% (60 mg) and 2.7% (120 mg) P<0.001 for all comparisons.  Women receiving raloxifene had increased risk of venous thromboembolus vs. placebo (RR, 3.1; 95% Cl, 1.5-6.2).  Raloxifene did not cause vaginal bleeding or breast pain and was assocd. with a lower incidence of breast cancer.  In postmenopausal women with osteoporosis, raloxifene increases bone mineral d. in the spine and femoral neck and reduces risk of vertebral fracture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWVFZnEfO09bVg90H21EOLACvtfcHk0ljhVmdQw0zgcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvVKqurg%253D&md5=8dae1a241ff597c689298cfc033b6acb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1001%2Fjama.282.7.637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.282.7.637%26sid%3Dliteratum%253Aachs%26aulast%3DEttinger%26aufirst%3DB.%26aulast%3DBlack%26aufirst%3DD.%2BM.%26aulast%3DMitlak%26aufirst%3DB.%2BH.%26aulast%3DKnickerbocker%26aufirst%3DR.%2BK.%26aulast%3DNickelsen%26aufirst%3DT.%26aulast%3DGenant%26aufirst%3DH.%2BK.%26aulast%3DChristiansen%26aufirst%3DC.%26aulast%3DDelmas%26aufirst%3DP.%2BD.%26aulast%3DZanchetta%26aufirst%3DJ.%2BR.%26aulast%3DStakkestad%26aufirst%3DJ.%26aulast%3DGl%25C3%25BCer%26aufirst%3DC.%2BC.%26aulast%3DKrueger%26aufirst%3DK.%26aulast%3DCohen%26aufirst%3DF.%2BJ.%26aulast%3DEckert%26aufirst%3DS.%26aulast%3DEnsrud%26aufirst%3DK.%2BE.%26aulast%3DAvioli%26aufirst%3DL.%2BV.%26aulast%3DLips%26aufirst%3DP.%26aulast%3DCummings%26aufirst%3DS.%2BR.%26atitle%3DReduction%2520of%2520vertebral%2520fracture%2520risk%2520in%2520postmenopausal%2520women%2520with%2520osteoporosis%2520treated%2520with%2520raloxifene%253A%2520results%2520from%2520a%25203-year%2520randomized%2520clinical%2520trial.%2520Multiple%2520Outcomes%2520of%2520Raloxifene%2520Evaluation%2520%2528MORE%2529%2520Investigators%26jtitle%3DJAMA%26date%3D1999%26volume%3D282%26spage%3D637%26epage%3D645%26doi%3D10.1001%2Fjama.282.7.637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span> <span> </span><span class="NLM_article-title">Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease</span>. <i>Clin Cancer Res</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2420</span>– <span class="NLM_lpage">2431</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-3771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F1078-0432.CCR-12-3771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=23536434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVWru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2420-2431&author=S.+E.+Wardellauthor=E.+R.+Nelsonauthor=C.+A.+Chaoauthor=D.+P.+McDonnell&title=Bazedoxifene+exhibits+antiestrogenic+activity+in+animal+models+of+tamoxifen-resistant+breast+cancer%3A+implications+for+treatment+of+advanced+disease&doi=10.1158%2F1078-0432.CCR-12-3771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease</span></div><div class="casAuthors">Wardell, Suzanne E.; Nelson, Erik R.; Chao, Christina A.; McDonnell, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2420-2431</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">There is compelling evidence to suggest that drugs that function as pure estrogen receptor (ER-α) antagonists, or that downregulate the expression of ER-α, would have clin. use in the treatment of advanced tamoxifen- and aromatase-resistant breast cancer.  Although such compds. are currently in development, we reasoned, based on our understanding of ER-α pharmacol., that there may already exist among the most recently developed selective estrogen receptor modulators (SERM) compds. that would have usage as breast cancer therapeutics.  Thus, our objective was to identify among available SERMs those with unique pharmacol. activities and to evaluate their potential clin. use with predictive models of advanced breast cancer.  A validated mol. profiling technol. was used to classify clin. relevant SERMs based on their impact on ER-α conformation.  The functional consequences of these obsd. mechanistic differences on (i) gene expression, (ii) receptor stability, and (iii) activity in cellular and animal models of advanced endocrine-resistant breast cancer were assessed.  The high-affinity SERM bazedoxifene was shown to function as a pure ER-α antagonist in cellular models of breast cancer and effectively inhibited the growth of both tamoxifen-sensitive and -resistant breast tumor xenografts.  Interestingly, bazedoxifene induced a unique conformational change in ER-α that resulted in its proteasomal degrdn., although the latter activity was dispensable for its antagonist efficacy.  Bazedoxifene was recently approved for use in the European Union for the treatment of osteoporosis and thus may represent a near-term therapeutic option for patients with advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEy3scPx9VTrVg90H21EOLACvtfcHk0ljhVmdQw0zgcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVWru7g%253D&md5=a3ca719d84b74a24bfd6147b6cc2366e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3771%26sid%3Dliteratum%253Aachs%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNelson%26aufirst%3DE.%2BR.%26aulast%3DChao%26aufirst%3DC.%2BA.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DBazedoxifene%2520exhibits%2520antiestrogenic%2520activity%2520in%2520animal%2520models%2520of%2520tamoxifen-resistant%2520breast%2520cancer%253A%2520implications%2520for%2520treatment%2520of%2520advanced%2520disease%26jtitle%3DClin%2520Cancer%2520Res%26date%3D2013%26volume%3D19%26spage%3D2420%26epage%3D2431%26doi%3D10.1158%2F1078-0432.CCR-12-3771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyttle, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattersley, G.</span></span> <span> </span><span class="NLM_article-title">Rad1901: A Novel, Orally Bioavailable Selective Estrogen Receptor Degrader That Demonstrates Antitumor Activity in Breast Cancer Xenograft Models</span>. <i>Anticancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1097/cad.0000000000000271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1097%2Fcad.0000000000000271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=26164151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FitlKitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=948-956&author=F.+Garnerauthor=M.+Shomaliauthor=D.+Paquinauthor=C.+R.+Lyttleauthor=G.+Hattersley&title=Rad1901%3A+A+Novel%2C+Orally+Bioavailable+Selective+Estrogen+Receptor+Degrader+That+Demonstrates+Antitumor+Activity+in+Breast+Cancer+Xenograft+Models&doi=10.1097%2Fcad.0000000000000271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models</span></div><div class="casAuthors">Garner Fiona; Shomali Maysoun; Paquin Dotty; Lyttle C Richard; Hattersley Gary</div><div class="citationInfo"><span class="NLM_cas:title">Anti-cancer drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">948-56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Agents that inhibit estrogen production, such as aromatase inhibitors or those that directly block estrogen receptor (ER) activity, such as selective estrogen receptor modulators and selective estrogen receptor degraders, are routinely used in the treatment of ER-positive breast cancers.  However, although initial treatment with these agents is often successful, many women eventually relapse with drug-resistant breast cancers.  To overcome some of the challenges associated with current endocrine therapies and to combat the development of resistance, there is a need for more durable and more effective ER-targeted therapies.  Here we describe and characterize a novel, orally bioavailable small-molecule selective estrogen receptor degrader, RAD1901, and evaluate its therapeutic potential for the treatment of breast cancer.  RAD1901 selectively binds to and degrades the ER and is a potent antagonist of ER-positive breast cancer cell proliferation.  Importantly, RAD1901 produced a robust and profound inhibition of tumor growth in MCF-7 xenograft models.  In an intracranial MCF-7 model, RAD1901-treated animals survived longer than those treated with either control or fulvestrant, suggesting the potential benefit of RAD1901 in the treatment of ER-positive breast cancer that has metastasized to the brain.  Finally, RAD1901 preserved ovariectomy-induced bone loss and prevented the uterotropic effects of E2, suggesting that it may act selectively as an agonist in bone but as an antagonist in breast and uterine tissues.  RAD1901 is currently under clinical study in postmenopausal women with ER-positive advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTP8U29TPTqVZZoeNcnHOQ9fW6udTcc2eZy4fNnKc3OIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FitlKitA%253D%253D&md5=0189275b74c147ec76684979dac05d76</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1097%2Fcad.0000000000000271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fcad.0000000000000271%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DF.%26aulast%3DShomali%26aufirst%3DM.%26aulast%3DPaquin%26aufirst%3DD.%26aulast%3DLyttle%26aufirst%3DC.%2BR.%26aulast%3DHattersley%26aufirst%3DG.%26atitle%3DRad1901%253A%2520A%2520Novel%252C%2520Orally%2520Bioavailable%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520That%2520Demonstrates%2520Antitumor%2520Activity%2520in%2520Breast%2520Cancer%2520Xenograft%2520Models%26jtitle%3DAnticancer%2520Drugs%26date%3D2015%26volume%3D26%26spage%3D948%26epage%3D956%26doi%3D10.1097%2Fcad.0000000000000271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alley, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the Pharmacological Activities of Rad1901, a Selective Estrogen Receptor Degrader</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1530/erc-15-0287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1530%2Ferc-15-0287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=26162914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1WktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=713-724&author=S.+E.+Wardellauthor=E.+R.+Nelsonauthor=C.+A.+Chaoauthor=H.+M.+Alleyauthor=D.+P.+McDonnell&title=Evaluation+of+the+Pharmacological+Activities+of+Rad1901%2C+a+Selective+Estrogen+Receptor+Degrader&doi=10.1530%2Ferc-15-0287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader</span></div><div class="casAuthors">Wardell, Suzanne E.; Nelson, Erik R.; Chao, Christina A.; Alley, Holly M.; McDonnell, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">713-724</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains a first-line treatment for estrogen receptor 1 (ESR1) pos. breast cancer.  However, tumor resistance limits the duration of response.  The clin. efficacy of fulvestrant, a selective ER degrader (SERD) that triggers receptor degrdn., has confirmed that ESR1 often remains engaged in endocrine therapy resistant cancers.  Recently developed, selective ER modulators (SERMs)/SERD hybrids (SSHs) that facilitate ESR1 degrdn. in breast cancer cells and reproductive tissues have been advanced as an alternative treatment for advanced breast cancer, particularly in the metastatic setting.  RAD1901 is one SSH currently being evaluated clin. that is unique among ESR1 modulators in that it readily enters the brain, a common site of breast cancer metastasis.  In this study, RAD1901 inhibited estrogen activation of ESR1 in vitro and in vivo, inhibited estrogen-dependent breast cancer cell proliferation and xenograft tumor growth, and mediated dose-dependent downregulation of ESR1 protein.  However, doses of RAD1901 insufficient to induce ESR1 degrdn. were shown to result in the activation of ESR1 target genes and in the stimulation of xenograft tumor growth.  RAD1901 is an SSH that exhibits complex pharmacol. in breast cancer models, having dose-dependent agonist/antagonist activity displayed in a tissue-selective manner.  It remains unclear how this unique pharmacol. will impact the utility of RAD1901 for breast cancer treatment.  However, being the only SERD currently known to access the brain, RAD1901 merits evaluation as a targeted therapy for the treatment of breast cancer brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZozvILn25g7Vg90H21EOLACvtfcHk0lgs8j-0BmxrFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1WktLg%253D&md5=0749b230c2a16355345c884438681d47</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1530%2Ferc-15-0287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252Ferc-15-0287%26sid%3Dliteratum%253Aachs%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNelson%26aufirst%3DE.%2BR.%26aulast%3DChao%26aufirst%3DC.%2BA.%26aulast%3DAlley%26aufirst%3DH.%2BM.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DEvaluation%2520of%2520the%2520Pharmacological%2520Activities%2520of%2520Rad1901%252C%2520a%2520Selective%2520Estrogen%2520Receptor%2520Degrader%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2015%26volume%3D22%26spage%3D713%26epage%3D724%26doi%3D10.1530%2Ferc-15-0287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, N. U.</span></span> <span> </span><span class="NLM_article-title">Updates on the management of breast cancer brain metastases</span>. <i>Oncology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">572</span>– <span class="NLM_lpage">578</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=25144276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FotlKjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=572-578&author=E.+Limauthor=N.+U.+Lin&title=Updates+on+the+management+of+breast+cancer+brain+metastases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Updates on the management of breast cancer brain metastases</span></div><div class="casAuthors">Lim Elgene; Lin Nancy U</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">572-8</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">Breast cancer brain metastases (BCBMs) are common in patients with advanced disease.  Breast cancer subtype and performance status are the major determinants of the course of the disease and survival time following a diagnosis of brain metastasis.  Unique challenges specific to the management of BCBMs include overcoming the blood-brain barrier and resistance to conventional systemic therapies, as BCBMs typically occur in the pretreated patient population.  The development of new systemic therapies for breast cancer, coupled with improvements in trial design, imaging modalities, and methods of defining and measuring clinical endpoints, has led to a renewed interest in developing novel therapeutic approaches for BCBMs.  In this overview, we will review recent developments in the management of BCBMs and current prospective trials of systemic therapies specifically for patients with BCBMs, with a focus on novel pathway-specific therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQC6-XPxs-YDzDnmmyUf5qOfW6udTcc2eZy4fNnKc3OIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FotlKjsQ%253D%253D&md5=81552aa65962a287ff133cb44466b8af</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DN.%2BU.%26atitle%3DUpdates%2520on%2520the%2520management%2520of%2520breast%2520cancer%2520brain%2520metastases%26jtitle%3DOncology%26date%3D2014%26volume%3D28%26spage%3D572%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagney, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalano, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Punglia, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claus, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas-Kogan, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aizer, A. A.</span></span> <span> </span><span class="NLM_article-title">Brain Metastases in Newly Diagnosed Breast Cancer</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1077</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2017.0001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1001%2Fjamaoncol.2017.0001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=28301662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BC1czntVWksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=1069-1077&author=A.+M.+Martinauthor=D.+N.+Cagneyauthor=P.+J.+Catalanoauthor=L.+E.+Warrenauthor=J.+R.+Bellonauthor=R.+S.+Pungliaauthor=E.+B.+Clausauthor=E.+Q.+Leeauthor=P.+Y.+Wenauthor=D.+A.+Haas-Koganauthor=B.+M.+Alexanderauthor=N.+U.+Linauthor=A.+A.+Aizer&title=Brain+Metastases+in+Newly+Diagnosed+Breast+Cancer&doi=10.1001%2Fjamaoncol.2017.0001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study</span></div><div class="casAuthors">Martin Allison M; Cagney Daniel N; Warren Laura E; Bellon Jennifer R; Punglia Rinaa S; Haas-Kogan Daphne A; Alexander Brian M; Aizer Ayal A; Catalano Paul J; Claus Elizabeth B; Claus Elizabeth B; Lee Eudocia Q; Wen Patrick Y; Lin Nancy U</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1069-1077</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Population-based estimates of the incidence and prognosis of brain metastases at diagnosis of breast cancer are lacking.  Objective:  To characterize the incidence proportions and median survivals of patients with breast cancer and brain metastases at the time of cancer diagnosis.  Design, Setting, and Participants:  Patients with breast cancer and brain metastases at the time of diagnosis were identified using the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute.  Data were stratified by subtype, age, sex, and race.  Multivariable logistic and Cox regression were performed to identify predictors of the presence of brain metastases at diagnosis and factors associated with all-cause mortality, respectively.  For incidence, we identified a population-based sample of 238 726 adult patients diagnosed as having invasive breast cancer between 2010 and 2013 for whom the presence or absence of brain metastases at diagnosis was known.  Patients diagnosed at autopsy or with an unknown follow-up were excluded from the survival analysis, leaving 231 684 patients in this cohort.  Main Outcomes and Measures:  Incidence proportion and median survival of patients with brain metastases and newly diagnosed breast cancer.  Results:  We identified 968 patients with brain metastases at the time of diagnosis of breast cancer, representing 0.41% of the entire cohort and 7.56% of the subset with metastatic disease to any site.  A total of 57 were 18 to 40 years old, 423 were 41 to 60 years old, 425 were 61-80 years old, and 63 were older than 80 years.  Ten were male and 958 were female.  Incidence proportions were highest among patients with hormone receptor (HR)-negative human epidermal growth factor receptor 2 (HER2)-positive (1.1% among entire cohort, 11.5% among patients with metastatic disease to any distant site) and triple-negative (0.7% among entire cohort, 11.4% among patients with metastatic disease to any distant site) subtypes.  Median survival among the entire cohort with brain metastases was 10.0 months.  Patients with HR-positive HER2-positive subtype displayed the longest median survival (21.0 months); patients with triple-negative subtype had the shortest median survival (6.0 months).  Conclusions and Relevance:  The findings of this study provides population-based estimates of the incidence and prognosis for patients with brain metastases at time of diagnosis of breast cancer.  The findings lend support to consideration of screening imaging of the brain for patients with HER2-positive or triple-negative subtypes and extracranial metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkU6HFRYrVILZpSb_XWfMrfW6udTcc2eaU2cOOSyyCR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czntVWksg%253D%253D&md5=3545044ba6c67337eac6b9be2f7a163e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2017.0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2017.0001%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DCagney%26aufirst%3DD.%2BN.%26aulast%3DCatalano%26aufirst%3DP.%2BJ.%26aulast%3DWarren%26aufirst%3DL.%2BE.%26aulast%3DBellon%26aufirst%3DJ.%2BR.%26aulast%3DPunglia%26aufirst%3DR.%2BS.%26aulast%3DClaus%26aufirst%3DE.%2BB.%26aulast%3DLee%26aufirst%3DE.%2BQ.%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DHaas-Kogan%26aufirst%3DD.%2BA.%26aulast%3DAlexander%26aufirst%3DB.%2BM.%26aulast%3DLin%26aufirst%3DN.%2BU.%26aulast%3DAizer%26aufirst%3DA.%2BA.%26atitle%3DBrain%2520Metastases%2520in%2520Newly%2520Diagnosed%2520Breast%2520Cancer%26jtitle%3DJAMA%2520Oncol.%26date%3D2017%26volume%3D3%26spage%3D1069%26epage%3D1077%26doi%3D10.1001%2Fjamaoncol.2017.0001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri-Kordestani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liewehr, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeg, P. S.</span></span> <span> </span><span class="NLM_article-title">Cns Metastases in Breast Cancer: Old Challenge, New Frontiers</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6404</span>– <span class="NLM_lpage">6418</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-13-0790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F1078-0432.ccr-13-0790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=24298071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOitb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6404-6418&author=N.+U.+Linauthor=L.+Amiri-Kordestaniauthor=D.+Palmieriauthor=D.+J.+Liewehrauthor=P.+S.+Steeg&title=Cns+Metastases+in+Breast+Cancer%3A+Old+Challenge%2C+New+Frontiers&doi=10.1158%2F1078-0432.ccr-13-0790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">CNS Metastases in Breast Cancer: Old Challenge, New Frontiers</span></div><div class="casAuthors">Lin, Nancy U.; Amiri-Kordestani, Laleh; Palmieri, Diane; Liewehr, David J.; Steeg, Patricia S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6404-6418</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Despite major therapeutic advances in the management of patients with breast cancer, central nervous system (CNS) metastases remain an intractable problem, particularly in patients with metastatic HER2-pos. and triple-neg. breast cancer.  As systemic therapies to treat extracranial disease improve, some patients are surviving longer, and the frequency of CNS involvement seems to be increasing.  Furthermore, in the early-stage setting, the CNS remains a potential sanctuary site for relapse.  This review highlights advances in the development of biol. relevant preclin. models, including the development of brain-tropic cell lines for testing of agents to prevent and treat brain metastases, and summarizes our current understanding of the biol. of CNS relapse.  From a clin. perspective, a variety of therapeutic approaches are discussed, including methods to improve drug delivery, novel cytotoxic agents, and targeted therapies.  Challenges in current trial design and endpoints are reviewed.  Finally, we discuss promising new directions, including novel trial designs, correlative imaging techniques, and enhanced translational opportunities.  Clin Cancer Res; 19(23); 6404-18. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAvG-idsLscLVg90H21EOLACvtfcHk0lix8j4-xZzKhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOitb7F&md5=1e27650f764980ea0f6bb3199a6281c0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-13-0790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-13-0790%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DN.%2BU.%26aulast%3DAmiri-Kordestani%26aufirst%3DL.%26aulast%3DPalmieri%26aufirst%3DD.%26aulast%3DLiewehr%26aufirst%3DD.%2BJ.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26atitle%3DCns%2520Metastases%2520in%2520Breast%2520Cancer%253A%2520Old%2520Challenge%252C%2520New%2520Frontiers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D6404%26epage%3D6418%26doi%3D10.1158%2F1078-0432.ccr-13-0790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karumudi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Novel Selective Estrogen Receptor Downregulators (Serds) Developed against Treatment-Resistant Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1342</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01355</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01355" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1325-1342&author=R.+Xiongauthor=J.+Zhaoauthor=L.+M.+Gutgesellauthor=Y.+Wangauthor=S.+Leeauthor=B.+Karumudiauthor=H.+Zhaoauthor=Y.+Luauthor=D.+A.+Tonettiauthor=G.+R.+J.+Thatcher&title=Novel+Selective+Estrogen+Receptor+Downregulators+%28Serds%29+Developed+against+Treatment-Resistant+Breast+Cancer&doi=10.1021%2Facs.jmedchem.6b01355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer</span></div><div class="casAuthors">Xiong, Rui; Zhao, Jiong; Gutgesell, Lauren M.; Wang, Yueting; Lee, Sue; Karumudi, Bhargava; Zhao, Huiping; Lu, Yunlong; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1325-1342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Resistance to the selective estrogen receptor modulator (SERM) tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-independent ER+ phenotype.  Selective ER downregulators (SERDs) are able to ablate ER and thus theor. to prevent survival of both endocrine-dependent and independent ER+ tumors.  The clin. SERD, fulvestrant, is hampered by i.m. administration and undesirable pharmacokinetics.  Novel SERDs were designed using the 6-OH-benzothiophene (BT) scaffold common to arzoxifene and raloxifene.  Treatment-resistant (TR) ER+ cell lines (MCF-7:5C and MCF-7:TAM1) were used for optimization, followed by validation in the parent endocrine-dependent cell line (MCF-7:WS8), in 2D and 3D cultures, using ERα in-cell westerns, ERE-luciferase, and cell viability assays, with GDC-0810 (ARN-810) used for comparison.  Two BT SERDs with superior in vitro activity to GDC-0810 were studied for bioavailability and shown to cause regression of a TR, endocrine-independent ER+ xenograft superior to GDC-0810.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLqe0A8df78rVg90H21EOLACvtfcHk0lgR5w_kWm005g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWqu70%253D&md5=71dbdfa2152f9e9019e8d138ed41313e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01355%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKarumudi%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DNovel%2520Selective%2520Estrogen%2520Receptor%2520Downregulators%2520%2528Serds%2529%2520Developed%2520against%2520Treatment-Resistant%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1325%26epage%3D1342%26doi%3D10.1021%2Facs.jmedchem.6b01355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado-Rivera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, T. N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Selective Human Estrogen Receptor Partial Agonists (Sherpas) for Tamoxifen-Resistant Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01276</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01276" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=219-237&author=R.+Xiongauthor=H.+K.+Patelauthor=L.+M.+Gutgesellauthor=J.+Zhaoauthor=L.+Delgado-Riveraauthor=T.+N.+D.+Phamauthor=H.+Zhaoauthor=K.+Carlsonauthor=T.+Martinauthor=J.+A.+Katzenellenbogenauthor=T.+W.+Mooreauthor=D.+A.+Tonettiauthor=G.+R.+J.+Thatcher&title=Selective+Human+Estrogen+Receptor+Partial+Agonists+%28Sherpas%29+for+Tamoxifen-Resistant+Breast+Cancer&doi=10.1021%2Facs.jmedchem.5b01276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Xiong, Rui; Patel, Hitisha K.; Gutgesell, Lauren M.; Zhao, Jiong; Delgado-Rivera, Loruhama; Pham, Thao N. D.; Zhao, Huiping; Carlson, Kathryn; Martin, Teresa; Katzenellenbogen, John A.; Moore, Terry W.; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-237</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Almost 70% of breast cancers are estrogen receptor α (ERα) pos.  Tamoxifen, a selective estrogen receptor modulator (SERM), represents the std. of care for many patients; however, 30-50% develop resistance, underlining the need for alternative therapeutics.  Paradoxically, agonists at ERα such as estradiol (E2) have demonstrated clin. efficacy in patients with heavily treated breast cancer, although side effects in gynecol. tissues are unacceptable.  A drug that selectively mimics the actions of E2 in breast cancer therapy but minimizes estrogenic effects in other tissues is a novel, therapeutic alternative.  We hypothesized that a selective human estrogen receptor partial agonist (ShERPA) at ERα would provide such an agent.  Novel benzothiophene derivs. with nanomolar potency in breast cancer cell cultures were designed.  Several showed partial agonist activity, with potency of 0.8-76 nM, mimicking E2 in inhibiting growth of tamoxifen-resistant breast cancer cell lines.  Three ShERPAs were tested and validated in xenograft models of endocrine-independent and tamoxifen-resistant breast cancer, and in contrast to E2, ShERPAs did not cause significant uterine growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF_Xh3QGtO4LVg90H21EOLACvtfcHk0lgR5w_kWm005g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzK&md5=f2bffc241b3de9c7537f9b5fa0c56f54</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01276%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DDelgado-Rivera%26aufirst%3DL.%26aulast%3DPham%26aufirst%3DT.%2BN.%2BD.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCarlson%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DMoore%26aufirst%3DT.%2BW.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DSelective%2520Human%2520Estrogen%2520Receptor%2520Partial%2520Agonists%2520%2528Sherpas%2529%2520for%2520Tamoxifen-Resistant%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D219%26epage%3D237%26doi%3D10.1021%2Facs.jmedchem.5b01276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kastrati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edirisinghe, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemachandra, L.-P.-M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasena, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Raloxifene and Desmethylarzoxifene Block Estrogen-Induced Malignant Transformation of Human Breast Epithelial Cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e27876</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0027876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1371%2Fjournal.pone.0027876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=22140478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Cnur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&author=I.+Kastratiauthor=P.+D.+Edirisingheauthor=L.-P.-M.+P.+Hemachandraauthor=E.+R.+Chandrasenaauthor=J.+Choiauthor=Y.-T.+Wangauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Raloxifene+and+Desmethylarzoxifene+Block+Estrogen-Induced+Malignant+Transformation+of+Human+Breast+Epithelial+Cells&doi=10.1371%2Fjournal.pone.0027876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells</span></div><div class="casAuthors">Kastrati, Irida; Edirisinghe, Praneeth D.; Hemachandra, L-P-Madhubani P.; Chandrasena, Esala R.; Choi, Jaewoo; Wang, Yue-Ting; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e27876</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">There is assocn. between exposure to estrogens and the development and progression of hormone-dependent gynecol. cancers.  Chem. carcinogenesis by catechol estrogens derived from oxidative metab. is thought to contribute to breast cancer, yet exact mechanisms remain elusive.  Malignant transformation was studied in MCF-10A human mammary epithelial cells, since estrogens are not proliferative in this cell line.  The human and equine estrogen components of estrogen replacement therapy (ERT) and their catechol metabolites were studied, along with the influence of co-administration of selective estrogen receptor modulators (SERMs), raloxifene and desmethyl-arzoxifene (DMA) and histone deacetylase inhibitors.  Transformation was induced by human estrogens and selectively by the 4-OH catechol metabolite and to a lesser extent by an equine estrogen metabolite.  The obsd. estrogen-induced upregulation of CYP450 1B1 in estrogen receptor neg. MCF-10A cells, was compatible with a causal role for 4-OH catechol estrogens, as was attenuated transformation by CYP450 inhibitors.  Estrogen-induced malignant transformation was blocked by SERMs correlating with a redn. in formation of nucleobase catechol estrogen (NCE) adducts and formation of 8-oxo-dG.  NCE adducts can be formed consequent to DNA abasic site formation, but NCE adducts were also obsd. on incubation of estrogen quinones with free nucleotides.  These results suggest that NCE adducts may be a biomarker for cellular electrophilic stress, which together with 8-oxo-dG as a biomarker of oxidative stress correlate with malignant transformation induced by estrogen oxidative metabolites.  The obsd. attenuation of transformation by SERMs correlated with these biomarkers and may also be of clin. significance in breast cancer chemoprevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocTxGgBUQJyLVg90H21EOLACvtfcHk0lhmzVK-6oTZNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Cnur3L&md5=70b8c37494d3ef4f48789ef0d1235dc9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0027876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0027876%26sid%3Dliteratum%253Aachs%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DEdirisinghe%26aufirst%3DP.%2BD.%26aulast%3DHemachandra%26aufirst%3DL.-P.-M.%2BP.%26aulast%3DChandrasena%26aufirst%3DE.%2BR.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.-T.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DRaloxifene%2520and%2520Desmethylarzoxifene%2520Block%2520Estrogen-Induced%2520Malignant%2520Transformation%2520of%2520Human%2520Breast%2520Epithelial%2520Cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26doi%3D10.1371%2Fjournal.pone.0027876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelhamid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandevrede, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litosh, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiefer, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gherezghiher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Benzothiophene Selective Estrogen Receptor Modulators Provide Neuroprotection by a Novel Gpr30-Dependent Mechanism</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1021/cn100106a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100106a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFektLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=256-268&author=R.+Abdelhamidauthor=J.+Luoauthor=L.+Vandevredeauthor=I.+Kunduauthor=B.+Michalsenauthor=V.+A.+Litoshauthor=I.+T.+Schieferauthor=T.+Gherezghiherauthor=P.+Yaoauthor=Z.+Qinauthor=G.+R.+J.+Thatcher&title=Benzothiophene+Selective+Estrogen+Receptor+Modulators+Provide+Neuroprotection+by+a+Novel+Gpr30-Dependent+Mechanism&doi=10.1021%2Fcn100106a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothiophene Selective Estrogen Receptor Modulators Provide Neuroprotection by a Novel GPR30-Dependent Mechanism</span></div><div class="casAuthors">Abdelhamid, Ramy; Luo, Jia; Vande Vrede, Lawren; Kundu, Indraneel; Michalsen, Bradley; Litosh, Vladislav A.; Schiefer, Isaac T.; Gherezghiher, Teshome; Yao, Ping; Qin, Zhihui; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">256-268</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The clin. benzothiophene SERM (BT-SERM) raloxifene was compared with estrogens in protection of primary rat neurons against oxygen-glucose deprivation (OGD).  Structure-activity relationships for neuroprotection were detd. for a family of BT-SERMs displaying a spectrum of ERα and ERβ binding affinity and agonist/antagonist activity, leading to discovery of a neuroprotective pharmacophore, present in the clin. relevant SERMS, raloxifene, and desmethylarzoxifene (DMA), for which submicromolar potency was obsd. for neuroprotection.  BT-SERM neuroprotection did not correlate with binding to ER or classical ER activity; however, both the neuroprotective SERMs and estrogens were shown, using pharmacol. probes, to activate the same kinase signaling cascades.  The antiestrogen ICI 182,780 inhibited the actions of estrogens but not those of BT-SERMs, whereas antagonism of the G-protein coupled receptor, GPR30, was effective for both SERMs and estrogens.  Since SERMs have antioxidant activity, ER-independent mechanisms were studied using the classical phenolic antioxidants, BHT and Trolox, and the Nrf2-dependent cytoprotective electrophile, sulforaphane.  However, neuroprotection by these agents was not sensitive to GPR30 antagonism.  Collectively, these data indicate that the activity of neuroprotective BT-SERMs is GPR30-dependent and ER-independent and not mediated by antioxidant effects.  Comparison of novel BT-SERM derivs. and analogs identified a neuroprotective pharmacophore of potential use in design of novel neuroprotective agents with a spectrum of ER activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvBt-wQmRmLrVg90H21EOLACvtfcHk0lhmzVK-6oTZNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFektLg%253D&md5=c1d5a55aee4f2271ec666b42f62b50c1</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fcn100106a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100106a%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelhamid%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DVandevrede%26aufirst%3DL.%26aulast%3DKundu%26aufirst%3DI.%26aulast%3DMichalsen%26aufirst%3DB.%26aulast%3DLitosh%26aufirst%3DV.%2BA.%26aulast%3DSchiefer%26aufirst%3DI.%2BT.%26aulast%3DGherezghiher%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DBenzothiophene%2520Selective%2520Estrogen%2520Receptor%2520Modulators%2520Provide%2520Neuroprotection%2520by%2520a%2520Novel%2520Gpr30-Dependent%2520Mechanism%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2011%26volume%3D2%26spage%3D256%26epage%3D268%26doi%3D10.1021%2Fcn100106a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashgodom, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lantvit, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overk, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Breemen, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Structural Modulation of Oxidative Metabolism in Design of Improved Benzothiophene Selective Estrogen Receptor Modulators</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.023408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1124%2Fdmd.108.023408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=18936111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=161-169&author=Z.+Qinauthor=I.+Kastratiauthor=R.+T.+Ashgodomauthor=D.+D.+Lantvitauthor=C.+R.+Overkauthor=Y.+Choiauthor=R.+B.+van+Breemenauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Structural+Modulation+of+Oxidative+Metabolism+in+Design+of+Improved+Benzothiophene+Selective+Estrogen+Receptor+Modulators&doi=10.1124%2Fdmd.108.023408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators</span></div><div class="casAuthors">Qin, Zhihui; Kastrati, Irida; Ashgodom, Rezene T.; Lantvit, Daniel D.; Overk, Cassia R.; Choi, Yongsoo; van Breemen, Richard B.; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">161-169</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Raloxifene and arzoxifene are benzothiophene selective estrogen receptor modulators (SERMs) of clin. use in postmenopausal osteoporosis and treatment of breast cancer and potentially in hormone replacement therapy.  The benefits of arzoxifene are attributed to improved bioavailability over raloxifene, whereas the arzoxifene metabolite, desmethylarzoxifene (DMA) is a more potent antiestrogen.  As polyarom. phenolics, benzothiophene SERMs undergo oxidative metab. to electrophilic quinoids.  The long-term clin. use of SERMs demands increased understanding of correlations between structure and toxicity, with metab. being a key component.  A homologous series of 4'-substituted 4'-desmethoxyarzoxifene derivs. was developed, and metab. was studied in liver and intestinal microsomes.  Formation of glutathione conjugates was assayed in rat liver microsomes and novel adducts were characterized by liq. chromatog.-tandem mass spectrometry.  Formation of glucuronide conjugates was assayed in human intestine and liver microsomes, demonstrating formation of glucuronides ranging from 5 to 100% for the benzothiophene SERMs: this trend was inversely correlated with the loss of parent SERM in rat liver microsomal incubations.  MO calcns. generated thermodn. parameters for oxidn. that correlated with Hammett substituent consts.; however, metab. in liver microsomes correlated with a combination of both Hammett and Hansch lipophilicity parameters.  The results demonstrate a rich oxidative chem. for the benzothiophene SERMs, the amplitude of which can be powerfully modulated, in a predictable manner, by structural tuning of the 4'-substituent.  The predicted extensive metab. of DMA was confirmed in vivo and compared with the relatively stable arzoxifene and F-DMA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXNnv4iRadE7Vg90H21EOLACvtfcHk0lgQx7245iQ0lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSltw%253D%253D&md5=0fb317771152e0fbe4ddfb9c79f0fb3d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.023408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.023408%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DAshgodom%26aufirst%3DR.%2BT.%26aulast%3DLantvit%26aufirst%3DD.%2BD.%26aulast%3DOverk%26aufirst%3DC.%2BR.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3Dvan%2BBreemen%26aufirst%3DR.%2BB.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DStructural%2520Modulation%2520of%2520Oxidative%2520Metabolism%2520in%2520Design%2520of%2520Improved%2520Benzothiophene%2520Selective%2520Estrogen%2520Receptor%2520Modulators%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D161%26epage%3D169%26doi%3D10.1124%2Fdmd.108.023408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietz, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunlap, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lantvit, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overk, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Structural Modulation of Reactivity/Activity in Design of Improved Benzothiophene Selective Estrogen Receptor Modulators: Induction of Chemopreventive Mechanisms</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2418</span>– <span class="NLM_lpage">2428</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-07-0268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F1535-7163.mct-07-0268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=17876041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCgtbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2418-2428&author=B.+Yuauthor=B.+M.+Dietzauthor=T.+Dunlapauthor=I.+Kastratiauthor=D.+D.+Lantvitauthor=C.+R.+Overkauthor=P.+Yaoauthor=Z.+Qinauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Structural+Modulation+of+Reactivity%2FActivity+in+Design+of+Improved+Benzothiophene+Selective+Estrogen+Receptor+Modulators%3A+Induction+of+Chemopreventive+Mechanisms&doi=10.1158%2F1535-7163.mct-07-0268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: Induction of chemopreventive mechanisms</span></div><div class="casAuthors">Yu, Bolan; Dietz, Birgit M.; Dunlap, Tareisha; Kastrati, Irida; Lantvit, Daniel D.; Overk, Cassia R.; Yao, Ping; Qin, Zhihui; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2418-2428</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The benzothiophene selective estrogen receptor modulators (SERM) raloxifene and arzoxifene are in clin. use and clin. trials for chemoprevention of breast cancer and other indications.  These SERMs are "oxidatively labile" and therefore have potential to activate antioxidant responsive element (ARE) transcription of genes for cytoprotective phase II enzymes such as NAD(P)H-dependent quinone oxidoreductase 1 (NQO1).  To study this possible mechanism of cancer chemoprevention, a family of benzothiophene SERMs was developed with modulated redox activity, including arzoxifene and its metabolite desmethylarzoxifene (DMA).  The relative antioxidant activity of these SERMs was assayed and correlated with induction of NQO1 in murine and human liver cells.  DMA was found to induce NQO1 and to activate ARE more strongly than other SERMs, including raloxifene and 4-hydroxytamoxifen.  Livers from female, juvenile rats treated for 3 days with estradiol and/or with the benzothiophene SERMs arzoxifene, DMA, and F-DMA showed substantial induction of NQO1 by the benzothiophene SERMs.  No persuasive evidence in this assay or in MCF-7 breast cancer cells was obtained of a major role for the estrogen receptor in induction of NQO1 by the benzothiophene SERMs.  These results suggest that arzoxifene might provide chemopreventive benefits over raloxifene and other SERMs via metab. to DMA and stimulation of ARE-mediated induction of phase II enzymes.  The correlation of SERM structure with antioxidant activity and NQO1 induction also suggests that oxidative bioactivation of SERMs may be modulated to enhance chemopreventive activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosSszy7YqBrrVg90H21EOLACvtfcHk0lgQx7245iQ0lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCgtbfF&md5=11008f981dbbacdf5bd87e8919ef678a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-07-0268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-07-0268%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DB.%26aulast%3DDietz%26aufirst%3DB.%2BM.%26aulast%3DDunlap%26aufirst%3DT.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DLantvit%26aufirst%3DD.%2BD.%26aulast%3DOverk%26aufirst%3DC.%2BR.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DStructural%2520Modulation%2520of%2520Reactivity%252FActivity%2520in%2520Design%2520of%2520Improved%2520Benzothiophene%2520Selective%2520Estrogen%2520Receptor%2520Modulators%253A%2520Induction%2520of%2520Chemopreventive%2520Mechanisms%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2418%26epage%3D2428%26doi%3D10.1158%2F1535-7163.mct-07-0268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Overk, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, K.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asghodom, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lantvit, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships for a Family of Benzothiophene Selective Estrogen Receptor Modulators Including Raloxifene and Arzoxifene</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1520</span>– <span class="NLM_lpage">1526</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1002%2Fcmdc.200700104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=17654759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2qtb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1520-1526&author=C.+R.+Overkauthor=K.-W.+Pengauthor=R.+T.+Asghodomauthor=I.+Kastratiauthor=D.+D.+Lantvitauthor=Z.+Qinauthor=J.+Frasorauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Structure-Activity+Relationships+for+a+Family+of+Benzothiophene+Selective+Estrogen+Receptor+Modulators+Including+Raloxifene+and+Arzoxifene&doi=10.1002%2Fcmdc.200700104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene</span></div><div class="casAuthors">Overk, Cassia R.; Peng, Kuan-Wei; Asghodom, Rezene T.; Kastrati, Irida; Lantvit, Daniel D.; Qin, Zhihui; Frasor, Jonna; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1520-1526</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The search for the "ideal" selective estrogen receptor modulator (SERM) as a substitute for hormone replacement therapy (HRT) or use in cancer chemoprevention has focused on optimization of estrogen receptor (ER) ligand binding.  Based on the clin. and preclin. benzothiophene SERMs, raloxifene and arzoxifene, a family of SERMs has been developed to modulate activity and oxidative lability.  Antiestrogenic potency measured in human endometrial and breast cancer cells, and ER ligand binding data were correlated and seen to provide a guide to SERM design only when viewed in toto.  The in vitro studies were extended to the juvenile rat model, in which the desired antiestrogenic profile and putative cardiovascular benefits of SERMs were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZJnWIhlKprLVg90H21EOLACvtfcHk0liz-Hrts0wWSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2qtb3E&md5=da626d457446a6ed78ffa3f9939872b1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700104%26sid%3Dliteratum%253Aachs%26aulast%3DOverk%26aufirst%3DC.%2BR.%26aulast%3DPeng%26aufirst%3DK.-W.%26aulast%3DAsghodom%26aufirst%3DR.%2BT.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DLantvit%26aufirst%3DD.%2BD.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DFrasor%26aufirst%3DJ.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DStructure-Activity%2520Relationships%2520for%2520a%2520Family%2520of%2520Benzothiophene%2520Selective%2520Estrogen%2520Receptor%2520Modulators%2520Including%2520Raloxifene%2520and%2520Arzoxifene%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D1520%26epage%3D1526%26doi%3D10.1002%2Fcmdc.200700104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasena, R. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petukhov, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Benzothiophene Selective Estrogen Receptor Modulators with Modulated Oxidative Activity and Receptor Affinity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2682</span>– <span class="NLM_lpage">2692</span>, <span class="refDoi"> DOI: 10.1021/jm070079j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070079j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2682-2692&author=Z.+Qinauthor=I.+Kastratiauthor=R.+E.+P.+Chandrasenaauthor=H.+Liuauthor=P.+Yaoauthor=P.+A.+Petukhovauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Benzothiophene+Selective+Estrogen+Receptor+Modulators+with+Modulated+Oxidative+Activity+and+Receptor+Affinity&doi=10.1021%2Fjm070079j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity</span></div><div class="casAuthors">Qin, Zhihui; Kastrati, Irida; Chandrasena, R. Esala P.; Liu, Hong; Yao, Ping; Petukhov, Pavel A.; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2682-2692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The regulation of estrogenic and antiestrogenic effects of selective estrogen receptor modulators (SERMs) is thought to underlie their clin. use.  Most SERMs are polyarom. phenols susceptible to oxidative metab. to quinoids, which are proposed to be genotoxic.  Conversely, the redox reactivity of SERMs may contribute to antioxidant and chemopreventive mechanisms, providing a new approach to improve the therapeutic properties of SERMs.  An improved synthetic strategy was developed to generate a family of benzothiophene SERMs.  Using computational modeling methods and measurements of antioxidant activity and estrogen receptor (ER) ligand binding, this SERM family was shown to provide both a range of ERα/ERβ selectivity from 1.2- to 67-fold and a range of redox activity.  Antioxidant activity was successfully modulated by varying a substituent remote from the OH group; the source of the antioxidant capacity.  An efficient synthetic procedure is reported yielding benzothiophene SERMs wherein redox activity and ER affinity are modulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_CGhCcopaULVg90H21EOLACvtfcHk0liz-Hrts0wWSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D&md5=594ddb689931d8629c9f5c9443f88cb4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm070079j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070079j%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DChandrasena%26aufirst%3DR.%2BE.%2BP.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DPetukhov%26aufirst%3DP.%2BA.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DBenzothiophene%2520Selective%2520Estrogen%2520Receptor%2520Modulators%2520with%2520Modulated%2520Oxidative%2520Activity%2520and%2520Receptor%2520Affinity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2682%26epage%3D2692%26doi%3D10.1021%2Fjm070079j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Chemical Modification Modulates Estrogenic Activity, Oxidative Reactivity, and Metabolic Stability in 4’f-Dma, a New Benzothiophene Selective Estrogen Receptor Modulator</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1021/tx050326r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx050326r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFKktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=779-787&author=H.+Liuauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Chemical+Modification+Modulates+Estrogenic+Activity%2C+Oxidative+Reactivity%2C+and+Metabolic+Stability+in+4%E2%80%99f-Dma%2C+a+New+Benzothiophene+Selective+Estrogen+Receptor+Modulator&doi=10.1021%2Ftx050326r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Modification Modulates Estrogenic Activity, Oxidative Reactivity, and Metabolic Stability in 4'F-DMA, a New Benzothiophene Selective Estrogen Receptor Modulator</span></div><div class="casAuthors">Liu, Hong; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">779-787</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The benzothiophene selective estrogen receptor modulators (SERMs), raloxifene and arzoxifene, in the clinic or clin. trials for treatment of breast cancer and postmenopausal symptoms, are highly susceptible to oxidative metab. and formation of electrophilic metabolites.  4'F-DMA, fluoro-substituted desmethyl arzoxifene (DMA), showed attenuated oxidn. to quinoids in incubation with rat hepatocytes as well as in rat and human liver microsomes.  Incubations of 4'F-DMA with hepatocytes yielded only one glucuronide conjugate and no GSH conjugates, whereas DMA underwent greater metab. giving two glucuronide conjugates, one sulfate conjugate, and two GSH conjugates.  Phase I and phase II metab. were further evaluated in human small intestine microsomes and in human intestinal Caco-2 cells.  In comparison to DMA, 4'F-DMA formed significantly less glucuronide and sulfate conjugates.  The formation of quinoids was further explored in hepatocytes in which DMA was obsd. to give concn.- and time-dependent depletion of GSH accompanied by damage to DNA, which showed inverse dependence on GSH; in contrast, GSH depletion and DNA damage were almost completely abrogated in incubations with 4'F-DMA. 4'F-DMA shows ligand binding affinity to estrogen receptor (ER)α and ERβ with similarity to both raloxifene and to DMA.  ER-mediated biol. activity was measured with the ERE-luciferase reporter system in transfected MCF-7 cells and Ishikawa cells, and in MCF-7 cells, proliferation was measured.  In all systems, 4'F-DMA exhibited antiestrogenic activity of comparable potency to raloxifene but did not manifest estrogenic properties, mirroring previous results on inhibition of estradiol-mediated induction of alk. phosphatase activity in Ishikawa cells.  These results suggest that 4'F-DMA might be an improved benzothiophene SERM with similar antiestrogenic activity to raloxifene but improved metabolic stability and attenuated toxicity, showing that simple chem. modification can abrogate oxidative bioactivation to potentially toxic metabolites without loss of activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-FltiqRoLAbVg90H21EOLACvtfcHk0lhSiHAkvj6OFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFKktLo%253D&md5=2ce12134bb346a54dc42bca0bb432063</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Ftx050326r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx050326r%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DChemical%2520Modification%2520Modulates%2520Estrogenic%2520Activity%252C%2520Oxidative%2520Reactivity%252C%2520and%2520Metabolic%2520Stability%2520in%25204%25E2%2580%2599f-Dma%252C%2520a%2520New%2520Benzothiophene%2520Selective%2520Estrogen%2520Receptor%2520Modulator%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2006%26volume%3D19%26spage%3D779%26epage%3D787%26doi%3D10.1021%2Ftx050326r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brzozowski, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, A. C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauter, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engström, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öhman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, J.-Å.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlquist, M.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis of Agonism and Antagonism in the Oestrogen Receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1038/39645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1038%2F39645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=9338790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=1997&pages=753-758&author=A.+M.+Brzozowskiauthor=A.+C.+W.+Pikeauthor=Z.+Dauterauthor=R.+E.+Hubbardauthor=T.+Bonnauthor=O.+Engstr%C3%B6mauthor=L.+%C3%96hmanauthor=G.+L.+Greeneauthor=J.-%C3%85.+Gustafssonauthor=M.+Carlquist&title=Molecular+Basis+of+Agonism+and+Antagonism+in+the+Oestrogen+Receptor&doi=10.1038%2F39645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of agonism and antagonism in the estrogen receptor</span></div><div class="casAuthors">Brzozowski, Andrzej M.; Pike, Ashley C. W.; Dauter, Zbigniew; Hubbard, Roderick E.; Bonn, Tomas; Engstrom, Owe; Ohman, Lars; Greene, Geoffrey L.; Gustafsson, Jan-Ake; Carlquist, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6652</span>),
    <span class="NLM_cas:pages">753-758</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Estrogens are involved in the growth, development and homeostasis of a no. of tissues.  The physiol. effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the estrogen receptor (ER).  Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of mol. events culminating in the activation or repression of target genes.  Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery.  Here we report the crystal structures of the LBD of ER in complex with the endogenous estrogen, 17β-estradiol, and the selective antagonist raloxifene, at resolns. of 3.1 and 2.6Å, resp.  The structures provide a mol. basis for the distinctive pharmacophore of the ER and its catholic binding properties.  Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes.  In addn., each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAXbSo66V1LrVg90H21EOLACvtfcHk0lhSiHAkvj6OFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D&md5=2a63951b881b329ff142c9fbc82a13e3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2F39645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F39645%26sid%3Dliteratum%253Aachs%26aulast%3DBrzozowski%26aufirst%3DA.%2BM.%26aulast%3DPike%26aufirst%3DA.%2BC.%2BW.%26aulast%3DDauter%26aufirst%3DZ.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DBonn%26aufirst%3DT.%26aulast%3DEngstr%25C3%25B6m%26aufirst%3DO.%26aulast%3D%25C3%2596hman%26aufirst%3DL.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DGustafsson%26aufirst%3DJ.-%25C3%2585.%26aulast%3DCarlquist%26aufirst%3DM.%26atitle%3DMolecular%2520Basis%2520of%2520Agonism%2520and%2520Antagonism%2520in%2520the%2520Oestrogen%2520Receptor%26jtitle%3DNature%26date%3D1997%26volume%3D389%26spage%3D753%26epage%3D758%26doi%3D10.1038%2F39645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiau, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barstad, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loria, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agard, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span> <span> </span><span class="NLM_article-title">The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">927</span>– <span class="NLM_lpage">937</span>, <span class="refDoi"> DOI: 10.1016/s0092-8674(00)81717-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2FS0092-8674%2800%2981717-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=9875847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK1MXjslyltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=927-937&author=A.+K.+Shiauauthor=D.+Barstadauthor=P.+M.+Loriaauthor=L.+Chengauthor=P.+J.+Kushnerauthor=D.+A.+Agardauthor=G.+L.+Greene&title=The+Structural+Basis+of+Estrogen+Receptor%2FCoactivator+Recognition+and+the+Antagonism+of+This+Interaction+by+Tamoxifen&doi=10.1016%2Fs0092-8674%2800%2981717-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen</span></div><div class="casAuthors">Shiau, Andrew K.; Barstad, Danielle; Loria, Paula M.; Cheng, Lin; Kushner, Peter J.; Agard, David A.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">927-937</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Ligand-dependent activation of transcription by nuclear receptors (NRs) is mediated by interactions with coactivators.  Receptor agonists promote coactivator binding, and antagonists block coactivator binding.  Here we report the crystal structure of the human estrogen receptor α (hERα) ligand-binding domain (LBD) bound to both the agonist diethylstilbestrol (DES) and a peptide derived from the NR box II region of the coactivator GRIP1 and the crystal structure of the hERα LBD bound to the selective antagonist 4-hydroxytamoxifen (OHT).  In the DES-LBD-peptide complex, the peptide binds as a short α helix to a hydrophobic groove on the surface of the LBD.  In the OHT-LBD complex, helix 12 occludes the coactivator recognition groove by mimicking the interactions of the NR box peptide with the LBD.  These structures reveal the two distinct mechanisms by which structural features of OHT promote this "autoinhibitory" helix 12 conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrjqf40oHhE7Vg90H21EOLACvtfcHk0lhSiHAkvj6OFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslyltQ%253D%253D&md5=074d616cf353f0d98cea5b26c4595c10</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981717-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981717-1%26sid%3Dliteratum%253Aachs%26aulast%3DShiau%26aufirst%3DA.%2BK.%26aulast%3DBarstad%26aufirst%3DD.%26aulast%3DLoria%26aufirst%3DP.%2BM.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DP.%2BJ.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DThe%2520Structural%2520Basis%2520of%2520Estrogen%2520Receptor%252FCoactivator%2520Recognition%2520and%2520the%2520Antagonism%2520of%2520This%2520Interaction%2520by%2520Tamoxifen%26jtitle%3DCell%26date%3D1998%26volume%3D95%26spage%3D927%26epage%3D937%26doi%3D10.1016%2Fs0092-8674%2800%2981717-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (Serd) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7917</span>– <span class="NLM_lpage">7928</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7917-7928&author=J.+Nagasawaauthor=S.+Govekauthor=M.+Kahramanauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Maheuauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+an+Orally+Bioavailable+Chromene-Based+Selective+Estrogen+Receptor+Degrader+%28Serd%29+That+Demonstrates+Robust+Activity+in+a+Model+of+Tamoxifen-Resistant+Breast+Cancer&doi=10.1021%2Facs.jmedchem.8b00921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Nagasawa, Johnny; Govek, Steven; Kahraman, Mehmet; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Maheu, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7917-7928</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. eighty percent of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to anti-hormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α, and is active in patients who have progressed on anti-hormonal agents.  However fulvestrant suffers from poor pharmaceutical properties and must be administered by intra-muscular injections that limit the total amt. of drug that can be administered, and hence lead to the potential for incomplete receptor blockade.  The authors describe the optimization of ER-α degrdn. efficacy of a chromene series of ER modulators resulting in highly potent and efficacious SERDs such as 14n (3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol).  The side-chain ring size and stereochem. elements were central in driving degrdn. efficacy, leading to the identification of 14n.  When examd. in a xenograft model of tamoxifen-resistant breast cancer, biphenol chromene 14n (ER-α degrdn. efficacy = 91%) demonstrated robust activity, while despite superior oral exposure, a mono-phenol chromene 15g (3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol) (ER-α degrdn. efficacy = 82%) was essentially inactive.  Although not definitively causative, this result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects models of tamoxifen-resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8I60s9csFRrVg90H21EOLACvtfcHk0lgMLqzNzKpNTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E&md5=9ae708199592455e0a691c7af2e43967</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00921%26sid%3Dliteratum%253Aachs%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DMaheu%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520an%2520Orally%2520Bioavailable%2520Chromene-Based%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520%2528Serd%2529%2520That%2520Demonstrates%2520Robust%2520Activity%2520in%2520a%2520Model%2520of%2520Tamoxifen-Resistant%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7917%26epage%3D7928%26doi%3D10.1021%2Facs.jmedchem.8b00921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges-Gallagher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myles, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, P. J.</span></span> <span> </span><span class="NLM_article-title">Specific Stereochemistry of Op-1074 Disrupts Estrogen Receptor Alpha Helix 12 and Confers Pure Antiestrogenic Activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2368</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-04413-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1038%2Fs41467-018-04413-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=29915250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BC1MbosF2gtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2368&author=S.+W.+Fanningauthor=L.+Hodges-Gallagherauthor=D.+C.+Mylesauthor=R.+Sunauthor=C.+E.+Fowlerauthor=I.+N.+Plantauthor=B.+D.+Greenauthor=C.+L.+Harmonauthor=G.+L.+Greeneauthor=P.+J.+Kushner&title=Specific+Stereochemistry+of+Op-1074+Disrupts+Estrogen+Receptor+Alpha+Helix+12+and+Confers+Pure+Antiestrogenic+Activity&doi=10.1038%2Fs41467-018-04413-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity</span></div><div class="casAuthors">Fanning S W; Fowler C E; Green B D; Greene G L; Hodges-Gallagher L; Myles D C; Sun R; Harmon C L; Kushner P J; Plant I N</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2368</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Complex tissue-specific and cell-specific signaling by the estrogen receptor (ER) frequently leads to the development of resistance to endocrine therapy for breast cancer.  Pure ER antagonists, which completely lack tissue-specific agonist activity, hold promise for preventing and treating endocrine resistance, however an absence of structural information hinders the development of novel candidates.  Here we synthesize a small panel of benzopyrans with variable side chains to identify pure antiestrogens in a uterotrophic assay.  We identify OP-1074 as a pure antiestrogen and a selective ER degrader (PA-SERD) that is efficacious in shrinking tumors in a tamoxifen-resistant xenograft model.  Biochemical and crystal structure analyses reveal a structure activity relationship implicating the importance of a stereospecific methyl on the pyrrolidine side chain of OP-1074, particularly on helix 12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYJ5LDE5uCtbjnyZkbE8yXfW6udTcc2eZwcmUeUhuogbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbosF2gtg%253D%253D&md5=a381a76b8363cda16ac9ac5ec0c702d8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04413-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04413-3%26sid%3Dliteratum%253Aachs%26aulast%3DFanning%26aufirst%3DS.%2BW.%26aulast%3DHodges-Gallagher%26aufirst%3DL.%26aulast%3DMyles%26aufirst%3DD.%2BC.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DFowler%26aufirst%3DC.%2BE.%26aulast%3DPlant%26aufirst%3DI.%2BN.%26aulast%3DGreen%26aufirst%3DB.%2BD.%26aulast%3DHarmon%26aufirst%3DC.%2BL.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DKushner%26aufirst%3DP.%2BJ.%26atitle%3DSpecific%2520Stereochemistry%2520of%2520Op-1074%2520Disrupts%2520Estrogen%2520Receptor%2520Alpha%2520Helix%252012%2520and%2520Confers%2520Pure%2520Antiestrogenic%2520Activity%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D2368%26doi%3D10.1038%2Fs41467-018-04413-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=50-55&author=M.+Kahramanauthor=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Liuauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Maximizing+ER-%CE%B1+Degradation+Maximizes+Activity+in+a+Tamoxifen-Resistant+Breast+Cancer+Model%3A+Identification+of+GDC-0927&doi=10.1021%2Facsmedchemlett.8b00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927</span></div><div class="casAuthors">Kahraman, Mehmet; Govek, Steven P.; Nagasawa, Johnny Y.; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Liu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-55</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The further optimization of ER-α degrdn. efficacy of a series of ER modulators by refining side-chain substitution led to efficacious selective estrogen receptor degraders (SERDs).  A fluoromethyl azetidine group was found to be preferred and resulted in the identification of bis-phenol chromene 17ha.  In a tamoxifen-resistant breast cancer xenograft model, 17ha (ER-α degrdn. efficacy = 97%) demonstrated tumor regression, together with robust redn. of intratumoral ER-α levels.  However, despite superior oral exposure, 5a (ER-α degrdn. efficacy = 91%) had inferior activity.  This result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects in a model of tamoxifen-resistant breast cancer.  Compd. 17ha (GDC-0927) was evaluated in clin. trials in women with metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgyUydsTFnYrVg90H21EOLACvtfcHk0lgpk9jUivMBBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M&md5=324c1697ef350d169a97960de72ee8a9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00414%26sid%3Dliteratum%253Aachs%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DMaximizing%2520ER-%25CE%25B1%2520Degradation%2520Maximizes%2520Activity%2520in%2520a%2520Tamoxifen-Resistant%2520Breast%2520Cancer%2520Model%253A%2520Identification%2520of%2520GDC-0927%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D50%26epage%3D55%26doi%3D10.1021%2Facsmedchemlett.8b00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yingling, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span> <span> </span><span class="NLM_article-title">An Estrogen Receptor Positive Mcf-7 Clone That Is Resistant to Antiestrogens and Estradiol</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/0303-7207(92)90104-e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2F0303-7207%2892%2990104-e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1301400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1GhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1992&pages=77-86&author=S.-y.+Jiangauthor=D.+M.+Wolfauthor=J.+M.+Yinglingauthor=C.+Changauthor=V.+C.+Jordan&title=An+Estrogen+Receptor+Positive+Mcf-7+Clone+That+Is+Resistant+to+Antiestrogens+and+Estradiol&doi=10.1016%2F0303-7207%2892%2990104-e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol</span></div><div class="casAuthors">Jiang, Shun Yuan; Wolf, Douglas M.; Yingling, Jonathan M.; Chang, Chawnshang; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-86</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    </div><div class="casAbstract">The antiestrogen tamoxifen has been successfully used to control estrogen receptor (ER)- and progesterone receptor-pos. breast cancer.  However, the development of antiestrogen resistance is frequently obsd. in patients following long-term treatment.  The development of antiestrogen resistance was studied in vitro, and an antiestrogen resistant variant of MCF-7 cells (clone 5C) was established after long-term culture in estrogen-free medium.  The growth of clone 5C cells was not altered by either estradiol or the antiestrogens 4-hydroxytamoxifen and ICI 164,384.  Estrogen-stimulated progesterone receptor and reporter gene expression were markedly reduced in 5C cells compared to wild-type MCF-7 cells.  Only minor alteration in the levels of ER and no alteration in the affinity of ER for ligand were found in 5C cells.  No mutation of ER cDNA in 5C cells was detected by polymerase chain reaction and DNA sequencing.  This study demonstrates that change(s) in ER-mediated gene expression rather than the amino acid sequence of the ER itself may be assocd. with the development of at least one form of antiestrogen resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7D95adwlHwLVg90H21EOLACvtfcHk0lgpk9jUivMBBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1GhtA%253D%253D&md5=3bfb8ea4c10526f1477410c7cf6a03d7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0303-7207%2892%2990104-e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0303-7207%252892%252990104-e%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DS.-y.%26aulast%3DWolf%26aufirst%3DD.%2BM.%26aulast%3DYingling%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DAn%2520Estrogen%2520Receptor%2520Positive%2520Mcf-7%2520Clone%2520That%2520Is%2520Resistant%2520to%2520Antiestrogens%2520and%2520Estradiol%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D1992%26volume%3D90%26spage%3D77%26epage%3D86%26doi%3D10.1016%2F0303-7207%2892%2990104-e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livezey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D. J.</span></span> <span> </span><span class="NLM_article-title">Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and Are Killed by Bhpi</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">34753</span>, <span class="refDoi"> DOI: 10.1038/srep34753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1038%2Fsrep34753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=27713477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Kmu7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=34753&author=C.+Maoauthor=M.+Livezeyauthor=J.+E.+Kimauthor=D.+J.+Shapiro&title=Antiestrogen+Resistant+Cell+Lines+Expressing+Estrogen+Receptor+%CE%B1+Mutations+Upregulate+the+Unfolded+Protein+Response+and+Are+Killed+by+Bhpi&doi=10.1038%2Fsrep34753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI</span></div><div class="casAuthors">Mao, Chengjian; Livezey, Mara; Kim, Ji Eun; Shapiro, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34753</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Outgrowth of metastases expressing ERα mutations Y537S and D538G is common after endocrine therapy for estrogen receptor α (ERα) pos. breast cancer.  The effect of replacing wild type ERα in breast cancer cells with these mutations was unclear.  We used the CRISPR-Cas9 genome editing system and homol. directed repair to isolate and characterize 14 T47D cell lines in which ERαY537S or ERαD538G replace one or both wild-type ERα genes.  In 2-dimensional, and in quant. anchorage-independent 3-dimensional cell culture, ERαY537S and ERαD538G cells exhibited estrogen-independent growth.  A progestin further increased their already substantial proliferation in micromolar 4-hydroxytamoxifen and fulvestrant/ICI 182,780 (ICI).  Our recently described ERα biomodulator, BHPI, which hyperactivates the unfolded protein response (UPR), completely blocked proliferation.  In ERαY537S and ERαD538G cells, estrogen-ERα target genes were constitutively active and partially antiestrogen resistant.  The UPR marker sp-XBP1 was constitutively activated in ERαY537S cells and further induced by progesterone in both cell lines.  UPR-regulated genes assocd. with tamoxifen resistance, including the oncogenic chaperone BiP/GRP78, were upregulated.  ICI displayed a greater than 2 fold redn. in its ability to induce ERαY537S and ERαD538G degrdn.  Progestins, UPR activation and perhaps reduced ICI-stimulated ERα degrdn. likely contribute to antiestrogen resistance seen in ERαY537S and ERαD538G cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnk6TbVl3BX7Vg90H21EOLACvtfcHk0lg-Hv_NXaPK2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Kmu7zF&md5=a823b3cbf233db08a026b76f615424e4</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fsrep34753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep34753%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DC.%26aulast%3DLivezey%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DJ.%2BE.%26aulast%3DShapiro%26aufirst%3DD.%2BJ.%26atitle%3DAntiestrogen%2520Resistant%2520Cell%2520Lines%2520Expressing%2520Estrogen%2520Receptor%2520%25CE%25B1%2520Mutations%2520Upregulate%2520the%2520Unfolded%2520Protein%2520Response%2520and%2520Are%2520Killed%2520by%2520Bhpi%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D34753%26doi%3D10.1038%2Fsrep34753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samoila, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moynahan, M. E.</span></span> <span> </span><span class="NLM_article-title">Prevalence of Esr1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the Bolero-2 Clinical Trial</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1310</span>– <span class="NLM_lpage">1315</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2016.1279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1001%2Fjamaoncol.2016.1279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=27532364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BC2szht1WjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=1310-1315&author=S.+Chandarlapatyauthor=D.+Chenauthor=W.+Heauthor=P.+Sungauthor=A.+Samoilaauthor=D.+Youauthor=T.+Bhattauthor=P.+Patelauthor=M.+Voiauthor=M.+Gnantauthor=G.+Hortobagyiauthor=J.+Baselgaauthor=M.+E.+Moynahan&title=Prevalence+of+Esr1+Mutations+in+Cell-Free+DNA+and+Outcomes+in+Metastatic+Breast+Cancer%3A+A+Secondary+Analysis+of+the+Bolero-2+Clinical+Trial&doi=10.1001%2Fjamaoncol.2016.1279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial</span></div><div class="casAuthors">Chandarlapaty Sarat; Sung Patricia; Samoila Aliaksandra; You Daoqi; Bhatt Trusha; Baselga Jose; Moynahan Mary Ellen; Chen David; He Wei; Patel Parul; Voi Maurizio; Gnant Michael; Hortobagyi Gabriel</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1310-1315</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Estrogen receptor α (ESR1) mutations found in metastatic breast cancer (MBC) promote ligand-independent receptor activation and resistance to estrogen-deprivation therapy in laboratory models.  The prevalence of these mutations and their potential impact on clinical outcomes has not been established.  Objective:  To determine the prevalence of ESR1 mutations (Y537S and D538G) in estrogen receptor (ER)-positive MBC and determine whether mutation is associated with inferior outcomes.  Design, Setting, and Participants:  From December 16, 2014, to August 26, 2015, we analyzed cell-free DNA (cfDNA) from baseline plasma samples from participants in the BOLERO-2 double-blind phase 3 study that randomized patients from 189 centers in 24 countries with MBC to exemestane plus placebo or exemestane plus everolimus.  The study enrolled postmenopausal women with a diagnosis of MBC and prior exposure to an aromatase inhibitor.  Baseline plasma samples were available from 541 of 724 patients (74.7%).  We assessed the effect of mutation on overall survival of the population and the effect of mutation on progression-free survival (PFS) by treatment arm.  Interventions:  Patients were randomized to treatment with exemestane (25 mg oral daily) together with everolimus (10 mg oral daily) or with placebo.  Main Outcomes and Measures:  The 2 most frequent mutations in ESR1 (Y537S and D538G) were analyzed from cfDNA using droplet digital polymerase chain reaction and samples scored as wild-type, D538G, Y537S, or double mutant.  Cox-proportional hazards model was used to assess PFS in patient subgroups defined by mutations, and the effect of each mutation on overall survival.  Results:  Of 541 evaluable patients, 156 (28.8%) had ESR1 mutation D538G (21.1%) and/or Y537S (13.3%), and 30 had both.  These mutations were associated with shorter overall survival (wild-type, 32.1 months [95% CI, 28.09-36.40 months]; D538G, 25.99 months [95% CI, 19.19-32.36 months]; Y537S, 19.98 months [13.01-29.31 months]; both mutations, 15.15 months [95% CI, 10.87-27.43 months]).  The D538G group (hazard ratio, 0.34 [95% CI, 0.02-0.57]) derived a similar PFS benefit as wild type from addition of everolimus to exemestane.  Conclusions and Relevance:  ESR1 mutations are prevalent in ER-positive aromatase inhibitor-treated MBC.  Both Y537S and D538G mutations are associated with more aggressive disease biology.  Trial Registration:  clinicaltrials.gov Identifier: NCT00863655.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTuJT9GSPJ0sK3uFsUIZtkfW6udTcc2ebGl44YBSWtRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szht1WjtQ%253D%253D&md5=b6ccddcfc1f9ace84aeab93b215d9b36</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2016.1279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2016.1279%26sid%3Dliteratum%253Aachs%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DSung%26aufirst%3DP.%26aulast%3DSamoila%26aufirst%3DA.%26aulast%3DYou%26aufirst%3DD.%26aulast%3DBhatt%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26atitle%3DPrevalence%2520of%2520Esr1%2520Mutations%2520in%2520Cell-Free%2520DNA%2520and%2520Outcomes%2520in%2520Metastatic%2520Breast%2520Cancer%253A%2520A%2520Secondary%2520Analysis%2520of%2520the%2520Bolero-2%2520Clinical%2520Trial%26jtitle%3DJAMA%2520Oncol.%26date%3D2016%26volume%3D2%26spage%3D1310%26epage%3D1315%26doi%3D10.1001%2Fjamaoncol.2016.1279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breslin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Driscoll, L.</span></span> <span> </span><span class="NLM_article-title">Three-Dimensional Cell Culture: The Missing Link in Drug Discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2012.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fj.drudis.2012.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=23073387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1aqs7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=240-249&author=S.+Breslinauthor=L.+O%E2%80%99Driscoll&title=Three-Dimensional+Cell+Culture%3A+The+Missing+Link+in+Drug+Discovery&doi=10.1016%2Fj.drudis.2012.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Three-dimensional cell culture: the missing link in drug discovery</span></div><div class="casAuthors">Breslin, Susan; O'Driscoll, Lorraine</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">240-249</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cells, grown as monolayers (2D models), are routinely used as initial model systems for evaluating the effectiveness and safety of libraries of mols. with potential as therapeutic drugs.  While this initial screening precedes preclin. animal studies before advancing to human clin. trials, cultured cells frequently det. the initial, yet crucial, 'stop/go' decisions on the progressing of the development of a drug.  Growing cells as three-dimensional (3D) models more analogous to their existence in vivo, for example, akin to a tumor, and possibly co-cultured with other cells and cellular components that naturally occur in their microenvironment may be more clin. relevant.  Here, in the context of anti-cancer drug screening, we review 2D and 3D culture approaches, consider the strengths and relevance of each method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6L1vxblLJJbVg90H21EOLACvtfcHk0lhPvpCZlapupQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1aqs7%252FN&md5=caec0a115779d0204fea9e083963487f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DBreslin%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Driscoll%26aufirst%3DL.%26atitle%3DThree-Dimensional%2520Cell%2520Culture%253A%2520The%2520Missing%2520Link%2520in%2520Drug%2520Discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D240%26epage%3D249%26doi%3D10.1016%2Fj.drudis.2012.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalouni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruyn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidersbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houtman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kategaya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daemen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fj.cell.2019.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=31353221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=949-963&author=J.+Guanauthor=W.+Zhouauthor=M.+Hafnerauthor=R.+A.+Blakeauthor=C.+Chalouniauthor=I.+P.+Chenauthor=T.+De+Bruynauthor=J.+M.+Giltnaneauthor=S.+J.+Hartmanauthor=A.+Heidersbachauthor=R.+Houtmanauthor=E.+Ingallaauthor=L.+Kategayaauthor=T.+Kleinheinzauthor=J.+Liauthor=S.+E.+Martinauthor=Z.+Modrusanauthor=M.+Nanniniauthor=J.+Oehauthor=S.+Ubhayakarauthor=X.+Wangauthor=I.+E.+Wertzauthor=A.+Youngauthor=M.+Yuauthor=D.+Sampathauthor=J.+H.+Hagerauthor=L.+S.+Friedmanauthor=A.+Daemenauthor=C.+Metcalfe&title=Therapeutic+Ligands+Antagonize+Estrogen+Receptor+Function+by+Impairing+Its+Mobility&doi=10.1016%2Fj.cell.2019.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility</span></div><div class="casAuthors">Guan, Jane; Zhou, Wei; Hafner, Marc; Blake, Robert A.; Chalouni, Cecile; Chen, Irene P.; De Bruyn, Tom; Giltnane, Jennifer M.; Hartman, Steven J.; Heidersbach, Amy; Houtman, Rene; Ingalla, Ellen; Kategaya, Lorn; Kleinheinz, Tracy; Li, Jun; Martin, Scott E.; Modrusan, Zora; Nannini, Michelle; Oeh, Jason; Ubhayakar, Savita; Wang, Xiaojing; Wertz, Ingrid E.; Young, Amy; Yu, Mamie; Sampath, Deepak; Hager, Jeffrey H.; Friedman, Lori S.; Daemen, Anneleen; Metcalfe, Ciara</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-963.e18</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Estrogen receptor-pos. (ER+) breast cancers frequently remain dependent on ER signaling even after acquiring resistance to endocrine agents, prompting the development of optimized ER antagonists.  Fulvestrant is unique among approved ER therapeutics due to its capacity for full ER antagonism, thought to be achieved through ER degrdn.  The clin. potential of fulvestrant is limited by poor physicochem. features, spurring attempts to generate ER degraders with improved drug-like properties.  We show that optimization of ER degrdn. does not guarantee full ER antagonism in breast cancer cells; ER "degraders" exhibit a spectrum of transcriptional activities and anti-proliferative potential.  Mechanistically, we find that fulvestrant-like antagonists suppress ER transcriptional activity not by ER elimination, but by markedly slowing the intra-nuclear mobility of ER.  Increased ER turnover occurs as a consequence of ER immobilization.  These findings provide proof-of-concept that small mol. perturbation of transcription factor mobility may enable therapeutic targeting of this challenging target class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX7uBE7ualk7Vg90H21EOLACvtfcHk0lhPvpCZlapupQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM&md5=96dddd56a1d3d4244ea38f0e7d17941e</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHafner%26aufirst%3DM.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DChalouni%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DI.%2BP.%26aulast%3DDe%2BBruyn%26aufirst%3DT.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DHartman%26aufirst%3DS.%2BJ.%26aulast%3DHeidersbach%26aufirst%3DA.%26aulast%3DHoutman%26aufirst%3DR.%26aulast%3DIngalla%26aufirst%3DE.%26aulast%3DKategaya%26aufirst%3DL.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DS.%2BE.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DDaemen%26aufirst%3DA.%26aulast%3DMetcalfe%26aufirst%3DC.%26atitle%3DTherapeutic%2520Ligands%2520Antagonize%2520Estrogen%2520Receptor%2520Function%2520by%2520Impairing%2520Its%2520Mobility%26jtitle%3DCell%26date%3D2019%26volume%3D178%26spage%3D949%26epage%3D963%26doi%3D10.1016%2Fj.cell.2019.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, H. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, H. N.</span></span> <span> </span><span class="NLM_article-title">Photoaffinity Labels for Estrogen Binding Proteins of Rat Uterus</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">4085</span>– <span class="NLM_lpage">4092</span>, <span class="refDoi"> DOI: 10.1021/bi00745a010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00745a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaE2cXnvVGrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1973&pages=4085-4092&author=J.+A.+Katzenellenbogenauthor=H.+J.+Johnsonauthor=H.+N.+Myers&title=Photoaffinity+Labels+for+Estrogen+Binding+Proteins+of+Rat+Uterus&doi=10.1021%2Fbi00745a010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Photoaffinity labels for estrogen binding proteins of rat uterus</span></div><div class="casAuthors">Katzenellenbogen, John A.; Johnson, Howard J., Jr.; Myers, Harvey N.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4085-92</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The binding affinity of 14 estrone, estradiol, and hexestrol derivs. bearing a photosensitive function (either diazocarbonyl group or aryl azide) and their precursors for rat uterine estrogen binding protein was measured by a competitive binding assay.  Introduction of substituents lowered binding affinity in all cases, esp. when 1 or both of the hydroxyl groups were blocked.  Substituents at positions 2, 4, and 16 were tolerated reasonably well.  Derivs. in which the A-ring hydroxyl is internally hydrogen bonded to a nitro group have very low affinity, but the nitro group was well tolerated at position 4, where it does not hydrogen bond to the hydroxyl.  The binding affinity of all the derivs. reflected the relative binding affinity of the parent ligands:  hexestrol > estradiol > estrone.  3-Azidohexestrol [50548-21-5] and 3,3'-diazidohexestrol [50548-22-6] >5%, had the greatest binding affinity and could selectively label estrogen binding protein directly in the impure state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzUNSnonz6bLVg90H21EOLACvtfcHk0lj71TThArvXiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXnvVGrsA%253D%253D&md5=99f1bdfa830d881939130942394e47be</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fbi00745a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00745a010%26sid%3Dliteratum%253Aachs%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DH.%2BJ.%26aulast%3DMyers%26aufirst%3DH.%2BN.%26atitle%3DPhotoaffinity%2520Labels%2520for%2520Estrogen%2520Binding%2520Proteins%2520of%2520Rat%2520Uterus%26jtitle%3DBiochemistry%26date%3D1973%26volume%3D12%26spage%3D4085%26epage%3D4092%26doi%3D10.1021%2Fbi00745a010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span> <span> </span><span class="NLM_article-title">Altered Ligand Binding Properties and Enhanced Stability of a Constitutively Active Estrogen Receptor: Evidence That an Open Pocket Conformation Is Required for Ligand Interaction</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">14897</span>– <span class="NLM_lpage">14905</span>, <span class="refDoi"> DOI: 10.1021/bi971746l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi971746l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK2sXnt1Sls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=14897-14905&author=K.+E.+Carlsonauthor=I.+Choiauthor=A.+Geeauthor=B.+S.+Katzenellenbogenauthor=J.+A.+Katzenellenbogen&title=Altered+Ligand+Binding+Properties+and+Enhanced+Stability+of+a+Constitutively+Active+Estrogen+Receptor%3A+Evidence+That+an+Open+Pocket+Conformation+Is+Required+for+Ligand+Interaction&doi=10.1021%2Fbi971746l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: Evidence that an open pocket conformation is required for ligand interaction</span></div><div class="casAuthors">Carlson, Kathryn E.; Choi, Inho; Gee, Arvin; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">14897-14905</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To elucidate the ligand binding properties of the estrogen receptor (ER) and how ligand access to and release from the ligand binding pocket is affected by the conformational state of the receptor, the authors have measured the rates of estradiol assocn. and dissocn., the equil. binding, and the stability of estradiol binding to denaturants, comparing wild-type human ER and a point mutant (Y537S ER) that shows full constitutive activity, i.e., the same full transcriptional activity in the absence or presence of estrogen.  Ligand binding kinetics and affinity were measured with the full-length (1-595) ERs and with truncated forms of both receptors contg. domains C through F (including the DNA binding, hinge, and ligand binding domains, amino acids 175-595) or domains E and F (the ligand binding domain; amino acids 304-595).  With all ERs, the rates of ligand assocn. and dissocn. were considerably slower with the Y537S mutant ER than with wild-type ER (6-fold and 3-4-fold, resp.).  These marked differences in ligand on and off rates for the wild-type and Y537S receptors result in a predicted (k-1/k+1) and measured Kd that is 2-fold lower for Y537S ER compared to wild-type ER.  The binding of estradiol by wild-type ER was disrupted by high concns. of urea (above 2 M), whereas the Y537S ER was distinctly more resistant to this disruption.  These results are consistent with a model in which wild-type ER in the absence of ligand adopts a transcriptionally inactive collapsed pocket conformation, stabilized by specific interactions of Y537 with nearby regions of ER.  When estradiol is bound, the wild-type ER adopts a transcriptionally active, closed pocket (ligand occupied) conformation.  By contrast, the Y537S mutant ER favors the transcriptionally active closed pocket conformation, whether occupied by ligand or not, the latter state (closed pocket but unoccupied) accounting for its constitutive activity.  The authors' findings suggest that the entry or exit of ligand from the binding pocket requires that ER adopt an open pocket conformation.  The reduced rates of ligand assocn. and dissocn. in the constitutively active form of the ER, as well as its greater resistance to disruption of ligand binding by urea, support the supposition that the rate at which this open pocket conformation can be accessed from the unoccupied or ligand-occupied Y537S ER is slower than from the unoccupied or occupied forms of wild-type ER.  Thus, the binding and release of ligand by ER require that the receptor access an open pocket state, and the ease with which this state can be accessed is affected by mutations that alter receptor conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpASth-0158cLVg90H21EOLACvtfcHk0ljoYoO4LecVAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt1Sls7o%253D&md5=905b74d7bd576c661a10daad28913fd8</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fbi971746l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi971746l%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DChoi%26aufirst%3DI.%26aulast%3DGee%26aufirst%3DA.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26atitle%3DAltered%2520Ligand%2520Binding%2520Properties%2520and%2520Enhanced%2520Stability%2520of%2520a%2520Constitutively%2520Active%2520Estrogen%2520Receptor%253A%2520Evidence%2520That%2520an%2520Open%2520Pocket%2520Conformation%2520Is%2520Required%2520for%2520Ligand%2520Interaction%26jtitle%3DBiochemistry%26date%3D1997%26volume%3D36%26spage%3D14897%26epage%3D14905%26doi%3D10.1021%2Fbi971746l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chisamore, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentrem, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span> <span> </span><span class="NLM_article-title">Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase C alpha</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3156</span>– <span class="NLM_lpage">3165</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-1772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F1078-0432.CCR-16-1772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=11595710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvF2rsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=3156-3165&author=M.+J.+Chisamoreauthor=Y.+Ahmedauthor=D.+J.+Bentremauthor=V.+C.+Jordanauthor=D.+A.+Tonetti&title=Novel+antitumor+effect+of+estradiol+in+athymic+mice+injected+with+a+T47D+breast+cancer+cell+line+overexpressing+protein+kinase+C+alpha&doi=10.1158%2F1078-0432.CCR-16-1772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase cα</span></div><div class="casAuthors">Chisamore, Michael J.; Ahmed, Yasmin; Bentrem, David J.; Jordan, V. Craig; Tonetti, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3156-3165</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Resistance to tamoxifen (TAM) represents a significant challenge to the management of breast cancer.  We previously reported that the estrogen receptor (ER)-neg. hormone-independent T47D:C42 cell line has both elevated protein kinase Cα (PKCα) protein expression and basal activator protein-1 activity compared with the parental ER+ (hormone-dependent) T47D:A18 cell line.  Stable transfection of PKCα to the T47D:A18 breast cancer cell line results in increased basal activator protein-1 activity, reduced ER function, increased proliferation rate, and hormone-independent growth (Tonetti et al., Br. J. Cancer, 83: 782-791, 2000).  In this report, we further characterize the role of PKCα overexpression in vivo to elucidate a possible mol. mechanism of tamoxifen resistance.  To det. whether the T47D:A18/PKCα cell line would produce hormone-independent tumors in athymic mice, we injected T47D:A18, T47D:A18/neo, or the T47D:A18/PKCα20 cell clones bilaterally into the mammary fat pads of athymic mice.  Tumor growth was evaluated following treatment with estradiol (E2), TAM, and the pure antiestrogen, ICI 182780.  Mice receiving either T47D:A18 or T47D:A18/neo cells produced tumors that grew in response to E2 treatment, whereas the untreated control and TAM-treated groups showed no tumor growth.  Interestingly, mice receiving the T47D:A18/PKCα20 clone produced tumors in both the control and TAM groups, whereas tumor growth was inhibited in mice treated with E2.  PKCα was also overexpressed in an MCF-7 tumor model that also exhibited TAM-stimulated and E2-induced regression.  These results suggest that overexpression of PKCα in breast tumors results in hormone-independent tumor growth that cannot be inhibited by TAM treatment.  Furthermore, the finding that E2 has an antitumor effect on breast tumors overexpressing PKCα is a novel observation that may have important therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Yd2zilR7XbVg90H21EOLACvtfcHk0ljoYoO4LecVAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvF2rsr0%253D&md5=e132ea7de154480f42b7f701b796401c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-1772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-1772%26sid%3Dliteratum%253Aachs%26aulast%3DChisamore%26aufirst%3DM.%2BJ.%26aulast%3DAhmed%26aufirst%3DY.%26aulast%3DBentrem%26aufirst%3DD.%2BJ.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26atitle%3DNovel%2520antitumor%2520effect%2520of%2520estradiol%2520in%2520athymic%2520mice%2520injected%2520with%2520a%2520T47D%2520breast%2520cancer%2520cell%2520line%2520overexpressing%2520protein%2520kinase%2520C%2520alpha%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D3156%26epage%3D3165%26doi%3D10.1158%2F1078-0432.CCR-16-1772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molloy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, B. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gherezghiher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalsen, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maximov, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span> <span> </span><span class="NLM_article-title">Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2515</span>– <span class="NLM_lpage">2526</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-14-0319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F1535-7163.mct-14-0319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=25205655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2515-2526&author=M.+E.+Molloyauthor=B.+E.+P.+Whiteauthor=T.+Gherezghiherauthor=B.+T.+Michalsenauthor=R.+Xiongauthor=H.+Patelauthor=H.+Zhaoauthor=P.+Y.+Maximovauthor=V.+C.+Jordanauthor=G.+R.+J.+Thatcherauthor=D.+A.+Tonetti&title=Novel+Selective+Estrogen+Mimics+for+the+Treatment+of+Tamoxifen-Resistant+Breast+Cancer&doi=10.1158%2F1535-7163.mct-14-0319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Molloy, Mary Ellen; White, Bethany E. Perez; Gherezghiher, Teshome; Michalsen, Bradley T.; Xiong, Rui; Patel, Hitisha; Zhao, Huiping; Maximov, Philipp Y.; Jordan, V. Craig; Thatcher, Gregory R. J.; Tonetti, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2515-2526</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Endocrine-resistant breast cancer is a major clin. obstacle.  The use of 17β-estradiol (E2) has reemerged as a potential treatment option following exhaustive use of tamoxifen or aromatase inhibitors, although side effects have hindered its clin. usage.  Protein kinase C alpha (PKCα) expression was shown to be a predictor of disease outcome for patients receiving endocrine therapy and may predict a pos. response to an estrogenic treatment.  Here, we have investigated the use of novel benzothiophene selective estrogen mimics (SEM) as an alternative to E2 for the treatment of tamoxifen-resistant breast cancer.  Following in vitro characterization of SEMs, a panel of clin. relevant PKCα-expressing, tamoxifen-resistant models were used to investigate the antitumor effects of these compds.  SEM treatment resulted in growth inhibition and apoptosis of tamoxifen-resistant cell lines in vitro.  In vivo SEM treatment induced tumor regression of tamoxifen-resistant T47D:A18/PKCα and T47D:A18-TAM1 tumor models.  T47D:A18/PKCα tumor regression was accompanied by translocation of estrogen receptor (ER) α to extranuclear sites, possibly defining a mechanism through which these SEMs initiate tumor regression.  SEM treatment did not stimulate growth of E2-dependent T47D:A18/neo tumors.  In addn., unlike E2 or tamoxifen, treatment with SEMs did not stimulate uterine wt. gain.  These findings suggest the further development of SEMs as a feasible therapeutic strategy for the treatment of endocrine-resistant breast cancer without the side effects assocd. with E2.  Mol Cancer Ther; 13(11); 2515-26. cpr2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp64x3RCcDeYbVg90H21EOLACvtfcHk0ljSFIbKSErzjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73N&md5=203055e50477bcb1c98ea4c7844cf4b9</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-14-0319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-14-0319%26sid%3Dliteratum%253Aachs%26aulast%3DMolloy%26aufirst%3DM.%2BE.%26aulast%3DWhite%26aufirst%3DB.%2BE.%2BP.%26aulast%3DGherezghiher%26aufirst%3DT.%26aulast%3DMichalsen%26aufirst%3DB.%2BT.%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DMaximov%26aufirst%3DP.%2BY.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26atitle%3DNovel%2520Selective%2520Estrogen%2520Mimics%2520for%2520the%2520Treatment%2520of%2520Tamoxifen-Resistant%2520Breast%2520Cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2515%26epage%3D2526%26doi%3D10.1158%2F1535-7163.mct-14-0319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yunlong Lu, <span class="NLM_string-name hlFld-ContribAuthor">Wukun Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15094-15114. <a href="https://doi.org/10.1021/acs.jmedchem.0c00913" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00913</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00913%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSelective%252BEstrogen%252BReceptor%252BDegraders%252B%252528SERDs%252529%25253A%252BA%252BPromising%252BStrategy%252Bfor%252BEstrogen%252BReceptor%252BPositive%252BEndocrine-Resistant%252BBreast%252BCancer%26aulast%3DLu%26aufirst%3DYunlong%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29052020%26date%3D02112020%26volume%3D63%26issue%3D24%26spage%3D15094%26epage%3D15114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James S. Scott, Thomas A. Moss, Amber Balazs, Bernard Barlaam, Jason Breed, Rodrigo J. Carbajo, Elisabetta Chiarparin, Paul R. J. Davey, Oona Delpuech, Stephen Fawell, David I. Fisher, Sladjana Gagrica, Eric T. Gangl, Tyler Grebe, Ryan D. Greenwood, Sudhir Hande, Holia Hatoum-Mokdad, Kara Herlihy, Samantha Hughes, Thomas A. Hunt, Hoan Huynh, Sophie L. M. Janbon, Tony Johnson, Stefan Kavanagh, Teresa Klinowska, Mandy Lawson, Andrew S. Lister, Stacey Marden, Dermot F. McGinnity, Christopher J. Morrow, J. Willem M. Nissink, Daniel H. O’Donovan, Bo Peng, Radoslaw Polanski, Darren S. Stead, Stephen Stokes, Kumar Thakur, Scott R. Throner, Michael J. Tucker, Jeffrey Varnes, Haixia Wang, David M. Wilson, Dedong Wu, Ye Wu, Bin Yang, <span class="NLM_string-name hlFld-ContribAuthor">Wenzhan Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14530-14559. <a href="https://doi.org/10.1021/acs.jmedchem.0c01163" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01163</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01163%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BAZD9833%25252C%252Ba%252BPotent%252Band%252BOrally%252BBioavailable%252BSelective%252BEstrogen%252BReceptor%252BDegrader%252Band%252BAntagonist%26aulast%3DScott%26aufirst%3DJames%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D07072020%26date%3D29092020%26date%3D10092020%26volume%3D63%26issue%3D23%26spage%3D14530%26epage%3D14559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Laura Cooper, Adam Schafer, Yangfeng Li, Han Cheng, Bani Medegan Fagla, Zhengnan Shen, Raghad Nowar, Katherine Dye, Manu Anantpadma, Robert A. Davey, Gregory R. J. Thatcher, Lijun Rong, <span class="NLM_string-name hlFld-ContribAuthor">Rui Xiong</span>. </span><span class="cited-content_cbyCitation_article-title">Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 11085-11099. <a href="https://doi.org/10.1021/acs.jmedchem.0c01001" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01001%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DScreening%252Band%252BReverse-Engineering%252Bof%252BEstrogen%252BReceptor%252BLigands%252Bas%252BPotent%252BPan-Filovirus%252BInhibitors%26aulast%3DCooper%26aufirst%3DLaura%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D11062020%26date%3D22092020%26date%3D04092020%26volume%3D63%26issue%3D19%26spage%3D11085%26epage%3D11099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jun Liang, Robert Blake, Jae Chang, Lori S. Friedman, Simon Goodacre, Steven Hartman, Ellen Rei Ingalla, James R. Kiefer, Tracy Kleinheinz, Sharada Labadie, Jun Li, Kwong Wah Lai, Jiangpeng Liao, Vidhi Mody, Neville McLean, Ciara Metcalfe, Michelle Nannini, Daniel Otwine, Yingqing Ran, Nick Ray, Fabien Roussel, Amy Sambrone, Deepak Sampath, Maia Vinogradova, John Wai, Tao Wang, Kuen Yeap, Amy Young, Jason Zbieg, Birong Zhang, Xiaoping Zheng, Yu Zhong, <span class="NLM_string-name hlFld-ContribAuthor">Xiaojing Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1342-1347. <a href="https://doi.org/10.1021/acsmedchemlett.0c00224" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00224</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00224%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BGNE-149%252Bas%252Ba%252BFull%252BAntagonist%252Band%252BEfficient%252BDegrader%252Bof%252BEstrogen%252BReceptor%252Balpha%252Bfor%252BER%25252B%252BBreast%252BCancer%26aulast%3DLiang%26aufirst%3DJun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28042020%26date%3D26052020%26date%3D29052020%26date%3D26052020%26volume%3D11%26issue%3D6%26spage%3D1342%26epage%3D1347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Seiya Uchida, Hidenori Kinoshita, <span class="NLM_string-name hlFld-ContribAuthor">Katsukiyo Miura</span>. </span><span class="cited-content_cbyCitation_article-title">Diisobutylaluminum Hydride Promoted Selectivity-Switchable Synthesis of Benzothiophene Oxides and Benzothiophenes via an Al–Li-Dimetalated Intermediate. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (8)
                                     , 3123-3127. <a href="https://doi.org/10.1021/acs.orglett.0c00884" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c00884</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c00884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c00884%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DDiisobutylaluminum%252BHydride%252BPromoted%252BSelectivity-Switchable%252BSynthesis%252Bof%252BBenzothiophene%252BOxides%252Band%252BBenzothiophenes%252Bvia%252Ban%252BAl%2525E2%252580%252593Li-Dimetalated%252BIntermediate%26aulast%3DUchida%26aufirst%3DSeiya%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09032020%26date%3D02042020%26volume%3D22%26issue%3D8%26spage%3D3123%26epage%3D3127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristina  Hernando</span>, <span class="hlFld-ContribAuthor ">Belén  Ortega-Morillo</span>, <span class="hlFld-ContribAuthor ">Marta  Tapia</span>, <span class="hlFld-ContribAuthor ">Santiago  Moragón</span>, <span class="hlFld-ContribAuthor ">María Teresa  Martínez</span>, <span class="hlFld-ContribAuthor ">Pilar  Eroles</span>, <span class="hlFld-ContribAuthor ">Iris  Garrido-Cano</span>, <span class="hlFld-ContribAuthor ">Anna  Adam-Artigues</span>, <span class="hlFld-ContribAuthor ">Ana  Lluch</span>, <span class="hlFld-ContribAuthor ">Begoña  Bermejo</span>, <span class="hlFld-ContribAuthor ">Juan Miguel  Cejalvo</span>. </span><span class="cited-content_cbyCitation_article-title">Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (15)
                                     , 7812. <a href="https://doi.org/10.3390/ijms22157812" title="DOI URL">https://doi.org/10.3390/ijms22157812</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22157812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22157812%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DOral%252BSelective%252BEstrogen%252BReceptor%252BDegraders%252B%252528SERDs%252529%252Bas%252Ba%252BNovel%252BBreast%252BCancer%252BTherapy%25253A%252BPresent%252Band%252BFuture%252Bfrom%252Ba%252BClinical%252BPerspective%26aulast%3DHernando%26aufirst%3DCristina%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D15%26spage%3D7812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zunyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Zhen  Ma</span>, <span class="hlFld-ContribAuthor ">Zhengrong  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Selective degradation of the estrogen receptor in the treatment of cancers. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Steroid Biochemistry and Molecular Biology</span><span> <strong>2021,</strong> <em>209 </em>, 105848. <a href="https://doi.org/10.1016/j.jsbmb.2021.105848" title="DOI URL">https://doi.org/10.1016/j.jsbmb.2021.105848</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jsbmb.2021.105848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jsbmb.2021.105848%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Steroid%2520Biochemistry%2520and%2520Molecular%2520Biology%26atitle%3DSelective%252Bdegradation%252Bof%252Bthe%252Bestrogen%252Breceptor%252Bin%252Bthe%252Btreatment%252Bof%252Bcancers%26aulast%3DWang%26aufirst%3DZunyuan%26date%3D2021%26volume%3D209%26spage%3D105848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  Wang</span>, <span class="hlFld-ContribAuthor ">Abhishek  Sharma</span>. </span><span class="cited-content_cbyCitation_article-title">The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs). </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (22)
                                     , 2072-2097. <a href="https://doi.org/10.1002/cmdc.202000473" title="DOI URL">https://doi.org/10.1002/cmdc.202000473</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000473%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DThe%252BQuest%252Bfor%252BOrally%252BAvailable%252BSelective%252BEstrogen%252BReceptor%252BDegraders%252B%252528SERDs%252529%26aulast%3DWang%26aufirst%3DLucia%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D22%26spage%3D2072%26epage%3D2097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tsubasa  Matsuzawa</span>, <span class="hlFld-ContribAuthor ">Takamitsu  Hosoya</span>, <span class="hlFld-ContribAuthor ">Suguru  Yoshida</span>. </span><span class="cited-content_cbyCitation_article-title">One-step synthesis of benzo[
              b
              ]thiophenes by aryne reaction with alkynyl sulfides. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2020,</strong> <em>11 </em>
                                    (35)
                                     , 9691-9696. <a href="https://doi.org/10.1039/D0SC04450D" title="DOI URL">https://doi.org/10.1039/D0SC04450D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0SC04450D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0SC04450D%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DOne-step%252Bsynthesis%252Bof%252Bbenzo%25255B%252Bb%252B%25255Dthiophenes%252Bby%252Baryne%252Breaction%252Bwith%252Balkynyl%252Bsulfides%26aulast%3DMatsuzawa%26aufirst%3DTsubasa%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D35%26spage%3D9691%26epage%3D9696" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the SERD fulvestrant (<b>2</b>), oral SERDs (<b>3</b>, <b>4</b>, <b>8</b>, <b>9</b>), together with “SERM/SERDs” (<b>5</b>, <b>7</b>), and SERMs (<b>1</b>, <b>6</b>). Several of these SERDs are currently being studied in clinical trials: NCT01823835, NCT02316509, NCT03332797, NCT03236974, NCT03616587, NCT02734615, NCT03284957, NCT02338349, NCT03455270.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure design. H-bonding of the amine side chain to Asp-351 in the ERα ligand-binding pocket should allow engagement of ring substituents with hydrophobic pockets formed in the region of Leu-384 and Leu-428 (increasing affinity), whilst displacing H12 (causing ERα degradation). The design of the amine side chain using a conformationally restricted heterocycle considered the ability to interact with H12 (A); the amine basicity (B); and susceptibility to oxidation (C,D). DFT molecular orbital calculations of proton affinity (dPA) (B), ionization energy (dIE) (C), and H-atom abstraction (dHA) (D) were normalized relative to the calculated free energy for the piperidine side chain: dHAr corresponds to heterocyclic ring-C oxidation; dHA refers to oxidation of the alternate carbon. The R group in (A) is modeled by H in calculations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthetic Routes for Precursor Synthons<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) SOCI<sub>2</sub>, pyridine, chlorobenzene, reflux, 50%. (b) <i>N</i>-Methoxymethylamine, Et<sub>3</sub>N, DCM, rt, 90%. (c) DIBAL-H, THF, −40 °C, 60%. (d) Grignard reagent, THF, 0 °C to rt, 75–85%. (e) PCC, DCM, rt, 55–65%. (f) (4-Fluoro-2,6-dimethylphenyl)magnesium bromide, CuCN·2LiCl, THF, 0 °C to rt, 90%. (g) Grignard reagent, THF, 0 °C to rt, 70–80%. (h) BBr<sub>3</sub>, DCM, −78 °C to rt, 40–60%. (i) 3,4-Dihydro-2<i>H</i>-pyran, PPTS, DCM, rt, 70–80%. (aa) Methanesulfonyl chloride, Et<sub>3</sub>N, DCM, 0 °C to rt, 95%. (bb) TBAF, 80 °C, 70%. (cc) 6 M HCI MeOH, rt, 60%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Routes for Candidate Piperidine, Azetidine, and Pyrrolidine B-SERDs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1,2-dibromoethane, KOH, THF, reflux, 50%. (b) Azetidine hydrochloride, 3-methylazetidine hydrochloride, <b>20</b>, <b>24</b>, piperidine, NaH, THF, 0–60 °C, 55%, (c) <i>p</i>-TsOH, MeOH, rt, 60%. (d) <b>16a–i</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C, 55–75%. (e) <i>p</i>-TsOH, MeOH, rt, 60–80%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthetic Routes for Candidate Reverse-Azetidine B-SERDs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 11-boc-3-iodoazetidine, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 140 °C, 50%. (b) CF<sub>3</sub>COOH, DCM, rt, 70%. (c) 1-Bromo-3-fluoropropane, NaH, 0–60 °C, 55%; or (1-methoxycyclopropoxy)trimethylsilane, AcOH, NaBH<sub>3</sub>CH, 80% (d) H<sub>2</sub>, Pd/C, rt, 70%. (e) <b>16a</b>, <b>16b</b>, <b>16d</b>, <b>16f</b>, <b>16g</b>, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 90 °C, 75–85%. (f) <i>p</i>-TsOH, MeOH, rt, 70–80%.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Spheroid viability. (A) MCF7:WS8 and MCF7:TAM1 spheroid viability following treatment with B-SERDs (<b>30f</b>, <b>30i</b>, <b>27b</b>, and <b>37d</b>, 10 nM) compared to <b>2</b> (10 nM). (B) Representative images on day 10 of treatment with DMSO (0.01%), <b>2</b> (10 nM), and <b>37d</b> (10 nM) in MCF7:WS8 and MCF7:TAM1 spheroids. (C) T47D:WT, T47D:TYS, and T47D:TGD cells grown for 3 days were treated for a further 11 days with test compounds (10 nM). (A,C) Luminescence normalized to vehicle/control (1.0) and background (0.0). Data shown as mean ± SEM from three biological and analytical replicates. Significance compared to vehicle/control by one-way ANOVA: <i>p</i> <0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. B-SERD vs SERD comparisons. (A). ERα degradation after 24 h treatment of MCF7:WS8 cells with 10 nM <b>37d</b> or <b>2</b> measured by western blot and inhibited by proteasomal inhibitor MG-132 (1 μM) normalized to vehicle (1.0). (B) ERα western blots after 24 h treatment of MCF7:WS8 cells with 100 nM <b>2</b>, <b>37d</b>, <b>5</b>, and <b>9a</b> measured by the western blot. (C) ERα degradation after oral dosing of female mice with vehicle, <b>37d</b> or <b>9a</b>, measued by western blot analysis of tissues, with representative immunoblots shown from individual mouse uterus. (D) Uterine weight from juvenile female rats dosed with <b>2</b>, <b>7</b>, and <b>37d</b>, compared to EE2 as a positive control. Cell culture data shown as mean ± SEM from three biological and analytical replicates. Statistical analysis by one-way ANOVA with multiple comparisons (<i>p</i>* < 0.01; *** > 0.001; **** < 0.0001).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effect on tumor growth. (A) Tumor growth or regression of MCF7:TAM1 CDX grown to 0.3 cm<sup>2</sup> before initiating daily treatment with TAM (<b>1a</b>), <b>37d</b> (100 mg/kg oral gavage) or <b>2</b> (5 mg s.c.). (B) Individual tumor % area change after 4 weeks treatment: ****<i>p</i> < 0.0001 vs NT group, by one-way ANOVA with Dunnett’s test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Summary of B-SERD in vitro activity. 2D growth inhibition in MCF7:WS8 (A) and MCF7:5C (B) cells as a result of treatment with <b>37d</b> (green) or <b>2</b> (orange). Data normalized to vehicle, dimethyl sulfoxide (DMSO) (1.0) and no cells (0.0) shown as mean ± SEM, from three biological and analytical replicates. (C) ER level following treatment for 24 h with <b>37d</b> or <b>2</b> evaluated by ICW. Data corrected to vehicle (1) and 1 μM <b>2</b> shown as mean ± SEM, from three biological and analytical replicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/medium/jm9b01580_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. B-SERD docking to ER. B-SERDs <b>30f</b> and <b>37d</b> have a common basic side-arm motif: 3-fluoro-<i>N</i>-(2-oxyethyl)propan-1-amine. The structure design envisaged the occupation of the hydrophobic pockets formed by leucines 384, 428, 525, and isoleucine 424 by the substituted benzoyl ring, allowing a salt bridge interaction between the amine side arm amine and Asp-351 in the ERα ligand binding site. B-SERD <b>37d</b> (green) was docked to the ligand binding domain of ERα obtained from the co-crystal structure with the SERD <i>R</i>-<b>38</b> (magenta) (pdb <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UFX">5UFX</a>) confirming the proposed binding site interactions leading to destabilization of H12.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-24/acs.jmedchem.9b01580/20191219/images/large/jm9b01580_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01580&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i132">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02114" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02114" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 55 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soerjomataram, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Global Cancer Statistics 2018: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.3322/caac.21492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.3322%2Fcaac.21492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=30207593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BB3c3otVGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2018&pages=394-424&author=F.+Brayauthor=J.+Ferlayauthor=I.+Soerjomataramauthor=R.+L.+Siegelauthor=L.+A.+Torreauthor=A.+Jemal&title=Global+Cancer+Statistics+2018%3A+Globocan+Estimates+of+Incidence+and+Mortality+Worldwide+for+36+Cancers+in+185+Countries&doi=10.3322%2Fcaac.21492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</span></div><div class="casAuthors">Bray Freddie; Ferlay Jacques; Soerjomataram Isabelle; Siegel Rebecca L; Torre Lindsey A; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">394-424</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.  There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018.  In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality.  Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality).  Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality.  The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors.  It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries.  The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts.  CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQaW5wv8ocuhLxanA7vODO6fW6udTcc2eaxuJLcjaWajrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3otVGlsg%253D%253D&md5=48529f8f794092779d70a27eec5c9017</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21492%26sid%3Dliteratum%253Aachs%26aulast%3DBray%26aufirst%3DF.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DSoerjomataram%26aufirst%3DI.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520Cancer%2520Statistics%25202018%253A%2520Globocan%2520Estimates%2520of%2520Incidence%2520and%2520Mortality%2520Worldwide%2520for%252036%2520Cancers%2520in%2520185%2520Countries%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2018%26volume%3D68%26spage%3D394%26epage%3D424%26doi%3D10.3322%2Fcaac.21492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuqua, S.</span></span> <span> </span><span class="NLM_article-title">The Role of the Estrogen Receptor in Tumor Progression</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/0960-0760(95)00269-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2F0960-0760%2895%2900269-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=8603051" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK28XitVeqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1996&pages=87-91&author=P.+Lemieuxauthor=S.+Fuqua&title=The+Role+of+the+Estrogen+Receptor+in+Tumor+Progression&doi=10.1016%2F0960-0760%2895%2900269-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the estrogen receptor in tumor progression</span></div><div class="casAuthors">Lemieux, Pierre; Fuqua, Suzanne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1-6</span>),
    <span class="NLM_cas:pages">87-91</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review, with 21 refs., on two estrogen receptor (ER) variants that may play a role in breast cancer initiation or progression.  One is a truncated receptor, which has been named the exon 5 ER deletion variant, and the other is called a hypersensitive variant of the ER that is sensitive to low levels of hormone.  Both ER variants differ from the wild-type ER in their hormone binding domains (HBD).  The exon 5 ER deletion variant lacks a large portion of the HBD, while the hypersensitive ER variant has a point mutation is a conserved region of the HBD.  The exon 5 ER deletion variant is transcriptionally active in the absence of hormone, and is thus considered constitutively-active.  In contrast, the hypersensitive ER variant is functionally active in response to subphysiol. concns. of estrogen.  Both ER variants may form productive heterodimers with wild-type receptor to modify the normal function of ER in the breast.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMqMnUTYnH0LVg90H21EOLACvtfcHk0likEN-JKiquZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XitVeqt70%253D&md5=4dc70b88baf6be60b13b3aff06762f35</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2F0960-0760%2895%2900269-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-0760%252895%252900269-3%26sid%3Dliteratum%253Aachs%26aulast%3DLemieux%26aufirst%3DP.%26aulast%3DFuqua%26aufirst%3DS.%26atitle%3DThe%2520Role%2520of%2520the%2520Estrogen%2520Receptor%2520in%2520Tumor%2520Progression%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D1996%26volume%3D56%26spage%3D87%26epage%3D91%26doi%3D10.1016%2F0960-0760%2895%2900269-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sommer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuqua, S. A. W.</span></span> <span> </span><span class="NLM_article-title">Estrogen Receptor and Breast Cancer</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1006/scbi.2001.0389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1006%2Fscbi.2001.0389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=11562176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmvVGgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=339-352&author=S.+Sommerauthor=S.+A.+W.+Fuqua&title=Estrogen+Receptor+and+Breast+Cancer&doi=10.1006%2Fscbi.2001.0389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen receptor and breast cancer</span></div><div class="casAuthors">Sommer, Stephanie; Fuqua, Suzanne A. W.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">339-352</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review.  Breast cancer, the most common malignancy in women, was already known to be assocd. with the steroid hormone estrogen more than a century ago.  The discovery of the estrogen receptor (ER) provided not only a powerful predictive and prognostic marker, but also an efficient target for the treatment of hormone-dependent breast cancer with antiestrogens.  In this paper the authors will sketch the important role of ER in the development, progression, and treatment of the disease, which is complicated by the receptor's interaction with co-regulatory proteins, its cross-talk with other signal transduction pathways, and its involvement in the development of antiestrogen resistance.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosLN8VQ1UX_bVg90H21EOLACvtfcHk0likEN-JKiquZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmvVGgtro%253D&md5=6681648d7604b4c3c3404e6782888818</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1006%2Fscbi.2001.0389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fscbi.2001.0389%26sid%3Dliteratum%253Aachs%26aulast%3DSommer%26aufirst%3DS.%26aulast%3DFuqua%26aufirst%3DS.%2BA.%2BW.%26atitle%3DEstrogen%2520Receptor%2520and%2520Breast%2520Cancer%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2001%26volume%3D11%26spage%3D339%26epage%3D352%26doi%3D10.1006%2Fscbi.2001.0389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S. R.</span></span> <span> </span><span class="NLM_article-title">Endocrine Therapy—Current Benefits and Limitations</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">S3</span>– <span class="NLM_lpage">S10</span>, <span class="refDoi"> DOI: 10.1007/s10549-005-9036-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1007%2Fs10549-005-9036-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=16247594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFCrtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2005&pages=S3-S10&author=R.+I.+Nicholsonauthor=S.+R.+Johnston&title=Endocrine+Therapy%E2%80%94Current+Benefits+and+Limitations&doi=10.1007%2Fs10549-005-9036-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Endocrine therapy - current benefits and limitations</span></div><div class="casAuthors">Nicholson, Robert I.; Johnston, Stephen R.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S3-S10</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Endocrine therapy is a valuable option for the treatment of postmenopausal women with estrogen receptor (ER)-pos. breast cancer due to its demonstrated efficacy and favorable safety profile.  Although tamoxifen has been the established treatment for more than 20 years its long-term use is assocd. with several tolerability concerns and may lead to increased risk of endometrial cancer and thromboembolic complications.  In addn., many patients who initially respond to treatment with endocrine agents such as tamoxifen eventually relapse with resistant disease.  Sequential use of endocrine therapies is often used in patients as resistance to individual agents develops.  Several endocrine approaches have been developed that deprive the tumor of estrogen stimulation, either by directly modulating the ER-signaling pathway or by lowering serum or tumor concns. of estrogen.  In the classic pathway of estrogen signal transduction, the steroid hormone binds to its intracellular ER, triggering a cascade of events that ultimately leads to altered gene transcription.  More recently, it has become apparent that ER activation can also occur via estrogen-independent receptor activation or by non-nuclear action through cell surface receptors.  Consequently, mol. cross-talk exists between the ER and growth factor signaling cascades, which is a key factor in de novo and acquired resistance to endocrine therapy.  Inappropriate activation of growth factor signaling can readily promote endocrine therapy failure in breast cancer cells, either by overriding the growth-inhibitory properties of antiestrogenic drugs or by establishment of a new self-propagating autocrine loop that efficiently drives resistant cell growth.  Fulvestrant is a new type of ER antagonist with no agonist effects that binds, blocks and causes degrdn. of the ER.  As multiple signaling pathways are involved in the activation of ER, the use of agents such as fulvestrant that directly target the ER and lead to both degrdn. of the receptor and abrogation of ER signaling may prevent or delay the development of abs. endocrine resistance.  In addn., combining antiestrogenic drugs with inhibitors of cell signaling mols. to target both the ER and growth factor signaling pathways is likely to provide a means of delaying endocrine therapy resistance, leading the way to more effective breast cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnw_J604wgnrVg90H21EOLACvtfcHk0lgknCuCZU1pxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFCrtb3O&md5=458ae0143f990ddd739e9ae4dd1cfaea</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs10549-005-9036-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-005-9036-4%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26aulast%3DJohnston%26aufirst%3DS.%2BR.%26atitle%3DEndocrine%2520Therapy%25E2%2580%2594Current%2520Benefits%2520and%2520Limitations%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2005%26volume%3D93%26spage%3DS3%26epage%3DS10%26doi%3D10.1007%2Fs10549-005-9036-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowsett, M.</span></span> <span> </span><span class="NLM_article-title">Aromatase Inhibitors in Breast Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">2431</span>– <span class="NLM_lpage">2442</span>, <span class="refDoi"> DOI: 10.1056/nejmra023246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1056%2Fnejmra023246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=12802030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD3sXksFKguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=2431-2442&author=I.+E.+Smithauthor=M.+Dowsett&title=Aromatase+Inhibitors+in+Breast+Cancer&doi=10.1056%2Fnejmra023246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Aromatase inhibitors in breast cancer</span></div><div class="casAuthors">Smith, Ian E.; Dowsett, Mitch</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2431-2442</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  This review discusses the role of aromatase inhibitors and assess their potential for clin. use in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYF49NFDFgm7Vg90H21EOLACvtfcHk0lgknCuCZU1pxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXksFKguro%253D&md5=da7b56d4a1f0e7b2e27c8819a0ae0951</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2Fnejmra023246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252Fnejmra023246%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DDowsett%26aufirst%3DM.%26atitle%3DAromatase%2520Inhibitors%2520in%2520Breast%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D2431%26epage%3D2442%26doi%3D10.1056%2Fnejmra023246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for an Unexpected Mode of Serm-Mediated Er Antagonism</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2005.04.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fj.molcel.2005.04.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=15893725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=413-424&author=Y.-L.+Wuauthor=X.+Yangauthor=Z.+Renauthor=D.+P.+McDonnellauthor=J.+D.+Norrisauthor=T.+M.+Willsonauthor=G.+L.+Greene&title=Structural+Basis+for+an+Unexpected+Mode+of+Serm-Mediated+Er+Antagonism&doi=10.1016%2Fj.molcel.2005.04.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for an unexpected mode of SERM-mediated ER antagonism</span></div><div class="casAuthors">Wu, Ya-Ling; Yang, Xiaojing; Ren, Zhong; McDonnell, Donald P.; Norris, John D.; Willson, Timothy M.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">413-424</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Tamoxifen is effective for the prevention and treatment of estrogen-dependent breast cancers, but is assocd. with an increased incidence of endometrial tumors.  The authors report the crystal structure of the estrogen receptor α (ERα) ligand binding domain (LBD) bound to the structurally similar compd. GW5638, which has therapeutic potential and does not stimulate the uterus.  Like tamoxifen, GW5638 relocates the carboxy-terminal helix (H12) to the known coactivator-docking site in the ERα LBD.  However, GW5638 repositions residues in H12 through specific contacts with the N terminus of this helix.  In contrast to tamoxifen, the resulting increase in exposed hydrophobic surface of ERα LBD correlates with a significant destabilization of ERα in MCF-7 cells.  Thus, the GW5638-ERα LBD structure reveals an unexpected mode of SERM-mediated ER antagonism, in which the stability of ERα is decreased through an altered position of H12.  This dual mechanism of antagonism may explain why GW5638 can inhibit tamoxifen-resistant breast tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBuyhLNSdbQbVg90H21EOLACvtfcHk0lggWoth9mxpfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslaqu7s%253D&md5=c60e01b31b57c07b934da01a34efb255</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.04.014%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26aulast%3DNorris%26aufirst%3DJ.%2BD.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DStructural%2520Basis%2520for%2520an%2520Unexpected%2520Mode%2520of%2520Serm-Mediated%2520Er%2520Antagonism%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D18%26spage%3D413%26epage%3D424%26doi%3D10.1016%2Fj.molcel.2005.04.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span> <span> </span><span class="NLM_article-title">Tamoxifen: Catalyst for the Change to Targeted Therapy</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2007.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fj.ejca.2007.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=18068350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVOrurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=30-38&author=V.+C.+Jordan&title=Tamoxifen%3A+Catalyst+for+the+Change+to+Targeted+Therapy&doi=10.1016%2Fj.ejca.2007.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Tamoxifen: Catalyst for the change to targeted therapy</span></div><div class="casAuthors">Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-38</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In the early 1970s, a failed post-coital contraceptive, ICI 46,474, was reinvented as tamoxifen, the first targeted therapy for breast cancer.  A cluster of papers published in the European Journal of Cancer described the idea of targeting tamoxifen to patients with estrogen receptor pos. tumors, and proposed the strategic value of using long-term tamoxifen therapy in an adjuvant setting with a consideration of the antitumor properties of the hydroxylated metabolites of tamoxifen.  At the time, these lab. results were slow to be embraced by the clin. community.  Today, it is estd. that hundreds of thousands of breast cancer patients are alive today because of targeted long-term adjuvant tamoxifen therapy.  Addnl., the first lab. studies for the use of tamoxifen as a chemopreventive were published.  Eventually, the worth of tamoxifen was tested as a chemopreventive and the drug is now known to have an excellent risk benefit ratio in high risk pre-menopausal women.  Overall, the rigorous investigation of the pharmacol. of tamoxifen facilitated tamoxifen's ubiquitous use for the targeted treatment of breast cancer, chemoprevention and pioneered the exploration of selective estrogen receptor modulators (SERMs).  This new concept subsequently heralded the development of raloxifene, a failed breast cancer drug, for the prevention of osteoporosis and breast cancer without the troublesome side-effect of endometrial cancer noted in post-menopausal women who take tamoxifen.  Currently, the pharmaceutical industry is exploiting the SERM concept for all members of the nuclear receptor superfamily so that medicines can now be developed for diseases once thought impossible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVfO9kqT3cB7Vg90H21EOLACvtfcHk0lhNLnza47ldaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVOrurvL&md5=2be14fc39925c60ce7ffe1c0b9991784</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2007.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2007.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DTamoxifen%253A%2520Catalyst%2520for%2520the%2520Change%2520to%2520Targeted%2520Therapy%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2008%26volume%3D44%26spage%3D30%26epage%3D38%26doi%3D10.1016%2Fj.ejca.2007.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haque, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inzhakova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polikoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enger, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Press, M. F.</span></span> <span> </span><span class="NLM_article-title">Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades</span>. <i>Cancer Epidemiol., Biomarkers Prev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1848</span>– <span class="NLM_lpage">1855</span>, <span class="refDoi"> DOI: 10.1158/1055-9965.epi-12-0474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F1055-9965.epi-12-0474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=22989461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BC38botV2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=1848-1855&author=R.+Haqueauthor=S.+A.+Ahmedauthor=G.+Inzhakovaauthor=J.+Shiauthor=C.+Avilaauthor=J.+Polikoffauthor=L.+Bernsteinauthor=S.+M.+Engerauthor=M.+F.+Press&title=Impact+of+Breast+Cancer+Subtypes+and+Treatment+on+Survival%3A+An+Analysis+Spanning+Two+Decades&doi=10.1158%2F1055-9965.epi-12-0474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades</span></div><div class="casAuthors">Haque Reina; Ahmed Syed A; Inzhakova Galina; Shi Jiaxiao; Avila Chantal; Polikoff Jonathan; Bernstein Leslie; Enger Shelley M; Press Michael F</div><div class="citationInfo"><span class="NLM_cas:title">Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1848-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  We investigated the impact of breast cancer molecular subtypes and treatment on survival in a cohort of medically insured women followed for more than 20 years.  METHODS:  We examined 934 female members of an integrated health care delivery system newly diagnosed with invasive breast cancer between 1988 and 1995 and followed them through 2008.  Tumors were classified into four molecular subtypes on the basis of their expression profile: luminal A; luminal B; basal-like; and HER2-enriched.  We followed women from the surgery date to death, health plan disenrollment, or study's end.  HR and 95% confidence intervals (CI) were fit using Cox proportional hazards models adjusting for cancer treatments and tumor characteristics.  RESULTS:  A total of 223 (23.9%) women died because of breast cancer during the 21-year study period.  Compared with women with luminal A tumors, women with HER2-enriched (HR 2.56, 95% CI 1.53-4.29) and luminal B tumors (HR 1.96, 95% CI: 1.08-3.54) had roughly a two-fold increased adjusted risk of breast cancer mortality.  In addition, the survival curves suggest that risk of late mortality persists in women with luminal A tumors.  CONCLUSION:  Among women with health care coverage, molecular subtypes were important predictors of breast cancer mortality.  Women with HER2-enriched tumors and luminal B subtypes had the poorest survival despite adjusting for important covariates.  IMPACT:  In a cohort followed for more than 20 years, women with HER2-enriched tumors had worse survival, but interestingly, the survival curve for women with luminal A tumors continued to steadily decline after 10 years of follow-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeN7vhwbxeaiCEBeYuoi7AfW6udTcc2eaXLdwYvN3Gzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38botV2juw%253D%253D&md5=5b4b12706786b4ce33dbef167afce819</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1055-9965.epi-12-0474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1055-9965.epi-12-0474%26sid%3Dliteratum%253Aachs%26aulast%3DHaque%26aufirst%3DR.%26aulast%3DAhmed%26aufirst%3DS.%2BA.%26aulast%3DInzhakova%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DAvila%26aufirst%3DC.%26aulast%3DPolikoff%26aufirst%3DJ.%26aulast%3DBernstein%26aufirst%3DL.%26aulast%3DEnger%26aufirst%3DS.%2BM.%26aulast%3DPress%26aufirst%3DM.%2BF.%26atitle%3DImpact%2520of%2520Breast%2520Cancer%2520Subtypes%2520and%2520Treatment%2520on%2520Survival%253A%2520An%2520Analysis%2520Spanning%2520Two%2520Decades%26jtitle%3DCancer%2520Epidemiol.%252C%2520Biomarkers%2520Prev.%26date%3D2012%26volume%3D21%26spage%3D1848%26epage%3D1855%26doi%3D10.1158%2F1055-9965.epi-12-0474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maximov, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span> <span> </span><span class="NLM_article-title">Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations</span>. <i>Horm. Mol. Biol. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1515/hmbci-2011-0004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1515%2Fhmbci-2011-0004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=23308083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtFaitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=143-163&author=E.+E.+Sweeneyauthor=R.+E.+McDanielauthor=P.+Y.+Maximovauthor=P.+Fanauthor=V.+C.+Jordan&title=Models+and+Mechanisms+of+Acquired+Antihormone+Resistance+in+Breast+Cancer%3A+Significant+Clinical+Progress+Despite+Limitations&doi=10.1515%2Fhmbci-2011-0004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations</span></div><div class="casAuthors">Sweeney, Elizabeth E.; McDaniel, Russell E.; Maximov, Philipp Y.; Fan, Ping; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Hormone Molecular Biology and Clinical Investigation</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-163</span>CODEN:
                <span class="NLM_cas:coden">HMBCA4</span>;
        ISSN:<span class="NLM_cas:issn">1868-1883</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH</span>)
        </div><div class="casAbstract">A review.  Translational research for the treatment and prevention of breast cancer depends upon the four Ms: models, mols., and mechanisms in order to create medicines.  The process, to target the estrogen receptor (ER) in estrogen-dependent breast cancer, has yielded significant advances in patient survivorship and the first approved medicines (tamoxifen and raloxifene) to reduce the incidence of any cancer in high- or low-risk women.  This review focuses on the crit. role of the few ER-pos. cell lines (MCF-7, T47D, BT474, ZR-75-1) that continue to advance our understanding of the estrogen-regulated biol. of breast cancer.  More importantly, the model cell lines have provided an opportunity to document the development and evolution of acquired antihormone resistance.  The description of this evolutionary process that occurs in micrometastatic disease during up to a decade of adjuvant therapy would not be possible in the patient.  The use of the MCF-7 breast cancer cell line, in particular, has been instrumental in discovering a vulnerability of ER-pos. breast cancer exhaustively treated with antihormone therapy.  Physiol. estradiol acts as an apoptotic trigger to cause tumor regression.  These unanticipated findings in the lab. have translated to clin. advances in our knowledge of the paradoxical role of estrogen in the life and death of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtyanTJfE_vrVg90H21EOLACvtfcHk0lg3e363PoroNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtFaitLk%253D&md5=8a5f9d296eced660a25d8292287f7dda</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1515%2Fhmbci-2011-0004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fhmbci-2011-0004%26sid%3Dliteratum%253Aachs%26aulast%3DSweeney%26aufirst%3DE.%2BE.%26aulast%3DMcDaniel%26aufirst%3DR.%2BE.%26aulast%3DMaximov%26aufirst%3DP.%2BY.%26aulast%3DFan%26aufirst%3DP.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DModels%2520and%2520Mechanisms%2520of%2520Acquired%2520Antihormone%2520Resistance%2520in%2520Breast%2520Cancer%253A%2520Significant%2520Clinical%2520Progress%2520Despite%2520Limitations%26jtitle%3DHorm.%2520Mol.%2520Biol.%2520Clin.%2520Invest.%26date%3D2012%26volume%3D9%26spage%3D143%26epage%3D163%26doi%3D10.1515%2Fhmbci-2011-0004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuukasjärvi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kononen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holli, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isola, J.</span></span> <span> </span><span class="NLM_article-title">Loss of Estrogen Receptor in Recurrent Breast Cancer Is Associated with Poor Response to Endocrine Therapy</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2584</span>– <span class="NLM_lpage">2589</span>, <span class="refDoi"> DOI: 10.1200/jco.1996.14.9.2584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1200%2Fjco.1996.14.9.2584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=8823339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK28XlvVGisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1996&pages=2584-2589&author=T.+Kuukasj%C3%A4rviauthor=J.+Kononenauthor=H.+Helinauthor=K.+Holliauthor=J.+Isola&title=Loss+of+Estrogen+Receptor+in+Recurrent+Breast+Cancer+Is+Associated+with+Poor+Response+to+Endocrine+Therapy&doi=10.1200%2Fjco.1996.14.9.2584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy</span></div><div class="casAuthors">Kuukasjarvi, Tuula; Kononen, Juha; Helin, Heikki; Holli, Kaija; Isola, Jorma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2584-2589</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Saunders</span>)
        </div><div class="casAbstract">Up to 30% to 40% of metastases from hormone receptor-pos. primary breast cancer do not respond to endocrine therapy.  The authors studied how often hormone receptor status changes between primary and recurrent tumors and whether such a change might explain unresponsiveness to endocrine therapy.  Primary breast cancer samples and matched asynchronous recurrences were studied from 50 patients who had not received any adjuvant therapy.  Estrogen receptor (ER) and progesterone receptor (PR) status was detd. immunohistochem. from histol. representative formalin-fixed paraffin-embedded tumor samples.  ER status was ascertained by mRNA in situ hybridization.  Thirty-five (70%) of 50 primary tumors were pos. for ER and 30 (60%) for PR.  Hormone receptor status of the recurrent tumor differed from that of the primary tumor in 18 cases (36%).  Discordant cases were due to the loss of ER, loss of PR, or loss of both receptors.  Receptor-neg. primary tumors were always accompanied by receptor-neg. recurrences.  Among 27 patients with ER-pos. primary tumors, loss of ER was a significant predictor of poor response to subsequent endocrine therapy.  Only one of eight patients (12.5%) with lost ER expression responded to tamoxifen therapy, whereas the response rate was 74% (14 of 19) for patients whose recurrent tumors retained ER expression.  Loss of ER expression in recurrent breast cancer should be considered as a cause for poor response to endocrine therapy in primarily ER-pos. patients.  The authors conclude that anal. of recurrent tumor samples may improve the predictive value of ER and PR assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHkl2YS9_wdrVg90H21EOLACvtfcHk0lhatGUs4IaEkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XlvVGisL0%253D&md5=5164f876315a64eb023a10552ce21ed6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1200%2Fjco.1996.14.9.2584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.1996.14.9.2584%26sid%3Dliteratum%253Aachs%26aulast%3DKuukasj%25C3%25A4rvi%26aufirst%3DT.%26aulast%3DKononen%26aufirst%3DJ.%26aulast%3DHelin%26aufirst%3DH.%26aulast%3DHolli%26aufirst%3DK.%26aulast%3DIsola%26aufirst%3DJ.%26atitle%3DLoss%2520of%2520Estrogen%2520Receptor%2520in%2520Recurrent%2520Breast%2520Cancer%2520Is%2520Associated%2520with%2520Poor%2520Response%2520to%2520Endocrine%2520Therapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1996%26volume%3D14%26spage%3D2584%26epage%3D2589%26doi%3D10.1200%2Fjco.1996.14.9.2584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boér, K.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant in Advanced Breast Cancer: Evidence to Date and Place in Therapy</span>. <i>Ther. Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1177/1758834017711097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1177%2F1758834017711097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=28717399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVSntrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=465-479&author=K.+Bo%C3%A9r&title=Fulvestrant+in+Advanced+Breast+Cancer%3A+Evidence+to+Date+and+Place+in+Therapy&doi=10.1177%2F1758834017711097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant in advanced breast cancer: evidence to date and place in therapy</span></div><div class="casAuthors">Boer, Katalin</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Medical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">465-479</span>CODEN:
                <span class="NLM_cas:coden">TAMOB8</span>;
        ISSN:<span class="NLM_cas:issn">1758-8340</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Breast cancer is a classical hormone-dependent tumor; therefore, endocrine therapy is the mainstay of treatment for hormone receptor-pos., human epidermal growth factor 2-neg. advanced breast cancer.  Until recently, classical endocrine agents such as tamoxifen, steroidal and nonsteroidal aromatase inhibitors and fulvestrant have been widely used in postmenopausal patients to treat locally advanced or metastatic disease.  However, for patients with this subtype of breast cancer, the landscape of endocrine therapy is rapidly changing.  Therapies targeting estrogen modulation have evolved in recent years following the introduction of targeted agents, mTOR and CDK 4/6 inhibitors that are administered in combination with hormone therapy.  As a result, options for endocrine therapy have expanded in recent years, and a variety of single-agent or combinations of targeted drugs and endocrine therapies are accepted.  Fulvestrant is a selective estrogen receptor downregulator (SERD) which was introduced to clin. practice in 2002, initially with the indication to treat postmenopausal women with hormone-receptor-pos. advanced breast cancer as second-line therapy postdisease progression after aromatase inhibitors or tamoxifen.  Addnl., fulvestrant has also been shown to be active in patients previously untreated with endocrine therapy, either both in the neoadjuvant and the metastatic setting, alone or in combination with other targeted therapies.  Currently, the std. dose is 500 mg, which is administered with a loading dose.  Fulvestrant received a new FDA indication in Dec. 2016, in combination with palbociclib, both in pre/peri/postmenopausal women with breast cancer progressing after endocrine therapy.  This manuscript aims to give an overview of new efficacy data and the current role of fulvestrant in the systemic therapy of hormone-receptor-pos. advanced breast cancer, in the context of other available therapeutic modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRi8P0FTgbVrVg90H21EOLACvtfcHk0lhatGUs4IaEkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVSntrs%253D&md5=c8ce774327a3523edabfe23c557c5a19</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1177%2F1758834017711097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758834017711097%26sid%3Dliteratum%253Aachs%26aulast%3DBo%25C3%25A9r%26aufirst%3DK.%26atitle%3DFulvestrant%2520in%2520Advanced%2520Breast%2520Cancer%253A%2520Evidence%2520to%2520Date%2520and%2520Place%2520in%2520Therapy%26jtitle%3DTher.%2520Adv.%2520Med.%2520Oncol.%26date%3D2017%26volume%3D9%26spage%3D465%26epage%3D479%26doi%3D10.1177%2F1758834017711097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skaar, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouker, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonessa, F.</span></span> <span> </span><span class="NLM_article-title">Molecular and Pharmacological Aspects of Antiestrogen Resistance</span>. <i>J. Steroid Biochem. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">71</span>– <span class="NLM_lpage">84</span>, <span class="refDoi"> DOI: 10.1016/s0960-0760(00)00193-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fs0960-0760%2800%2900193-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=11384865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD3MXks1altr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2001&pages=71-84&author=R.+Clarkeauthor=T.+C.+Skaarauthor=K.+B.+Boukerauthor=N.+Davisauthor=Y.+R.+Leeauthor=J.+N.+Welchauthor=F.+Leonessa&title=Molecular+and+Pharmacological+Aspects+of+Antiestrogen+Resistance&doi=10.1016%2Fs0960-0760%2800%2900193-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular and pharmacological aspects of antiestrogen resistance</span></div><div class="casAuthors">Clarke, Robert; Skaar, Todd C.; Bouker, Kerrie B.; Davis, Natalie; Lee, Y. Richard; Welch, James N.; Leonessa, Fabio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Steroid Biochemistry and Molecular Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1-5</span>),
    <span class="NLM_cas:pages">71-84</span>CODEN:
                <span class="NLM_cas:coden">JSBBEZ</span>;
        ISSN:<span class="NLM_cas:issn">0960-0760</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 131 refs.  Endocrine therapy is effective in approx. one-third of all breast cancers and up to 80% of tumors that express both estrogen and progesterone receptors.  Despite the low toxicity, good overall response rates, and addnl. benefits assocd. with its partial agonist activity, most Tamoxifen-responsive breast cancers acquire resistance.  The development of new antiestrogens, both steroidal and non-steroidal, provides the opportunity for the development of non-cross-resistant therapies and the identification of addnl. mechanisms of action and resistance.  Drug-specific pharmacol. mechanisms may confer a resistance phenotype, reflecting the complexities of both tumor biol./pharmacol. and the mol. endocrinol. of steroid hormone action.  However, since all antiestrogens will be effective only in cells that express estrogen receptors (ER), many mechanisms will likely be directly related to ER expression and signaling.  For example, loss of ER expression/function is likely to confer a cross-resistance phenotype across all structural classes of antiestrogens.  Altered expression of ERα and ERβ, and/or signaling from transcription complexes driven by these receptors, may produce drug-specific resistance phenotypes.  We have begun to study the possible changes in gene expression that may occur as cells acquire resistance to steroidal and non-steroidal antiestrogens.  Our preliminary studies implicate the altered expression of several estrogen-regulated genes.  However, resistance to antiestrogens is likely to be a multigene phenomenon, involving a network of interrelated signaling pathways.  The way in which this network is adapted by cells may vary among tumors, consistent with the existence of a highly plastic and adaptable genotype within breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7v8b2zxroubVg90H21EOLACvtfcHk0lgq8W5jYuYBoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXks1altr4%253D&md5=b6425acb62b6eb712b972e3da6dd4553</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fs0960-0760%2800%2900193-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0960-0760%252800%252900193-x%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DR.%26aulast%3DSkaar%26aufirst%3DT.%2BC.%26aulast%3DBouker%26aufirst%3DK.%2BB.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DY.%2BR.%26aulast%3DWelch%26aufirst%3DJ.%2BN.%26aulast%3DLeonessa%26aufirst%3DF.%26atitle%3DMolecular%2520and%2520Pharmacological%2520Aspects%2520of%2520Antiestrogen%2520Resistance%26jtitle%3DJ.%2520Steroid%2520Biochem.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D76%26spage%3D71%26epage%3D84%26doi%3D10.1016%2Fs0960-0760%2800%2900193-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciruelos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arroyo Vozmediano, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parrilla, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderón, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sancho, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortes-Funes, H.</span></span> <span> </span><span class="NLM_article-title">The Therapeutic Role of Fulvestrant in the Management of Patients with Hormone Receptor-Positive Breast Cancer</span>. <i>Breast</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">208</span>, <span class="refDoi"> DOI: 10.1016/j.breast.2014.01.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fj.breast.2014.01.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=24589524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BC2cvpvFSqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=201-208&author=E.+Ciruelosauthor=T.+Pascualauthor=M.+L.+Arroyo+Vozmedianoauthor=M.+Blancoauthor=L.+Mansoauthor=L.+Parrillaauthor=C.+Mu%C3%B1ozauthor=E.+Vegaauthor=M.+J.+Calder%C3%B3nauthor=B.+Sanchoauthor=H.+Cortes-Funes&title=The+Therapeutic+Role+of+Fulvestrant+in+the+Management+of+Patients+with+Hormone+Receptor-Positive+Breast+Cancer&doi=10.1016%2Fj.breast.2014.01.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer</span></div><div class="casAuthors">Ciruelos Eva; Pascual Tomas; Manso Luis; Parrilla Lucia; Munoz Cesar; Vega Estela; Calderon Monica Jackelin; Cortes-Funes Hernan; Arroyo Vozmediano Maria Luisa; Blanco Marta; Sancho Blanca</div><div class="citationInfo"><span class="NLM_cas:title">Breast (Edinburgh, Scotland)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">201-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although selective estrogen receptor modulators (SERMs), such as tamoxifen, or aromatase inhibitors (AIs), such as anastrozole, are the preferred endocrine treatment approach for most patients with hormone receptor-positive breast cancer, many patients progress despite this therapy or become resistant.  Fulvestrant is a selective estrogen receptor down-regulator (SERD) that has demonstrated activity and efficacy in patients with hormone receptor-positive breast cancer previously untreated or treated with hormonal therapy.  The efficacy of fulvestrant has been demonstrated in the neoadjuvant and metastatic settings, either alone or in combination with other therapies such as anastrozole or targeted drugs.  Additionally, 500 mg of fulvestrant have been shown to be more effective than 250 mg, without significant differences in the toxicity profile.  In this review, the unique mode of action of fulvestrant and the clinical data for different dosing regimens both alone or in combination with other drugs is critically assessed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS2l_K7JP7ftZPlX7E30qdzfW6udTcc2eZ7FjMCuiKBH7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cvpvFSqtw%253D%253D&md5=6fe2964c573e1370c2fc65efac3dbab0</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.breast.2014.01.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.breast.2014.01.016%26sid%3Dliteratum%253Aachs%26aulast%3DCiruelos%26aufirst%3DE.%26aulast%3DPascual%26aufirst%3DT.%26aulast%3DArroyo%2BVozmediano%26aufirst%3DM.%2BL.%26aulast%3DBlanco%26aufirst%3DM.%26aulast%3DManso%26aufirst%3DL.%26aulast%3DParrilla%26aufirst%3DL.%26aulast%3DMu%25C3%25B1oz%26aufirst%3DC.%26aulast%3DVega%26aufirst%3DE.%26aulast%3DCalder%25C3%25B3n%26aufirst%3DM.%2BJ.%26aulast%3DSancho%26aufirst%3DB.%26aulast%3DCortes-Funes%26aufirst%3DH.%26atitle%3DThe%2520Therapeutic%2520Role%2520of%2520Fulvestrant%2520in%2520the%2520Management%2520of%2520Patients%2520with%2520Hormone%2520Receptor-Positive%2520Breast%2520Cancer%26jtitle%3DBreast%26date%3D2014%26volume%3D23%26spage%3D201%26epage%3D208%26doi%3D10.1016%2Fj.breast.2014.01.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perey, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paridaens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolé, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildiers, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietrich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clément, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Köberle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldhirsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thürlimann, B.</span></span> <span> </span><span class="NLM_article-title">Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdl341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1093%2Fannonc%2Fmdl341" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=17030543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252FisVWntQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2007&pages=64-69&author=L.+Pereyauthor=R.+Paridaensauthor=H.+Hawleauthor=K.+Zamanauthor=F.+Nol%C3%A9author=H.+Wildiersauthor=M.+Ficheauthor=D.+Dietrichauthor=P.+Cl%C3%A9mentauthor=D.+K%C3%B6berleauthor=A.+Goldhirschauthor=B.+Th%C3%BCrlimann&title=Clinical+benefit+of+fulvestrant+in+postmenopausal+women+with+advanced+breast+cancer+and+primary+or+acquired+resistance+to+aromatase+inhibitors%3A+final+results+of+phase+II+Swiss+Group+for+Clinical+Cancer+Research+Trial+%28SAKK+21%2F00%29&doi=10.1093%2Fannonc%2Fmdl341"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)</span></div><div class="casAuthors">Perey L; Paridaens R; Hawle H; Zaman K; Nole F; Wildiers H; Fiche M; Dietrich D; Clement P; Koberle D; Goldhirsch A; Thurlimann B</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-9</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI) treatment.  PATIENTS AND METHODS:  This is a phase II, open, multicenter, noncomparative study.  Two patient groups were prospectively considered: group A (n=70) with AI-responsive disease and group B (n=20) with AI-resistant disease.  Fulvestrant 250 mg was administered as intramuscular injection every 28 (+/-3) days.  RESULTS:  All patients were pretreated with AI and 84% also with tamoxifen or toremifene; 67% had bone metastases and 45% liver metastases.  Fulvestrant administration was well tolerated and yielded a clinical benefit (CB; defined as objective response or stable disease [SD] for >or=24 weeks) in 28% (90% confidence interval [CI] 19% to 39%) of patients in group A and 37% (90% CI 19% to 58%) of patients in group B.  Median time to progression (TTP) was 3.6 (95% CI 3.0 to 4.8) months in group A and 3.4 (95% CI 2.5 to 6.7) months in group B.  CONCLUSIONS:  Overall, 30% of patients who had progressed following prior AI treatment gained CB with fulvestrant, thereby delaying indication to start chemotherapy.  Prior response to an AI did not appear to be predictive for benefit with fulvestrant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgdgcuVoVvhr7NkxioyDXTfW6udTcc2eaObN7sMr4Kr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252FisVWntQ%253D%253D&md5=33f52d40ebeba134195a6311c0e8d854</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdl341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdl341%26sid%3Dliteratum%253Aachs%26aulast%3DPerey%26aufirst%3DL.%26aulast%3DParidaens%26aufirst%3DR.%26aulast%3DHawle%26aufirst%3DH.%26aulast%3DZaman%26aufirst%3DK.%26aulast%3DNol%25C3%25A9%26aufirst%3DF.%26aulast%3DWildiers%26aufirst%3DH.%26aulast%3DFiche%26aufirst%3DM.%26aulast%3DDietrich%26aufirst%3DD.%26aulast%3DCl%25C3%25A9ment%26aufirst%3DP.%26aulast%3DK%25C3%25B6berle%26aufirst%3DD.%26aulast%3DGoldhirsch%26aufirst%3DA.%26aulast%3DTh%25C3%25BCrlimann%26aufirst%3DB.%26atitle%3DClinical%2520benefit%2520of%2520fulvestrant%2520in%2520postmenopausal%2520women%2520with%2520advanced%2520breast%2520cancer%2520and%2520primary%2520or%2520acquired%2520resistance%2520to%2520aromatase%2520inhibitors%253A%2520final%2520results%2520of%2520phase%2520II%2520Swiss%2520Group%2520for%2520Clinical%2520Cancer%2520Research%2520Trial%2520%2528SAKK%252021%252F00%2529%26jtitle%3DAnn.%2520Oncol.%26date%3D2007%26volume%3D18%26spage%3D64%26epage%3D69%26doi%3D10.1093%2Fannonc%2Fmdl341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montano, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekena, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McInerney, E. M.</span></span> <span> </span><span class="NLM_article-title">Antiestrogens: Mechanisms of action and resistance in breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1023/a:1005835428423</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1023%2Fa%3A1005835428423" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=9164675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK2sXjsFOqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1997&pages=23-38&author=B.+S.+Katzenellenbogenauthor=M.+M.+Montanoauthor=K.+Ekenaauthor=M.+E.+Hermanauthor=E.+M.+McInerney&title=Antiestrogens%3A+Mechanisms+of+action+and+resistance+in+breast+cancer&doi=10.1023%2Fa%3A1005835428423"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Antiestrogens: mechanisms of action and resistance in breast cancer</span></div><div class="casAuthors">Katzenellenbogen, Benita S.; Montano, Monica M.; Ekena, Kirk; Herman, Mary E.; McInerney, Eileen M.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-38</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Kluwer</span>)
        </div><div class="casAbstract">A review, with 96 refs.  Antiestrogens have proven to be highly effective in the treatment of hormone-responsive breast cancer.  However, resistance to antiestrogen therapy often develops.  In addn., although tamoxifen-like antiestrogens are largely inhibitory and function as estrogen antagonists in breast cancer cells, they also have some estrogen-like activity in other cells of the body.  Thus, recent efforts are being directed toward the development of even more tissue-selective antiestrogens, i.e. compds. that are antiestrogenic on breast and uterus while maintaining the beneficial estrogen-like actions on bone and the cardiovascular system.  Efforts are also being directed toward understanding ligand structure-estrogen receptor (ER) activity relationships and characterizing the mol. changes that underlie alterations in parallel signal transduction pathways that impact on the ER.  Recent findings show that antiestrogens, which are known to exert most of their effects through the ER of breast cancer cells, contact a different set of amino acids in the hormone-binding domain of the ER than those contacted by estrogen, and evoke a different receptor conformation that results in reduced or no transcriptional activity on most genes.  Resistance to antiestrogen therapy may develop due to changes at the level of the ER itself, and at pre- ad post-receptor points in the estrogen receptor-response pathway.  Resistance could arise in ≥4 ways: (1) ER loss or mutation; (2) post-receptor alterations including changes in cAMP and phosphorylation pathways, or changes in coregulator and transcription factor interactions that affect the transcriptional activity of the ER; (3) changes in growth factor prodn./sensitivity or paracrine cell-cell interactions; or (4) pharmacol. changes in the antiestrogen itself, including altered uptake and retention or metab. of the antiestrogen.  Model cell systems have been developed to study changes that accompany and define the antiestrogen resistant vs. sensitive breast cancer phenotype.  This information should lead to the development of antiestrogens with optimized tissue selectivity and agents to which resistance may develop more slowly.  In addn., antiestrogens which work through somewhat different mechanisms of interaction with ER should prove useful in treatment of some breast cancers that become resistant to a different category of antiestrogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPS2AZBTCG27Vg90H21EOLACvtfcHk0linGTpUewckhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjsFOqs70%253D&md5=7bd30e25f2402cdf83576add26cd6ade</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1023%2Fa%3A1005835428423&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252Fa%253A1005835428423%26sid%3Dliteratum%253Aachs%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DMontano%26aufirst%3DM.%2BM.%26aulast%3DEkena%26aufirst%3DK.%26aulast%3DHerman%26aufirst%3DM.%2BE.%26aulast%3DMcInerney%26aufirst%3DE.%2BM.%26atitle%3DAntiestrogens%253A%2520Mechanisms%2520of%2520action%2520and%2520resistance%2520in%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D1997%26volume%3D44%26spage%3D23%26epage%3D38%26doi%3D10.1023%2Fa%3A1005835428423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Massarweh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span> <span> </span><span class="NLM_article-title">Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1950</span>– <span class="NLM_lpage">1954</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-06-2540</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F1078-0432.ccr-06-2540" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=17404074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs12rsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=1950-1954&author=S.+Massarwehauthor=R.+Schiff&title=Unraveling+the+Mechanisms+of+Endocrine+Resistance+in+Breast+Cancer%3A+New+Therapeutic+Opportunities&doi=10.1158%2F1078-0432.ccr-06-2540"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities</span></div><div class="casAuthors">Massarweh, Suleiman; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1950-1954</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Two thirds of breast cancers express the estrogen receptor (ER), which contributes to tumor development and progression.  ER-targeted therapy is therefore widely used in breast cancer to inhibit signaling through ER and disrupt breast cancer growth.  This therapeutic strategy, particularly using the antiestrogen tamoxifen, is proven to increase the cure rates in early breast cancer, improve patient outcomes in advanced disease, and reduce breast cancer incidence in the prevention setting.  Despite the recent integration of more powerful endocrine agents into breast cancer care, resistance to all forms of endocrine therapy remains a major problem.  New insight into ER biol. and progress in understanding resistance mechanisms, mediated by mol. crosstalk between ER and various growth factor signaling pathways, are generating tremendous promise for new therapeutic opportunities to target resistance and improve breast cancer disease outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPnrEsFNPYurVg90H21EOLACvtfcHk0lidJA_4WQmNiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs12rsbo%253D&md5=b13ced2100827f7eb1e1d87b54c6794d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-06-2540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-06-2540%26sid%3Dliteratum%253Aachs%26aulast%3DMassarweh%26aufirst%3DS.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DUnraveling%2520the%2520Mechanisms%2520of%2520Endocrine%2520Resistance%2520in%2520Breast%2520Cancer%253A%2520New%2520Therapeutic%2520Opportunities%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D1950%26epage%3D1954%26doi%3D10.1158%2F1078-0432.ccr-06-2540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiff, R.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Endocrine Resistance in Breast Cancer</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.1146/annurev-med-070909-182917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1146%2Fannurev-med-070909-182917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=20887199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC3MXivVWhtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2011&pages=233-247&author=C.+K.+Osborneauthor=R.+Schiff&title=Mechanisms+of+Endocrine+Resistance+in+Breast+Cancer&doi=10.1146%2Fannurev-med-070909-182917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of endocrine resistance in breast cancer</span></div><div class="casAuthors">Osborne, C. Kent; Schiff, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">233-247</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The estrogen receptor (ER) pathway plays a pivotal role in breast cancer development and progression.  Endocrine therapy to block the ER pathway is highly effective, but its usefulness is limited by common intrinsic and acquired resistance.  Multiple mechanisms responsible for endocrine resistance have been proposed and include deregulation of various components of the ER pathway itself, alterations in cell cycle and cell survival signaling mols., and the activation of escape pathways that can provide tumors with alternative proliferative and survival stimuli.  Among these, increased expression or signaling of growth factor receptor pathways, esp. the EGFR/HER2 pathway, has been assocd. with both exptl. and clin. endocrine therapy resistance.  New treatment combinations targeting both ER and growth factor receptor signaling to block the crosstalk between these pathways and eliminate escape routes have been proven highly effective in preclin. models.  Results of recent clin. studies, while partly supporting this approach, also highlight the need to better identify a priori the patients whose tumors are most likely to benefit from these specific cotargeting strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp23PYELtZJrbVg90H21EOLACvtfcHk0lidJA_4WQmNiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXivVWhtLo%253D&md5=48573e39ea81057b53b5b43b1d72d2d9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-070909-182917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-070909-182917%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DSchiff%26aufirst%3DR.%26atitle%3DMechanisms%2520of%2520Endocrine%2520Resistance%2520in%2520Breast%2520Cancer%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2011%26volume%3D62%26spage%3D233%26epage%3D247%26doi%3D10.1146%2Fannurev-med-070909-182917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mills, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkovsky, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Resistance in Estrogen Receptor Positive Breast Cancer: Overcoming Resistance to Tamoxifen/Aromatase Inhibitors</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2018.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fj.coph.2018.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=29719270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotlOksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=59-65&author=J.+N.+Millsauthor=A.+C.+Rutkovskyauthor=A.+Giordano&title=Mechanisms+of+Resistance+in+Estrogen+Receptor+Positive+Breast+Cancer%3A+Overcoming+Resistance+to+Tamoxifen%2FAromatase+Inhibitors&doi=10.1016%2Fj.coph.2018.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors</span></div><div class="casAuthors">Mills, Jamie N.; Rutkovsky, Alex C.; Giordano, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59-65</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Several mechanisms of resistance have been identified, underscoring the complex nature of estrogen receptor (ER) signaling and the many connections between this pathway and other essential signaling pathways in breast cancer cells.  Many therapeutic targets of cell signaling and cell cycle pathways have met success with endocrine therapy and remain an ongoing area of investigation.  This review focuses on two major pathways that have recently emerged as important opportunities for therapeutic intervention in endocrine resistant breast tumors: PI3K/AKT/mTOR cell signaling and cyclinD1/cyclin-dependent kinase 4/6 cell cycle pathways.  Addnl., we highlight individual and combination strategies in current clin. trials that target these pathways and others under investigation for the treatment of ER pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVYQkU5BQS2LVg90H21EOLACvtfcHk0lidJA_4WQmNiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotlOksbg%253D&md5=7eb380dd5c8e441b8dd2602b40aa94b5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2018.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2018.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DMills%26aufirst%3DJ.%2BN.%26aulast%3DRutkovsky%26aufirst%3DA.%2BC.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DMechanisms%2520of%2520Resistance%2520in%2520Estrogen%2520Receptor%2520Positive%2520Breast%2520Cancer%253A%2520Overcoming%2520Resistance%2520to%2520Tamoxifen%252FAromatase%2520Inhibitors%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2018%26volume%3D41%26spage%3D59%26epage%3D65%26doi%3D10.1016%2Fj.coph.2018.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleshin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slamon, D. J.</span></span> <span> </span><span class="NLM_article-title">Targeting the Cyclin-Dependent Kinases (Cdk) 4/6 in Estrogen Receptor-Positive Breast Cancers</span>. <i>Breast Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">17</span>, <span class="refDoi"> DOI: 10.1186/s13058-015-0661-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1186%2Fs13058-015-0661-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=26857361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCksr3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=17&author=R.+S.+Finnauthor=A.+Aleshinauthor=D.+J.+Slamon&title=Targeting+the+Cyclin-Dependent+Kinases+%28Cdk%29+4%2F6+in+Estrogen+Receptor-Positive+Breast+Cancers&doi=10.1186%2Fs13058-015-0661-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers</span></div><div class="casAuthors">Finn, Richard S.; Aleshin, Alexey; Slamon, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17/1-17/11</span>CODEN:
                <span class="NLM_cas:coden">BRCRFS</span>;
        ISSN:<span class="NLM_cas:issn">1465-542X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Despite significant advances in early detection and treatment, breast cancer still remains a major cause of morbidity and mortality for women.  Our understanding of the mol. heterogeneity of the disease has significantly expanded over the past decade and the role of cell cycle signaling in both breast cancer oncogenesis and anti-estrogen resistance has gained increasing attention.  The mammalian cell cycle is driven by a complex interplay between cyclins and their assocd. cyclin-dependent kinase (CDK) partners, and dysregulation of this process is one of the hallmarks of cancer.  Despite this, initial results with broadly acting CDK inhibitors were largely disappointing.  However, recent preclin. and phase I/II clin. studies using a novel, oral, reversible CDK4/6 inhibitor, palbociclib (PD-0332991), have validated the role of CDK4/6 as a potential target in estrogen receptor-pos. (ER+) breast cancers.  This review highlights our current understanding of CDK signaling in both normal and malignant breast tissues, with special attention placed on recent clin. advances in inhibition of CDK4/6 in ER+ disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoawxkcYxKDGLVg90H21EOLACvtfcHk0lhYzhpgGkcRGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCksr3F&md5=6e343e8b171ad2528d6cd989476ac961</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1186%2Fs13058-015-0661-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13058-015-0661-5%26sid%3Dliteratum%253Aachs%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DAleshin%26aufirst%3DA.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26atitle%3DTargeting%2520the%2520Cyclin-Dependent%2520Kinases%2520%2528Cdk%2529%25204%252F6%2520in%2520Estrogen%2520Receptor-Positive%2520Breast%2520Cancers%26jtitle%3DBreast%2520Cancer%2520Res.%26date%3D2016%26volume%3D18%26spage%3D17%26doi%3D10.1186%2Fs13058-015-0661-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pernas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolaney, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, S.</span></span> <span> </span><span class="NLM_article-title">Cdk4/6 Inhibition in Breast Cancer: Current Practice and Future Directions</span>. <i>Ther. Adv. Med. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1758835918786451</span>, <span class="refDoi"> DOI: 10.1177/1758835918786451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1177%2F1758835918786451" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1758835918786451&author=S.+Pernasauthor=S.+M.+Tolaneyauthor=E.+P.+Winerauthor=S.+Goel&title=Cdk4%2F6+Inhibition+in+Breast+Cancer%3A+Current+Practice+and+Future+Directions&doi=10.1177%2F1758835918786451"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1177%2F1758835918786451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1758835918786451%26sid%3Dliteratum%253Aachs%26aulast%3DPernas%26aufirst%3DS.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DGoel%26aufirst%3DS.%26atitle%3DCdk4%252F6%2520Inhibition%2520in%2520Breast%2520Cancer%253A%2520Current%2520Practice%2520and%2520Future%2520Directions%26jtitle%3DTher.%2520Adv.%2520Med.%2520Oncol.%26date%3D2018%26volume%3D10%26spage%3D1758835918786451%26doi%3D10.1177%2F1758835918786451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Leary, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span> <span> </span><span class="NLM_article-title">Treating Cancer with Selective Cdk4/6 Inhibitors</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2016.26</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1038%2Fnrclinonc.2016.26" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=27030077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsF2iurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2016&pages=417-430&author=B.+O%E2%80%99Learyauthor=R.+S.+Finnauthor=N.+C.+Turner&title=Treating+Cancer+with+Selective+Cdk4%2F6+Inhibitors&doi=10.1038%2Fnrclinonc.2016.26"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Treating cancer with selective CDK4/6 inhibitors</span></div><div class="casAuthors">O'Leary, Ben; Finn, Richard S.; Turner, Nicholas C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">417-430</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathol. process.  Clin. implementation of first-generation, nonselective CDK inhibitors, designed to inhibit this proliferation, was originally hampered by the high risk of toxicity and lack of efficacy noted with these agents.  The emergence of a new generation of selective CDK4/6 inhibitors, including ribociclib, abemaciclib and palbociclib, has enabled tumor types in which CDK4/6 has a pivotal role in the G1-to-S-phase cell-cycle transition to be targeted with improved effectiveness, and fewer adverse effects.  Results of pivotal phase III trials investigating palbociclib in patients with advanced-stage estrogen receptor (ER)-pos. breast cancer have demonstrated a substantial improvement in progression-free survival, with a well-tolerated toxicity profile.  Mechanisms of acquired resistance to CDK4/6 inhibitors are beginning to emerge that, although unwelcome, might enable rational post-CDK4/6 inhibitor therapeutic strategies to be identified.  Extending the use of CDK4/6 inhibitors beyond ER-pos. breast cancer is challenging, and will likely require biomarkers that are predictive of a response, and the use of combination therapies in order to optimize CDK4/6 targeting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGNYw6CRUf17Vg90H21EOLACvtfcHk0lhYzhpgGkcRGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsF2iurc%253D&md5=6641dc6ab3cbd70edac46319ce4e6f45</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2016.26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2016.26%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DB.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26atitle%3DTreating%2520Cancer%2520with%2520Selective%2520Cdk4%252F6%2520Inhibitors%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D13%26spage%3D417%26epage%3D430%26doi%3D10.1038%2Fnrclinonc.2016.26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, C. C.</span></span> <span> </span><span class="NLM_article-title">Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-the Emerging Role of Cdk4/6 Inhibitors</span>. <i>Int. J. Cancer Clin. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">4</span>, <span class="refDoi"> DOI: 10.23937/2378-3419/2/4/1029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.23937%2F2378-3419%2F2%2F4%2F1029" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=4&author=C.+C.+O%E2%80%99Sullivan&title=Overcoming+Endocrine+Resistance+in+Hormone-Receptor+Positive+Advanced+Breast+Cancer-the+Emerging+Role+of+Cdk4%2F6+Inhibitors&doi=10.23937%2F2378-3419%2F2%2F4%2F1029"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.23937%2F2378-3419%2F2%2F4%2F1029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.23937%252F2378-3419%252F2%252F4%252F1029%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DC.%2BC.%26atitle%3DOvercoming%2520Endocrine%2520Resistance%2520in%2520Hormone-Receptor%2520Positive%2520Advanced%2520Breast%2520Cancer-the%2520Emerging%2520Role%2520of%2520Cdk4%252F6%2520Inhibitors%26jtitle%3DInt.%2520J.%2520Cancer%2520Clin.%2520Res.%26date%3D2015%26volume%3D2%26spage%3D4%26doi%3D10.23937%2F2378-3419%2F2%2F4%2F1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Kruchten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glaudemans, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Lanschot, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Faassen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kema, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schröder, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hospers, G. A.</span></span> <span> </span><span class="NLM_article-title">Measuring Residual Estrogen Receptor Availability During Fulvestrant Therapy in Patients with Metastatic Breast Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.cd-14-0697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F2159-8290.cd-14-0697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=25380844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=72-81&author=M.+van%0AKruchtenauthor=E.+G.+de+Vriesauthor=A.+W.+Glaudemansauthor=M.+C.+van+Lanschotauthor=M.+van+Faassenauthor=I.+P.+Kemaauthor=M.+Brownauthor=C.+P.+Schr%C3%B6derauthor=E.+F.+de+Vriesauthor=G.+A.+Hospers&title=Measuring+Residual+Estrogen+Receptor+Availability+During+Fulvestrant+Therapy+in+Patients+with+Metastatic+Breast+Cancer&doi=10.1158%2F2159-8290.cd-14-0697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer</span></div><div class="casAuthors">van Kruchten, Michel; de Vries, Elisabeth G.; Glaudemans, Andor W.; van Lanschot, Meta C.; van Faassen, Martijn; Kema, Ido P.; Brown, Myles; Schroeder, Carolien P.; de Vries, Erik F.; Hospers, Geke A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-81</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Decreased [18F]fluoroestradiol uptake visualized by PET/CT provides a measure of tumor ER availability and correlates with fulvestrant treatment outcome in patients with metastatic breast cancer.  It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer.  We performed a feasibility study to assess ER availability before and during fulvestrant.  Sixteen patients with ER-pos. metastatic breast cancer underwent positron emission tomog./computed tomog. (PET/CT) at baseline (scan 1), day 28 (scan 2), and day 84 (scan 3) to monitor tumor [18F]fluoroestradiol (FES) uptake.  Incomplete redn. in ER availability was predefined as <75% decrease in median tumor FES uptake and a residual standardized uptake value (SUVmax) of ≥1.5.  In total, 131 FES-pos. lesions were identified (median SUVmax of 2.9; range, 1.7-6.5).  The median change in patients during fulvestrant treatment was -85% at scan 2, but varied widely (-99% to +60%).  Fulvestrant reduced tumor FES uptake incompletely at scan 2 in 6 (38%) of the 16 patients, which was assocd. with early progression.  Significance: Serial imaging of tumor estrogen uptake by FES-PET can give insight into the dose needed for ER antagonists to completely abolish ER.  FES-PET showed significant residual ER availability in tumors during fulvestrant therapy in 38% of patients, which was assocd. with early progression.  Cancer Discov; 5(1); 72-81. ©2014 AACR.  This article is highlighted in the In This Issue feature, p. 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyAIvv5LaIyrVg90H21EOLACvtfcHk0li1hgafXN7A5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCnur8%253D&md5=c5e8291be59caa5bf772cb6da80d52fb</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.cd-14-0697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.cd-14-0697%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BKruchten%26aufirst%3DM.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BG.%26aulast%3DGlaudemans%26aufirst%3DA.%2BW.%26aulast%3Dvan%2BLanschot%26aufirst%3DM.%2BC.%26aulast%3Dvan%2BFaassen%26aufirst%3DM.%26aulast%3DKema%26aufirst%3DI.%2BP.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DC.%2BP.%26aulast%3Dde%2BVries%26aufirst%3DE.%2BF.%26aulast%3DHospers%26aufirst%3DG.%2BA.%26atitle%3DMeasuring%2520Residual%2520Estrogen%2520Receptor%2520Availability%2520During%2520Fulvestrant%2520Therapy%2520in%2520Patients%2520with%2520Metastatic%2520Breast%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D72%26epage%3D81%26doi%3D10.1158%2F2159-8290.cd-14-0697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, O. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renshaw, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaskill, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faratian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, J. M.</span></span> <span> </span><span class="NLM_article-title">Effects of Fulvestrant 750mg in Premenopausal Women with Oestrogen-Receptor-Positive Primary Breast Cancer</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">391</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2007.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fj.ejca.2007.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=18083023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2isLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=391-399&author=O.+E.+Youngauthor=L.+Renshawauthor=E.+J.+Macaskillauthor=S.+Whiteauthor=D.+Faratianauthor=J.+S.+J.+Thomasauthor=J.+M.+Dixon&title=Effects+of+Fulvestrant+750mg+in+Premenopausal+Women+with+Oestrogen-Receptor-Positive+Primary+Breast+Cancer&doi=10.1016%2Fj.ejca.2007.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer</span></div><div class="casAuthors">Young, O. E.; Renshaw, L.; Macaskill, E. J.; White, S.; Faratian, D.; Thomas, J. St. J.; Dixon, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">391-399</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Fulvestrant (Faslodextm) is a pure anti-estrogen that reduces markers of hormone sensitivity and proliferation in postmenopausal women with estrogen-receptor (ER)-pos. breast cancer.  This randomized trial compared the effects on the tumors of a single dose of 750 mg fulvestrant to those of daily tamoxifen (20 mg) taken 14-16 days prior to surgery in 60 premenopausal women with ER-pos. primary breast cancer.  There were statistically significant falls in the expression of ER and Ki67 levels compared to the baseline with both drugs.  Both drugs caused a decrease in PgR expression from baseline but this was only statistically significant with fulvestrant.  No statistically significant differences were seen between the two treatment groups.  Fulvestrant caused an increase in circulating levels of estradiol, irresp. of the stage of the menstrual cycle at which patients commenced treatment.  No major changes were seen in LH, FSH and progesterone levels with either drug.  The most common adverse events with fulvestrant were headaches, hot flushes, nausea and disturbance of menses.  Contrary to previous studies with fulvestrant 250 mg, these findings suggest that at a dose of 750 mg fulvestrant is effective at reducing the effects of estrogen on ER-pos. breast cancer in premenopausal women.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp7qL-r2mUbrVg90H21EOLACvtfcHk0li1hgafXN7A5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2isLg%253D&md5=e7e2fa3d26f37aa2bfe0b131d2ec3981</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2007.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2007.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DO.%2BE.%26aulast%3DRenshaw%26aufirst%3DL.%26aulast%3DMacaskill%26aufirst%3DE.%2BJ.%26aulast%3DWhite%26aufirst%3DS.%26aulast%3DFaratian%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DJ.%2BS.%2BJ.%26aulast%3DDixon%26aufirst%3DJ.%2BM.%26atitle%3DEffects%2520of%2520Fulvestrant%2520750mg%2520in%2520Premenopausal%2520Women%2520with%2520Oestrogen-Receptor-Positive%2520Primary%2520Breast%2520Cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2008%26volume%3D44%26spage%3D391%26epage%3D399%26doi%3D10.1016%2Fj.ejca.2007.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osborne, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, R. I.</span></span> <span> </span><span class="NLM_article-title">Fulvestrant: An Oestrogen Receptor Antagonist with a Novel Mechanism of Action</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">S2</span>– <span class="NLM_lpage">S6</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6601629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1038%2Fsj.bjc.6601629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=15094757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtFaktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2004&pages=S2-S6&author=C.+K.+Osborneauthor=A.+Wakelingauthor=R.+I.+Nicholson&title=Fulvestrant%3A+An+Oestrogen+Receptor+Antagonist+with+a+Novel+Mechanism+of+Action&doi=10.1038%2Fsj.bjc.6601629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Fulvestrant: an estrogen receptor antagonist with a novel mechanism of action</span></div><div class="casAuthors">Osborne, C. K.; Wakeling, A.; Nicholson, R. I.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S2-S6</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Due to their favorable tolerability profiles, endocrine therapies have long been considered the treatment of choice for hormone-sensitive metastatic breast cancer.  However, the estrogen agonist effects of the available selective estrogen receptor modulators, such as tamoxifen, and the development of cross-resistance between endocrine therapies with similar modes of action have led to the need for new treatments that act through different mechanisms.  Fulvestrant (Faslodex') is the first of a new type of endocrine treatment-an estrogen receptor (ER) antagonist that downregulates the ER and has no agonist effects.  This article provides an overview of the current understanding of ER signaling and illustrates the unique mode of action of fulvestrant.  Preclin. and clin. study data are presented in support of the novel mechanism of action of this new type of ER antagonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8myn0Hcy0CrVg90H21EOLACvtfcHk0li1hgafXN7A5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtFaktbY%253D&md5=291a738f1d67db894e83d88ddfa000e4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6601629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6601629%26sid%3Dliteratum%253Aachs%26aulast%3DOsborne%26aufirst%3DC.%2BK.%26aulast%3DWakeling%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DR.%2BI.%26atitle%3DFulvestrant%253A%2520An%2520Oestrogen%2520Receptor%2520Antagonist%2520with%2520a%2520Novel%2520Mechanism%2520of%2520Action%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2004%26volume%3D90%26spage%3DS2%26epage%3DS6%26doi%3D10.1038%2Fsj.bjc.6601629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ettinger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitlak, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knickerbocker, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickelsen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genant, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiansen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delmas, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanchetta, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stakkestad, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glüer, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensrud, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avioli, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lips, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, S. R.</span></span> <span> </span><span class="NLM_article-title">Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">637</span>– <span class="NLM_lpage">645</span>, <span class="refDoi"> DOI: 10.1001/jama.282.7.637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1001%2Fjama.282.7.637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10517716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK1MXlvVKqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=1999&pages=637-645&author=B.+Ettingerauthor=D.+M.+Blackauthor=B.+H.+Mitlakauthor=R.+K.+Knickerbockerauthor=T.+Nickelsenauthor=H.+K.+Genantauthor=C.+Christiansenauthor=P.+D.+Delmasauthor=J.+R.+Zanchettaauthor=J.+Stakkestadauthor=C.+C.+Gl%C3%BCerauthor=K.+Kruegerauthor=F.+J.+Cohenauthor=S.+Eckertauthor=K.+E.+Ensrudauthor=L.+V.+Avioliauthor=P.+Lipsauthor=S.+R.+Cummings&title=Reduction+of+vertebral+fracture+risk+in+postmenopausal+women+with+osteoporosis+treated+with+raloxifene%3A+results+from+a+3-year+randomized+clinical+trial.+Multiple+Outcomes+of+Raloxifene+Evaluation+%28MORE%29+Investigators&doi=10.1001%2Fjama.282.7.637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene Results from a 3-year randomized clinical trial</span></div><div class="casAuthors">Ettinger, Bruce; Black, Dennis M.; Mitlak, Bruce H.; Knickerbocker, Ronald K.; Nickelsen, Thomas; Genant, Harry K.; Christiansen, Claus; Delmas, Pierre D.; Zanchetta, Jose R.; Stakkestad, Jacob; Gluer, Claus C.; Krueger, Kathryn; Cohen, Fredric J.; Eckert, Stephen; Ensrud, Kristine E.; Avioli, Louis V.; Lips, Paul; Cummings, Steven R.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">637-645</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known.  The objective of the study was to det. the effect of raloxifene therapy on risk of vertebral and non-vertebral fractures.  The Multiple Outcomes of Raloxifene Evaluation (MORE) study, a multicenter, randomized, blinded, placebo-controlled trial.  A total of 7705 women aged 31 to 80 yr in 25 countries who had been postmenopausal for at least 2 yr and who met World Health Organization criteria for having osteoporosis.  The study began in 1994 and had up to 36 mo of follow-up for primary efficacy measurements and nonserious adverse events and up to 40 mo of follow-up for serious adverse events.  Participants were randomized to 60 mg/day or 120 mg/day of raloxifene or to identically appearing placebo pills; in addn., all women received supplemental calcium and cholecalciferol.  Incident vertebral fracture was detd. radiog. at baseline and at scheduled 24- and 36-mo visits.  Nonvertebral fracture was ascertained by interview at 6-mo-interim visits.  Bone mineral d. was detd. annually by dual-energy x-ray absorptiometry.  At 36 mo of the evaluable radiographs in 6828 women, 503 (7.4%) had at least 1 new vertebral fracture, including 10.1% of women receiving placebo, 6.6% of those receiving 60 mg/d of raloxifene, and 5.4% of those receiving 120 mg/d of raloxifene.  Risk of vertebral fracture was reduced in both study groups receiving raloxifene (for 60-mg/d group: relative risk [RR], 0.7; 95% confidence interval [Cl], 0.5-0.8; for 120-mg/d group: RR, 0.5; 95% Cl, 0.4-0.7).  Frequency of vertebral fracture was reduced both in women who did and did not have prevalent fracture.  Risk of nonvertebral fracture for raloxifene vs. placebo did not differs significantly (RR, 0.9; 95% Cl, 0.8-1.1 for both raloxifene groups combined).  Compared with placebo, raloxifene increased bone mineral d. in the femoral neck by 2.1% (60 mg) and 2.4% (120 mg) and in the spine by 2.6% (60 mg) and 2.7% (120 mg) P<0.001 for all comparisons.  Women receiving raloxifene had increased risk of venous thromboembolus vs. placebo (RR, 3.1; 95% Cl, 1.5-6.2).  Raloxifene did not cause vaginal bleeding or breast pain and was assocd. with a lower incidence of breast cancer.  In postmenopausal women with osteoporosis, raloxifene increases bone mineral d. in the spine and femoral neck and reduces risk of vertebral fracture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWVFZnEfO09bVg90H21EOLACvtfcHk0lhN2JU1rw4PNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvVKqurg%253D&md5=8dae1a241ff597c689298cfc033b6acb</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1001%2Fjama.282.7.637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.282.7.637%26sid%3Dliteratum%253Aachs%26aulast%3DEttinger%26aufirst%3DB.%26aulast%3DBlack%26aufirst%3DD.%2BM.%26aulast%3DMitlak%26aufirst%3DB.%2BH.%26aulast%3DKnickerbocker%26aufirst%3DR.%2BK.%26aulast%3DNickelsen%26aufirst%3DT.%26aulast%3DGenant%26aufirst%3DH.%2BK.%26aulast%3DChristiansen%26aufirst%3DC.%26aulast%3DDelmas%26aufirst%3DP.%2BD.%26aulast%3DZanchetta%26aufirst%3DJ.%2BR.%26aulast%3DStakkestad%26aufirst%3DJ.%26aulast%3DGl%25C3%25BCer%26aufirst%3DC.%2BC.%26aulast%3DKrueger%26aufirst%3DK.%26aulast%3DCohen%26aufirst%3DF.%2BJ.%26aulast%3DEckert%26aufirst%3DS.%26aulast%3DEnsrud%26aufirst%3DK.%2BE.%26aulast%3DAvioli%26aufirst%3DL.%2BV.%26aulast%3DLips%26aufirst%3DP.%26aulast%3DCummings%26aufirst%3DS.%2BR.%26atitle%3DReduction%2520of%2520vertebral%2520fracture%2520risk%2520in%2520postmenopausal%2520women%2520with%2520osteoporosis%2520treated%2520with%2520raloxifene%253A%2520results%2520from%2520a%25203-year%2520randomized%2520clinical%2520trial.%2520Multiple%2520Outcomes%2520of%2520Raloxifene%2520Evaluation%2520%2528MORE%2529%2520Investigators%26jtitle%3DJAMA%26date%3D1999%26volume%3D282%26spage%3D637%26epage%3D645%26doi%3D10.1001%2Fjama.282.7.637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span> <span> </span><span class="NLM_article-title">Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease</span>. <i>Clin Cancer Res</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2420</span>– <span class="NLM_lpage">2431</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-3771</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F1078-0432.CCR-12-3771" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=23536434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVWru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2420-2431&author=S.+E.+Wardellauthor=E.+R.+Nelsonauthor=C.+A.+Chaoauthor=D.+P.+McDonnell&title=Bazedoxifene+exhibits+antiestrogenic+activity+in+animal+models+of+tamoxifen-resistant+breast+cancer%3A+implications+for+treatment+of+advanced+disease&doi=10.1158%2F1078-0432.CCR-12-3771"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease</span></div><div class="casAuthors">Wardell, Suzanne E.; Nelson, Erik R.; Chao, Christina A.; McDonnell, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2420-2431</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">There is compelling evidence to suggest that drugs that function as pure estrogen receptor (ER-α) antagonists, or that downregulate the expression of ER-α, would have clin. use in the treatment of advanced tamoxifen- and aromatase-resistant breast cancer.  Although such compds. are currently in development, we reasoned, based on our understanding of ER-α pharmacol., that there may already exist among the most recently developed selective estrogen receptor modulators (SERM) compds. that would have usage as breast cancer therapeutics.  Thus, our objective was to identify among available SERMs those with unique pharmacol. activities and to evaluate their potential clin. use with predictive models of advanced breast cancer.  A validated mol. profiling technol. was used to classify clin. relevant SERMs based on their impact on ER-α conformation.  The functional consequences of these obsd. mechanistic differences on (i) gene expression, (ii) receptor stability, and (iii) activity in cellular and animal models of advanced endocrine-resistant breast cancer were assessed.  The high-affinity SERM bazedoxifene was shown to function as a pure ER-α antagonist in cellular models of breast cancer and effectively inhibited the growth of both tamoxifen-sensitive and -resistant breast tumor xenografts.  Interestingly, bazedoxifene induced a unique conformational change in ER-α that resulted in its proteasomal degrdn., although the latter activity was dispensable for its antagonist efficacy.  Bazedoxifene was recently approved for use in the European Union for the treatment of osteoporosis and thus may represent a near-term therapeutic option for patients with advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEy3scPx9VTrVg90H21EOLACvtfcHk0lhN2JU1rw4PNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVWru7g%253D&md5=a3ca719d84b74a24bfd6147b6cc2366e</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-3771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-3771%26sid%3Dliteratum%253Aachs%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNelson%26aufirst%3DE.%2BR.%26aulast%3DChao%26aufirst%3DC.%2BA.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DBazedoxifene%2520exhibits%2520antiestrogenic%2520activity%2520in%2520animal%2520models%2520of%2520tamoxifen-resistant%2520breast%2520cancer%253A%2520implications%2520for%2520treatment%2520of%2520advanced%2520disease%26jtitle%3DClin%2520Cancer%2520Res%26date%3D2013%26volume%3D19%26spage%3D2420%26epage%3D2431%26doi%3D10.1158%2F1078-0432.CCR-12-3771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garner, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomali, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyttle, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hattersley, G.</span></span> <span> </span><span class="NLM_article-title">Rad1901: A Novel, Orally Bioavailable Selective Estrogen Receptor Degrader That Demonstrates Antitumor Activity in Breast Cancer Xenograft Models</span>. <i>Anticancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">948</span>– <span class="NLM_lpage">956</span>, <span class="refDoi"> DOI: 10.1097/cad.0000000000000271</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1097%2Fcad.0000000000000271" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=26164151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FitlKitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=948-956&author=F.+Garnerauthor=M.+Shomaliauthor=D.+Paquinauthor=C.+R.+Lyttleauthor=G.+Hattersley&title=Rad1901%3A+A+Novel%2C+Orally+Bioavailable+Selective+Estrogen+Receptor+Degrader+That+Demonstrates+Antitumor+Activity+in+Breast+Cancer+Xenograft+Models&doi=10.1097%2Fcad.0000000000000271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models</span></div><div class="casAuthors">Garner Fiona; Shomali Maysoun; Paquin Dotty; Lyttle C Richard; Hattersley Gary</div><div class="citationInfo"><span class="NLM_cas:title">Anti-cancer drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">948-56</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Agents that inhibit estrogen production, such as aromatase inhibitors or those that directly block estrogen receptor (ER) activity, such as selective estrogen receptor modulators and selective estrogen receptor degraders, are routinely used in the treatment of ER-positive breast cancers.  However, although initial treatment with these agents is often successful, many women eventually relapse with drug-resistant breast cancers.  To overcome some of the challenges associated with current endocrine therapies and to combat the development of resistance, there is a need for more durable and more effective ER-targeted therapies.  Here we describe and characterize a novel, orally bioavailable small-molecule selective estrogen receptor degrader, RAD1901, and evaluate its therapeutic potential for the treatment of breast cancer.  RAD1901 selectively binds to and degrades the ER and is a potent antagonist of ER-positive breast cancer cell proliferation.  Importantly, RAD1901 produced a robust and profound inhibition of tumor growth in MCF-7 xenograft models.  In an intracranial MCF-7 model, RAD1901-treated animals survived longer than those treated with either control or fulvestrant, suggesting the potential benefit of RAD1901 in the treatment of ER-positive breast cancer that has metastasized to the brain.  Finally, RAD1901 preserved ovariectomy-induced bone loss and prevented the uterotropic effects of E2, suggesting that it may act selectively as an agonist in bone but as an antagonist in breast and uterine tissues.  RAD1901 is currently under clinical study in postmenopausal women with ER-positive advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTP8U29TPTqVZZoeNcnHOQ9fW6udTcc2eYTLz5pswHvA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FitlKitA%253D%253D&md5=0189275b74c147ec76684979dac05d76</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1097%2Fcad.0000000000000271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fcad.0000000000000271%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DF.%26aulast%3DShomali%26aufirst%3DM.%26aulast%3DPaquin%26aufirst%3DD.%26aulast%3DLyttle%26aufirst%3DC.%2BR.%26aulast%3DHattersley%26aufirst%3DG.%26atitle%3DRad1901%253A%2520A%2520Novel%252C%2520Orally%2520Bioavailable%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520That%2520Demonstrates%2520Antitumor%2520Activity%2520in%2520Breast%2520Cancer%2520Xenograft%2520Models%26jtitle%3DAnticancer%2520Drugs%26date%3D2015%26volume%3D26%26spage%3D948%26epage%3D956%26doi%3D10.1097%2Fcad.0000000000000271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wardell, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alley, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, D. P.</span></span> <span> </span><span class="NLM_article-title">Evaluation of the Pharmacological Activities of Rad1901, a Selective Estrogen Receptor Degrader</span>. <i>Endocr.-Relat. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">713</span>– <span class="NLM_lpage">724</span>, <span class="refDoi"> DOI: 10.1530/erc-15-0287</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1530%2Ferc-15-0287" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=26162914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1WktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=713-724&author=S.+E.+Wardellauthor=E.+R.+Nelsonauthor=C.+A.+Chaoauthor=H.+M.+Alleyauthor=D.+P.+McDonnell&title=Evaluation+of+the+Pharmacological+Activities+of+Rad1901%2C+a+Selective+Estrogen+Receptor+Degrader&doi=10.1530%2Ferc-15-0287"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader</span></div><div class="casAuthors">Wardell, Suzanne E.; Nelson, Erik R.; Chao, Christina A.; Alley, Holly M.; McDonnell, Donald P.</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine-Related Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">713-724</span>CODEN:
                <span class="NLM_cas:coden">ERCAE9</span>;
        ISSN:<span class="NLM_cas:issn">1351-0088</span>.
    
            (<span class="NLM_cas:orgname">BioScientifica Ltd.</span>)
        </div><div class="casAbstract">Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains a first-line treatment for estrogen receptor 1 (ESR1) pos. breast cancer.  However, tumor resistance limits the duration of response.  The clin. efficacy of fulvestrant, a selective ER degrader (SERD) that triggers receptor degrdn., has confirmed that ESR1 often remains engaged in endocrine therapy resistant cancers.  Recently developed, selective ER modulators (SERMs)/SERD hybrids (SSHs) that facilitate ESR1 degrdn. in breast cancer cells and reproductive tissues have been advanced as an alternative treatment for advanced breast cancer, particularly in the metastatic setting.  RAD1901 is one SSH currently being evaluated clin. that is unique among ESR1 modulators in that it readily enters the brain, a common site of breast cancer metastasis.  In this study, RAD1901 inhibited estrogen activation of ESR1 in vitro and in vivo, inhibited estrogen-dependent breast cancer cell proliferation and xenograft tumor growth, and mediated dose-dependent downregulation of ESR1 protein.  However, doses of RAD1901 insufficient to induce ESR1 degrdn. were shown to result in the activation of ESR1 target genes and in the stimulation of xenograft tumor growth.  RAD1901 is an SSH that exhibits complex pharmacol. in breast cancer models, having dose-dependent agonist/antagonist activity displayed in a tissue-selective manner.  It remains unclear how this unique pharmacol. will impact the utility of RAD1901 for breast cancer treatment.  However, being the only SERD currently known to access the brain, RAD1901 merits evaluation as a targeted therapy for the treatment of breast cancer brain metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZozvILn25g7Vg90H21EOLACvtfcHk0lgugZuWXSGqoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1WktLg%253D&md5=0749b230c2a16355345c884438681d47</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1530%2Ferc-15-0287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1530%252Ferc-15-0287%26sid%3Dliteratum%253Aachs%26aulast%3DWardell%26aufirst%3DS.%2BE.%26aulast%3DNelson%26aufirst%3DE.%2BR.%26aulast%3DChao%26aufirst%3DC.%2BA.%26aulast%3DAlley%26aufirst%3DH.%2BM.%26aulast%3DMcDonnell%26aufirst%3DD.%2BP.%26atitle%3DEvaluation%2520of%2520the%2520Pharmacological%2520Activities%2520of%2520Rad1901%252C%2520a%2520Selective%2520Estrogen%2520Receptor%2520Degrader%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2015%26volume%3D22%26spage%3D713%26epage%3D724%26doi%3D10.1530%2Ferc-15-0287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, N. U.</span></span> <span> </span><span class="NLM_article-title">Updates on the management of breast cancer brain metastases</span>. <i>Oncology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">572</span>– <span class="NLM_lpage">578</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=25144276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FotlKjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=572-578&author=E.+Limauthor=N.+U.+Lin&title=Updates+on+the+management+of+breast+cancer+brain+metastases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Updates on the management of breast cancer brain metastases</span></div><div class="casAuthors">Lim Elgene; Lin Nancy U</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">572-8</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">Breast cancer brain metastases (BCBMs) are common in patients with advanced disease.  Breast cancer subtype and performance status are the major determinants of the course of the disease and survival time following a diagnosis of brain metastasis.  Unique challenges specific to the management of BCBMs include overcoming the blood-brain barrier and resistance to conventional systemic therapies, as BCBMs typically occur in the pretreated patient population.  The development of new systemic therapies for breast cancer, coupled with improvements in trial design, imaging modalities, and methods of defining and measuring clinical endpoints, has led to a renewed interest in developing novel therapeutic approaches for BCBMs.  In this overview, we will review recent developments in the management of BCBMs and current prospective trials of systemic therapies specifically for patients with BCBMs, with a focus on novel pathway-specific therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQC6-XPxs-YDzDnmmyUf5qOfW6udTcc2eZu9I9nNM8FJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FotlKjsQ%253D%253D&md5=81552aa65962a287ff133cb44466b8af</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DE.%26aulast%3DLin%26aufirst%3DN.%2BU.%26atitle%3DUpdates%2520on%2520the%2520management%2520of%2520breast%2520cancer%2520brain%2520metastases%26jtitle%3DOncology%26date%3D2014%26volume%3D28%26spage%3D572%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagney, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalano, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellon, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Punglia, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claus, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas-Kogan, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aizer, A. A.</span></span> <span> </span><span class="NLM_article-title">Brain Metastases in Newly Diagnosed Breast Cancer</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1077</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2017.0001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1001%2Fjamaoncol.2017.0001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=28301662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BC1czntVWksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2017&pages=1069-1077&author=A.+M.+Martinauthor=D.+N.+Cagneyauthor=P.+J.+Catalanoauthor=L.+E.+Warrenauthor=J.+R.+Bellonauthor=R.+S.+Pungliaauthor=E.+B.+Clausauthor=E.+Q.+Leeauthor=P.+Y.+Wenauthor=D.+A.+Haas-Koganauthor=B.+M.+Alexanderauthor=N.+U.+Linauthor=A.+A.+Aizer&title=Brain+Metastases+in+Newly+Diagnosed+Breast+Cancer&doi=10.1001%2Fjamaoncol.2017.0001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study</span></div><div class="casAuthors">Martin Allison M; Cagney Daniel N; Warren Laura E; Bellon Jennifer R; Punglia Rinaa S; Haas-Kogan Daphne A; Alexander Brian M; Aizer Ayal A; Catalano Paul J; Claus Elizabeth B; Claus Elizabeth B; Lee Eudocia Q; Wen Patrick Y; Lin Nancy U</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1069-1077</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Population-based estimates of the incidence and prognosis of brain metastases at diagnosis of breast cancer are lacking.  Objective:  To characterize the incidence proportions and median survivals of patients with breast cancer and brain metastases at the time of cancer diagnosis.  Design, Setting, and Participants:  Patients with breast cancer and brain metastases at the time of diagnosis were identified using the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute.  Data were stratified by subtype, age, sex, and race.  Multivariable logistic and Cox regression were performed to identify predictors of the presence of brain metastases at diagnosis and factors associated with all-cause mortality, respectively.  For incidence, we identified a population-based sample of 238 726 adult patients diagnosed as having invasive breast cancer between 2010 and 2013 for whom the presence or absence of brain metastases at diagnosis was known.  Patients diagnosed at autopsy or with an unknown follow-up were excluded from the survival analysis, leaving 231 684 patients in this cohort.  Main Outcomes and Measures:  Incidence proportion and median survival of patients with brain metastases and newly diagnosed breast cancer.  Results:  We identified 968 patients with brain metastases at the time of diagnosis of breast cancer, representing 0.41% of the entire cohort and 7.56% of the subset with metastatic disease to any site.  A total of 57 were 18 to 40 years old, 423 were 41 to 60 years old, 425 were 61-80 years old, and 63 were older than 80 years.  Ten were male and 958 were female.  Incidence proportions were highest among patients with hormone receptor (HR)-negative human epidermal growth factor receptor 2 (HER2)-positive (1.1% among entire cohort, 11.5% among patients with metastatic disease to any distant site) and triple-negative (0.7% among entire cohort, 11.4% among patients with metastatic disease to any distant site) subtypes.  Median survival among the entire cohort with brain metastases was 10.0 months.  Patients with HR-positive HER2-positive subtype displayed the longest median survival (21.0 months); patients with triple-negative subtype had the shortest median survival (6.0 months).  Conclusions and Relevance:  The findings of this study provides population-based estimates of the incidence and prognosis for patients with brain metastases at time of diagnosis of breast cancer.  The findings lend support to consideration of screening imaging of the brain for patients with HER2-positive or triple-negative subtypes and extracranial metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkU6HFRYrVILZpSb_XWfMrfW6udTcc2eZu9I9nNM8FJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czntVWksg%253D%253D&md5=3545044ba6c67337eac6b9be2f7a163e</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2017.0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2017.0001%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DCagney%26aufirst%3DD.%2BN.%26aulast%3DCatalano%26aufirst%3DP.%2BJ.%26aulast%3DWarren%26aufirst%3DL.%2BE.%26aulast%3DBellon%26aufirst%3DJ.%2BR.%26aulast%3DPunglia%26aufirst%3DR.%2BS.%26aulast%3DClaus%26aufirst%3DE.%2BB.%26aulast%3DLee%26aufirst%3DE.%2BQ.%26aulast%3DWen%26aufirst%3DP.%2BY.%26aulast%3DHaas-Kogan%26aufirst%3DD.%2BA.%26aulast%3DAlexander%26aufirst%3DB.%2BM.%26aulast%3DLin%26aufirst%3DN.%2BU.%26aulast%3DAizer%26aufirst%3DA.%2BA.%26atitle%3DBrain%2520Metastases%2520in%2520Newly%2520Diagnosed%2520Breast%2520Cancer%26jtitle%3DJAMA%2520Oncol.%26date%3D2017%26volume%3D3%26spage%3D1069%26epage%3D1077%26doi%3D10.1001%2Fjamaoncol.2017.0001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, N. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri-Kordestani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liewehr, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeg, P. S.</span></span> <span> </span><span class="NLM_article-title">Cns Metastases in Breast Cancer: Old Challenge, New Frontiers</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6404</span>– <span class="NLM_lpage">6418</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-13-0790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F1078-0432.ccr-13-0790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=24298071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOitb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=6404-6418&author=N.+U.+Linauthor=L.+Amiri-Kordestaniauthor=D.+Palmieriauthor=D.+J.+Liewehrauthor=P.+S.+Steeg&title=Cns+Metastases+in+Breast+Cancer%3A+Old+Challenge%2C+New+Frontiers&doi=10.1158%2F1078-0432.ccr-13-0790"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">CNS Metastases in Breast Cancer: Old Challenge, New Frontiers</span></div><div class="casAuthors">Lin, Nancy U.; Amiri-Kordestani, Laleh; Palmieri, Diane; Liewehr, David J.; Steeg, Patricia S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6404-6418</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Despite major therapeutic advances in the management of patients with breast cancer, central nervous system (CNS) metastases remain an intractable problem, particularly in patients with metastatic HER2-pos. and triple-neg. breast cancer.  As systemic therapies to treat extracranial disease improve, some patients are surviving longer, and the frequency of CNS involvement seems to be increasing.  Furthermore, in the early-stage setting, the CNS remains a potential sanctuary site for relapse.  This review highlights advances in the development of biol. relevant preclin. models, including the development of brain-tropic cell lines for testing of agents to prevent and treat brain metastases, and summarizes our current understanding of the biol. of CNS relapse.  From a clin. perspective, a variety of therapeutic approaches are discussed, including methods to improve drug delivery, novel cytotoxic agents, and targeted therapies.  Challenges in current trial design and endpoints are reviewed.  Finally, we discuss promising new directions, including novel trial designs, correlative imaging techniques, and enhanced translational opportunities.  Clin Cancer Res; 19(23); 6404-18. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAvG-idsLscLVg90H21EOLACvtfcHk0lhlG8nqN7KA8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOitb7F&md5=1e27650f764980ea0f6bb3199a6281c0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-13-0790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-13-0790%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DN.%2BU.%26aulast%3DAmiri-Kordestani%26aufirst%3DL.%26aulast%3DPalmieri%26aufirst%3DD.%26aulast%3DLiewehr%26aufirst%3DD.%2BJ.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26atitle%3DCns%2520Metastases%2520in%2520Breast%2520Cancer%253A%2520Old%2520Challenge%252C%2520New%2520Frontiers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D6404%26epage%3D6418%26doi%3D10.1158%2F1078-0432.ccr-13-0790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karumudi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Novel Selective Estrogen Receptor Downregulators (Serds) Developed against Treatment-Resistant Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1342</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01355</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01355" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFWqu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1325-1342&author=R.+Xiongauthor=J.+Zhaoauthor=L.+M.+Gutgesellauthor=Y.+Wangauthor=S.+Leeauthor=B.+Karumudiauthor=H.+Zhaoauthor=Y.+Luauthor=D.+A.+Tonettiauthor=G.+R.+J.+Thatcher&title=Novel+Selective+Estrogen+Receptor+Downregulators+%28Serds%29+Developed+against+Treatment-Resistant+Breast+Cancer&doi=10.1021%2Facs.jmedchem.6b01355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer</span></div><div class="casAuthors">Xiong, Rui; Zhao, Jiong; Gutgesell, Lauren M.; Wang, Yueting; Lee, Sue; Karumudi, Bhargava; Zhao, Huiping; Lu, Yunlong; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1325-1342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Resistance to the selective estrogen receptor modulator (SERM) tamoxifen and to aromatase inhibitors that lower circulating estradiol occurs in up to 50% of patients, generally leading to an endocrine-independent ER+ phenotype.  Selective ER downregulators (SERDs) are able to ablate ER and thus theor. to prevent survival of both endocrine-dependent and independent ER+ tumors.  The clin. SERD, fulvestrant, is hampered by i.m. administration and undesirable pharmacokinetics.  Novel SERDs were designed using the 6-OH-benzothiophene (BT) scaffold common to arzoxifene and raloxifene.  Treatment-resistant (TR) ER+ cell lines (MCF-7:5C and MCF-7:TAM1) were used for optimization, followed by validation in the parent endocrine-dependent cell line (MCF-7:WS8), in 2D and 3D cultures, using ERα in-cell westerns, ERE-luciferase, and cell viability assays, with GDC-0810 (ARN-810) used for comparison.  Two BT SERDs with superior in vitro activity to GDC-0810 were studied for bioavailability and shown to cause regression of a TR, endocrine-independent ER+ xenograft superior to GDC-0810.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLqe0A8df78rVg90H21EOLACvtfcHk0lhlG8nqN7KA8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFWqu70%253D&md5=71dbdfa2152f9e9019e8d138ed41313e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01355%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DKarumudi%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DNovel%2520Selective%2520Estrogen%2520Receptor%2520Downregulators%2520%2528Serds%2529%2520Developed%2520against%2520Treatment-Resistant%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1325%26epage%3D1342%26doi%3D10.1021%2Facs.jmedchem.6b01355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutgesell, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado-Rivera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pham, T. N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Selective Human Estrogen Receptor Partial Agonists (Sherpas) for Tamoxifen-Resistant Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01276</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01276" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=219-237&author=R.+Xiongauthor=H.+K.+Patelauthor=L.+M.+Gutgesellauthor=J.+Zhaoauthor=L.+Delgado-Riveraauthor=T.+N.+D.+Phamauthor=H.+Zhaoauthor=K.+Carlsonauthor=T.+Martinauthor=J.+A.+Katzenellenbogenauthor=T.+W.+Mooreauthor=D.+A.+Tonettiauthor=G.+R.+J.+Thatcher&title=Selective+Human+Estrogen+Receptor+Partial+Agonists+%28Sherpas%29+for+Tamoxifen-Resistant+Breast+Cancer&doi=10.1021%2Facs.jmedchem.5b01276"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Xiong, Rui; Patel, Hitisha K.; Gutgesell, Lauren M.; Zhao, Jiong; Delgado-Rivera, Loruhama; Pham, Thao N. D.; Zhao, Huiping; Carlson, Kathryn; Martin, Teresa; Katzenellenbogen, John A.; Moore, Terry W.; Tonetti, Debra A.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">219-237</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Almost 70% of breast cancers are estrogen receptor α (ERα) pos.  Tamoxifen, a selective estrogen receptor modulator (SERM), represents the std. of care for many patients; however, 30-50% develop resistance, underlining the need for alternative therapeutics.  Paradoxically, agonists at ERα such as estradiol (E2) have demonstrated clin. efficacy in patients with heavily treated breast cancer, although side effects in gynecol. tissues are unacceptable.  A drug that selectively mimics the actions of E2 in breast cancer therapy but minimizes estrogenic effects in other tissues is a novel, therapeutic alternative.  We hypothesized that a selective human estrogen receptor partial agonist (ShERPA) at ERα would provide such an agent.  Novel benzothiophene derivs. with nanomolar potency in breast cancer cell cultures were designed.  Several showed partial agonist activity, with potency of 0.8-76 nM, mimicking E2 in inhibiting growth of tamoxifen-resistant breast cancer cell lines.  Three ShERPAs were tested and validated in xenograft models of endocrine-independent and tamoxifen-resistant breast cancer, and in contrast to E2, ShERPAs did not cause significant uterine growth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF_Xh3QGtO4LVg90H21EOLACvtfcHk0lhlG8nqN7KA8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVeqtrzK&md5=f2bffc241b3de9c7537f9b5fa0c56f54</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01276%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DGutgesell%26aufirst%3DL.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DDelgado-Rivera%26aufirst%3DL.%26aulast%3DPham%26aufirst%3DT.%2BN.%2BD.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCarlson%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DT.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DMoore%26aufirst%3DT.%2BW.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DSelective%2520Human%2520Estrogen%2520Receptor%2520Partial%2520Agonists%2520%2528Sherpas%2529%2520for%2520Tamoxifen-Resistant%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D219%26epage%3D237%26doi%3D10.1021%2Facs.jmedchem.5b01276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kastrati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edirisinghe, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemachandra, L.-P.-M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasena, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Raloxifene and Desmethylarzoxifene Block Estrogen-Induced Malignant Transformation of Human Breast Epithelial Cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">e27876</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0027876</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1371%2Fjournal.pone.0027876" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=22140478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Cnur3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&author=I.+Kastratiauthor=P.+D.+Edirisingheauthor=L.-P.-M.+P.+Hemachandraauthor=E.+R.+Chandrasenaauthor=J.+Choiauthor=Y.-T.+Wangauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Raloxifene+and+Desmethylarzoxifene+Block+Estrogen-Induced+Malignant+Transformation+of+Human+Breast+Epithelial+Cells&doi=10.1371%2Fjournal.pone.0027876"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells</span></div><div class="casAuthors">Kastrati, Irida; Edirisinghe, Praneeth D.; Hemachandra, L-P-Madhubani P.; Chandrasena, Esala R.; Choi, Jaewoo; Wang, Yue-Ting; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e27876</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">There is assocn. between exposure to estrogens and the development and progression of hormone-dependent gynecol. cancers.  Chem. carcinogenesis by catechol estrogens derived from oxidative metab. is thought to contribute to breast cancer, yet exact mechanisms remain elusive.  Malignant transformation was studied in MCF-10A human mammary epithelial cells, since estrogens are not proliferative in this cell line.  The human and equine estrogen components of estrogen replacement therapy (ERT) and their catechol metabolites were studied, along with the influence of co-administration of selective estrogen receptor modulators (SERMs), raloxifene and desmethyl-arzoxifene (DMA) and histone deacetylase inhibitors.  Transformation was induced by human estrogens and selectively by the 4-OH catechol metabolite and to a lesser extent by an equine estrogen metabolite.  The obsd. estrogen-induced upregulation of CYP450 1B1 in estrogen receptor neg. MCF-10A cells, was compatible with a causal role for 4-OH catechol estrogens, as was attenuated transformation by CYP450 inhibitors.  Estrogen-induced malignant transformation was blocked by SERMs correlating with a redn. in formation of nucleobase catechol estrogen (NCE) adducts and formation of 8-oxo-dG.  NCE adducts can be formed consequent to DNA abasic site formation, but NCE adducts were also obsd. on incubation of estrogen quinones with free nucleotides.  These results suggest that NCE adducts may be a biomarker for cellular electrophilic stress, which together with 8-oxo-dG as a biomarker of oxidative stress correlate with malignant transformation induced by estrogen oxidative metabolites.  The obsd. attenuation of transformation by SERMs correlated with these biomarkers and may also be of clin. significance in breast cancer chemoprevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocTxGgBUQJyLVg90H21EOLACvtfcHk0lj_8udP1RC5Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Cnur3L&md5=70b8c37494d3ef4f48789ef0d1235dc9</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0027876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0027876%26sid%3Dliteratum%253Aachs%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DEdirisinghe%26aufirst%3DP.%2BD.%26aulast%3DHemachandra%26aufirst%3DL.-P.-M.%2BP.%26aulast%3DChandrasena%26aufirst%3DE.%2BR.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.-T.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DRaloxifene%2520and%2520Desmethylarzoxifene%2520Block%2520Estrogen-Induced%2520Malignant%2520Transformation%2520of%2520Human%2520Breast%2520Epithelial%2520Cells%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26doi%3D10.1371%2Fjournal.pone.0027876" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdelhamid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandevrede, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kundu, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litosh, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiefer, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gherezghiher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Benzothiophene Selective Estrogen Receptor Modulators Provide Neuroprotection by a Novel Gpr30-Dependent Mechanism</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">256</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1021/cn100106a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn100106a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFektLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=256-268&author=R.+Abdelhamidauthor=J.+Luoauthor=L.+Vandevredeauthor=I.+Kunduauthor=B.+Michalsenauthor=V.+A.+Litoshauthor=I.+T.+Schieferauthor=T.+Gherezghiherauthor=P.+Yaoauthor=Z.+Qinauthor=G.+R.+J.+Thatcher&title=Benzothiophene+Selective+Estrogen+Receptor+Modulators+Provide+Neuroprotection+by+a+Novel+Gpr30-Dependent+Mechanism&doi=10.1021%2Fcn100106a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothiophene Selective Estrogen Receptor Modulators Provide Neuroprotection by a Novel GPR30-Dependent Mechanism</span></div><div class="casAuthors">Abdelhamid, Ramy; Luo, Jia; Vande Vrede, Lawren; Kundu, Indraneel; Michalsen, Bradley; Litosh, Vladislav A.; Schiefer, Isaac T.; Gherezghiher, Teshome; Yao, Ping; Qin, Zhihui; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">256-268</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The clin. benzothiophene SERM (BT-SERM) raloxifene was compared with estrogens in protection of primary rat neurons against oxygen-glucose deprivation (OGD).  Structure-activity relationships for neuroprotection were detd. for a family of BT-SERMs displaying a spectrum of ERα and ERβ binding affinity and agonist/antagonist activity, leading to discovery of a neuroprotective pharmacophore, present in the clin. relevant SERMS, raloxifene, and desmethylarzoxifene (DMA), for which submicromolar potency was obsd. for neuroprotection.  BT-SERM neuroprotection did not correlate with binding to ER or classical ER activity; however, both the neuroprotective SERMs and estrogens were shown, using pharmacol. probes, to activate the same kinase signaling cascades.  The antiestrogen ICI 182,780 inhibited the actions of estrogens but not those of BT-SERMs, whereas antagonism of the G-protein coupled receptor, GPR30, was effective for both SERMs and estrogens.  Since SERMs have antioxidant activity, ER-independent mechanisms were studied using the classical phenolic antioxidants, BHT and Trolox, and the Nrf2-dependent cytoprotective electrophile, sulforaphane.  However, neuroprotection by these agents was not sensitive to GPR30 antagonism.  Collectively, these data indicate that the activity of neuroprotective BT-SERMs is GPR30-dependent and ER-independent and not mediated by antioxidant effects.  Comparison of novel BT-SERM derivs. and analogs identified a neuroprotective pharmacophore of potential use in design of novel neuroprotective agents with a spectrum of ER activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvBt-wQmRmLrVg90H21EOLACvtfcHk0lj_8udP1RC5Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFektLg%253D&md5=c1d5a55aee4f2271ec666b42f62b50c1</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fcn100106a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn100106a%26sid%3Dliteratum%253Aachs%26aulast%3DAbdelhamid%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DVandevrede%26aufirst%3DL.%26aulast%3DKundu%26aufirst%3DI.%26aulast%3DMichalsen%26aufirst%3DB.%26aulast%3DLitosh%26aufirst%3DV.%2BA.%26aulast%3DSchiefer%26aufirst%3DI.%2BT.%26aulast%3DGherezghiher%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DBenzothiophene%2520Selective%2520Estrogen%2520Receptor%2520Modulators%2520Provide%2520Neuroprotection%2520by%2520a%2520Novel%2520Gpr30-Dependent%2520Mechanism%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2011%26volume%3D2%26spage%3D256%26epage%3D268%26doi%3D10.1021%2Fcn100106a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashgodom, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lantvit, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overk, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Breemen, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Structural Modulation of Oxidative Metabolism in Design of Improved Benzothiophene Selective Estrogen Receptor Modulators</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1124/dmd.108.023408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1124%2Fdmd.108.023408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=18936111" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2009&pages=161-169&author=Z.+Qinauthor=I.+Kastratiauthor=R.+T.+Ashgodomauthor=D.+D.+Lantvitauthor=C.+R.+Overkauthor=Y.+Choiauthor=R.+B.+van+Breemenauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Structural+Modulation+of+Oxidative+Metabolism+in+Design+of+Improved+Benzothiophene+Selective+Estrogen+Receptor+Modulators&doi=10.1124%2Fdmd.108.023408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators</span></div><div class="casAuthors">Qin, Zhihui; Kastrati, Irida; Ashgodom, Rezene T.; Lantvit, Daniel D.; Overk, Cassia R.; Choi, Yongsoo; van Breemen, Richard B.; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">161-169</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Raloxifene and arzoxifene are benzothiophene selective estrogen receptor modulators (SERMs) of clin. use in postmenopausal osteoporosis and treatment of breast cancer and potentially in hormone replacement therapy.  The benefits of arzoxifene are attributed to improved bioavailability over raloxifene, whereas the arzoxifene metabolite, desmethylarzoxifene (DMA) is a more potent antiestrogen.  As polyarom. phenolics, benzothiophene SERMs undergo oxidative metab. to electrophilic quinoids.  The long-term clin. use of SERMs demands increased understanding of correlations between structure and toxicity, with metab. being a key component.  A homologous series of 4'-substituted 4'-desmethoxyarzoxifene derivs. was developed, and metab. was studied in liver and intestinal microsomes.  Formation of glutathione conjugates was assayed in rat liver microsomes and novel adducts were characterized by liq. chromatog.-tandem mass spectrometry.  Formation of glucuronide conjugates was assayed in human intestine and liver microsomes, demonstrating formation of glucuronides ranging from 5 to 100% for the benzothiophene SERMs: this trend was inversely correlated with the loss of parent SERM in rat liver microsomal incubations.  MO calcns. generated thermodn. parameters for oxidn. that correlated with Hammett substituent consts.; however, metab. in liver microsomes correlated with a combination of both Hammett and Hansch lipophilicity parameters.  The results demonstrate a rich oxidative chem. for the benzothiophene SERMs, the amplitude of which can be powerfully modulated, in a predictable manner, by structural tuning of the 4'-substituent.  The predicted extensive metab. of DMA was confirmed in vivo and compared with the relatively stable arzoxifene and F-DMA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXNnv4iRadE7Vg90H21EOLACvtfcHk0ljE9IayOygDkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSltw%253D%253D&md5=0fb317771152e0fbe4ddfb9c79f0fb3d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1124%2Fdmd.108.023408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.108.023408%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DAshgodom%26aufirst%3DR.%2BT.%26aulast%3DLantvit%26aufirst%3DD.%2BD.%26aulast%3DOverk%26aufirst%3DC.%2BR.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3Dvan%2BBreemen%26aufirst%3DR.%2BB.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DStructural%2520Modulation%2520of%2520Oxidative%2520Metabolism%2520in%2520Design%2520of%2520Improved%2520Benzothiophene%2520Selective%2520Estrogen%2520Receptor%2520Modulators%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2009%26volume%3D37%26spage%3D161%26epage%3D169%26doi%3D10.1124%2Fdmd.108.023408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dietz, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunlap, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lantvit, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overk, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Structural Modulation of Reactivity/Activity in Design of Improved Benzothiophene Selective Estrogen Receptor Modulators: Induction of Chemopreventive Mechanisms</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2418</span>– <span class="NLM_lpage">2428</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-07-0268</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F1535-7163.mct-07-0268" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=17876041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVCgtbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=2418-2428&author=B.+Yuauthor=B.+M.+Dietzauthor=T.+Dunlapauthor=I.+Kastratiauthor=D.+D.+Lantvitauthor=C.+R.+Overkauthor=P.+Yaoauthor=Z.+Qinauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Structural+Modulation+of+Reactivity%2FActivity+in+Design+of+Improved+Benzothiophene+Selective+Estrogen+Receptor+Modulators%3A+Induction+of+Chemopreventive+Mechanisms&doi=10.1158%2F1535-7163.mct-07-0268"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: Induction of chemopreventive mechanisms</span></div><div class="casAuthors">Yu, Bolan; Dietz, Birgit M.; Dunlap, Tareisha; Kastrati, Irida; Lantvit, Daniel D.; Overk, Cassia R.; Yao, Ping; Qin, Zhihui; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2418-2428</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The benzothiophene selective estrogen receptor modulators (SERM) raloxifene and arzoxifene are in clin. use and clin. trials for chemoprevention of breast cancer and other indications.  These SERMs are "oxidatively labile" and therefore have potential to activate antioxidant responsive element (ARE) transcription of genes for cytoprotective phase II enzymes such as NAD(P)H-dependent quinone oxidoreductase 1 (NQO1).  To study this possible mechanism of cancer chemoprevention, a family of benzothiophene SERMs was developed with modulated redox activity, including arzoxifene and its metabolite desmethylarzoxifene (DMA).  The relative antioxidant activity of these SERMs was assayed and correlated with induction of NQO1 in murine and human liver cells.  DMA was found to induce NQO1 and to activate ARE more strongly than other SERMs, including raloxifene and 4-hydroxytamoxifen.  Livers from female, juvenile rats treated for 3 days with estradiol and/or with the benzothiophene SERMs arzoxifene, DMA, and F-DMA showed substantial induction of NQO1 by the benzothiophene SERMs.  No persuasive evidence in this assay or in MCF-7 breast cancer cells was obtained of a major role for the estrogen receptor in induction of NQO1 by the benzothiophene SERMs.  These results suggest that arzoxifene might provide chemopreventive benefits over raloxifene and other SERMs via metab. to DMA and stimulation of ARE-mediated induction of phase II enzymes.  The correlation of SERM structure with antioxidant activity and NQO1 induction also suggests that oxidative bioactivation of SERMs may be modulated to enhance chemopreventive activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosSszy7YqBrrVg90H21EOLACvtfcHk0ljE9IayOygDkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVCgtbfF&md5=11008f981dbbacdf5bd87e8919ef678a</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-07-0268&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-07-0268%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DB.%26aulast%3DDietz%26aufirst%3DB.%2BM.%26aulast%3DDunlap%26aufirst%3DT.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DLantvit%26aufirst%3DD.%2BD.%26aulast%3DOverk%26aufirst%3DC.%2BR.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DStructural%2520Modulation%2520of%2520Reactivity%252FActivity%2520in%2520Design%2520of%2520Improved%2520Benzothiophene%2520Selective%2520Estrogen%2520Receptor%2520Modulators%253A%2520Induction%2520of%2520Chemopreventive%2520Mechanisms%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D2418%26epage%3D2428%26doi%3D10.1158%2F1535-7163.mct-07-0268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Overk, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, K.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asghodom, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lantvit, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frasor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships for a Family of Benzothiophene Selective Estrogen Receptor Modulators Including Raloxifene and Arzoxifene</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1520</span>– <span class="NLM_lpage">1526</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1002%2Fcmdc.200700104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=17654759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtF2qtb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1520-1526&author=C.+R.+Overkauthor=K.-W.+Pengauthor=R.+T.+Asghodomauthor=I.+Kastratiauthor=D.+D.+Lantvitauthor=Z.+Qinauthor=J.+Frasorauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Structure-Activity+Relationships+for+a+Family+of+Benzothiophene+Selective+Estrogen+Receptor+Modulators+Including+Raloxifene+and+Arzoxifene&doi=10.1002%2Fcmdc.200700104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene</span></div><div class="casAuthors">Overk, Cassia R.; Peng, Kuan-Wei; Asghodom, Rezene T.; Kastrati, Irida; Lantvit, Daniel D.; Qin, Zhihui; Frasor, Jonna; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1520-1526</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The search for the "ideal" selective estrogen receptor modulator (SERM) as a substitute for hormone replacement therapy (HRT) or use in cancer chemoprevention has focused on optimization of estrogen receptor (ER) ligand binding.  Based on the clin. and preclin. benzothiophene SERMs, raloxifene and arzoxifene, a family of SERMs has been developed to modulate activity and oxidative lability.  Antiestrogenic potency measured in human endometrial and breast cancer cells, and ER ligand binding data were correlated and seen to provide a guide to SERM design only when viewed in toto.  The in vitro studies were extended to the juvenile rat model, in which the desired antiestrogenic profile and putative cardiovascular benefits of SERMs were obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZJnWIhlKprLVg90H21EOLACvtfcHk0ljE9IayOygDkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtF2qtb3E&md5=da626d457446a6ed78ffa3f9939872b1</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700104%26sid%3Dliteratum%253Aachs%26aulast%3DOverk%26aufirst%3DC.%2BR.%26aulast%3DPeng%26aufirst%3DK.-W.%26aulast%3DAsghodom%26aufirst%3DR.%2BT.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DLantvit%26aufirst%3DD.%2BD.%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DFrasor%26aufirst%3DJ.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DStructure-Activity%2520Relationships%2520for%2520a%2520Family%2520of%2520Benzothiophene%2520Selective%2520Estrogen%2520Receptor%2520Modulators%2520Including%2520Raloxifene%2520and%2520Arzoxifene%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D1520%26epage%3D1526%26doi%3D10.1002%2Fcmdc.200700104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastrati, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasena, R. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petukhov, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Benzothiophene Selective Estrogen Receptor Modulators with Modulated Oxidative Activity and Receptor Affinity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">2682</span>– <span class="NLM_lpage">2692</span>, <span class="refDoi"> DOI: 10.1021/jm070079j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070079j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2682-2692&author=Z.+Qinauthor=I.+Kastratiauthor=R.+E.+P.+Chandrasenaauthor=H.+Liuauthor=P.+Yaoauthor=P.+A.+Petukhovauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Benzothiophene+Selective+Estrogen+Receptor+Modulators+with+Modulated+Oxidative+Activity+and+Receptor+Affinity&doi=10.1021%2Fjm070079j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity</span></div><div class="casAuthors">Qin, Zhihui; Kastrati, Irida; Chandrasena, R. Esala P.; Liu, Hong; Yao, Ping; Petukhov, Pavel A.; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2682-2692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The regulation of estrogenic and antiestrogenic effects of selective estrogen receptor modulators (SERMs) is thought to underlie their clin. use.  Most SERMs are polyarom. phenols susceptible to oxidative metab. to quinoids, which are proposed to be genotoxic.  Conversely, the redox reactivity of SERMs may contribute to antioxidant and chemopreventive mechanisms, providing a new approach to improve the therapeutic properties of SERMs.  An improved synthetic strategy was developed to generate a family of benzothiophene SERMs.  Using computational modeling methods and measurements of antioxidant activity and estrogen receptor (ER) ligand binding, this SERM family was shown to provide both a range of ERα/ERβ selectivity from 1.2- to 67-fold and a range of redox activity.  Antioxidant activity was successfully modulated by varying a substituent remote from the OH group; the source of the antioxidant capacity.  An efficient synthetic procedure is reported yielding benzothiophene SERMs wherein redox activity and ER affinity are modulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_CGhCcopaULVg90H21EOLACvtfcHk0lii8AyPFKeemw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVequ78%253D&md5=594ddb689931d8629c9f5c9443f88cb4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm070079j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070079j%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DZ.%26aulast%3DKastrati%26aufirst%3DI.%26aulast%3DChandrasena%26aufirst%3DR.%2BE.%2BP.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DP.%26aulast%3DPetukhov%26aufirst%3DP.%2BA.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DBenzothiophene%2520Selective%2520Estrogen%2520Receptor%2520Modulators%2520with%2520Modulated%2520Oxidative%2520Activity%2520and%2520Receptor%2520Affinity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2682%26epage%3D2692%26doi%3D10.1021%2Fjm070079j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span> <span> </span><span class="NLM_article-title">Chemical Modification Modulates Estrogenic Activity, Oxidative Reactivity, and Metabolic Stability in 4’f-Dma, a New Benzothiophene Selective Estrogen Receptor Modulator</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1021/tx050326r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx050326r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFKktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2006&pages=779-787&author=H.+Liuauthor=J.+L.+Boltonauthor=G.+R.+J.+Thatcher&title=Chemical+Modification+Modulates+Estrogenic+Activity%2C+Oxidative+Reactivity%2C+and+Metabolic+Stability+in+4%E2%80%99f-Dma%2C+a+New+Benzothiophene+Selective+Estrogen+Receptor+Modulator&doi=10.1021%2Ftx050326r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical Modification Modulates Estrogenic Activity, Oxidative Reactivity, and Metabolic Stability in 4'F-DMA, a New Benzothiophene Selective Estrogen Receptor Modulator</span></div><div class="casAuthors">Liu, Hong; Bolton, Judy L.; Thatcher, Gregory R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">779-787</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The benzothiophene selective estrogen receptor modulators (SERMs), raloxifene and arzoxifene, in the clinic or clin. trials for treatment of breast cancer and postmenopausal symptoms, are highly susceptible to oxidative metab. and formation of electrophilic metabolites.  4'F-DMA, fluoro-substituted desmethyl arzoxifene (DMA), showed attenuated oxidn. to quinoids in incubation with rat hepatocytes as well as in rat and human liver microsomes.  Incubations of 4'F-DMA with hepatocytes yielded only one glucuronide conjugate and no GSH conjugates, whereas DMA underwent greater metab. giving two glucuronide conjugates, one sulfate conjugate, and two GSH conjugates.  Phase I and phase II metab. were further evaluated in human small intestine microsomes and in human intestinal Caco-2 cells.  In comparison to DMA, 4'F-DMA formed significantly less glucuronide and sulfate conjugates.  The formation of quinoids was further explored in hepatocytes in which DMA was obsd. to give concn.- and time-dependent depletion of GSH accompanied by damage to DNA, which showed inverse dependence on GSH; in contrast, GSH depletion and DNA damage were almost completely abrogated in incubations with 4'F-DMA. 4'F-DMA shows ligand binding affinity to estrogen receptor (ER)α and ERβ with similarity to both raloxifene and to DMA.  ER-mediated biol. activity was measured with the ERE-luciferase reporter system in transfected MCF-7 cells and Ishikawa cells, and in MCF-7 cells, proliferation was measured.  In all systems, 4'F-DMA exhibited antiestrogenic activity of comparable potency to raloxifene but did not manifest estrogenic properties, mirroring previous results on inhibition of estradiol-mediated induction of alk. phosphatase activity in Ishikawa cells.  These results suggest that 4'F-DMA might be an improved benzothiophene SERM with similar antiestrogenic activity to raloxifene but improved metabolic stability and attenuated toxicity, showing that simple chem. modification can abrogate oxidative bioactivation to potentially toxic metabolites without loss of activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-FltiqRoLAbVg90H21EOLACvtfcHk0lii8AyPFKeemw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFKktLo%253D&md5=2ce12134bb346a54dc42bca0bb432063</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Ftx050326r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx050326r%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DBolton%26aufirst%3DJ.%2BL.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26atitle%3DChemical%2520Modification%2520Modulates%2520Estrogenic%2520Activity%252C%2520Oxidative%2520Reactivity%252C%2520and%2520Metabolic%2520Stability%2520in%25204%25E2%2580%2599f-Dma%252C%2520a%2520New%2520Benzothiophene%2520Selective%2520Estrogen%2520Receptor%2520Modulator%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2006%26volume%3D19%26spage%3D779%26epage%3D787%26doi%3D10.1021%2Ftx050326r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brzozowski, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, A. C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dauter, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubbard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engström, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öhman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafsson, J.-Å.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlquist, M.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis of Agonism and Antagonism in the Oestrogen Receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>389</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1038/39645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1038%2F39645" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=9338790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=389&publication_year=1997&pages=753-758&author=A.+M.+Brzozowskiauthor=A.+C.+W.+Pikeauthor=Z.+Dauterauthor=R.+E.+Hubbardauthor=T.+Bonnauthor=O.+Engstr%C3%B6mauthor=L.+%C3%96hmanauthor=G.+L.+Greeneauthor=J.-%C3%85.+Gustafssonauthor=M.+Carlquist&title=Molecular+Basis+of+Agonism+and+Antagonism+in+the+Oestrogen+Receptor&doi=10.1038%2F39645"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular basis of agonism and antagonism in the estrogen receptor</span></div><div class="casAuthors">Brzozowski, Andrzej M.; Pike, Ashley C. W.; Dauter, Zbigniew; Hubbard, Roderick E.; Bonn, Tomas; Engstrom, Owe; Ohman, Lars; Greene, Geoffrey L.; Gustafsson, Jan-Ake; Carlquist, Mats</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">389</span>
        (<span class="NLM_cas:issue">6652</span>),
    <span class="NLM_cas:pages">753-758</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Estrogens are involved in the growth, development and homeostasis of a no. of tissues.  The physiol. effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the estrogen receptor (ER).  Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of mol. events culminating in the activation or repression of target genes.  Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery.  Here we report the crystal structures of the LBD of ER in complex with the endogenous estrogen, 17β-estradiol, and the selective antagonist raloxifene, at resolns. of 3.1 and 2.6Å, resp.  The structures provide a mol. basis for the distinctive pharmacophore of the ER and its catholic binding properties.  Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes.  In addn., each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAXbSo66V1LrVg90H21EOLACvtfcHk0lii8AyPFKeemw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvVSnt74%253D&md5=2a63951b881b329ff142c9fbc82a13e3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2F39645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F39645%26sid%3Dliteratum%253Aachs%26aulast%3DBrzozowski%26aufirst%3DA.%2BM.%26aulast%3DPike%26aufirst%3DA.%2BC.%2BW.%26aulast%3DDauter%26aufirst%3DZ.%26aulast%3DHubbard%26aufirst%3DR.%2BE.%26aulast%3DBonn%26aufirst%3DT.%26aulast%3DEngstr%25C3%25B6m%26aufirst%3DO.%26aulast%3D%25C3%2596hman%26aufirst%3DL.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DGustafsson%26aufirst%3DJ.-%25C3%2585.%26aulast%3DCarlquist%26aufirst%3DM.%26atitle%3DMolecular%2520Basis%2520of%2520Agonism%2520and%2520Antagonism%2520in%2520the%2520Oestrogen%2520Receptor%26jtitle%3DNature%26date%3D1997%26volume%3D389%26spage%3D753%26epage%3D758%26doi%3D10.1038%2F39645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiau, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barstad, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loria, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agard, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span> <span> </span><span class="NLM_article-title">The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">927</span>– <span class="NLM_lpage">937</span>, <span class="refDoi"> DOI: 10.1016/s0092-8674(00)81717-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2FS0092-8674%2800%2981717-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=9875847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK1MXjslyltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=927-937&author=A.+K.+Shiauauthor=D.+Barstadauthor=P.+M.+Loriaauthor=L.+Chengauthor=P.+J.+Kushnerauthor=D.+A.+Agardauthor=G.+L.+Greene&title=The+Structural+Basis+of+Estrogen+Receptor%2FCoactivator+Recognition+and+the+Antagonism+of+This+Interaction+by+Tamoxifen&doi=10.1016%2Fs0092-8674%2800%2981717-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen</span></div><div class="casAuthors">Shiau, Andrew K.; Barstad, Danielle; Loria, Paula M.; Cheng, Lin; Kushner, Peter J.; Agard, David A.; Greene, Geoffrey L.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">927-937</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Ligand-dependent activation of transcription by nuclear receptors (NRs) is mediated by interactions with coactivators.  Receptor agonists promote coactivator binding, and antagonists block coactivator binding.  Here we report the crystal structure of the human estrogen receptor α (hERα) ligand-binding domain (LBD) bound to both the agonist diethylstilbestrol (DES) and a peptide derived from the NR box II region of the coactivator GRIP1 and the crystal structure of the hERα LBD bound to the selective antagonist 4-hydroxytamoxifen (OHT).  In the DES-LBD-peptide complex, the peptide binds as a short α helix to a hydrophobic groove on the surface of the LBD.  In the OHT-LBD complex, helix 12 occludes the coactivator recognition groove by mimicking the interactions of the NR box peptide with the LBD.  These structures reveal the two distinct mechanisms by which structural features of OHT promote this "autoinhibitory" helix 12 conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrjqf40oHhE7Vg90H21EOLACvtfcHk0ljlumghI3XPJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjslyltQ%253D%253D&md5=074d616cf353f0d98cea5b26c4595c10</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2981717-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252981717-1%26sid%3Dliteratum%253Aachs%26aulast%3DShiau%26aufirst%3DA.%2BK.%26aulast%3DBarstad%26aufirst%3DD.%26aulast%3DLoria%26aufirst%3DP.%2BM.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DKushner%26aufirst%3DP.%2BJ.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26atitle%3DThe%2520Structural%2520Basis%2520of%2520Estrogen%2520Receptor%252FCoactivator%2520Recognition%2520and%2520the%2520Antagonism%2520of%2520This%2520Interaction%2520by%2520Tamoxifen%26jtitle%3DCell%26date%3D1998%26volume%3D95%26spage%3D927%26epage%3D937%26doi%3D10.1016%2Fs0092-8674%2800%2981717-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (Serd) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">7917</span>– <span class="NLM_lpage">7928</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00921</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00921" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=7917-7928&author=J.+Nagasawaauthor=S.+Govekauthor=M.+Kahramanauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Luauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=K.+Maheuauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Identification+of+an+Orally+Bioavailable+Chromene-Based+Selective+Estrogen+Receptor+Degrader+%28Serd%29+That+Demonstrates+Robust+Activity+in+a+Model+of+Tamoxifen-Resistant+Breast+Cancer&doi=10.1021%2Facs.jmedchem.8b00921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Nagasawa, Johnny; Govek, Steven; Kahraman, Mehmet; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Lu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Maheu, Kate; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7917-7928</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Approx. eighty percent of breast cancers are estrogen receptor alpha (ER-α) pos., and although women typically initially respond well to anti-hormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges.  Fulvestrant is a steroid-based, selective estrogen receptor degrader (SERD) that both antagonizes and degrades ER-α, and is active in patients who have progressed on anti-hormonal agents.  However fulvestrant suffers from poor pharmaceutical properties and must be administered by intra-muscular injections that limit the total amt. of drug that can be administered, and hence lead to the potential for incomplete receptor blockade.  The authors describe the optimization of ER-α degrdn. efficacy of a chromene series of ER modulators resulting in highly potent and efficacious SERDs such as 14n (3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol).  The side-chain ring size and stereochem. elements were central in driving degrdn. efficacy, leading to the identification of 14n.  When examd. in a xenograft model of tamoxifen-resistant breast cancer, biphenol chromene 14n (ER-α degrdn. efficacy = 91%) demonstrated robust activity, while despite superior oral exposure, a mono-phenol chromene 15g (3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-chromen-6-ol) (ER-α degrdn. efficacy = 82%) was essentially inactive.  Although not definitively causative, this result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects models of tamoxifen-resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8I60s9csFRrVg90H21EOLACvtfcHk0ljlumghI3XPJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOjsL7E&md5=9ae708199592455e0a691c7af2e43967</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00921%26sid%3Dliteratum%253Aachs%26aulast%3DNagasawa%26aufirst%3DJ.%26aulast%3DGovek%26aufirst%3DS.%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DMaheu%26aufirst%3DK.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DIdentification%2520of%2520an%2520Orally%2520Bioavailable%2520Chromene-Based%2520Selective%2520Estrogen%2520Receptor%2520Degrader%2520%2528Serd%2529%2520That%2520Demonstrates%2520Robust%2520Activity%2520in%2520a%2520Model%2520of%2520Tamoxifen-Resistant%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D7917%26epage%3D7928%26doi%3D10.1021%2Facs.jmedchem.8b00921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fanning, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodges-Gallagher, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myles, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plant, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kushner, P. J.</span></span> <span> </span><span class="NLM_article-title">Specific Stereochemistry of Op-1074 Disrupts Estrogen Receptor Alpha Helix 12 and Confers Pure Antiestrogenic Activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">2368</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-04413-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1038%2Fs41467-018-04413-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=29915250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BC1MbosF2gtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=2368&author=S.+W.+Fanningauthor=L.+Hodges-Gallagherauthor=D.+C.+Mylesauthor=R.+Sunauthor=C.+E.+Fowlerauthor=I.+N.+Plantauthor=B.+D.+Greenauthor=C.+L.+Harmonauthor=G.+L.+Greeneauthor=P.+J.+Kushner&title=Specific+Stereochemistry+of+Op-1074+Disrupts+Estrogen+Receptor+Alpha+Helix+12+and+Confers+Pure+Antiestrogenic+Activity&doi=10.1038%2Fs41467-018-04413-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity</span></div><div class="casAuthors">Fanning S W; Fowler C E; Green B D; Greene G L; Hodges-Gallagher L; Myles D C; Sun R; Harmon C L; Kushner P J; Plant I N</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2368</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Complex tissue-specific and cell-specific signaling by the estrogen receptor (ER) frequently leads to the development of resistance to endocrine therapy for breast cancer.  Pure ER antagonists, which completely lack tissue-specific agonist activity, hold promise for preventing and treating endocrine resistance, however an absence of structural information hinders the development of novel candidates.  Here we synthesize a small panel of benzopyrans with variable side chains to identify pure antiestrogens in a uterotrophic assay.  We identify OP-1074 as a pure antiestrogen and a selective ER degrader (PA-SERD) that is efficacious in shrinking tumors in a tamoxifen-resistant xenograft model.  Biochemical and crystal structure analyses reveal a structure activity relationship implicating the importance of a stereospecific methyl on the pyrrolidine side chain of OP-1074, particularly on helix 12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYJ5LDE5uCtbjnyZkbE8yXfW6udTcc2eaQRL3HF8o5Wrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbosF2gtg%253D%253D&md5=a381a76b8363cda16ac9ac5ec0c702d8</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-04413-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-04413-3%26sid%3Dliteratum%253Aachs%26aulast%3DFanning%26aufirst%3DS.%2BW.%26aulast%3DHodges-Gallagher%26aufirst%3DL.%26aulast%3DMyles%26aufirst%3DD.%2BC.%26aulast%3DSun%26aufirst%3DR.%26aulast%3DFowler%26aufirst%3DC.%2BE.%26aulast%3DPlant%26aufirst%3DI.%2BN.%26aulast%3DGreen%26aufirst%3DB.%2BD.%26aulast%3DHarmon%26aufirst%3DC.%2BL.%26aulast%3DGreene%26aufirst%3DG.%2BL.%26aulast%3DKushner%26aufirst%3DP.%2BJ.%26atitle%3DSpecific%2520Stereochemistry%2520of%2520Op-1074%2520Disrupts%2520Estrogen%2520Receptor%2520Alpha%2520Helix%252012%2520and%2520Confers%2520Pure%2520Antiestrogenic%2520Activity%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D2368%26doi%3D10.1038%2Fs41467-018-04413-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kahraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govek, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagasawa, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefous, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sensintaffar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aparicio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prudente, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darimont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brigham, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heyman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rix, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, N. D.</span></span> <span> </span><span class="NLM_article-title">Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">55</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=50-55&author=M.+Kahramanauthor=S.+P.+Govekauthor=J.+Y.+Nagasawaauthor=A.+Laiauthor=C.+Bonnefousauthor=K.+Douglasauthor=J.+Sensintaffarauthor=N.+Liuauthor=K.+Leeauthor=A.+Aparicioauthor=J.+Kaufmanauthor=J.+Qianauthor=G.+Shaoauthor=R.+Prudenteauthor=J.+D.+Josephauthor=B.+Darimontauthor=D.+Brighamauthor=R.+Heymanauthor=P.+J.+Rixauthor=J.+H.+Hagerauthor=N.+D.+Smith&title=Maximizing+ER-%CE%B1+Degradation+Maximizes+Activity+in+a+Tamoxifen-Resistant+Breast+Cancer+Model%3A+Identification+of+GDC-0927&doi=10.1021%2Facsmedchemlett.8b00414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927</span></div><div class="casAuthors">Kahraman, Mehmet; Govek, Steven P.; Nagasawa, Johnny Y.; Lai, Andiliy; Bonnefous, Celine; Douglas, Karensa; Sensintaffar, John; Liu, Nhin; Lee, KyoungJin; Aparicio, Anna; Kaufman, Josh; Qian, Jing; Shao, Gang; Prudente, Rene; Joseph, James D.; Darimont, Beatrice; Brigham, Daniel; Heyman, Richard; Rix, Peter J.; Hager, Jeffrey H.; Smith, Nicholas D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-55</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The further optimization of ER-α degrdn. efficacy of a series of ER modulators by refining side-chain substitution led to efficacious selective estrogen receptor degraders (SERDs).  A fluoromethyl azetidine group was found to be preferred and resulted in the identification of bis-phenol chromene 17ha.  In a tamoxifen-resistant breast cancer xenograft model, 17ha (ER-α degrdn. efficacy = 97%) demonstrated tumor regression, together with robust redn. of intratumoral ER-α levels.  However, despite superior oral exposure, 5a (ER-α degrdn. efficacy = 91%) had inferior activity.  This result suggests that optimizing ER-α degrdn. efficacy leads to compds. with robust effects in a model of tamoxifen-resistant breast cancer.  Compd. 17ha (GDC-0927) was evaluated in clin. trials in women with metastatic estrogen receptor-pos. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgyUydsTFnYrVg90H21EOLACvtfcHk0li14TrWxQt3gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVensr3M&md5=324c1697ef350d169a97960de72ee8a9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00414%26sid%3Dliteratum%253Aachs%26aulast%3DKahraman%26aufirst%3DM.%26aulast%3DGovek%26aufirst%3DS.%2BP.%26aulast%3DNagasawa%26aufirst%3DJ.%2BY.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DBonnefous%26aufirst%3DC.%26aulast%3DDouglas%26aufirst%3DK.%26aulast%3DSensintaffar%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DAparicio%26aufirst%3DA.%26aulast%3DKaufman%26aufirst%3DJ.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DG.%26aulast%3DPrudente%26aufirst%3DR.%26aulast%3DJoseph%26aufirst%3DJ.%2BD.%26aulast%3DDarimont%26aufirst%3DB.%26aulast%3DBrigham%26aufirst%3DD.%26aulast%3DHeyman%26aufirst%3DR.%26aulast%3DRix%26aufirst%3DP.%2BJ.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DSmith%26aufirst%3DN.%2BD.%26atitle%3DMaximizing%2520ER-%25CE%25B1%2520Degradation%2520Maximizes%2520Activity%2520in%2520a%2520Tamoxifen-Resistant%2520Breast%2520Cancer%2520Model%253A%2520Identification%2520of%2520GDC-0927%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D50%26epage%3D55%26doi%3D10.1021%2Facsmedchemlett.8b00414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.-y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yingling, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span> <span> </span><span class="NLM_article-title">An Estrogen Receptor Positive Mcf-7 Clone That Is Resistant to Antiestrogens and Estradiol</span>. <i>Mol. Cell. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/0303-7207(92)90104-e</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2F0303-7207%2892%2990104-e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1301400" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1GhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1992&pages=77-86&author=S.-y.+Jiangauthor=D.+M.+Wolfauthor=J.+M.+Yinglingauthor=C.+Changauthor=V.+C.+Jordan&title=An+Estrogen+Receptor+Positive+Mcf-7+Clone+That+Is+Resistant+to+Antiestrogens+and+Estradiol&doi=10.1016%2F0303-7207%2892%2990104-e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol</span></div><div class="casAuthors">Jiang, Shun Yuan; Wolf, Douglas M.; Yingling, Jonathan M.; Chang, Chawnshang; Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-86</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    </div><div class="casAbstract">The antiestrogen tamoxifen has been successfully used to control estrogen receptor (ER)- and progesterone receptor-pos. breast cancer.  However, the development of antiestrogen resistance is frequently obsd. in patients following long-term treatment.  The development of antiestrogen resistance was studied in vitro, and an antiestrogen resistant variant of MCF-7 cells (clone 5C) was established after long-term culture in estrogen-free medium.  The growth of clone 5C cells was not altered by either estradiol or the antiestrogens 4-hydroxytamoxifen and ICI 164,384.  Estrogen-stimulated progesterone receptor and reporter gene expression were markedly reduced in 5C cells compared to wild-type MCF-7 cells.  Only minor alteration in the levels of ER and no alteration in the affinity of ER for ligand were found in 5C cells.  No mutation of ER cDNA in 5C cells was detected by polymerase chain reaction and DNA sequencing.  This study demonstrates that change(s) in ER-mediated gene expression rather than the amino acid sequence of the ER itself may be assocd. with the development of at least one form of antiestrogen resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7D95adwlHwLVg90H21EOLACvtfcHk0li14TrWxQt3gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1GhtA%253D%253D&md5=3bfb8ea4c10526f1477410c7cf6a03d7</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0303-7207%2892%2990104-e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0303-7207%252892%252990104-e%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DS.-y.%26aulast%3DWolf%26aufirst%3DD.%2BM.%26aulast%3DYingling%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DAn%2520Estrogen%2520Receptor%2520Positive%2520Mcf-7%2520Clone%2520That%2520Is%2520Resistant%2520to%2520Antiestrogens%2520and%2520Estradiol%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D1992%26volume%3D90%26spage%3D77%26epage%3D86%26doi%3D10.1016%2F0303-7207%2892%2990104-e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livezey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, D. J.</span></span> <span> </span><span class="NLM_article-title">Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and Are Killed by Bhpi</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">34753</span>, <span class="refDoi"> DOI: 10.1038/srep34753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1038%2Fsrep34753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=27713477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Kmu7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=34753&author=C.+Maoauthor=M.+Livezeyauthor=J.+E.+Kimauthor=D.+J.+Shapiro&title=Antiestrogen+Resistant+Cell+Lines+Expressing+Estrogen+Receptor+%CE%B1+Mutations+Upregulate+the+Unfolded+Protein+Response+and+Are+Killed+by+Bhpi&doi=10.1038%2Fsrep34753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI</span></div><div class="casAuthors">Mao, Chengjian; Livezey, Mara; Kim, Ji Eun; Shapiro, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">34753</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Outgrowth of metastases expressing ERα mutations Y537S and D538G is common after endocrine therapy for estrogen receptor α (ERα) pos. breast cancer.  The effect of replacing wild type ERα in breast cancer cells with these mutations was unclear.  We used the CRISPR-Cas9 genome editing system and homol. directed repair to isolate and characterize 14 T47D cell lines in which ERαY537S or ERαD538G replace one or both wild-type ERα genes.  In 2-dimensional, and in quant. anchorage-independent 3-dimensional cell culture, ERαY537S and ERαD538G cells exhibited estrogen-independent growth.  A progestin further increased their already substantial proliferation in micromolar 4-hydroxytamoxifen and fulvestrant/ICI 182,780 (ICI).  Our recently described ERα biomodulator, BHPI, which hyperactivates the unfolded protein response (UPR), completely blocked proliferation.  In ERαY537S and ERαD538G cells, estrogen-ERα target genes were constitutively active and partially antiestrogen resistant.  The UPR marker sp-XBP1 was constitutively activated in ERαY537S cells and further induced by progesterone in both cell lines.  UPR-regulated genes assocd. with tamoxifen resistance, including the oncogenic chaperone BiP/GRP78, were upregulated.  ICI displayed a greater than 2 fold redn. in its ability to induce ERαY537S and ERαD538G degrdn.  Progestins, UPR activation and perhaps reduced ICI-stimulated ERα degrdn. likely contribute to antiestrogen resistance seen in ERαY537S and ERαD538G cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnk6TbVl3BX7Vg90H21EOLACvtfcHk0liEdu4yw-gHTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Kmu7zF&md5=a823b3cbf233db08a026b76f615424e4</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fsrep34753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep34753%26sid%3Dliteratum%253Aachs%26aulast%3DMao%26aufirst%3DC.%26aulast%3DLivezey%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DJ.%2BE.%26aulast%3DShapiro%26aufirst%3DD.%2BJ.%26atitle%3DAntiestrogen%2520Resistant%2520Cell%2520Lines%2520Expressing%2520Estrogen%2520Receptor%2520%25CE%25B1%2520Mutations%2520Upregulate%2520the%2520Unfolded%2520Protein%2520Response%2520and%2520Are%2520Killed%2520by%2520Bhpi%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D34753%26doi%3D10.1038%2Fsrep34753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chandarlapaty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samoila, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moynahan, M. E.</span></span> <span> </span><span class="NLM_article-title">Prevalence of Esr1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the Bolero-2 Clinical Trial</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1310</span>– <span class="NLM_lpage">1315</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2016.1279</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1001%2Fjamaoncol.2016.1279" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=27532364" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A280%3ADC%252BC2szht1WjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2016&pages=1310-1315&author=S.+Chandarlapatyauthor=D.+Chenauthor=W.+Heauthor=P.+Sungauthor=A.+Samoilaauthor=D.+Youauthor=T.+Bhattauthor=P.+Patelauthor=M.+Voiauthor=M.+Gnantauthor=G.+Hortobagyiauthor=J.+Baselgaauthor=M.+E.+Moynahan&title=Prevalence+of+Esr1+Mutations+in+Cell-Free+DNA+and+Outcomes+in+Metastatic+Breast+Cancer%3A+A+Secondary+Analysis+of+the+Bolero-2+Clinical+Trial&doi=10.1001%2Fjamaoncol.2016.1279"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial</span></div><div class="casAuthors">Chandarlapaty Sarat; Sung Patricia; Samoila Aliaksandra; You Daoqi; Bhatt Trusha; Baselga Jose; Moynahan Mary Ellen; Chen David; He Wei; Patel Parul; Voi Maurizio; Gnant Michael; Hortobagyi Gabriel</div><div class="citationInfo"><span class="NLM_cas:title">JAMA oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1310-1315</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Importance:  Estrogen receptor α (ESR1) mutations found in metastatic breast cancer (MBC) promote ligand-independent receptor activation and resistance to estrogen-deprivation therapy in laboratory models.  The prevalence of these mutations and their potential impact on clinical outcomes has not been established.  Objective:  To determine the prevalence of ESR1 mutations (Y537S and D538G) in estrogen receptor (ER)-positive MBC and determine whether mutation is associated with inferior outcomes.  Design, Setting, and Participants:  From December 16, 2014, to August 26, 2015, we analyzed cell-free DNA (cfDNA) from baseline plasma samples from participants in the BOLERO-2 double-blind phase 3 study that randomized patients from 189 centers in 24 countries with MBC to exemestane plus placebo or exemestane plus everolimus.  The study enrolled postmenopausal women with a diagnosis of MBC and prior exposure to an aromatase inhibitor.  Baseline plasma samples were available from 541 of 724 patients (74.7%).  We assessed the effect of mutation on overall survival of the population and the effect of mutation on progression-free survival (PFS) by treatment arm.  Interventions:  Patients were randomized to treatment with exemestane (25 mg oral daily) together with everolimus (10 mg oral daily) or with placebo.  Main Outcomes and Measures:  The 2 most frequent mutations in ESR1 (Y537S and D538G) were analyzed from cfDNA using droplet digital polymerase chain reaction and samples scored as wild-type, D538G, Y537S, or double mutant.  Cox-proportional hazards model was used to assess PFS in patient subgroups defined by mutations, and the effect of each mutation on overall survival.  Results:  Of 541 evaluable patients, 156 (28.8%) had ESR1 mutation D538G (21.1%) and/or Y537S (13.3%), and 30 had both.  These mutations were associated with shorter overall survival (wild-type, 32.1 months [95% CI, 28.09-36.40 months]; D538G, 25.99 months [95% CI, 19.19-32.36 months]; Y537S, 19.98 months [13.01-29.31 months]; both mutations, 15.15 months [95% CI, 10.87-27.43 months]).  The D538G group (hazard ratio, 0.34 [95% CI, 0.02-0.57]) derived a similar PFS benefit as wild type from addition of everolimus to exemestane.  Conclusions and Relevance:  ESR1 mutations are prevalent in ER-positive aromatase inhibitor-treated MBC.  Both Y537S and D538G mutations are associated with more aggressive disease biology.  Trial Registration:  clinicaltrials.gov Identifier: NCT00863655.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTuJT9GSPJ0sK3uFsUIZtkfW6udTcc2eb9N4g-S5Ysm7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szht1WjtQ%253D%253D&md5=b6ccddcfc1f9ace84aeab93b215d9b36</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2016.1279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2016.1279%26sid%3Dliteratum%253Aachs%26aulast%3DChandarlapaty%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DSung%26aufirst%3DP.%26aulast%3DSamoila%26aufirst%3DA.%26aulast%3DYou%26aufirst%3DD.%26aulast%3DBhatt%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DMoynahan%26aufirst%3DM.%2BE.%26atitle%3DPrevalence%2520of%2520Esr1%2520Mutations%2520in%2520Cell-Free%2520DNA%2520and%2520Outcomes%2520in%2520Metastatic%2520Breast%2520Cancer%253A%2520A%2520Secondary%2520Analysis%2520of%2520the%2520Bolero-2%2520Clinical%2520Trial%26jtitle%3DJAMA%2520Oncol.%26date%3D2016%26volume%3D2%26spage%3D1310%26epage%3D1315%26doi%3D10.1001%2Fjamaoncol.2016.1279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Breslin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Driscoll, L.</span></span> <span> </span><span class="NLM_article-title">Three-Dimensional Cell Culture: The Missing Link in Drug Discovery</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">249</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2012.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fj.drudis.2012.10.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=23073387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1aqs7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=240-249&author=S.+Breslinauthor=L.+O%E2%80%99Driscoll&title=Three-Dimensional+Cell+Culture%3A+The+Missing+Link+in+Drug+Discovery&doi=10.1016%2Fj.drudis.2012.10.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Three-dimensional cell culture: the missing link in drug discovery</span></div><div class="casAuthors">Breslin, Susan; O'Driscoll, Lorraine</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">240-249</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cells, grown as monolayers (2D models), are routinely used as initial model systems for evaluating the effectiveness and safety of libraries of mols. with potential as therapeutic drugs.  While this initial screening precedes preclin. animal studies before advancing to human clin. trials, cultured cells frequently det. the initial, yet crucial, 'stop/go' decisions on the progressing of the development of a drug.  Growing cells as three-dimensional (3D) models more analogous to their existence in vivo, for example, akin to a tumor, and possibly co-cultured with other cells and cellular components that naturally occur in their microenvironment may be more clin. relevant.  Here, in the context of anti-cancer drug screening, we review 2D and 3D culture approaches, consider the strengths and relevance of each method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6L1vxblLJJbVg90H21EOLACvtfcHk0liEdu4yw-gHTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1aqs7%252FN&md5=caec0a115779d0204fea9e083963487f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DBreslin%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Driscoll%26aufirst%3DL.%26atitle%3DThree-Dimensional%2520Cell%2520Culture%253A%2520The%2520Missing%2520Link%2520in%2520Drug%2520Discovery%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D240%26epage%3D249%26doi%3D10.1016%2Fj.drudis.2012.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hafner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chalouni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Bruyn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giltnane, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heidersbach, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houtman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingalla, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kategaya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleinheinz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nannini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wertz, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hager, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daemen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalfe, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">949</span>– <span class="NLM_lpage">963</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2019.06.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1016%2Fj.cell.2019.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=31353221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=949-963&author=J.+Guanauthor=W.+Zhouauthor=M.+Hafnerauthor=R.+A.+Blakeauthor=C.+Chalouniauthor=I.+P.+Chenauthor=T.+De+Bruynauthor=J.+M.+Giltnaneauthor=S.+J.+Hartmanauthor=A.+Heidersbachauthor=R.+Houtmanauthor=E.+Ingallaauthor=L.+Kategayaauthor=T.+Kleinheinzauthor=J.+Liauthor=S.+E.+Martinauthor=Z.+Modrusanauthor=M.+Nanniniauthor=J.+Oehauthor=S.+Ubhayakarauthor=X.+Wangauthor=I.+E.+Wertzauthor=A.+Youngauthor=M.+Yuauthor=D.+Sampathauthor=J.+H.+Hagerauthor=L.+S.+Friedmanauthor=A.+Daemenauthor=C.+Metcalfe&title=Therapeutic+Ligands+Antagonize+Estrogen+Receptor+Function+by+Impairing+Its+Mobility&doi=10.1016%2Fj.cell.2019.06.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility</span></div><div class="casAuthors">Guan, Jane; Zhou, Wei; Hafner, Marc; Blake, Robert A.; Chalouni, Cecile; Chen, Irene P.; De Bruyn, Tom; Giltnane, Jennifer M.; Hartman, Steven J.; Heidersbach, Amy; Houtman, Rene; Ingalla, Ellen; Kategaya, Lorn; Kleinheinz, Tracy; Li, Jun; Martin, Scott E.; Modrusan, Zora; Nannini, Michelle; Oeh, Jason; Ubhayakar, Savita; Wang, Xiaojing; Wertz, Ingrid E.; Young, Amy; Yu, Mamie; Sampath, Deepak; Hager, Jeffrey H.; Friedman, Lori S.; Daemen, Anneleen; Metcalfe, Ciara</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">949-963.e18</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Estrogen receptor-pos. (ER+) breast cancers frequently remain dependent on ER signaling even after acquiring resistance to endocrine agents, prompting the development of optimized ER antagonists.  Fulvestrant is unique among approved ER therapeutics due to its capacity for full ER antagonism, thought to be achieved through ER degrdn.  The clin. potential of fulvestrant is limited by poor physicochem. features, spurring attempts to generate ER degraders with improved drug-like properties.  We show that optimization of ER degrdn. does not guarantee full ER antagonism in breast cancer cells; ER "degraders" exhibit a spectrum of transcriptional activities and anti-proliferative potential.  Mechanistically, we find that fulvestrant-like antagonists suppress ER transcriptional activity not by ER elimination, but by markedly slowing the intra-nuclear mobility of ER.  Increased ER turnover occurs as a consequence of ER immobilization.  These findings provide proof-of-concept that small mol. perturbation of transcription factor mobility may enable therapeutic targeting of this challenging target class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX7uBE7ualk7Vg90H21EOLACvtfcHk0lhYUS1aCkBDag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVOgsr%252FM&md5=96dddd56a1d3d4244ea38f0e7d17941e</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2019.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2019.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHafner%26aufirst%3DM.%26aulast%3DBlake%26aufirst%3DR.%2BA.%26aulast%3DChalouni%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DI.%2BP.%26aulast%3DDe%2BBruyn%26aufirst%3DT.%26aulast%3DGiltnane%26aufirst%3DJ.%2BM.%26aulast%3DHartman%26aufirst%3DS.%2BJ.%26aulast%3DHeidersbach%26aufirst%3DA.%26aulast%3DHoutman%26aufirst%3DR.%26aulast%3DIngalla%26aufirst%3DE.%26aulast%3DKategaya%26aufirst%3DL.%26aulast%3DKleinheinz%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DS.%2BE.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNannini%26aufirst%3DM.%26aulast%3DOeh%26aufirst%3DJ.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWertz%26aufirst%3DI.%2BE.%26aulast%3DYoung%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DHager%26aufirst%3DJ.%2BH.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DDaemen%26aufirst%3DA.%26aulast%3DMetcalfe%26aufirst%3DC.%26atitle%3DTherapeutic%2520Ligands%2520Antagonize%2520Estrogen%2520Receptor%2520Function%2520by%2520Impairing%2520Its%2520Mobility%26jtitle%3DCell%26date%3D2019%26volume%3D178%26spage%3D949%26epage%3D963%26doi%3D10.1016%2Fj.cell.2019.06.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, H. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, H. N.</span></span> <span> </span><span class="NLM_article-title">Photoaffinity Labels for Estrogen Binding Proteins of Rat Uterus</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1973</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">4085</span>– <span class="NLM_lpage">4092</span>, <span class="refDoi"> DOI: 10.1021/bi00745a010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00745a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaE2cXnvVGrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1973&pages=4085-4092&author=J.+A.+Katzenellenbogenauthor=H.+J.+Johnsonauthor=H.+N.+Myers&title=Photoaffinity+Labels+for+Estrogen+Binding+Proteins+of+Rat+Uterus&doi=10.1021%2Fbi00745a010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Photoaffinity labels for estrogen binding proteins of rat uterus</span></div><div class="casAuthors">Katzenellenbogen, John A.; Johnson, Howard J., Jr.; Myers, Harvey N.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1973</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4085-92</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">The binding affinity of 14 estrone, estradiol, and hexestrol derivs. bearing a photosensitive function (either diazocarbonyl group or aryl azide) and their precursors for rat uterine estrogen binding protein was measured by a competitive binding assay.  Introduction of substituents lowered binding affinity in all cases, esp. when 1 or both of the hydroxyl groups were blocked.  Substituents at positions 2, 4, and 16 were tolerated reasonably well.  Derivs. in which the A-ring hydroxyl is internally hydrogen bonded to a nitro group have very low affinity, but the nitro group was well tolerated at position 4, where it does not hydrogen bond to the hydroxyl.  The binding affinity of all the derivs. reflected the relative binding affinity of the parent ligands:  hexestrol > estradiol > estrone.  3-Azidohexestrol [50548-21-5] and 3,3'-diazidohexestrol [50548-22-6] >5%, had the greatest binding affinity and could selectively label estrogen binding protein directly in the impure state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzUNSnonz6bLVg90H21EOLACvtfcHk0lhYUS1aCkBDag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXnvVGrsA%253D%253D&md5=99f1bdfa830d881939130942394e47be</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fbi00745a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00745a010%26sid%3Dliteratum%253Aachs%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DH.%2BJ.%26aulast%3DMyers%26aufirst%3DH.%2BN.%26atitle%3DPhotoaffinity%2520Labels%2520for%2520Estrogen%2520Binding%2520Proteins%2520of%2520Rat%2520Uterus%26jtitle%3DBiochemistry%26date%3D1973%26volume%3D12%26spage%3D4085%26epage%3D4092%26doi%3D10.1021%2Fbi00745a010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span> <span> </span><span class="NLM_article-title">Altered Ligand Binding Properties and Enhanced Stability of a Constitutively Active Estrogen Receptor: Evidence That an Open Pocket Conformation Is Required for Ligand Interaction</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">14897</span>– <span class="NLM_lpage">14905</span>, <span class="refDoi"> DOI: 10.1021/bi971746l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi971746l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADyaK2sXnt1Sls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=14897-14905&author=K.+E.+Carlsonauthor=I.+Choiauthor=A.+Geeauthor=B.+S.+Katzenellenbogenauthor=J.+A.+Katzenellenbogen&title=Altered+Ligand+Binding+Properties+and+Enhanced+Stability+of+a+Constitutively+Active+Estrogen+Receptor%3A+Evidence+That+an+Open+Pocket+Conformation+Is+Required+for+Ligand+Interaction&doi=10.1021%2Fbi971746l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: Evidence that an open pocket conformation is required for ligand interaction</span></div><div class="casAuthors">Carlson, Kathryn E.; Choi, Inho; Gee, Arvin; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">14897-14905</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To elucidate the ligand binding properties of the estrogen receptor (ER) and how ligand access to and release from the ligand binding pocket is affected by the conformational state of the receptor, the authors have measured the rates of estradiol assocn. and dissocn., the equil. binding, and the stability of estradiol binding to denaturants, comparing wild-type human ER and a point mutant (Y537S ER) that shows full constitutive activity, i.e., the same full transcriptional activity in the absence or presence of estrogen.  Ligand binding kinetics and affinity were measured with the full-length (1-595) ERs and with truncated forms of both receptors contg. domains C through F (including the DNA binding, hinge, and ligand binding domains, amino acids 175-595) or domains E and F (the ligand binding domain; amino acids 304-595).  With all ERs, the rates of ligand assocn. and dissocn. were considerably slower with the Y537S mutant ER than with wild-type ER (6-fold and 3-4-fold, resp.).  These marked differences in ligand on and off rates for the wild-type and Y537S receptors result in a predicted (k-1/k+1) and measured Kd that is 2-fold lower for Y537S ER compared to wild-type ER.  The binding of estradiol by wild-type ER was disrupted by high concns. of urea (above 2 M), whereas the Y537S ER was distinctly more resistant to this disruption.  These results are consistent with a model in which wild-type ER in the absence of ligand adopts a transcriptionally inactive collapsed pocket conformation, stabilized by specific interactions of Y537 with nearby regions of ER.  When estradiol is bound, the wild-type ER adopts a transcriptionally active, closed pocket (ligand occupied) conformation.  By contrast, the Y537S mutant ER favors the transcriptionally active closed pocket conformation, whether occupied by ligand or not, the latter state (closed pocket but unoccupied) accounting for its constitutive activity.  The authors' findings suggest that the entry or exit of ligand from the binding pocket requires that ER adopt an open pocket conformation.  The reduced rates of ligand assocn. and dissocn. in the constitutively active form of the ER, as well as its greater resistance to disruption of ligand binding by urea, support the supposition that the rate at which this open pocket conformation can be accessed from the unoccupied or ligand-occupied Y537S ER is slower than from the unoccupied or occupied forms of wild-type ER.  Thus, the binding and release of ligand by ER require that the receptor access an open pocket state, and the ease with which this state can be accessed is affected by mutations that alter receptor conformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpASth-0158cLVg90H21EOLACvtfcHk0lhYUS1aCkBDag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt1Sls7o%253D&md5=905b74d7bd576c661a10daad28913fd8</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fbi971746l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi971746l%26sid%3Dliteratum%253Aachs%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DChoi%26aufirst%3DI.%26aulast%3DGee%26aufirst%3DA.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26atitle%3DAltered%2520Ligand%2520Binding%2520Properties%2520and%2520Enhanced%2520Stability%2520of%2520a%2520Constitutively%2520Active%2520Estrogen%2520Receptor%253A%2520Evidence%2520That%2520an%2520Open%2520Pocket%2520Conformation%2520Is%2520Required%2520for%2520Ligand%2520Interaction%26jtitle%3DBiochemistry%26date%3D1997%26volume%3D36%26spage%3D14897%26epage%3D14905%26doi%3D10.1021%2Fbi971746l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chisamore, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentrem, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span> <span> </span><span class="NLM_article-title">Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase C alpha</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3156</span>– <span class="NLM_lpage">3165</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-1772</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F1078-0432.CCR-16-1772" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=11595710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnvF2rsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=3156-3165&author=M.+J.+Chisamoreauthor=Y.+Ahmedauthor=D.+J.+Bentremauthor=V.+C.+Jordanauthor=D.+A.+Tonetti&title=Novel+antitumor+effect+of+estradiol+in+athymic+mice+injected+with+a+T47D+breast+cancer+cell+line+overexpressing+protein+kinase+C+alpha&doi=10.1158%2F1078-0432.CCR-16-1772"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase cα</span></div><div class="casAuthors">Chisamore, Michael J.; Ahmed, Yasmin; Bentrem, David J.; Jordan, V. Craig; Tonetti, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3156-3165</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Resistance to tamoxifen (TAM) represents a significant challenge to the management of breast cancer.  We previously reported that the estrogen receptor (ER)-neg. hormone-independent T47D:C42 cell line has both elevated protein kinase Cα (PKCα) protein expression and basal activator protein-1 activity compared with the parental ER+ (hormone-dependent) T47D:A18 cell line.  Stable transfection of PKCα to the T47D:A18 breast cancer cell line results in increased basal activator protein-1 activity, reduced ER function, increased proliferation rate, and hormone-independent growth (Tonetti et al., Br. J. Cancer, 83: 782-791, 2000).  In this report, we further characterize the role of PKCα overexpression in vivo to elucidate a possible mol. mechanism of tamoxifen resistance.  To det. whether the T47D:A18/PKCα cell line would produce hormone-independent tumors in athymic mice, we injected T47D:A18, T47D:A18/neo, or the T47D:A18/PKCα20 cell clones bilaterally into the mammary fat pads of athymic mice.  Tumor growth was evaluated following treatment with estradiol (E2), TAM, and the pure antiestrogen, ICI 182780.  Mice receiving either T47D:A18 or T47D:A18/neo cells produced tumors that grew in response to E2 treatment, whereas the untreated control and TAM-treated groups showed no tumor growth.  Interestingly, mice receiving the T47D:A18/PKCα20 clone produced tumors in both the control and TAM groups, whereas tumor growth was inhibited in mice treated with E2.  PKCα was also overexpressed in an MCF-7 tumor model that also exhibited TAM-stimulated and E2-induced regression.  These results suggest that overexpression of PKCα in breast tumors results in hormone-independent tumor growth that cannot be inhibited by TAM treatment.  Furthermore, the finding that E2 has an antitumor effect on breast tumors overexpressing PKCα is a novel observation that may have important therapeutic implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4Yd2zilR7XbVg90H21EOLACvtfcHk0ljHEn4NPqh60w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnvF2rsr0%253D&md5=e132ea7de154480f42b7f701b796401c</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-1772&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-1772%26sid%3Dliteratum%253Aachs%26aulast%3DChisamore%26aufirst%3DM.%2BJ.%26aulast%3DAhmed%26aufirst%3DY.%26aulast%3DBentrem%26aufirst%3DD.%2BJ.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26atitle%3DNovel%2520antitumor%2520effect%2520of%2520estradiol%2520in%2520athymic%2520mice%2520injected%2520with%2520a%2520T47D%2520breast%2520cancer%2520cell%2520line%2520overexpressing%2520protein%2520kinase%2520C%2520alpha%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D3156%26epage%3D3165%26doi%3D10.1158%2F1078-0432.CCR-16-1772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molloy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, B. E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gherezghiher, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalsen, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maximov, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thatcher, G. R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tonetti, D. A.</span></span> <span> </span><span class="NLM_article-title">Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2515</span>– <span class="NLM_lpage">2526</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-14-0319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=10.1158%2F1535-7163.mct-14-0319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=25205655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2515-2526&author=M.+E.+Molloyauthor=B.+E.+P.+Whiteauthor=T.+Gherezghiherauthor=B.+T.+Michalsenauthor=R.+Xiongauthor=H.+Patelauthor=H.+Zhaoauthor=P.+Y.+Maximovauthor=V.+C.+Jordanauthor=G.+R.+J.+Thatcherauthor=D.+A.+Tonetti&title=Novel+Selective+Estrogen+Mimics+for+the+Treatment+of+Tamoxifen-Resistant+Breast+Cancer&doi=10.1158%2F1535-7163.mct-14-0319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Selective Estrogen Mimics for the Treatment of Tamoxifen-Resistant Breast Cancer</span></div><div class="casAuthors">Molloy, Mary Ellen; White, Bethany E. Perez; Gherezghiher, Teshome; Michalsen, Bradley T.; Xiong, Rui; Patel, Hitisha; Zhao, Huiping; Maximov, Philipp Y.; Jordan, V. Craig; Thatcher, Gregory R. J.; Tonetti, Debra A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2515-2526</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Endocrine-resistant breast cancer is a major clin. obstacle.  The use of 17β-estradiol (E2) has reemerged as a potential treatment option following exhaustive use of tamoxifen or aromatase inhibitors, although side effects have hindered its clin. usage.  Protein kinase C alpha (PKCα) expression was shown to be a predictor of disease outcome for patients receiving endocrine therapy and may predict a pos. response to an estrogenic treatment.  Here, we have investigated the use of novel benzothiophene selective estrogen mimics (SEM) as an alternative to E2 for the treatment of tamoxifen-resistant breast cancer.  Following in vitro characterization of SEMs, a panel of clin. relevant PKCα-expressing, tamoxifen-resistant models were used to investigate the antitumor effects of these compds.  SEM treatment resulted in growth inhibition and apoptosis of tamoxifen-resistant cell lines in vitro.  In vivo SEM treatment induced tumor regression of tamoxifen-resistant T47D:A18/PKCα and T47D:A18-TAM1 tumor models.  T47D:A18/PKCα tumor regression was accompanied by translocation of estrogen receptor (ER) α to extranuclear sites, possibly defining a mechanism through which these SEMs initiate tumor regression.  SEM treatment did not stimulate growth of E2-dependent T47D:A18/neo tumors.  In addn., unlike E2 or tamoxifen, treatment with SEMs did not stimulate uterine wt. gain.  These findings suggest the further development of SEMs as a feasible therapeutic strategy for the treatment of endocrine-resistant breast cancer without the side effects assocd. with E2.  Mol Cancer Ther; 13(11); 2515-26. cpr2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp64x3RCcDeYbVg90H21EOLACvtfcHk0ljHEn4NPqh60w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGju73N&md5=203055e50477bcb1c98ea4c7844cf4b9</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-14-0319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-14-0319%26sid%3Dliteratum%253Aachs%26aulast%3DMolloy%26aufirst%3DM.%2BE.%26aulast%3DWhite%26aufirst%3DB.%2BE.%2BP.%26aulast%3DGherezghiher%26aufirst%3DT.%26aulast%3DMichalsen%26aufirst%3DB.%2BT.%26aulast%3DXiong%26aufirst%3DR.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DMaximov%26aufirst%3DP.%2BY.%26aulast%3DJordan%26aufirst%3DV.%2BC.%26aulast%3DThatcher%26aufirst%3DG.%2BR.%2BJ.%26aulast%3DTonetti%26aufirst%3DD.%2BA.%26atitle%3DNovel%2520Selective%2520Estrogen%2520Mimics%2520for%2520the%2520Treatment%2520of%2520Tamoxifen-Resistant%2520Breast%2520Cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2515%26epage%3D2526%26doi%3D10.1158%2F1535-7163.mct-14-0319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K','PDB','1R5K'); return false;">PDB: 1R5K</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ACC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ACC','PDB','5ACC'); return false;">PDB: 5ACC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UFX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UFX','PDB','5UFX'); return false;">PDB: 5UFX</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i128"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01580">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_02763"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01580?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01580</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings, effect of <b>30o</b> treatment on the ER level. , representative western blot, PK profiles for <b>37d</b>., ER isoform binding specificity, molecular orbital calculations, final compound spectra, final compound purity, and PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1R5K">1R5K</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ACC">5ACC</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5UFX">5UFX</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_001.pdf">jm9b01580_si_001.pdf (7.8 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01580/suppl_file/jm9b01580_si_002.csv">jm9b01580_si_002.csv (2.8 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01580&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01580%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-24%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01580" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679985a57aca3ce8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
